WO2012099200A1 - Pyrazole derivative - Google Patents
Pyrazole derivative Download PDFInfo
- Publication number
- WO2012099200A1 WO2012099200A1 PCT/JP2012/051070 JP2012051070W WO2012099200A1 WO 2012099200 A1 WO2012099200 A1 WO 2012099200A1 JP 2012051070 W JP2012051070 W JP 2012051070W WO 2012099200 A1 WO2012099200 A1 WO 2012099200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- pyrazol
- oxadiazol
- trifluoromethyl
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 218
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 125000005549 heteroarylene group Chemical group 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 6
- 206010012289 Dementia Diseases 0.000 claims abstract description 6
- 208000019022 Mood disease Diseases 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 6
- 206010010904 Convulsion Diseases 0.000 claims abstract description 5
- 206010044565 Tremor Diseases 0.000 claims abstract description 5
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 5
- 230000036461 convulsion Effects 0.000 claims abstract description 5
- 206010013663 drug dependence Diseases 0.000 claims abstract description 5
- 208000019116 sleep disease Diseases 0.000 claims abstract description 5
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 5
- 208000027520 Somatoform disease Diseases 0.000 claims abstract description 4
- 208000027753 pain disease Diseases 0.000 claims abstract description 4
- -1 indoline-2-one-5-yl group Chemical group 0.000 claims description 204
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 82
- 125000005843 halogen group Chemical group 0.000 claims description 50
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 45
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 13
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004434 sulfur atom Chemical group 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000005605 benzo group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000005494 pyridonyl group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 239000003512 metabotropic receptor antagonist Substances 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000003042 antagnostic effect Effects 0.000 abstract description 5
- 229930195712 glutamate Natural products 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract description 3
- 206010034912 Phobia Diseases 0.000 abstract description 3
- 206010041250 Social phobia Diseases 0.000 abstract description 3
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract description 3
- 208000029364 generalized anxiety disease Diseases 0.000 abstract description 3
- 208000019906 panic disease Diseases 0.000 abstract description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract description 3
- 201000001716 specific phobia Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 113
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 85
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 74
- 238000005160 1H NMR spectroscopy Methods 0.000 description 65
- 239000000243 solution Substances 0.000 description 65
- 230000009977 dual effect Effects 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- 239000007787 solid Substances 0.000 description 46
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
- 238000000034 method Methods 0.000 description 40
- 239000000203 mixture Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000000741 silica gel Substances 0.000 description 27
- 229910002027 silica gel Inorganic materials 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 239000012442 inert solvent Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000000844 transformation Methods 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 8
- 210000000692 cap cell Anatomy 0.000 description 8
- 238000006482 condensation reaction Methods 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000007112 amidation reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VZIPGMMJVYJAGA-UHFFFAOYSA-N 1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1COC1=CC=C(C(F)(F)F)C=C1 VZIPGMMJVYJAGA-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- JCKOHHKBCPPZQL-UHFFFAOYSA-N CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)O Chemical compound CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)O JCKOHHKBCPPZQL-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 101001071429 Homo sapiens Metabotropic glutamate receptor 2 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 229960004838 phosphoric acid Drugs 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229940032330 sulfuric acid Drugs 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-n,n,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- NRNFOCWICHLLEQ-UHFFFAOYSA-N 2-(4-cyanophenyl)acetamide Chemical compound NC(=O)CC1=CC=C(C#N)C=C1 NRNFOCWICHLLEQ-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- SAWFGNBZCKDDMD-UHFFFAOYSA-N 3-[5-[1-methyl-5-[[5-(trifluoromethyl)pyridin-2-yl]oxymethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]aniline Chemical compound CN1N=CC(C=2ON=C(N=2)C=2C=C(N)C=CC=2)=C1COC1=CC=C(C(F)(F)F)C=N1 SAWFGNBZCKDDMD-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- XHJAOEKASUFHHN-UHFFFAOYSA-N 5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=C=NC=C[CH]1 XHJAOEKASUFHHN-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- MCVLOBXKJWDOQD-UHFFFAOYSA-N CN1N=CC(C=2OC(=NN=2)C=2C=C(CC#N)C=CC=2)=C1COC1=CC=C(C(F)(F)F)C=N1 Chemical compound CN1N=CC(C=2OC(=NN=2)C=2C=C(CC#N)C=CC=2)=C1COC1=CC=C(C(F)(F)F)C=N1 MCVLOBXKJWDOQD-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- UGWYUOOWNFXXHU-UHFFFAOYSA-N FC1=CC=C(C=N1)OCC1=C(C=NN1C)C(=O)OCC Chemical compound FC1=CC=C(C=N1)OCC1=C(C=NN1C)C(=O)OCC UGWYUOOWNFXXHU-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001071437 Homo sapiens Metabotropic glutamate receptor 1 Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000026345 acute stress disease Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940047583 cetamide Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 2
- ZXWRDKLWYHKIHO-UHFFFAOYSA-N n'-hydroxy-2-oxo-1h-pyridine-4-carboximidamide Chemical compound O\N=C(/N)C=1C=CNC(=O)C=1 ZXWRDKLWYHKIHO-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 229940074355 nitric acid Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000003431 oxalo group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000005702 oxyalkylene group Chemical group 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- PNGLEYLFMHGIQO-UHFFFAOYSA-M sodium;3-(n-ethyl-3-methoxyanilino)-2-hydroxypropane-1-sulfonate;dihydrate Chemical compound O.O.[Na+].[O-]S(=O)(=O)CC(O)CN(CC)C1=CC=CC(OC)=C1 PNGLEYLFMHGIQO-UHFFFAOYSA-M 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 125000005505 thiomorpholino group Chemical group 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- SYSFTTYJTWPOOR-UHFFFAOYSA-N (2-diphenylphosphanyl-1-naphthalen-1-yl-3h-naphthalen-2-yl)-diphenylphosphane Chemical group C1C=C2C=CC=CC2=C(C=2C3=CC=CC=C3C=CC=2)C1(P(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)C1=CC=CC=C1 SYSFTTYJTWPOOR-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- CDDGNGVFPQRJJM-BYPYZUCNSA-N (3s)-3-fluoropyrrolidine Chemical compound F[C@H]1CCNC1 CDDGNGVFPQRJJM-BYPYZUCNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000005923 1,2-dimethylpropyloxy group Chemical group 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- NRSROFSJAIJRAN-UHFFFAOYSA-N 1h-pyrazole-4-carbohydrazide Chemical compound NNC(=O)C=1C=NNC=1 NRSROFSJAIJRAN-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- WEBXRQONNWEETE-UHFFFAOYSA-N 2-(4-cyanophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(C#N)C=C1 WEBXRQONNWEETE-UHFFFAOYSA-N 0.000 description 1
- AZUDHLFVMCQNOF-UHFFFAOYSA-N 2-[4-[5-[1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]phenyl]acetic acid Chemical compound CN1N=CC(=C1COC1=CC=C(C=C1)C(F)(F)F)C1=NC(=NO1)C1=CC=C(C=C1)CC(=O)O AZUDHLFVMCQNOF-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- OSQYJPKSEWBNOE-UHFFFAOYSA-N 2-chloro-5-(difluoromethyl)pyridine Chemical compound FC(F)C1=CC=C(Cl)N=C1 OSQYJPKSEWBNOE-UHFFFAOYSA-N 0.000 description 1
- QOGXQLSFJCIDNY-UHFFFAOYSA-N 2-chloro-5-fluoropyridine Chemical compound FC1=CC=C(Cl)N=C1 QOGXQLSFJCIDNY-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- BTGMYVPZVARZKU-UHFFFAOYSA-N 3-(cyanomethyl)benzohydrazide Chemical compound NNC(=O)C1=CC=CC(CC#N)=C1 BTGMYVPZVARZKU-UHFFFAOYSA-N 0.000 description 1
- LJCLPFBIVUPTAR-UHFFFAOYSA-N 3-(n'-hydroxycarbamimidoyl)benzoic acid Chemical compound ON=C(N)C1=CC=CC(C(O)=O)=C1 LJCLPFBIVUPTAR-UHFFFAOYSA-N 0.000 description 1
- AVQMUKZVJCANSS-UHFFFAOYSA-N 3-[(Z)-N'-hydroxycarbamimidoyl]benzamide Chemical compound NC(=O)C1=CC=CC(C(\N)=N\O)=C1 AVQMUKZVJCANSS-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- TXUWTHNUGHXVCI-UHFFFAOYSA-N 3-[5-[1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound CN1N=CC(=C1COC1=CC=C(C=C1)C(F)(F)F)C1=NC(=NO1)C=1C=C(C(=O)O)C=CC1 TXUWTHNUGHXVCI-UHFFFAOYSA-N 0.000 description 1
- OPGWBTKZYLRPRW-UHFFFAOYSA-N 3-amino-n'-hydroxybenzenecarboximidamide Chemical compound O\N=C(/N)C1=CC=CC(N)=C1 OPGWBTKZYLRPRW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- KYKPMNVLZRQRHZ-UHFFFAOYSA-N 3-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC(C#N)=C1 KYKPMNVLZRQRHZ-UHFFFAOYSA-N 0.000 description 1
- YMKXCDDRWMQOBA-UHFFFAOYSA-N 4-(2-amino-2-oxoethyl)benzoic acid Chemical compound NC(=O)CC1=CC=C(C(O)=O)C=C1 YMKXCDDRWMQOBA-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- BAYGVMXZJBFEMB-UHFFFAOYSA-N 4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- AZTOWTOBHDLODP-UHFFFAOYSA-N 4-[(e)-n'-hydroxycarbamimidoyl]benzamide Chemical compound NC(=O)C1=CC=C(C(N)=NO)C=C1 AZTOWTOBHDLODP-UHFFFAOYSA-N 0.000 description 1
- VEEGPIDERPILTD-UHFFFAOYSA-N 4-[(e)-n'-hydroxycarbamimidoyl]benzoic acid Chemical compound O\N=C(/N)C1=CC=C(C(O)=O)C=C1 VEEGPIDERPILTD-UHFFFAOYSA-N 0.000 description 1
- BSRLDSQSXWYVFR-UHFFFAOYSA-N 4-[(z)-n'-hydroxycarbamimidoyl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(C(=N)NO)C=C1 BSRLDSQSXWYVFR-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- TUUMTZKLDOCUPC-UHFFFAOYSA-N 4-[5-[1-methyl-5-[[5-(trifluoromethyl)pyridin-2-yl]oxymethyl]pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]-1h-pyridin-2-one Chemical compound CN1N=CC(C=2ON=C(N=2)C2=CC(=O)NC=C2)=C1COC1=CC=C(C(F)(F)F)C=N1 TUUMTZKLDOCUPC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- UVRUOQVRUXGLPH-UHFFFAOYSA-N 5-[(3,4-difluorophenoxy)methyl]-1-methylpyrazole-4-carboxylic acid Chemical compound Cn1ncc(C(O)=O)c1COc1ccc(F)c(F)c1 UVRUOQVRUXGLPH-UHFFFAOYSA-N 0.000 description 1
- PUPOYFUDNIDLSK-UHFFFAOYSA-N 5-[(4-fluorophenoxy)methyl]-1-methylpyrazole-4-carboxylic acid Chemical compound Cn1ncc(C(O)=O)c1COc1ccc(F)cc1 PUPOYFUDNIDLSK-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ZXFSKYIVDJMMGS-UHFFFAOYSA-N 6-(N'-hydroxycarbamimidoyl)pyridine-2-carboxamide Chemical compound NC(=O)c1cccc(n1)C(N)=NO ZXFSKYIVDJMMGS-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PKLFQKCESJGOSU-UHFFFAOYSA-N C(#N)CC1=CC=C(C(=O)NN)C=C1 Chemical compound C(#N)CC1=CC=C(C(=O)NN)C=C1 PKLFQKCESJGOSU-UHFFFAOYSA-N 0.000 description 1
- YKFQEIZKILRBHA-UHFFFAOYSA-N C(#N)CC1=CC=C(C(=O)NNC(=O)C=2C=NN(C2COC2=NC=C(C=C2)C(F)(F)F)C)C=C1 Chemical compound C(#N)CC1=CC=C(C(=O)NNC(=O)C=2C=NN(C2COC2=NC=C(C=C2)C(F)(F)F)C)C=C1 YKFQEIZKILRBHA-UHFFFAOYSA-N 0.000 description 1
- DAQCJVDMCMPEMQ-UHFFFAOYSA-N C(#N)CC=1C=C(C(=O)NNC(=O)C=2C=NN(C2COC2=NC=C(C=C2)C(F)(F)F)C)C=CC1 Chemical compound C(#N)CC=1C=C(C(=O)NNC(=O)C=2C=NN(C2COC2=NC=C(C=C2)C(F)(F)F)C)C=CC1 DAQCJVDMCMPEMQ-UHFFFAOYSA-N 0.000 description 1
- FBTMKVFGAMFJQK-UHFFFAOYSA-N C(=O)C1=C(C=NN1C)C(=O)OCC.OCC1=C(C=NN1C)C(=O)OCC Chemical compound C(=O)C1=C(C=NN1C)C(=O)OCC.OCC1=C(C=NN1C)C(=O)OCC FBTMKVFGAMFJQK-UHFFFAOYSA-N 0.000 description 1
- ZKIXFSDYNHEHGU-UHFFFAOYSA-N C1(CC1)C=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)O Chemical compound C1(CC1)C=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)O ZKIXFSDYNHEHGU-UHFFFAOYSA-N 0.000 description 1
- JLSITJLPMPXYEH-UHFFFAOYSA-N CN1N=CC(=C1COC1=CC=C(C=C1)C(F)(F)F)C1=NC(=NO1)C1=CC=C(C(=O)O)C=C1 Chemical compound CN1N=CC(=C1COC1=CC=C(C=C1)C(F)(F)F)C1=NC(=NO1)C1=CC=C(C(=O)O)C=C1 JLSITJLPMPXYEH-UHFFFAOYSA-N 0.000 description 1
- GEVIGEBIUOFDFB-UHFFFAOYSA-N CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)O.CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)OCC Chemical compound CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)O.CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)OCC GEVIGEBIUOFDFB-UHFFFAOYSA-N 0.000 description 1
- YDLCPVNBSSJIIE-UHFFFAOYSA-N CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)OCC Chemical compound CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C(=O)OCC YDLCPVNBSSJIIE-UHFFFAOYSA-N 0.000 description 1
- YPYARHCJVOILEV-UHFFFAOYSA-N CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C1=NC(=NO1)C1=CC=C(C=C1)CC#N Chemical compound CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C1=NC(=NO1)C1=CC=C(C=C1)CC#N YPYARHCJVOILEV-UHFFFAOYSA-N 0.000 description 1
- NTECMORSCQLNNM-UHFFFAOYSA-N CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C1=NN=C(O1)C1=CC=C(C=C1)CC#N Chemical compound CN1N=CC(=C1COC1=NC=C(C=C1)C(F)(F)F)C1=NN=C(O1)C1=CC=C(C=C1)CC#N NTECMORSCQLNNM-UHFFFAOYSA-N 0.000 description 1
- VANNXPFXILZRAB-UHFFFAOYSA-N CN1N=CC(=C1COC1=NC=C(C=C1)C)C(=O)OCC Chemical compound CN1N=CC(=C1COC1=NC=C(C=C1)C)C(=O)OCC VANNXPFXILZRAB-UHFFFAOYSA-N 0.000 description 1
- JYOPBKUKPYSZHC-UHFFFAOYSA-N CN1N=CC(C=2ON=C(N=2)C=2C=C(CC(O)=O)C=CC=2)=C1COC1=CC=C(C(F)(F)F)C=C1 Chemical compound CN1N=CC(C=2ON=C(N=2)C=2C=C(CC(O)=O)C=CC=2)=C1COC1=CC=C(C(F)(F)F)C=C1 JYOPBKUKPYSZHC-UHFFFAOYSA-N 0.000 description 1
- LUDDDFPMEGSSEI-UHFFFAOYSA-N COC1=CC=C(C=N1)OCC1=C(C=NN1C)C(=O)O Chemical compound COC1=CC=C(C=N1)OCC1=C(C=NN1C)C(=O)O LUDDDFPMEGSSEI-UHFFFAOYSA-N 0.000 description 1
- YLLXVLZLIXNDDS-UHFFFAOYSA-N COC1=CC=C(C=N1)OCC1=C(C=NN1C)C(=O)OC Chemical compound COC1=CC=C(C=N1)OCC1=C(C=NN1C)C(=O)OC YLLXVLZLIXNDDS-UHFFFAOYSA-N 0.000 description 1
- VJZBHAQQJIKCRY-UHFFFAOYSA-N C[n]1ncc(-c2nnc(-c3ccc(CC(N)=O)cc3)[o]2)c1COc1ncc(C(F)(F)F)cc1 Chemical compound C[n]1ncc(-c2nnc(-c3ccc(CC(N)=O)cc3)[o]2)c1COc1ncc(C(F)(F)F)cc1 VJZBHAQQJIKCRY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- BMFMRUADSWJVQM-UHFFFAOYSA-N Cl.CN1N=CC(=C1COC1=CC=C(C=C1)C(F)(F)F)C(=O)NN Chemical compound Cl.CN1N=CC(=C1COC1=CC=C(C=C1)C(F)(F)F)C(=O)NN BMFMRUADSWJVQM-UHFFFAOYSA-N 0.000 description 1
- VCIFIZWEOZLLJK-UHFFFAOYSA-N ClC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)O Chemical compound ClC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)O VCIFIZWEOZLLJK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- QXRICODFDDFRKN-UHFFFAOYSA-N FC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)O Chemical compound FC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)O QXRICODFDDFRKN-UHFFFAOYSA-N 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101001032848 Homo sapiens Metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 101001032851 Homo sapiens Metabotropic glutamate receptor 4 Proteins 0.000 description 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 1
- 101001032841 Homo sapiens Metabotropic glutamate receptor 7 Proteins 0.000 description 1
- 101001027295 Homo sapiens Metabotropic glutamate receptor 8 Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- RURSKGGGBNWAIH-UHFFFAOYSA-N IC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC.C1(CC1)C=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC Chemical compound IC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC.C1(CC1)C=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC RURSKGGGBNWAIH-UHFFFAOYSA-N 0.000 description 1
- FFMKKLNFFLCRCN-UHFFFAOYSA-N IC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC.ClC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC Chemical compound IC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC.ClC=1C=CC(=NC1)OCC1=C(C=NN1C)C(=O)OCC FFMKKLNFFLCRCN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 1
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- AGUNAEZVIDLGJM-UHFFFAOYSA-N N'-hydroxy-2-(hydroxymethyl)pyridine-4-carboximidamide Chemical compound ON=C(N)C1=CC=NC(CO)=C1 AGUNAEZVIDLGJM-UHFFFAOYSA-N 0.000 description 1
- QAWFRWWKJQBDJH-UHFFFAOYSA-N N'-hydroxy-6-oxo-1H-pyridine-3-carboximidamide Chemical compound ON=C(N)C1=CC=C(O)N=C1 QAWFRWWKJQBDJH-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- NWZKUGCQSVZXFD-UHFFFAOYSA-N ON=C(N)C1=C(C=C(C(=O)N)C=C1)C Chemical compound ON=C(N)C1=C(C=C(C(=O)N)C=C1)C NWZKUGCQSVZXFD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 150000004292 cyclic ethers Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LNZMEOLVTKHUAS-UHFFFAOYSA-N cyclohexane;dichloromethane Chemical compound ClCCl.C1CCCCC1 LNZMEOLVTKHUAS-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- QGBQGMHXBSLYLZ-UHFFFAOYSA-N ditert-butyl-(1-naphthalen-1-ylnaphthalen-2-yl)phosphane Chemical group C1=CC=C2C(C3=C4C=CC=CC4=CC=C3P(C(C)(C)C)C(C)(C)C)=CC=CC2=C1 QGBQGMHXBSLYLZ-UHFFFAOYSA-N 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- BKBGCJVBZKDKKW-UHFFFAOYSA-N ethyl 1-methyl-5-[[4-(trifluoromethyl)phenoxy]methyl]pyrazole-4-carboxylate Chemical compound C1=NN(C)C(COC=2C=CC(=CC=2)C(F)(F)F)=C1C(=O)OCC BKBGCJVBZKDKKW-UHFFFAOYSA-N 0.000 description 1
- GXKQVOXCQOQZED-UHFFFAOYSA-N ethyl 1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C)C=1 GXKQVOXCQOQZED-UHFFFAOYSA-N 0.000 description 1
- UUPBFIKMQKJLAG-UHFFFAOYSA-N ethyl 5-(hydroxymethyl)-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NN(C)C=1CO UUPBFIKMQKJLAG-UHFFFAOYSA-N 0.000 description 1
- MCSZYKYXQVSNBB-UHFFFAOYSA-N ethyl 5-[(3,4-difluorophenoxy)methyl]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(COC=2C=C(F)C(F)=CC=2)=C1C(=O)OCC MCSZYKYXQVSNBB-UHFFFAOYSA-N 0.000 description 1
- UTIFLKFOJNUPHQ-UHFFFAOYSA-N ethyl 5-[(4-fluorophenoxy)methyl]-1-methylpyrazole-4-carboxylate Chemical compound CCOC(=O)c1cnn(C)c1COc1ccc(F)cc1 UTIFLKFOJNUPHQ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- MONIGHCKZUNWTN-UHFFFAOYSA-N ethyl formate;methanol Chemical compound OC.CCOC=O MONIGHCKZUNWTN-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000005453 ketone based solvent Substances 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 102000006239 metabotropic receptors Human genes 0.000 description 1
- 108020004083 metabotropic receptors Proteins 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- MFAFCVSXTYSPHD-UHFFFAOYSA-N n'-hydroxy-2-oxo-1,3-dihydrobenzimidazole-5-carboximidamide Chemical compound O\N=C(/N)C1=CC=C2NC(=O)NC2=C1 MFAFCVSXTYSPHD-UHFFFAOYSA-N 0.000 description 1
- BJGSQTAALUPTRP-UHFFFAOYSA-N n'-hydroxy-2-oxo-1,3-dihydroindole-5-carboximidamide Chemical compound ON=C(N)C1=CC=C2NC(=O)CC2=C1 BJGSQTAALUPTRP-UHFFFAOYSA-N 0.000 description 1
- OQWSBPZPWARWOC-UHFFFAOYSA-N n'-hydroxy-3-(2-oxopyrrolidin-1-yl)benzenecarboximidamide Chemical compound O\N=C(/N)C1=CC=CC(N2C(CCC2)=O)=C1 OQWSBPZPWARWOC-UHFFFAOYSA-N 0.000 description 1
- ZIFIPZQBKOIQOD-UHFFFAOYSA-N n'-hydroxy-4-(2-hydroxyethyl)benzenecarboximidamide Chemical compound OCCC1=CC=C(C(=N)NO)C=C1 ZIFIPZQBKOIQOD-UHFFFAOYSA-N 0.000 description 1
- LKTFEIYPDRMFON-UHFFFAOYSA-N n'-hydroxy-4-(2-hydroxypropan-2-yl)benzenecarboximidamide Chemical compound CC(C)(O)C1=CC=C(C(\N)=N\O)C=C1 LKTFEIYPDRMFON-UHFFFAOYSA-N 0.000 description 1
- XAVQRXUCPQYHBS-UHFFFAOYSA-N n'-hydroxy-4-(hydroxymethyl)benzenecarboximidamide Chemical compound OCC1=CC=C(C(=N)NO)C=C1 XAVQRXUCPQYHBS-UHFFFAOYSA-N 0.000 description 1
- YCNYDVGVRIYMJR-UHFFFAOYSA-N n-[amino-(hydroxyamino)methylidene]benzamide Chemical compound ONC(N)=NC(=O)C1=CC=CC=C1 YCNYDVGVRIYMJR-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- ZGNYUQSBJCCWGF-UHFFFAOYSA-N oxetan-3-amine;hydrochloride Chemical compound Cl.NC1COC1 ZGNYUQSBJCCWGF-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- HILRAMQWKMIWCB-UHFFFAOYSA-N tributyl(cyanomethyl)phosphanium Chemical compound CCCC[P+](CCCC)(CCCC)CC#N HILRAMQWKMIWCB-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-FIBGUPNXSA-N trideuteriomethanol Chemical compound [2H]C([2H])([2H])O OKKJLVBELUTLKV-FIBGUPNXSA-N 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- IKVDXUFZJARKPF-UHFFFAOYSA-M zinc;cyclopropane;bromide Chemical compound Br[Zn+].C1C[CH-]1 IKVDXUFZJARKPF-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a novel compound having an antagonistic action on a group II metabotropic glutamate (mGlu) receptor or a pharmaceutically acceptable salt thereof, and a mood disorder (depressive disorder, bipolar) containing them as an active ingredient sexual disorder), anxiety disorder (generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobia, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment
- the present invention relates to a preventive or therapeutic agent for diseases such as dementia, drug dependence, convulsions, tremors, pain, and sleep disorders.
- Glutamate is known as one of the major excitatory neurotransmitters that regulate higher-order functions such as memory and learning in the mammalian central nervous system.
- Glutamate receptors are ionotropic receptors (iGlu receptors) and G-protein coupled receptors (GPCRs), which are metabotropic receptors (metabolic glutamate receptors). ) are roughly divided.
- iGlu receptor is based on its agonist specificity, N-methyl-D-aspartate (NMDA) receptor, ⁇ -amino-3-hydroxy-5-methyl-4-isoxazolepropion There are three types of receptors: acid ( ⁇ -amino-3-hydroxy-5-methyl-4-isopropylpropionic acid (AMPA)) receptors and kainate receptors.
- NMDA N-methyl-D-aspartate
- AMPA ⁇ -amino-3-hydroxy-5-methyl-4-isopropylpropionic acid
- the mGlu receptor has eight subtypes (mGlu1 to 8), and group I (mGlu1, mGlu5), group II (mGlu2, mGlu3) and group III (mGlu4) depend on the signal transduction system and pharmacological properties to be coupled. , MGlu6, mGlu7, mGlu8). Group II and Group III mGlu receptors are expressed primarily as autoreceptors or heteroreceptors at nerve endings, suppress adenylate cyclase through Gi proteins, and regulate specific K + or Ca 2+ channel activity. ing.
- Non-patent Document 1 the concentration of glutamate in cerebrospinal fluid and plasma in patients with mental disorders such as mood disorders, anxiety disorders, and schizophrenia has changed, suggesting abnormal glutamate neuronal function in mental disorders.
- Group II mGlu receptor antagonists exhibit antidepressant and anxiolytic effects in various animal models (Non-patent Document 1), so Group II mGlu receptor antagonists are novel. The possibility of becoming an antidepressant and anxiolytic is suggested. Furthermore, the efficacy as a cognitive function enhancer (dementia, Alzheimer's disease) of a group II mGlu receptor antagonist is also suggested (nonpatent literature 2).
- Patent Documents 1 to 5 Recently, compounds having group II mGlu receptor antagonistic activity have been reported in Patent Documents 1 to 5 and the like. However, these patent documents do not disclose or suggest any compound having a heteroaryl-pyrazole skeleton.
- R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- Ring A includes a phenyl group, a heteroaryl group, an indoline-2-one-5-yl group, an isoindoline-1-one-5-yl group, an isoindoline-1-one-6-yl group, a benzo [d] Represents an imidazol-2-one-5-yl group or a pyridonyl group; Ring A is an indoline-2-one-5-yl group, an isoindoline-1-one-5-yl group, an isoindoline-1-one-6-yl group or a benzo [d] imidazol-2--
- the octan-6-yl group may be substituted with 1 to 2 halogen atoms. May be substituted with 1 to 3 substituents selected from the group consisting of ⁇ , A C 1-6 alkanoyl group, an oxetanyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group, Alternatively, R a and R b are formed together with a nitrogen atom to be bonded, and are a saturated or unsaturated 4- to 6-membered ring (here, which may further contain one or more nitrogen atom, oxygen atom or sulfur atom (wherein The saturated or unsaturated 4- to 6-membered ring may be substituted with 1 to 2 substituents selected from the group consisting of a C 1-6 alkyl group, an oxo group and a hydroxyl group.
- R a1 and R b1 are formed together with a nitrogen atom to which they are bonded, and are a saturated or unsaturated 4- to 6-membered ring that may contain one or more nitrogen atoms, oxygen atoms, or sulfur atoms, Or an unsaturated 4- to 6-membered ring may be substituted with 1 to 2 substituents selected from the group consisting of a C 1-6 alkyl group, an oxo group and a hydroxyl group.
- R c represents a C 1-6 alkyl group, a hydroxyl group or a C 1-6 alkoxy group
- R d represents a hydrogen atom or a C 1-6 alkyl group
- R e represents a C 1-6 alkoxy group, an amino group, a mono-C 1-6 alkylamino group or a di-C 1-6 alkylamino group
- R f and R g are the same or different and each represents a hydrogen atom or a C 1-6 alkyl group
- Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —
- n represents an integer of 1 to 6
- m represents an integer of 0 to 6
- Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6
- R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- Ring A represents a phenyl group or a heteroaryl group,
- R 3 represents a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group).
- R a and R b are the same or different and are each a hydrogen atom, a C 1-6 alkyl group, wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.
- R a and R b are formed together with a nitrogen atom to be bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen atom, oxygen atom or sulfur atom.
- R c represents a hydroxyl group or a C 1-6 alkoxy group
- Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —
- n represents an integer of 1 to 6
- m represents an integer of 0 to 6
- Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6 alkyl group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom It may be substituted with 3 substituents.
- Y 3 represents a 5-membered heteroarylene] Or a pharmaceutically acceptable salt thereof according to (1),
- the present compound and pharmaceutically acceptable salts thereof have been found to have strong group II mGlu receptor antagonistic activity.
- Halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the “C 1-6 alkyl group” is a linear or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, Examples include hexyl group, isopropyl group, isobutyl group, tert-butyl group, sec-butyl group, isopentyl group, neopentyl group, tert-pentyl group, 1,2-dimethylpropyl group and the like.
- the “C 1-6 alkoxy group” is a linear or branched alkoxy group having 1 to 6 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentyloxy group. Hexyloxy group, isopropoxy group, isobutoxy group, tert-butoxy group, sec-butoxy group, isopentyloxy group, neopentyloxy group, tert-pentyloxy group, 1,2-dimethylpropoxy group and the like.
- the “mono-C 1-6 alkylamino group” is an amino group substituted with one C 1-6 alkyl group, and examples thereof include a methylamino group, an ethylamino group, a propylamino group, a butylamino group, Pentylamino group, hexylamino group, isopropylamino group, isobutylamino group, tert-butylamino group, sec-butylamino group, isopentylamino group, neopentylamino group, tert-pentylamino group, 1,2-dimethylpropyl An amino group etc. are mentioned.
- the “di-C 1-6 alkylamino group” is an amino group substituted with two independent C 1-6 alkyl groups, such as a dimethylamino group, a diethylamino group, a dipropylamino group, a dibutyl group.
- Amino group dipentylamino group, dihexylamino group, diisopropylamino group, diisobutylamino group, di-tert-butylamino group, di-sec-butylamino group, di-isopentylamino group, di-neopentylamino group, di- -Tert-pentylamino group, di-1,2-dimethylpropylamino group, ethylmethylamino group, isopropylmethylamino group, isobutylisopropylamino group and the like.
- the “C 1-6 alkanoyl group” is a linear or branched alkanoyl group having 1 to 6 carbon atoms, such as formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, A valeryl group, a hexanoyl group, a pivaloyl group, etc. are mentioned.
- the “aryl group” is a monocyclic to tetracyclic aromatic carbocyclic group composed of 6 to 18 carbon atoms, such as a phenyl group, a naphthyl group, an anthryl group, a phenanthryl group, a tetracenyl group. And pyrenyl group.
- Heteroaryl group '' means a monocyclic or fused-ring aromatic heterocyclic group, for example, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, thienyl group, pyrrolyl group, thiazolyl group, isothiazolyl group, Pyrazolyl group, imidazolyl group, furyl group, oxazolyl group, isoxazolyl group, oxadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,3-triazolyl group, 1,2,4-triazolyl group, tetrazolyl group, quinolyl group , Isoquinolyl group, naphthyridinyl group, quinazolinyl group, benzofuranyl group, benzothienyl group, indolyl group, benzoxazolyl group, benzisoxazolyl group, 1H-in
- 6-membered heteroaryl group means a 6-membered aromatic heterocyclic group, and examples thereof include a pyridyl group, a pyridazinyl group, a pyrimidinyl group, and a pyrazinyl group.
- the “5-membered heteroaryl group” means a 5-membered aromatic heterocyclic group such as thienyl group, pyrrolyl group, thiazolyl group, isothiazolyl group, pyrazolyl group, imidazolyl group, furyl group, oxazolyl group, isoxazolyl group.
- C 3-6 cycloalkyl group means a cycloalkyl group having 3 to 6 carbon atoms, and means a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.
- 5-membered heteroarylene means a divalent group formed by removing any one hydrogen atom from the above-mentioned “5-membered heteroaryl group”.
- “Saturated or unsaturated 5- or 6-membered ring which is formed together with the nitrogen atom to be bonded and may further contain one or more nitrogen atom, oxygen atom or sulfur atom” means, for example, pyrrolidino group, piperidino group A piperazino group, a morpholino group, a thiomorpholino group, a 1,2,3,6-tetrahydropyridin-1-yl group, and the like.
- “Saturated or unsaturated 4- to 6-membered ring which is formed together with the nitrogen atom to be bonded and may further contain one or more nitrogen atom, oxygen atom or sulfur atom” means, for example, an azetidino group, a pyrrolidino group And piperidino group, piperazino group, morpholino group, thiomorpholino group, 1,2,3,6-tetrahydropyridin-1-yl group and the like.
- C 1-6 alkylene means a divalent group formed by removing any one hydrogen atom from the above “C 1-6 alkyl group”.
- C 1-6 oxyalkylene means a divalent group formed by removing any one hydrogen atom from the “C 1-6 alkoxy group”.
- R 1 is preferably a hydrogen atom or a C 1-6 alkyl group, more preferably a C 1-6 alkyl group. Particularly preferred R 1 is a methyl group.
- R 2 is a hydrogen atom.
- Preferred ring A is a phenyl group or a 6-membered heteroaryl group, more preferably a phenyl group or a pyridyl group.
- R 3 is preferably a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms), more preferably a hydrogen atom.
- R 4 is a C 1-3 alkyl group, a C 1-3 alkoxy group (wherein the C 1-3 alkyl group or C 1-3 alkoxy group is substituted with —CONR a R b , or a hydroxyl group. ), —CONR a R b , —NR d COR e or —NR d SO 2 R e (wherein R a , R b , R c , R d and R e are as defined above).
- Preferred Y 1 is —CH 2 —O—.
- Y 2 is preferably a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 The alkyl group, C 3-6 cycloalkyl group or C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.) 1 to 3 selected from the group consisting of a cyano group and a halogen atom May be substituted with one substituent.
- Preferred Y 3 is any of the structures shown in formula [II]
- R 1 is a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- R 2 is a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- Ring A is a phenyl group or a 6-membered heteroaryl group,
- R 3 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
- R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group).
- R a and R b are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group (wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.) Or a 4-6 membered cyclic ether group, Or, R a and R b are formed together with the nitrogen atom to which they are bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen, oxygen or sulfur atoms.
- R c is a hydroxyl group or a C 1-6 alkoxy group
- Y 1 is —CH 2 —O—
- Y 2 is a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl is Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 to 3 selected from the group consisting of a cyano group and a halogen atom It may be substituted with a substituent.
- Y 3 is a 5-membered heteroarylene.
- the compound of the present invention may have stereoisomers such as tautomers and geometric isomers, and optical isomers, and the present invention includes these isomers. Also included are various hydrates, solvates and polymorphic substances of the inventive compounds and their salts. Furthermore, the compound [I] of the present invention may be labeled with an isotope (eg, D, 3 H, 13 C, 14 C, 15 N, 31 P, 32 P, 35 S, 18 F, 125 I, etc.). Good.
- an isotope eg, D, 3 H, 13 C, 14 C, 15 N, 31 P, 32 P, 35 S, 18 F, 125 I, etc.
- the pharmaceutically acceptable salt means a pharmaceutically acceptable salt.
- the compound [I] or a pharmaceutically acceptable salt of the present invention can be formulated according to a method known per se as it is or together with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carriers include various organic or inorganic carrier materials commonly used as pharmaceutical materials, such as excipients in solid formulations (eg, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silica Acid), lubricant (eg, magnesium stearate, calcium stearate, talc, colloidal silica), binder (eg, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl) Pyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, etc.), disintegrants (eg starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose Sodium, carboxymethyl starch sodium, low
- preservatives for example, paraoxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.
- antioxidants for example, sulfites, Ascorbic acid and the like
- colorants for example, sweeteners, adsorbents, wetting agents and the like
- the compound [I] or pharmaceutically acceptable salt of the present invention can be administered orally or parenterally (for example, intravenous, topical, rectal administration, etc.).
- the dosage form includes, for example, tablets (including sugar-coated tablets and film-coated tablets), powders, granules, powders, troches, capsules (including soft capsules), liquids, injections (for example, subcutaneous injections, intravenous injections) Injections, intramuscular injections, intraperitoneal injections, etc.), external preparations (eg, nasal preparations, transdermal preparations, ointments, creams, etc.), suppositories (eg, rectal suppositories, vaginal suppositories, etc.) ), Sustained-release agents (eg, sustained-release microcapsules, etc.), pellets, infusions, etc., all of which can be produced by conventional formulation techniques (eg, the method described in the 15th revised Japanese Pharmacopoeia, etc
- the compound [I] of the present invention or a pharmaceutically acceptable salt is appropriately selected depending on the administration subject, administration route, disease, patient age, weight and symptoms. For example, when treating an adult patient, the dose is 1 to 2000 mg / day, and this amount is administered once or divided into several times a day.
- Group II mGlu receptor antagonist When Group II mGlu receptor antagonist is used as an active pharmaceutical ingredient, it is not intended for use only in humans, but in other animals other than humans (cats, dogs, cows, chickens, fish, etc.) Can also be used.
- the compound of the present invention and a pharmaceutically acceptable salt thereof can be synthesized, for example, by the method shown below, but the production method of the compound of the present invention is not limited thereto.
- “Inert solvent” means, for example, aromatic solvents such as benzene, toluene, xylene, pyridine; hydrocarbon solvents such as hexane, pentane, cyclohexane; dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, etc.
- Halogenated hydrocarbon solvents such as tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, 1,4-dioxane; ester solvents such as ethyl acetate and ethyl formate; methanol, ethanol, isopropyl alcohol, tert- Alcohol solvents such as butyl alcohol and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; amide solvents such as N, N-dimethylformamide, N-methylpyrrolidone and N, N-dimethylacetamide; sulfos such as dimethyl sulfoxide Sid solvents; acetonitrile, nitriles and water, such as propionitrile, and also these homogeneous and heterogeneous mixed solvents.
- inert solvents are appropriately selected according to various reaction conditions known to those skilled in the art.
- Examples of the “base” include hydrides of alkali metals or alkaline earth metals such as lithium hydride, sodium hydride, potassium hydride, calcium hydride; lithium amide, sodium amide, lithium diisopropylamide, lithium dicyclohexylamide, lithium Alkali metal or alkaline earth metal amides such as hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide; alkali metals such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, or alkaline earth Lower metal alkoxides; alkyl lithiums such as butyl lithium, sec-butyl lithium, tert-butyl lithium, methyl lithium; sodium hydroxide, potassium hydroxide, lithium hydroxide, Beauty hydroxide Alkali metal or alkaline earth metal hydroxides such as sodium carbonate; alkaline metal or alkaline earth metal carbonates such as sodium carbon
- Examples of the “acid” include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, formic acid and acetic acid. These acids are appropriately selected according to various reaction conditions known to those skilled in the art.
- R 5 is a protecting group of a carboxy group such as a methyl group, an ethyl group, a tert-butyl group, or a benzyl group ⁇ Protective Groups in Organic Synthesis 4th edition, John Wiley & Sons (John Wiley & Sons) Sons, INC.) ⁇ Or hydrogen atom.
- Step 1 Compound [II] of the present invention is a condensation reaction known to those skilled in the art of Compound (1) and Compound (2) in which R 5 is a protecting group for a carboxy group in an inert solvent in the presence of a base.
- the compound [II] of the present invention is obtained by subjecting the compound (1) in which R 5 is a hydrogen atom to an amidation reaction known to those skilled in the art in an inert solvent, followed by the subsequent intramolecular cyclization reaction. ⁇ See Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC. ⁇ .
- the compound (1) and the compound (2) a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
- the amidation reaction is, for example, O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro in an inert solvent in the presence or absence of a base.
- Nium hexafluorophosphoric acid (HATU) O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphoric acid (HBTU)
- the amidation reaction using the condensing agent additives such as 1-hydroxybenzotriazole (HOBt) and hydroxysuccinimide (HOSu) can be used as necessary.
- the intramolecular cyclization reaction is, for example, a cyclization reaction of an amide compound using an acid or a base as necessary under heating or non-heating conditions in an inert solvent.
- Step 2 Compound (4) can be produced by an amidation reaction known to those skilled in the art of Compound (1) and Compound (3) in which R 5 is a hydrogen atom in an inert solvent ⁇ Comprehensive Organic Transformations Second Edition (see John Wiley & Sons, INC., 1999) ⁇ .
- R 5 is a hydrogen atom in an inert solvent
- the compound (1) and the compound (3) a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
- the amidation reaction is, for example, O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro in an inert solvent in the presence or absence of a base.
- Nium hexafluorophosphoric acid (HATU) O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphoric acid (HBTU)
- Step 3 The compound [I-II] of the present invention can be produced by an intramolecular cyclization reaction of the compound (4) in an inert solvent.
- an activator such as tosyl chloride, thionyl chloride, phosphoryl chloride, Burgess Reagent ⁇ Methyl-N- (triethylammoniumsulfonyl) carbamate ⁇ can be used. ⁇ See Comprehensive Organic Transformations Second Edition, 1999, John Wiley & Sons, INC. ⁇ .
- compound (4) can be produced by the following method.
- R 6 is an amino group such as methoxymethyl group, trimethylsilylethoxymethyl group, tert-butoxycarbonyl group, benzyloxycarbonyl group, acetyl group, benzyl group, trityl group, methanesulfonyl group, benzenesulfonyl group, p-toluenesulfonyl group, etc.
- Protective group ⁇ see Protective Groups in Organic Synthesis 4th Edition, John Wiley & Sons, INC. ⁇ Or hydrogen atom.
- Step 4 Compound (6) can be produced from Compound (1) and Compound (5) wherein R 5 is a hydrogen atom by the same method as in Step 2 in ⁇ Scheme 2>.
- R 6 is an amino-protecting group
- compound (6) can be prepared by various organic synthesis methods known to those skilled in the art for protecting group R 6 ⁇ Protective Groups in Organic Synthesis). 4th edition, see John Wiley & Sons, Inc. ⁇ .
- compound (6) is produced by a condensation reaction known to those skilled in the art of compound (1) in which R 5 is a protecting group for a carboxy group and compound (5) in which R 6 is a hydrogen atom in an inert solvent.
- Step 5 Compound (4) can be produced from compound (6) and compound (7) by the same method as in Step 2 in ⁇ Scheme 2>.
- the compound (7) a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
- Step 6 Compound [I-IV] of the present invention can be produced from compound [I-III] of the present invention and compound (8) by the same method as in Step 2 in ⁇ Scheme 2>.
- the compound (8) a commercially available compound, a known compound, or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
- Step 7 The compound [IV] of the present invention is produced by a reductive amination reaction known to those skilled in the art of the compound (8) and the compound (9) in the presence of an acid and a reducing agent in an inert solvent. ⁇ Comprehensive Organic Transformations Second Edition 1999, see John Wiley & Sons, INC. ⁇ .
- the compound (8) and the compound (9) a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
- the acid herein include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, formic acid, and acetic acid.
- the reducing agent used in the reductive amination reaction is a reagent capable of reducing an imino group to convert it to an amino group.
- sodium borohydride, sodium triacetoxyborohydride, cyanoborohydride Sodium, borane, borane-pyridine, borane-picoline and the like can be mentioned.
- Step 8 Compound [I-VII] of the present invention can be produced by a hydration reaction known to those skilled in the art of Compound [I-VI] of the present invention ⁇ Comprehensive Organic Transformations Second Edition (Comprehensive Organic Transformations Second Edition) See 1999 John Wiley & Sons, INC. ⁇ .
- a compound in which compound (1) is represented by formula (1-1) or formula (1-2) can be produced by the following method.
- R 10 , R 10 ′ and R 10 ′′ are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), A cyano group and a halogen atom, and X 1 represents a chlorine atom, bromine An atom, an iodine atom, or a fluorine atom is shown.
- Step 9 Compound (1-1) can be produced by Mitsunobu reaction of compound (10) and compound (11) in an inert solvent.
- the compound (10) and the compound (11) a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
- Mitsunobu reaction is, for example, a method using an organic phosphorus compound such as triphenylphosphine or tributylphosphine and an azo compound such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, ditertbutyl azodicarboxylate, or cyanomethyltributylphosphorane. (See Chem.
- Step 10 Compound (1-2) is compound (10) and Compound (12) in an inert solvent in the presence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a palladium catalyst ligand.
- a base in the presence or absence of a palladium catalyst
- a palladium catalyst ligand in the presence or absence of a palladium catalyst ligand.
- Examples of the base here include sodium carbonate, potassium carbonate, cesium carbonate, triethylamine, diisopropylethylamine, lithium hydride, sodium hydride, potassium hydride, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide.
- Examples of the palladium catalyst include palladium acetate (II), dichlorobistriphenylphosphine palladium (II), dichlorobisacetonitrile palladium (II), tetrakistriphenylphosphine palladium (0), and the like.
- Examples of the ligand include rac-2- (di-t-butylphosphino) -1,1′-binaphthyl, triphenylphosphine, tributylphosphine, 2,2-bis (diphenylphosphino) -1,1-binaphthyl.
- BINAP 2- (di-tert-butylphosphino) biphenyl, 1,1′-bis (diphenylphosphino) ferrocene (dppf), 1,3-bis (diphenylphosphino) propane (dppp), etc. It is done.
- a compound in which compound (10) is represented by formula (10-1) can be produced by the following method.
- Step 11 Compound (14) can be produced by reacting compound (13) with N, N-dimethylformamide or the like in the presence of a base in an inert solvent.
- Compound (13) may be a commercially available compound, a known compound, or a compound synthesized from a commercially available compound or a known compound using various organic synthesis methods known to those skilled in the art.
- Step 12 Compound (10-1) can be produced by reacting compound (14) with a reducing agent in an inert solvent. ⁇ See Comprehensive Organic Transformations Second Edition, 1999, John Wiley & Sons, INC. ⁇ .
- the reducing agent is a reagent that can reduce a formyl group and convert it into a hydroxyl group.
- a reagent that can reduce a formyl group and convert it into a hydroxyl group.
- compound (2) can be produced by the following method.
- Step 13 Compound (16) is appropriately combined with Compound (15) in an inert solvent in the presence or absence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a palladium catalyst ligand. It can be produced by reaction with a cyanating agent.
- a cyanating agent As the compound (15), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
- suitable cyanating agents include, for example, zinc cyanide, copper cyanide, potassium cyanide or sodium cyanide.
- Step 14 Compound (2) can be produced by addition reaction of compound (16) with hydroxyamine or a salt thereof in an inert solvent in the presence or absence of a base.
- compound (16) synthesized from the compound (15) a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
- compound (3) can be produced by the following method.
- Step 15 Compound (3) can be produced from compound (17) and compound (5) by the same method as in Step 4 in ⁇ Scheme 3>.
- the compound (17) and the compound (5) a commercially available compound, a known compound or a compound synthesized from a known compound by using various organic synthesis methods known to those skilled in the art can be used.
- Biotage (registered trademark) SNAP cartridge KP-NH manufactured by Biotage was used for “NH silica gel cartridge” when purified using column chromatography, and Biotage was manufactured for “silica gel cartridge”.
- Biotage (registered trademark) SNAPCartridge KP-Sil and HP-Sil Biotage (registered trademark) SNAPCartridge KP-Sil and HP-Sil
- Silica gel 60 N is silica gel 60 N manufactured by Kanto Chemical Co.
- Chromatolex NH Chromatrex (registered trademark) NH manufactured by Fuji Silysia Chemical Ltd.
- NMR nuclear magnetic resonance
- Ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5-formyl-1-methyl-1H-pyrazole-4-carboxylate Diisopropylamine (27 1.6 g) in tetrahydrofuran (400 mL) was added dropwise n-butyllithium (105 mL, 2.60 M hexane solution) under ice bath cooling, and the mixture was stirred for 1 hour.
- reaction mixture was cooled to ⁇ 78 ° C., a solution of ethyl 1-methyl-1H-pyrazole-4-carboxylate (20.0 g) in tetrahydrofuran (100 mL) was added dropwise, and the mixture was stirred for 2 hr.
- N, N-dimethylformamide (79.7 g) was added dropwise to the reaction solution at ⁇ 78 ° C., and the mixture was stirred for 1 hour, and then 2M aqueous hydrogen chloride solution was added.
- the reaction mixture was acidified with 5M aqueous hydrogen chloride solution and extracted three times with ethyl acetate.
- reaction mixture was diluted with ethyl acetate, filtered through celite, and the filtrate was concentrated under reduced pressure.
- HATU Tetramethyluronium hexafluorophosphoric acid
- Example 2 Using the same method as in Example 1, the compounds of Examples 2 to 14 listed in Table 1-1 to Table 1-3 were obtained.
- Example 2 4- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl ⁇ benzamide
- Example 3 3- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl ⁇ benzamide
- Example 4 2- (3- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] Oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇ phenyl) acetamide
- Example 5 6- [5- (1-Methyl-5- ⁇ [4- (tri Fluor
- Example 16 Using the same method as in Example 15, the compounds of Example 16 to Example 31 described in Tables 2-1 to 2-3 were obtained.
- Example 16 4- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] Benzoic acid
- Example 17 3- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3- yl] benzoic acid
- example 18 2- ⁇ 4- [5- (1-methyl-5 - ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1,2,4 -Oxadiazol-3-yl] phenyl ⁇ acetamide
- Example 19 ⁇ 4- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1
- Example 33 Using the same method as in Example 32, the compounds of Example 33 to Example 41 described in Table 3-1 to Table 3-2 were obtained.
- Example 33 tert-butyl 3- [5- (1-methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3 -Yl] benzoate
- Example 34 4- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1,2,4-oxadiazol -3-yl] benzamide
- Example 35 3- [5- (5- ⁇ [(5-Fluoropyridin-2-yl) oxy] methyl ⁇ -1-methyl-1H-pyrazol-4-yl) -1,2 , 4-Oxadiazol-3-yl] benzamide
- Example 36 4- [5- (5- ⁇ [(5-Fluoropyridin-2-yl) oxy] methyl ⁇ -1-methyl-1H-pyrazol-4-yl) -1,2,4
- Example 45 Using the same method as in Example 44, the compounds of Example 45 to Example 49 listed in Table 4 were obtained.
- Example 45 2- ⁇ 3- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl) -1,3,4-oxadiazol-2 -Yl] phenyl ⁇ acetamide
- Example 46 4- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,3,4-oxadiazol-2-yl ⁇ benzamide
- Example 47 3- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol-4-yl ) -1,3,4-oxadiazol-2-yl] benzamide
- Example 48 4- [5- (1-Methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazol
- Example 20 Using the same procedure as in Example 50, ⁇ 3- [5- (1-methyl-5- ⁇ [4- (trifluoromethyl) phenoxy] methyl ⁇ -1H-pyrazole-4 obtained in Example 20 was used. -Il) -1,2,4-oxadiazol-3-yl] phenyl ⁇ acetic acid (43 mg) and methylamine (70 ⁇ L, 2M tetrahydrofuran solution) gave the title compound (34 mg) as a colorless solid.
- Example 53 3-Fluoro-4- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl ⁇ benzamide
- Example 54 2- (2-Bromo-4- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] Oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇ phenyl) acetamide
- Example 55 N- (2-hydroxyethyl) -3- ⁇ 5- [1-methyl -5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇ benzamide
- Example 56 2
- Example 50 Using the same method as in Example 50, the compounds of Examples 129 to 175 described in Table 6-1 to Table 6-8 were obtained.
- N- (2,2-dimethoxyethyl) -3- (N′-hydroxycarbamimidoyl) benzamide (846 mg) obtained in Production Example 5 was added to the reaction solution, and the mixture was stirred at 120 ° C. for 10 hours.
- the reaction mixture was allowed to cool to room temperature, ISOLUTE HM-N was added, and the mixture was concentrated under reduced pressure.
- Example 177 and Example 178 were obtained using the same method as in Example 176.
- Example 179 N- ⁇ 2-[(3S) -3-fluoropyrrolidin-1-yl] ethyl ⁇ -3- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridine-2 -Yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇ benzamide N- (2,2-dimethoxyethyl) -3- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy obtained in Example 176-1) ⁇ Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇ benzamide (52 mg) in tetrahydrofuran (1.0 mL) and p-toluenesulfonic acid monohydrate (8.4 mg) was added, and the mixture was stirred at room temperature for 19 hours.
- Example 180 In the same manner as in Example 179, the compounds of Example 180 to Example 187 described in Table 7-1 to Table 7-2 were obtained.
- Example 180 N- [2- (azetidin-1-yl) ethyl] -3- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇ benzamide
- Example 181 N- [2- (3,3-difluoroazetidin-1-yl) ethyl] -3- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl ⁇
- Example 182 N- [2- (3-Fluoroazetidin-1-yl) ethyl] -3- ⁇ 5- [1-methyl-5-( ⁇ [5- (triflu
- Example 188 N-acetyl-2- (4- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl ⁇ phenyl) acetamide 2- (4- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl obtained in Example 1 ] -1,2,4-oxadiazol-3-yl ⁇ phenyl) acetamide (100 mg), acetic anhydride (67 ⁇ L) and pyridine (2.0 mL) were stirred at 85 ° C.
- Example 189 (4- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl ⁇ phenyl) acetonitrile 2- (4- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl obtained in Example 1 ] To a solution of 1,2,4-oxadiazol-3-yl ⁇ phenyl) acetamide (100 mg) in pyridine (2.0 mL) under ice-cooling, phosphorus oxychloride (40 ⁇ L) was added at room temperature.
- Example 190 2- [4- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl ⁇ -2-oxopyridin-1 (2H) -yl] acetamide 1) 4- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl ⁇ pyridin-2 (1H) -one 1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H- obtained in Preparation Example 4 To a solution of pyrazole-4-carboxylic acid (100 mg) in N, N-dimethylformamide (2.0 mL) was added 1,1
- N'-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide (62 mg) obtained in Production Example 5 was added to the reaction solution, and the mixture was stirred at room temperature for 30 minutes and at 110 ° C. for 14 hours. did.
- the reaction solution was allowed to cool to room temperature, water was added, and the precipitated crystals were collected by filtration. This afford the title compound recrystallized from ethyl acetate (74 mg) as a colorless solid.
- Example 191 2- [5- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl ⁇ -2-oxopyridin-1 (2H) -yl] acetamide Using a method similar to that in Example 190, the title compound was obtained as a colorless solid.
- Example 192 N- (3- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl ⁇ phenyl) sulfuric diamide 1) 3- ⁇ 5- [1-Methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl ⁇ aniline 1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazole-4-carboxylic acid obtained in Production Example 4 To a solution of 800 mg) in N, N-dimethylformamide (3.0 mL) was added 1,1′-carbonyldiimidazole (517 mg) at room temperature and stirred for 30 minutes.
- Triethylamine (319 ⁇ L) and 3- ⁇ 5- [1-methyl-5-( ⁇ [5- (trifluoromethyl) pyridin-2-yl] oxy ⁇ methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl ⁇ aniline 159 mg was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 21 hours.
- a saturated aqueous sodium hydrogen carbonate solution (1.6 mL) and water (1.6 mL) were added to the reaction solution, and the two layers were separated.
- the organic layer was passed through a phase separator (manufactured by Biotage Corp.), water was removed, and the mixture was concentrated under reduced pressure. Chloroform was added to the residue, trifluoroacetic acid (3.2 mL) was added under ice cooling, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure, and chloroform (6.4 mL), saturated aqueous sodium hydrogen carbonate solution (3.2 mL), water (6.4 mL) and methanol (3.2 mL) were added to the residue. After separating the two layers, the aqueous layer was extracted with a mixed solvent of chloroform (3.2 mL) -methanol (1.6 mL).
- Test example 1 Preparation of crude membrane fraction of CHO cells stably expressing human metabotropic glutamate receptor (mGlu2)
- CHO cells stably expressing human mGlu2 receptor were mixed with Dulbecco's modified Eagle medium containing 10% dialyzed fetal bovine serum [1% proline, 50 units / mL penicillin, 50 ⁇ g / mL streptomycin, 400 ⁇ g / mL Hygromycin B, 2 mM L-glutamine (for use) Added)] and cultured at 37 ° C. under 5% CO 2 .
- Confluent cells were washed twice with PBS ( ⁇ ), detached with a cell scraper, and centrifuged at 4 ° C.
- the obtained precipitate was suspended in 20 mM HEPES buffer (pH 7.4), the suspension was homogenized with a Teflon (registered trademark) homogenizer, and then centrifuged at 4 ° C., 48,000 ⁇ g for 20 minutes. By getting sunk again. Further, the resulting precipitate was washed twice by centrifugation and then homogenized with the above buffer solution to obtain a crude membrane fraction. The obtained crude membrane fraction was stored at ⁇ 80 ° C.
- reaction solution was suction filtered onto a Whatman GF / C filter pre-soaked in 20 mM HEPES buffer (pH 7.4), and the filter was ice-cooled 20 mM HEPES buffer (pH 7.4). Washed 3 times with 300 ⁇ L. A scintillation cocktail was added to the obtained filter, and membrane-bound radioactivity was measured with a liquid scintillation counter.
- the amount of [ 35 S] GTP ⁇ S binding when the above reaction was performed in the absence of glutamic acid was defined as non-specific binding, and the difference from the amount of [ 35 S] GTP ⁇ S binding obtained in the presence of glutamic acid was defined as specific binding.
- Inhibition curves were obtained from the specific binding inhibition rates at various concentrations of each Example compound using nonlinear analysis.
- the concentration (IC 50 value) of each Example compound at which the specific [ 35 S] GTP ⁇ S binding amount was suppressed by 50% was calculated from the inhibition curve.
- a compound having an IC 50 value of 0.1 ⁇ M or less is represented by A
- a compound having 0.1 ⁇ M to 1 ⁇ M is represented by B
- a compound having 1 ⁇ M to 10 ⁇ M is represented by C
- a compound having 10 ⁇ M or more is represented by D.
- IC 50 values are exemplified in Table 9.
- the compound of the present invention has an antagonistic action on Group II mGlu receptor, and is a preventive and therapeutic agent for diseases related to Group II mGlu receptor, specifically mood disorders (depressive disorder, bipolar) Disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobia, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, It can be used as a preventive or therapeutic agent for dementia, drug dependence, convulsions, tremors, pain, sleep disorders and the like.
- mood disorders depressive disorder, bipolar) Disorders
- anxiety disorders generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobia, acute stress disorder, etc.
- schizophrenia Alzheimer's disease, cognitive impairment
- It can be used as a preventive or therapeutic agent for dementia, drug dependence, convulsions, tremors, pain, sleep disorders and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A compound represented by formula [I] [wherein R1 represents an alkyl group or the like; R2 represents a hydrogen atom or the like; the ring A represents a phenyl group or the like; R3 represents a hydrogen atom or the like; R4 represents -CONRaRb or the like; Ra and Rb independently represent a hydrogen atom or the like; Y1 represents -(CH2)n-O- or -(CH2)m-; n represents an integer of 1 to 6; m represents an integer of 0 to 6; Y2 represents a heteroaryl group or the like; and Y3 represents a five-membered heteroarylene] or a pharmaceutically acceptable salt thereof, which is a novel compound having an antagonistic activity on group-II metabotropic glutamate (mGlu) receptors or a pharmaceutically acceptable salt thereof and is suitable for a prophylactic or therapeutic agent for diseases including mood disorders (depressionic disorders, bipolar disorders, etc), anxiety disorders (generalized anxiety disorders, panic disorders, obsessive-compulsive disorders, social anxiety disorders, post-traumatic stress disorders, a specific phobia, acute stress disorders, etc), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsion, tremor, pain and sleep disorders which contains the compound or the pharmaceutically acceptable salt thereof as an active ingredient.
Description
本発明は、グループII代謝型グルタミン酸(mGlu)受容体に対して拮抗作用を有する新規な化合物又はその医薬上許容される塩、並びにそれらを有効成分として含有する気分障害(うつ病性障害、双極性障害等)、不安障害(全般性不安障害、パニック障害、強迫性障害、社会不安障害、外傷後ストレス障害、特定の恐怖症、急性ストレス障害等)、統合失調症、アルツハイマー病、認知機能障害、認知症、薬物依存、痙攣、振戦、疼痛、及び睡眠障害等の疾患の予防又は治療剤に関する。
The present invention relates to a novel compound having an antagonistic action on a group II metabotropic glutamate (mGlu) receptor or a pharmaceutically acceptable salt thereof, and a mood disorder (depressive disorder, bipolar) containing them as an active ingredient Sexual disorder), anxiety disorder (generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobia, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment The present invention relates to a preventive or therapeutic agent for diseases such as dementia, drug dependence, convulsions, tremors, pain, and sleep disorders.
グルタミン酸は哺乳類の中枢神経系において記憶・学習などの高次機能を調節する主要な興奮性神経伝達物質の1つとして知られている。グルタミン酸受容体は、イオンチャネル型受容体(ionotropic glutamate receptor:iGlu受容体)と、Gタンパク質共役型受容体(G-protein coupled receptor:GPCR)である代謝型受容体(metabotropic glutamate receptor:mGlu受容体)の2つに大別される。iGlu受容体はそのアゴニスト特異性に基づいてN-メチル-D-アスパラギン酸(N-methyl-D-aspartate: NMDA)受容体、α-アミノ-3-ヒドロキシ-5-メチル-4-イソオキサゾールプロピオン酸(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid:AMPA)受容体及びカイニン酸受容体の3つに分類される。一方、mGlu受容体は8つのサブタイプ(mGlu1~8)が存在し、共役する情報伝達系及び薬理学的特性によりグループI(mGlu1、mGlu5)、グループII(mGlu2、mGlu3)及びグループIII(mGlu4、mGlu6、mGlu7、mGlu8)に分類される。グループII及びグループIII mGlu受容体は主に神経終末で自己受容体或いはヘテロ受容体として発現し、Giタンパク質を介してアデニル酸シクラーゼを抑制し、特定のK+あるいはCa2+チャネル活性を調節している。
Glutamate is known as one of the major excitatory neurotransmitters that regulate higher-order functions such as memory and learning in the mammalian central nervous system. Glutamate receptors are ionotropic receptors (iGlu receptors) and G-protein coupled receptors (GPCRs), which are metabotropic receptors (metabolic glutamate receptors). ) Are roughly divided. iGlu receptor is based on its agonist specificity, N-methyl-D-aspartate (NMDA) receptor, α-amino-3-hydroxy-5-methyl-4-isoxazolepropion There are three types of receptors: acid (α-amino-3-hydroxy-5-methyl-4-isopropylpropionic acid (AMPA)) receptors and kainate receptors. On the other hand, the mGlu receptor has eight subtypes (mGlu1 to 8), and group I (mGlu1, mGlu5), group II (mGlu2, mGlu3) and group III (mGlu4) depend on the signal transduction system and pharmacological properties to be coupled. , MGlu6, mGlu7, mGlu8). Group II and Group III mGlu receptors are expressed primarily as autoreceptors or heteroreceptors at nerve endings, suppress adenylate cyclase through Gi proteins, and regulate specific K + or Ca 2+ channel activity. ing.
近年、気分障害、不安障害及び統合失調症等の精神疾患患者の脳脊髄液中及び血漿中グルタミン酸濃度が変化していることが報告され、精神疾患におけるグルタミン酸神経機能異常が示唆されている。グルタミン酸受容体の中でも、グループII mGlu受容体の拮抗剤は、種々の動物モデルに於いて抗うつ作用・抗不安作用を示すことから(非特許文献1)、グループII mGlu受容体拮抗剤は新規抗うつ薬・抗不安薬になる可能性が示唆されている。さらに、グループII mGlu受容体拮抗剤の認知機能増強剤(認知症、アルツハイマー病)としての効能も示唆されている(非特許文献2)。
Recently, it has been reported that the concentration of glutamate in cerebrospinal fluid and plasma in patients with mental disorders such as mood disorders, anxiety disorders, and schizophrenia has changed, suggesting abnormal glutamate neuronal function in mental disorders. Among the glutamate receptors, Group II mGlu receptor antagonists exhibit antidepressant and anxiolytic effects in various animal models (Non-patent Document 1), so Group II mGlu receptor antagonists are novel. The possibility of becoming an antidepressant and anxiolytic is suggested. Furthermore, the efficacy as a cognitive function enhancer (dementia, Alzheimer's disease) of a group II mGlu receptor antagonist is also suggested (nonpatent literature 2).
最近、グループII mGlu受容体拮抗作用を有する化合物が特許文献1~5等において報告されている。しかしながら、これらの特許文献にはヘテロアリール-ピラゾール骨格を有する化合物についてはなんら開示も示唆もない。
Recently, compounds having group II mGlu receptor antagonistic activity have been reported in Patent Documents 1 to 5 and the like. However, these patent documents do not disclose or suggest any compound having a heteroaryl-pyrazole skeleton.
本発明者らは、下記式[I]で表される化合物又はその医薬上許容される塩が上記課題を解決することを見出し、本発明を完結した。
すなわち、本発明は、
(1)式[I] The present inventors have found that a compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof can solve the above-mentioned problems, and has completed the present invention.
That is, the present invention
(1) Formula [I]
すなわち、本発明は、
(1)式[I] The present inventors have found that a compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof can solve the above-mentioned problems, and has completed the present invention.
That is, the present invention
(1) Formula [I]
R1は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R2は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
環Aは、フェニル基、ヘテロアリール基、インドリン-2-オン-5-イル基、イソインドリン-1-オン-5-イル基、イソインドリン-1-オン-6-イル基、ベンゾ[d]イミダゾール-2-オン-5-イル基又はピリドニル基を示し、
環Aがインドリン-2-オン-5-イル基、イソインドリン-1-オン-5-イル基、イソインドリン-1-オン-6-イル基又はベンゾ[d]イミダゾール-2-オン-5-イル基のとき、
R3及びR4は、同一又は異なって、水素原子、ハロゲン原子又はC1-6アルキル基を示し、
環Aがフェニル基、ヘテロアリール基又はピリドニル基のとき、
R3は、水素原子、ハロゲン原子、C1-6アルコキシ基又はC1-6アルキル基(ここで該C1-6アルコキシ基又はC1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R4は、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc、シアノ基又は水酸基で置換されている。)、-CONRaRb、-O-CONRaRb、-NRa1Rb1、-CORc、シアノ基、-NRdCORe又は-NRdSO2Reを示し、
Ra及びRbは、同一又は異なって、水素原子、C1-6アルキル基
{ここで該C1-6アルキル基は、
水酸基、
ハロゲン原子、
C1-6アルコキシ基
(ここで該C1-6アルコキシ基は、1から2個の水酸基で置換されてもよい。)、
-CONRfRg、
アミノ基、
モノ-C1-6アルキルアミノ基、
ジ-C1-6アルキルアミノ基、
モルホリノ基、
ピペリジノ基、
ピロリジノ基、
アゼチジノ基、
1,3-ジオキソラン-2-イル基、
1,3-ジオキサン-2-イル基、
2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル基及び
5,7-ジオキサスピロ[2.5]オクタン-6-イル基
(ここで該モルホリノ基、ピペリジノ基、ピロリジノ基、アゼチジノ基、1,3-ジオキソラン-2-イル基、1,3-ジオキサン-2-イル基、2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル基及び5,7-ジオキサスピロ[2.5]オクタン-6-イル基
は1から2個のハロゲン原子で置換されてもよい。)
からなる群より選択される1から3個の置換基で置換されてもよい。}、
C1-6アルカノイル基、オキセタニル基、テトラヒドロフラニル基又はテトラヒドロピラニル基を示すか、
又は、Ra及びRbは、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の4から6員環(ここで該飽和又は不飽和の4から6員環は、C1-6アルキル基、オキソ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)を形成してもよく、
Ra1及びRb1は、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の4から6員環(ここで該飽和又は不飽和の4から6員環は、C1-6アルキル基、オキソ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)を形成し、
Rcは、C1-6アルキル基、水酸基又はC1-6アルコキシ基を示し、
Rdは、水素原子又はC1-6アルキル基を示し、
Reは、C1-6アルコキシ基、アミノ基、モノ-C1-6アルキルアミノ基又はジ-C1-6アルキルアミノ基を示し、
Rf及びRgは、同一又は異なって、水素原子又はC1-6アルキル基を示し、
Y1は、-(CH2)n-O-又は-(CH2)m-を示し、
nは、1から6の整数を示し、
mは、0から6の整数を示し、
Y2は、アリール基又はヘテロアリール基{ここで該アリール基又はヘテロアリール基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}を示し、
Y3は、5員ヘテロアリーレンを示す]
で表される化合物又はその医薬上許容される塩、
R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A includes a phenyl group, a heteroaryl group, an indoline-2-one-5-yl group, an isoindoline-1-one-5-yl group, an isoindoline-1-one-6-yl group, a benzo [d] Represents an imidazol-2-one-5-yl group or a pyridonyl group;
Ring A is an indoline-2-one-5-yl group, an isoindoline-1-one-5-yl group, an isoindoline-1-one-6-yl group or a benzo [d] imidazol-2-one-5 When Iru group,
R 3 and R 4 are the same or different and each represents a hydrogen atom, a halogen atom or a C 1-6 alkyl group,
When ring A is a phenyl group, heteroaryl group or pyridonyl group,
R 3 represents a hydrogen atom, a halogen atom, a C 1-6 alkoxy group or a C 1-6 alkyl group (wherein the C 1-6 alkoxy group or C 1-6 alkyl group is substituted with 1 to 3 halogen atoms) May be)
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is —CONR a R b , —COR c , a cyano group or a hydroxyl group) -CONR a R b , —O—CONR a R b , —NR a1 R b1 , —COR c , a cyano group, —NR d COR e or —NR d SO 2 R e ,
R a and R b are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group (wherein the C 1-6 alkyl group is
Hydroxyl group,
A halogen atom,
A C 1-6 alkoxy group (wherein the C 1-6 alkoxy group may be substituted with 1 to 2 hydroxyl groups),
-CONR f R g ,
An amino group,
Mono-C 1-6 alkylamino group,
Di-C 1-6 alkylamino group,
Morpholino groups,
Piperidino group,
Pyrrolidino group,
Azetidino group,
1,3-dioxolan-2-yl group,
1,3-dioxane-2-yl group,
2-oxa-6-azaspiro [3.3] heptan-6-yl group and 5,7-dioxaspiro [2.5] octane-6-yl group (wherein the morpholino group, piperidino group, pyrrolidino group, azetidino group 1,3-dioxolan-2-yl group, 1,3-dioxane-2-yl group, 2-oxa-6-azaspiro [3.3] heptan-6-yl group and 5,7-dioxaspiro [2. 5] The octan-6-yl group may be substituted with 1 to 2 halogen atoms.
May be substituted with 1 to 3 substituents selected from the group consisting of },
A C 1-6 alkanoyl group, an oxetanyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group,
Alternatively, R a and R b are formed together with a nitrogen atom to be bonded, and are a saturated or unsaturated 4- to 6-membered ring (here, which may further contain one or more nitrogen atom, oxygen atom or sulfur atom (wherein The saturated or unsaturated 4- to 6-membered ring may be substituted with 1 to 2 substituents selected from the group consisting of a C 1-6 alkyl group, an oxo group and a hydroxyl group. Well,
R a1 and R b1 are formed together with a nitrogen atom to which they are bonded, and are a saturated or unsaturated 4- to 6-membered ring that may contain one or more nitrogen atoms, oxygen atoms, or sulfur atoms, Or an unsaturated 4- to 6-membered ring may be substituted with 1 to 2 substituents selected from the group consisting of a C 1-6 alkyl group, an oxo group and a hydroxyl group.
R c represents a C 1-6 alkyl group, a hydroxyl group or a C 1-6 alkoxy group,
R d represents a hydrogen atom or a C 1-6 alkyl group,
R e represents a C 1-6 alkoxy group, an amino group, a mono-C 1-6 alkylamino group or a di-C 1-6 alkylamino group,
R f and R g are the same or different and each represents a hydrogen atom or a C 1-6 alkyl group,
Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —,
n represents an integer of 1 to 6,
m represents an integer of 0 to 6,
Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6 alkyl group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom It may be substituted with 3 substituents. },
Y 3 represents a 5-membered heteroarylene]
Or a pharmaceutically acceptable salt thereof,
(2)[式[I]中、
R1は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R2は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
環Aは、フェニル基又はヘテロアリール基を示し、
R3は、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R4は、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc又はシアノ基で置換されている。)、-CONRaRb、-O-CONRaRb、-CORc又はシアノ基を示し、
Ra及びRbは、同一又は異なって、水素原子、C1-6アルキル基、(ここで該C1-6アルキル基はアミノ基、モノ-C1-6アルキルアミノ基、ジ-C1-6アルキルアミノ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)、オキセタニル基、テトラヒドロフラニル基又はテトラヒドロピラニル基を示すか、
又は、Ra及びRbは、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の5又は6員環を形成してもよく、
Rcは、水酸基又はC1-6アルコキシ基を示し、
Y1は、-(CH2)n-O-又は-(CH2)m-を示し、
nは、1から6の整数を示し、
mは、0から6の整数を示し、
Y2は、アリール基又はヘテロアリール基{ここで該アリール基又はヘテロアリール基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}を示し、
Y3は、5員ヘテロアリーレンを示す]
で表される、(1)に記載の化合物又はその医薬上許容される塩、 (2) [In the formula [I],
R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A represents a phenyl group or a heteroaryl group,
R 3 represents a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group). -CONR a R b , -O-CONR a R b , -COR c, or a cyano group,
R a and R b are the same or different and are each a hydrogen atom, a C 1-6 alkyl group, wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.), Represents an oxetanyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group,
Or, R a and R b are formed together with a nitrogen atom to be bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen atom, oxygen atom or sulfur atom. You can,
R c represents a hydroxyl group or a C 1-6 alkoxy group,
Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —,
n represents an integer of 1 to 6,
m represents an integer of 0 to 6,
Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6 alkyl group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom It may be substituted with 3 substituents. },
Y 3 represents a 5-membered heteroarylene]
Or a pharmaceutically acceptable salt thereof according to (1),
R1は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R2は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
環Aは、フェニル基又はヘテロアリール基を示し、
R3は、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R4は、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc又はシアノ基で置換されている。)、-CONRaRb、-O-CONRaRb、-CORc又はシアノ基を示し、
Ra及びRbは、同一又は異なって、水素原子、C1-6アルキル基、(ここで該C1-6アルキル基はアミノ基、モノ-C1-6アルキルアミノ基、ジ-C1-6アルキルアミノ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)、オキセタニル基、テトラヒドロフラニル基又はテトラヒドロピラニル基を示すか、
又は、Ra及びRbは、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の5又は6員環を形成してもよく、
Rcは、水酸基又はC1-6アルコキシ基を示し、
Y1は、-(CH2)n-O-又は-(CH2)m-を示し、
nは、1から6の整数を示し、
mは、0から6の整数を示し、
Y2は、アリール基又はヘテロアリール基{ここで該アリール基又はヘテロアリール基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}を示し、
Y3は、5員ヘテロアリーレンを示す]
で表される、(1)に記載の化合物又はその医薬上許容される塩、 (2) [In the formula [I],
R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A represents a phenyl group or a heteroaryl group,
R 3 represents a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group). -CONR a R b , -O-CONR a R b , -COR c, or a cyano group,
R a and R b are the same or different and are each a hydrogen atom, a C 1-6 alkyl group, wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.), Represents an oxetanyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group,
Or, R a and R b are formed together with a nitrogen atom to be bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen atom, oxygen atom or sulfur atom. You can,
R c represents a hydroxyl group or a C 1-6 alkoxy group,
Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —,
n represents an integer of 1 to 6,
m represents an integer of 0 to 6,
Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6 alkyl group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom It may be substituted with 3 substituents. },
Y 3 represents a 5-membered heteroarylene]
Or a pharmaceutically acceptable salt thereof according to (1),
(3)環Aが、フェニル基又は6員ヘテロアリール基である、(1)又は(2)に記載の化合物又はその医薬上許容される塩、
(4)環Aが、フェニル基又はピリジル基である、(3)に記載の化合物又はその医薬上許容される塩、
(5)Y1が、-CH2-O-である、(1)~(4)のいずれかに記載の化合物又はその医薬上許容される塩、
(6)Y2が、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}である、(1)~(5)のいずれかに記載の化合物又はその医薬上許容される塩、
(7)Y3が、式[II]に示す構造のいずれかである、(1)~(6)のいずれかに記載の化合物又はその医薬上許容される塩、
(8)R3が、水素原子又はハロゲン原子である、(1)~(7)のいずれかに記載の化合物又はその医薬上許容される塩、
(9)(1)~(8)のいずれかに記載の化合物又はその医薬上許容される塩を有効成分として含有する医薬、
(10)グループII代謝型グルタミン酸受容体拮抗物質である、(9)に記載の医薬、及び
(11)(1)~(10)のいずれかに記載の化合物又はその医薬上許容される塩を有効成分とする、気分障害、不安障害、統合失調症、アルツハイマー病、認知機能障害、認知症、薬物依存、痙攣、振戦、疼痛、又は睡眠障害の予防又は治療剤である。 (3) The compound according to (1) or (2) or a pharmaceutically acceptable salt thereof, wherein ring A is a phenyl group or a 6-membered heteroaryl group,
(4) The compound according to (3) or a pharmaceutically acceptable salt thereof, wherein ring A is a phenyl group or a pyridyl group,
(5) The compound or a pharmaceutically acceptable salt thereof according to any one of (1) to (4), wherein Y 1 is —CH 2 —O—,
(6) Y 2 is a phenyl group or a pyridyl group {wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1 -6 alkyl group, C 3-6 cycloalkyl group or C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom To 3 substituents. }, The compound according to any one of (1) to (5) or a pharmaceutically acceptable salt thereof,
(7) The compound or a pharmaceutically acceptable salt thereof according to any one of (1) to (6), wherein Y 3 is any one of the structures shown in formula [II],
(8) The compound or a pharmaceutically acceptable salt thereof according to any one of (1) to (7), wherein R 3 is a hydrogen atom or a halogen atom,
(9) A medicament comprising the compound according to any one of (1) to (8) or a pharmaceutically acceptable salt thereof as an active ingredient,
(10) The pharmaceutical according to (9), which is a group II metabotropic glutamate receptor antagonist, and the compound according to any one of (11) (1) to (10) or a pharmaceutically acceptable salt thereof. It is a preventive or therapeutic agent for mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremor, pain, or sleep disorder as an active ingredient.
(4)環Aが、フェニル基又はピリジル基である、(3)に記載の化合物又はその医薬上許容される塩、
(5)Y1が、-CH2-O-である、(1)~(4)のいずれかに記載の化合物又はその医薬上許容される塩、
(6)Y2が、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}である、(1)~(5)のいずれかに記載の化合物又はその医薬上許容される塩、
(7)Y3が、式[II]に示す構造のいずれかである、(1)~(6)のいずれかに記載の化合物又はその医薬上許容される塩、
(9)(1)~(8)のいずれかに記載の化合物又はその医薬上許容される塩を有効成分として含有する医薬、
(10)グループII代謝型グルタミン酸受容体拮抗物質である、(9)に記載の医薬、及び
(11)(1)~(10)のいずれかに記載の化合物又はその医薬上許容される塩を有効成分とする、気分障害、不安障害、統合失調症、アルツハイマー病、認知機能障害、認知症、薬物依存、痙攣、振戦、疼痛、又は睡眠障害の予防又は治療剤である。 (3) The compound according to (1) or (2) or a pharmaceutically acceptable salt thereof, wherein ring A is a phenyl group or a 6-membered heteroaryl group,
(4) The compound according to (3) or a pharmaceutically acceptable salt thereof, wherein ring A is a phenyl group or a pyridyl group,
(5) The compound or a pharmaceutically acceptable salt thereof according to any one of (1) to (4), wherein Y 1 is —CH 2 —O—,
(6) Y 2 is a phenyl group or a pyridyl group {wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1 -6 alkyl group, C 3-6 cycloalkyl group or C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom To 3 substituents. }, The compound according to any one of (1) to (5) or a pharmaceutically acceptable salt thereof,
(7) The compound or a pharmaceutically acceptable salt thereof according to any one of (1) to (6), wherein Y 3 is any one of the structures shown in formula [II],
(9) A medicament comprising the compound according to any one of (1) to (8) or a pharmaceutically acceptable salt thereof as an active ingredient,
(10) The pharmaceutical according to (9), which is a group II metabotropic glutamate receptor antagonist, and the compound according to any one of (11) (1) to (10) or a pharmaceutically acceptable salt thereof. It is a preventive or therapeutic agent for mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremor, pain, or sleep disorder as an active ingredient.
本発明化合物及びその医薬上許容される塩は、強いグループII mGlu受容体拮抗作用を有することを見出した。
The present compound and pharmaceutically acceptable salts thereof have been found to have strong group II mGlu receptor antagonistic activity.
以下、更に詳細に本発明を説明する。
Hereinafter, the present invention will be described in more detail.
本明細書で用いられている語句について説明する。
Explain the terms used in this specification.
「ハロゲン原子」とは、フッ素原子、塩素原子、臭素原子、ヨウ素原子である。
“Halogen atom” means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
「C1-6アルキル基」とは、直鎖状又は分枝鎖状の炭素原子数1から6個のアルキル基であり、例えば、メチル基、エチル基、プロピル基、ブチル基、ペンチル基、ヘキシル基、イソプロピル基、イソブチル基、tert-ブチル基、sec-ブチル基、イソペンチル基、ネオペンチル基、tert-ペンチル基、1,2-ジメチルプロピル基等が挙げられる。
The “C 1-6 alkyl group” is a linear or branched alkyl group having 1 to 6 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, Examples include hexyl group, isopropyl group, isobutyl group, tert-butyl group, sec-butyl group, isopentyl group, neopentyl group, tert-pentyl group, 1,2-dimethylpropyl group and the like.
「C1-6アルコキシ基」とは、直鎖状又は分枝鎖状の炭素原子数1から6個のアルコキシ基であり、例えば、メトキシ基、エトキシ基、プロポキシ基、ブトキシ基、ペンチルオキシ基、ヘキシルオキシ基、イソプロポキシ基、イソブトキシ基、tert-ブトキシ基、sec-ブトキシ基、イソペンチルオキシ基、ネオペンチルオキシ基、tert-ペンチルオキシ基、1,2-ジメチルプロポキシ基等が挙げられる。
The “C 1-6 alkoxy group” is a linear or branched alkoxy group having 1 to 6 carbon atoms, such as a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentyloxy group. Hexyloxy group, isopropoxy group, isobutoxy group, tert-butoxy group, sec-butoxy group, isopentyloxy group, neopentyloxy group, tert-pentyloxy group, 1,2-dimethylpropoxy group and the like.
「モノ-C1-6アルキルアミノ基」とは、1個のC1-6アルキル基で置換されたアミノ基であり、例えば、メチルアミノ基、エチルアミノ基、プロピルアミノ基、ブチルアミノ基、ペンチルアミノ基、ヘキシルアミノ基、イソプロピルアミノ基、イソブチルアミノ基、tert-ブチルアミノ基、sec-ブチルアミノ基、イソペンチルアミノ基、ネオペンチルアミノ基、tert-ペンチルアミノ基、1,2-ジメチルプロピルアミノ基等が挙げられる。
The “mono-C 1-6 alkylamino group” is an amino group substituted with one C 1-6 alkyl group, and examples thereof include a methylamino group, an ethylamino group, a propylamino group, a butylamino group, Pentylamino group, hexylamino group, isopropylamino group, isobutylamino group, tert-butylamino group, sec-butylamino group, isopentylamino group, neopentylamino group, tert-pentylamino group, 1,2-dimethylpropyl An amino group etc. are mentioned.
「ジ-C1-6アルキルアミノ基」とは、それぞれ独立した2個のC1-6アルキル基で置換されたアミノ基であり、例えば、ジメチルアミノ基、ジエチルアミノ基、ジプロピルアミノ基、ジブチルアミノ基、ジペンチルアミノ基、ジヘキシルアミノ基、ジイソプロピルアミノ基、ジイソブチルアミノ基、ジ-tert-ブチルアミノ基、ジ-sec-ブチルアミノ基、ジ-イソペンチルアミノ基、ジ-ネオペンチルアミノ基、ジ-tert-ペンチルアミノ基、ジ-1,2-ジメチルプロピルアミノ基、エチルメチルアミノ基、イソプロピルメチルアミノ基、イソブチルイソプロピルアミノ基等が挙げられる。
The “di-C 1-6 alkylamino group” is an amino group substituted with two independent C 1-6 alkyl groups, such as a dimethylamino group, a diethylamino group, a dipropylamino group, a dibutyl group. Amino group, dipentylamino group, dihexylamino group, diisopropylamino group, diisobutylamino group, di-tert-butylamino group, di-sec-butylamino group, di-isopentylamino group, di-neopentylamino group, di- -Tert-pentylamino group, di-1,2-dimethylpropylamino group, ethylmethylamino group, isopropylmethylamino group, isobutylisopropylamino group and the like.
「C1-6アルカノイル基」とは、直鎖状又は分枝鎖状の炭素原子数1から6個のアルカノイル基であり、例えば、ホルミル基、アセチル基、プロピオニル基、ブチリル基、イソブチリル基、バレリル基、ヘキサノイル基、ピバロイル基等が挙げられる。
The “C 1-6 alkanoyl group” is a linear or branched alkanoyl group having 1 to 6 carbon atoms, such as formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, A valeryl group, a hexanoyl group, a pivaloyl group, etc. are mentioned.
「アリール基」とは、炭素原子数6から18個で構成される単環から4環式の芳香族炭素環式基であり、例えば、フェニル基、ナフチル基、アントリル基、フェナントリル基、テトラセニル基、ピレニル基等が挙げられる。
The “aryl group” is a monocyclic to tetracyclic aromatic carbocyclic group composed of 6 to 18 carbon atoms, such as a phenyl group, a naphthyl group, an anthryl group, a phenanthryl group, a tetracenyl group. And pyrenyl group.
「ヘテロアリール基」とは、単環式又は縮合環式芳香族複素環基を意味し、例えば、ピリジル基、ピリダジニル基、ピリミジニル基、ピラジニル基、チエニル基、ピロリル基、チアゾリル基、イソチアゾリル基、ピラゾリル基、イミダゾリル基、フリル基、オキサゾリル基、イソオキサゾリル基、オキサジアゾリル基、1,3,4-チアジアゾリル基、1,2,3-トリアゾリル基、1,2,4-トリアゾリル基、テトラゾリル基、キノリル基、イソキノリル基、ナフチリジニル基、キナゾリニル基、ベンゾフラニル基、ベンゾチエニル基、インドリル基、ベンゾオキサゾリル基、ベンゾイソオキサゾリル基、1H-インダゾリル基、2H-インダゾリル基、ベンゾイミダゾリル基、ベンゾオキサジアゾリル基、ベンゾチアジアゾリル基、インドリジニル基、ベンゾフラザニル基、チエノピリジル基、ピラゾロピリジル基、イミダゾピリジル基、イミダゾピラジニル基、ピラゾロピリミジニル基、トリアゾロピリミジニル基、チエノチエニル基、イミダゾチアゾリル基等が挙げられる。
`` Heteroaryl group '' means a monocyclic or fused-ring aromatic heterocyclic group, for example, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, thienyl group, pyrrolyl group, thiazolyl group, isothiazolyl group, Pyrazolyl group, imidazolyl group, furyl group, oxazolyl group, isoxazolyl group, oxadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,3-triazolyl group, 1,2,4-triazolyl group, tetrazolyl group, quinolyl group , Isoquinolyl group, naphthyridinyl group, quinazolinyl group, benzofuranyl group, benzothienyl group, indolyl group, benzoxazolyl group, benzisoxazolyl group, 1H-indazolyl group, 2H-indazolyl group, benzoimidazolyl group, benzooxadiazolyl group Group, benzothiadiazolyl group, Ndorijiniru group, benzofurazanyl group, thienopyridyl group, pyrazolopyridyl group, imidazopyridyl group, imidazopyrazinyl group, pyrazolopyrimidinyl group, triazolopyrimidinyl group, thienothienyl group, imidazothiazolyl group, and the like.
「6員ヘテロアリール基」とは、6員環式芳香族複素環基を意味し、例えば、ピリジル基、ピリダジニル基、ピリミジニル基、ピラジニル基等が挙げられる。
“6-membered heteroaryl group” means a 6-membered aromatic heterocyclic group, and examples thereof include a pyridyl group, a pyridazinyl group, a pyrimidinyl group, and a pyrazinyl group.
「5員ヘテロアリール基」とは、5員環式芳香族複素環基を意味し、例えば、チエニル基、ピロリル基、チアゾリル基、イソチアゾリル基、ピラゾリル基、イミダゾリル基、フリル基、オキサゾリル基、イソオキサゾリル基、オキサジアゾリル基、1,3,4-チアジアゾリル基、1,2,3-トリアゾリル基、1,2,4-トリアゾリル基、テトラゾリル基等が挙げられる。
The “5-membered heteroaryl group” means a 5-membered aromatic heterocyclic group such as thienyl group, pyrrolyl group, thiazolyl group, isothiazolyl group, pyrazolyl group, imidazolyl group, furyl group, oxazolyl group, isoxazolyl group. Group, oxadiazolyl group, 1,3,4-thiadiazolyl group, 1,2,3-triazolyl group, 1,2,4-triazolyl group, tetrazolyl group and the like.
「C3-6シクロアルキル基」とは、炭素原子数3から6個のシクロアルキル基を示し、シクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基を意味する。
The “C 3-6 cycloalkyl group” means a cycloalkyl group having 3 to 6 carbon atoms, and means a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.
「5員ヘテロアリーレン」とは、前記の「5員のヘテロアリール基」から更に任意の1個の水素原子を除いてできる2価基を意味する。
“5-membered heteroarylene” means a divalent group formed by removing any one hydrogen atom from the above-mentioned “5-membered heteroaryl group”.
「結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の5又は6員環」とは、例えば、ピロリジノ基、ピペリジノ基、ピペラジノ基、モルホリノ基、チオモルホリノ基、1,2,3,6-テトラヒドロピリジン-1-イル基、等が挙げられる。
「結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の4から6員環」とは、例えば、アゼチジノ基、ピロリジノ基、ピペリジノ基、ピペラジノ基、モルホリノ基、チオモルホリノ基、1,2,3,6-テトラヒドロピリジン-1-イル基等が挙げられる。 “Saturated or unsaturated 5- or 6-membered ring which is formed together with the nitrogen atom to be bonded and may further contain one or more nitrogen atom, oxygen atom or sulfur atom” means, for example, pyrrolidino group, piperidino group A piperazino group, a morpholino group, a thiomorpholino group, a 1,2,3,6-tetrahydropyridin-1-yl group, and the like.
“Saturated or unsaturated 4- to 6-membered ring which is formed together with the nitrogen atom to be bonded and may further contain one or more nitrogen atom, oxygen atom or sulfur atom” means, for example, an azetidino group, a pyrrolidino group And piperidino group, piperazino group, morpholino group, thiomorpholino group, 1,2,3,6-tetrahydropyridin-1-yl group and the like.
「結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の4から6員環」とは、例えば、アゼチジノ基、ピロリジノ基、ピペリジノ基、ピペラジノ基、モルホリノ基、チオモルホリノ基、1,2,3,6-テトラヒドロピリジン-1-イル基等が挙げられる。 “Saturated or unsaturated 5- or 6-membered ring which is formed together with the nitrogen atom to be bonded and may further contain one or more nitrogen atom, oxygen atom or sulfur atom” means, for example, pyrrolidino group, piperidino group A piperazino group, a morpholino group, a thiomorpholino group, a 1,2,3,6-tetrahydropyridin-1-yl group, and the like.
“Saturated or unsaturated 4- to 6-membered ring which is formed together with the nitrogen atom to be bonded and may further contain one or more nitrogen atom, oxygen atom or sulfur atom” means, for example, an azetidino group, a pyrrolidino group And piperidino group, piperazino group, morpholino group, thiomorpholino group, 1,2,3,6-tetrahydropyridin-1-yl group and the like.
「C1-6アルキレン」とは、前記の「C1-6アルキル基」から更に任意の1個の水素原子を除いてできる2価基を意味する。
“C 1-6 alkylene” means a divalent group formed by removing any one hydrogen atom from the above “C 1-6 alkyl group”.
「C1-6オキシアルキレン」とは、前記の「C1-6アルコキシ基」から更に任意の1個の水素原子を除いてできる2価基を意味する。
“C 1-6 oxyalkylene” means a divalent group formed by removing any one hydrogen atom from the “C 1-6 alkoxy group”.
本発明化合物の好ましい形態は以下の通りである。
式[I]において、
好ましいR1は、水素原子又はC1-6アルキル基であり、さらに好ましくはC1-6アルキル基である。特に好ましいR1は、メチル基である。
好ましいR2は、水素原子である。
好ましい環Aは、フェニル基又は6員ヘテロアリール基であり、さらに好ましくはフェニル基又はピリジル基である。
好ましいR3は、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、さらに好ましくは水素原子又はハロゲン原子である。
好ましいR4は、C1-3アルキル基、C1-3アルコキシ基(ここで該C1-3アルキル基又はC1-3アルコキシ基は、-CONRaRb、又は水酸基で置換されている。)、-CONRaRb、-NRdCORe又は-NRdSO2Reである(ここでRa、Rb、Rc、Rd及びReは前記と同義である。)。
好ましいY1は、-CH2-O-である。
好ましいY2は、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}である。
好ましいY3は、式[II]に示す構造のいずれかである
Preferred forms of the compound of the present invention are as follows.
In the formula [I],
R 1 is preferably a hydrogen atom or a C 1-6 alkyl group, more preferably a C 1-6 alkyl group. Particularly preferred R 1 is a methyl group.
Preferable R 2 is a hydrogen atom.
Preferred ring A is a phenyl group or a 6-membered heteroaryl group, more preferably a phenyl group or a pyridyl group.
R 3 is preferably a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms), more preferably a hydrogen atom. An atom or a halogen atom.
Preferred R 4 is a C 1-3 alkyl group, a C 1-3 alkoxy group (wherein the C 1-3 alkyl group or C 1-3 alkoxy group is substituted with —CONR a R b , or a hydroxyl group. ), —CONR a R b , —NR d COR e or —NR d SO 2 R e (wherein R a , R b , R c , R d and R e are as defined above).
Preferred Y 1 is —CH 2 —O—.
Y 2 is preferably a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 The alkyl group, C 3-6 cycloalkyl group or C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.) 1 to 3 selected from the group consisting of a cyano group and a halogen atom May be substituted with one substituent. }.
Preferred Y 3 is any of the structures shown in formula [II]
式[I]において、
好ましいR1は、水素原子又はC1-6アルキル基であり、さらに好ましくはC1-6アルキル基である。特に好ましいR1は、メチル基である。
好ましいR2は、水素原子である。
好ましい環Aは、フェニル基又は6員ヘテロアリール基であり、さらに好ましくはフェニル基又はピリジル基である。
好ましいR3は、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、さらに好ましくは水素原子又はハロゲン原子である。
好ましいR4は、C1-3アルキル基、C1-3アルコキシ基(ここで該C1-3アルキル基又はC1-3アルコキシ基は、-CONRaRb、又は水酸基で置換されている。)、-CONRaRb、-NRdCORe又は-NRdSO2Reである(ここでRa、Rb、Rc、Rd及びReは前記と同義である。)。
好ましいY1は、-CH2-O-である。
好ましいY2は、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}である。
好ましいY3は、式[II]に示す構造のいずれかである
In the formula [I],
R 1 is preferably a hydrogen atom or a C 1-6 alkyl group, more preferably a C 1-6 alkyl group. Particularly preferred R 1 is a methyl group.
Preferable R 2 is a hydrogen atom.
Preferred ring A is a phenyl group or a 6-membered heteroaryl group, more preferably a phenyl group or a pyridyl group.
R 3 is preferably a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms), more preferably a hydrogen atom. An atom or a halogen atom.
Preferred R 4 is a C 1-3 alkyl group, a C 1-3 alkoxy group (wherein the C 1-3 alkyl group or C 1-3 alkoxy group is substituted with —CONR a R b , or a hydroxyl group. ), —CONR a R b , —NR d COR e or —NR d SO 2 R e (wherein R a , R b , R c , R d and R e are as defined above).
Preferred Y 1 is —CH 2 —O—.
Y 2 is preferably a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 The alkyl group, C 3-6 cycloalkyl group or C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.) 1 to 3 selected from the group consisting of a cyano group and a halogen atom May be substituted with one substituent. }.
Preferred Y 3 is any of the structures shown in formula [II]
式[I]における1つの好ましい形態は、
R1が、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、
R2が、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、
環Aが、フェニル基又は6員ヘテロアリール基であり、
R3が、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、
R4が、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc又はシアノ基で置換されている。)、-CONRaRb、-O-CONRaRb、-CORc又はシアノ基であり、
Ra及びRbが、同一又は異なって、水素原子、C1-6アルキル基、(ここで該C1-6アルキル基はアミノ基、モノ-C1-6アルキルアミノ基、ジ-C1-6アルキルアミノ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)又は4~6員の環状エーテル基であり、
又は、Ra及びRbが、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の5又は6員環を形成してもよく、
Rcが、水酸基又はC1-6アルコキシ基であり、
Y1が、-CH2-O-であり、
Y2が、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}であり、
Y3が、5員ヘテロアリーレンである。 One preferred form in formula [I] is
R 1 is a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 is a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A is a phenyl group or a 6-membered heteroaryl group,
R 3 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group). -CONR a R b , -O-CONR a R b , -COR c or a cyano group,
R a and R b are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group (wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.) Or a 4-6 membered cyclic ether group,
Or, R a and R b are formed together with the nitrogen atom to which they are bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen, oxygen or sulfur atoms. You can,
R c is a hydroxyl group or a C 1-6 alkoxy group,
Y 1 is —CH 2 —O—,
Y 2 is a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl is Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 to 3 selected from the group consisting of a cyano group and a halogen atom It may be substituted with a substituent. },
Y 3 is a 5-membered heteroarylene.
R1が、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、
R2が、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、
環Aが、フェニル基又は6員ヘテロアリール基であり、
R3が、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)であり、
R4が、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc又はシアノ基で置換されている。)、-CONRaRb、-O-CONRaRb、-CORc又はシアノ基であり、
Ra及びRbが、同一又は異なって、水素原子、C1-6アルキル基、(ここで該C1-6アルキル基はアミノ基、モノ-C1-6アルキルアミノ基、ジ-C1-6アルキルアミノ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)又は4~6員の環状エーテル基であり、
又は、Ra及びRbが、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の5又は6員環を形成してもよく、
Rcが、水酸基又はC1-6アルコキシ基であり、
Y1が、-CH2-O-であり、
Y2が、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}であり、
Y3が、5員ヘテロアリーレンである。 One preferred form in formula [I] is
R 1 is a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 is a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A is a phenyl group or a 6-membered heteroaryl group,
R 3 is a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group). -CONR a R b , -O-CONR a R b , -COR c or a cyano group,
R a and R b are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group (wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.) Or a 4-6 membered cyclic ether group,
Or, R a and R b are formed together with the nitrogen atom to which they are bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen, oxygen or sulfur atoms. You can,
R c is a hydroxyl group or a C 1-6 alkoxy group,
Y 1 is —CH 2 —O—,
Y 2 is a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl is Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 to 3 selected from the group consisting of a cyano group and a halogen atom It may be substituted with a substituent. },
Y 3 is a 5-membered heteroarylene.
式[I]における、他の1つの好ましい形態は、下記式[III]で表される化合物である。
(式中、環A、R3、R4及びY2は前記と同義である。)
Another preferred form in the formula [I] is a compound represented by the following formula [III].
(In the formula, ring A, R 3 , R 4 and Y 2 are as defined above.)
式[I]における、他の1つの好ましい形態は、下記式[IV]で表される化合物である。
(式中、環A、R3、R4及びY2は前記と同義である。)
Another preferred form in the formula [I] is a compound represented by the following formula [IV].
(In the formula, ring A, R 3 , R 4 and Y 2 are as defined above.)
本発明化合物には互変異性体、幾何異性体等の立体異性体及び光学異性体が存在しうるが、本発明はそれらも包含する。また、発明化合物及びその塩の各種水和物、溶媒和物及び結晶多形の物質をも包含する。さらに、本発明化合物[I]は同位元素(例えば、D、3H、13C、14C、15N、31P、32P、35S、18F、125I等)で標識されていてもよい。
The compound of the present invention may have stereoisomers such as tautomers and geometric isomers, and optical isomers, and the present invention includes these isomers. Also included are various hydrates, solvates and polymorphic substances of the inventive compounds and their salts. Furthermore, the compound [I] of the present invention may be labeled with an isotope (eg, D, 3 H, 13 C, 14 C, 15 N, 31 P, 32 P, 35 S, 18 F, 125 I, etc.). Good.
本発明において、医薬上許容される塩とは、薬剤的に許容することのできる塩を意味する。それらは例えば、酢酸、プロピオン酸、酪酸、ギ酸、トリフルオロ酢酸、マレイン酸、酒石酸、クエン酸、ステアリン酸、コハク酸、エチルコハク酸、マロン酸、ラクトビオン酸、グルコン酸、グルコヘプトン酸、安息香酸、メタンスルホン酸、エタンスルホン酸、2-ヒドロキシエタンスルホン酸、ベンゼンスルホン酸、パラトルエンスルホン酸(トシル酸)、ラウリル硫酸、リンゴ酸、アスパラギン酸、グルタミン酸、アジピン酸、システイン、N-アセチルシステイン、塩酸、臭化水素酸、リン酸、硫酸、ヨウ化水素酸、ニコチン酸、シュウ酸、ピクリン酸、チオシアン酸、ウンデカン酸、アクリル酸ポリマー及びカルボキシビニルポリマー等の酸との塩、リチウム塩、ナトリウム塩、カリウム塩及びカルシウム塩等の無機塩基との塩、モルホリン及びピペリジン等の有機アミン、並びにアミノ酸との塩を挙げることができる。
In the present invention, the pharmaceutically acceptable salt means a pharmaceutically acceptable salt. For example, acetic acid, propionic acid, butyric acid, formic acid, trifluoroacetic acid, maleic acid, tartaric acid, citric acid, stearic acid, succinic acid, ethyl succinic acid, malonic acid, lactobionic acid, gluconic acid, glucoheptonic acid, benzoic acid, methane Sulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, paratoluenesulfonic acid (tosylic acid), lauryl sulfuric acid, malic acid, aspartic acid, glutamic acid, adipic acid, cysteine, N-acetylcysteine, hydrochloric acid, Salts with acids such as hydrobromic acid, phosphoric acid, sulfuric acid, hydroiodic acid, nicotinic acid, oxalic acid, picric acid, thiocyanic acid, undecanoic acid, acrylic acid polymer and carboxyvinyl polymer, lithium salt, sodium salt, Salts with inorganic bases such as potassium and calcium salts Salts with organic amines, as well as amino acids, such as morpholine and piperidine can be exemplified.
本発明化合物[I]又は医薬上許容される塩は、そのまま或いは医薬上許容される担体とともに、自体公知の手段に従って製剤化することができる。医薬上許容される担体としては、製剤素材として慣用の各種有機或いは無機担体物質、例えば、固形製剤における賦形剤(例えば、乳糖、白糖、D-マンニトール、デンプン、コーンスターチ、結晶セルロース、軽質無水ケイ酸等)、滑沢剤(例えば、ステアリング酸マグネシウム、ステアリング酸カルシウム、タルク、コロイドシリカ等)、結合剤(例えば、結晶セルロース、白糖、D-マンニトール、デキストリン、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、デンプン、ショ糖、ゼラチン、メチルセルロース、カルボキシメチルセルロースナトリウム等)、崩壊剤(例えば、デンプン、カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、低置換度ヒドロキシプロピルセルロース等)、又は液状製剤における溶剤(例えば、注射用水、アルコール、プロピレングリコール、マクロゴール、ゴマ油、トウモロコシ油等)、溶解補助剤(例えば、ポリエチレングリコール、プロピレングリコール、D-マンニトール、安息香酸ベンジル、エタノール、トリスアミノメタン、コレステロール、トリエタノールアミン、炭酸ナトリウム、クエン酸ナトリウム等)、懸濁化剤(例えば、ステアリルトリエタノールアミン、ラウリル硫酸ナトリウム、ラウリルアミノプロピオン酸、レシチン、塩化ベンザルコニウム、塩化ベンゼトニウム、モノステアリン酸グリセリン等の界面活性剤、若しくは例えば、ポリビニルアルコール、ポリビニルピロリドン、カルボキシメチルセルロースナトリウム、メチルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルセルロース等の親水性高分子等)、等張化剤(例えば、ブドウ糖、D-ソルビトール、塩化ナトリウム、グリセリン、D-マンニトール等)、緩衝剤(例えば、リン酸塩、酢酸塩、炭酸塩、クエン酸塩等)、無痛化剤(例えば、ベンジルアルコール等)等が挙げられる。また、製剤化の際に、必要に応じて、防腐剤(例えば、パラオキシ安息香酸エステル類、クロロブタノール、ベンジルアルコール、フェネチルアルコール、デヒドロ酢酸、ソルビン酸等)、抗酸化剤(例えば、亜硫酸塩、アスコルビン酸等)、着色剤、甘味剤、吸着剤、湿潤剤等を用いることもできる。
The compound [I] or a pharmaceutically acceptable salt of the present invention can be formulated according to a method known per se as it is or together with a pharmaceutically acceptable carrier. Examples of pharmaceutically acceptable carriers include various organic or inorganic carrier materials commonly used as pharmaceutical materials, such as excipients in solid formulations (eg, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light anhydrous silica Acid), lubricant (eg, magnesium stearate, calcium stearate, talc, colloidal silica), binder (eg, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl) Pyrrolidone, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, etc.), disintegrants (eg starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose Sodium, carboxymethyl starch sodium, low substituted hydroxypropyl cellulose, etc.) or solvents in liquid formulations (eg water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, etc.), solubilizing agents (eg polyethylene glycol) , Propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.), suspending agents (eg, stearyltriethanolamine, sodium lauryl sulfate, lauryl) Surfactants such as aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glyceryl monostearate, or polyvinyl alcohol, polyvinyl Hydrophilic polymers such as redone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, etc.), isotonic agents (eg, glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol, etc.), buffering agents ( For example, phosphates, acetates, carbonates, citrates, etc.), soothing agents (eg, benzyl alcohol, etc.) and the like. In addition, preservatives (for example, paraoxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.), antioxidants (for example, sulfites, Ascorbic acid and the like), colorants, sweeteners, adsorbents, wetting agents and the like can also be used.
本発明化合物[I]又は医薬上許容される塩は、経口的又は非経口的(例えば、静脈、局所、直腸投与等)に投与することができる。その投与剤型は、例えば、錠剤(糖衣錠、フィルムコーティング錠を含む)、散剤、顆粒剤、粉剤、トローチ剤、カプセル剤(ソフトカプセルを含む)、液剤、注射剤(例えば、皮下注射剤、静脈内注射剤、筋肉内注射剤、腹腔内注射剤等)、外用剤(例えば、経鼻投与製剤、経皮製剤、軟膏剤、クリーム剤等)、坐剤(例えば、直腸坐剤、膣坐剤等)、徐放剤(例えば、徐放性マイクロカプセル等)、ペレット、点滴剤等であり、いずれも慣用の製剤技術(例えば、第15改正日本薬局方に記載する方法等)によって製造することができる。
The compound [I] or pharmaceutically acceptable salt of the present invention can be administered orally or parenterally (for example, intravenous, topical, rectal administration, etc.). The dosage form includes, for example, tablets (including sugar-coated tablets and film-coated tablets), powders, granules, powders, troches, capsules (including soft capsules), liquids, injections (for example, subcutaneous injections, intravenous injections) Injections, intramuscular injections, intraperitoneal injections, etc.), external preparations (eg, nasal preparations, transdermal preparations, ointments, creams, etc.), suppositories (eg, rectal suppositories, vaginal suppositories, etc.) ), Sustained-release agents (eg, sustained-release microcapsules, etc.), pellets, infusions, etc., all of which can be produced by conventional formulation techniques (eg, the method described in the 15th revised Japanese Pharmacopoeia, etc.). it can.
本発明化合物[I]又は医薬上許容される塩は、投与対象、投与経路、疾患、患者の年齢、体重及び症状によって適宜選択される。例えば、成人患者を治療する場合、その投与量は1日1~2000 mgであり、この量を1日1回又は数回に分けて投与する。
The compound [I] of the present invention or a pharmaceutically acceptable salt is appropriately selected depending on the administration subject, administration route, disease, patient age, weight and symptoms. For example, when treating an adult patient, the dose is 1 to 2000 mg / day, and this amount is administered once or divided into several times a day.
グループII mGlu受容体拮抗物質を医薬の活性成分として使用する場合、それはヒトだけに使用することを意図するのではなく、ヒト以外のその他の動物(ネコ、イヌ、ウシ、ニワトリ、魚等)にも使用することが可能である。
When Group II mGlu receptor antagonist is used as an active pharmaceutical ingredient, it is not intended for use only in humans, but in other animals other than humans (cats, dogs, cows, chickens, fish, etc.) Can also be used.
本発明化合物及びその医薬上許容される塩は、例えば、以下に示す方法によって合成することができるが、本発明の化合物の製造方法はこれらに限定されるものではない。
The compound of the present invention and a pharmaceutically acceptable salt thereof can be synthesized, for example, by the method shown below, but the production method of the compound of the present invention is not limited thereto.
「不活性溶媒」とは例えば、ベンゼン、トルエン、キシレン、ピリジン等の芳香族系溶媒;ヘキサン、ペンタン、シクロヘキサン等の炭化水素系溶媒;ジクロロメタン、クロロホルム、1,2-ジクロロエタン、四塩化炭素等のハロゲン化炭化水素系溶媒;テトラヒドロフラン、ジエチルエーテル、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル系溶媒;酢酸エチル、ギ酸エチル等のエステル系溶媒;メタノール、エタノール、イソプロピルアルコール、tert-ブチルアルコール、エチレングリコール等のアルコール系溶媒;アセトン、メチルエチルケトン等のケトン系溶媒;N、N-ジメチルホルムアミド、N-メチルピロリドン、N、N-ジメチルアセトアミド等のアミド系溶媒;ジメチルスルホキシド等のスルホキシド系溶媒;アセトニトリル、プロピオニトリル等のニトリル系溶媒及び水であり、並びにこれらの均一系及び不均一系混合溶媒等である。これらの不活性溶媒は当業者に公知である種々の反応条件に応じて適宜選択される。
“Inert solvent” means, for example, aromatic solvents such as benzene, toluene, xylene, pyridine; hydrocarbon solvents such as hexane, pentane, cyclohexane; dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride, etc. Halogenated hydrocarbon solvents; ether solvents such as tetrahydrofuran, diethyl ether, 1,2-dimethoxyethane, 1,4-dioxane; ester solvents such as ethyl acetate and ethyl formate; methanol, ethanol, isopropyl alcohol, tert- Alcohol solvents such as butyl alcohol and ethylene glycol; ketone solvents such as acetone and methyl ethyl ketone; amide solvents such as N, N-dimethylformamide, N-methylpyrrolidone and N, N-dimethylacetamide; sulfos such as dimethyl sulfoxide Sid solvents; acetonitrile, nitriles and water, such as propionitrile, and also these homogeneous and heterogeneous mixed solvents. These inert solvents are appropriately selected according to various reaction conditions known to those skilled in the art.
「塩基」とは例えば、水素化リチウム、水素化ナトリウム、水素化カリウム、水素化カルシウム等のアルカリ金属又はアルカリ土類金属の水素化物;リチウムアミド、ナトリウムアミド、リチウムジイソプロピルアミド、リチウムジシクロヘキシルアミド、リチウムヘキサメチルジシラジド、ナトリウムヘキサメチルジシラジド、カリウムヘキサメチルジシラジド等のアルカリ金属又はアルカリ土類金属のアミド;ナトリウムメトキシド、ナトリウムエトキシド、カリウム tert-ブトキシド等のアルカリ金属又はアルカリ土類金属の低級アルコキシド;ブチルリチウム、sec-ブチルリチウム、tert-ブチルリチウム、メチルリチウム等のアルキルリチウム;水酸化ナトリウム、水酸化カリウム、水酸化リチウム、水酸化バリウム等のアルカリ金属又はアルカリ土類金属の水酸化物;炭酸ナトリウム、炭酸カリウム、炭酸セシウム等のアルカリ金属又はアルカリ土類金属の炭酸塩;炭酸水素ナトリウム、炭酸水素カリウム等のアルカリ金属又はアルカリ土類金属の炭酸水素塩;トリエチルアミン、N-メチルモルホリン、N,N-ジイソプロピルエチルアミン、N,N-ジメチルアニリン等のアミン;フッ化テトラ-n-ブチルアンモニウム、ベンジルトリメチルアンモニウムヒドロキシド等の4級アンモニウム塩;ピリジン、イミダゾール、2,6-ルチジン、1,8-ジアザビシクロ[5.4.0]ウンデカ-7-エン(DBU)、1,5-ジアザビシクロ[4.3.0]ノン-5-エン(DBN)等の塩基性複素環化合物等である。これらの塩基は当業者に公知である種々の反応条件に応じて適宜選択される。
Examples of the “base” include hydrides of alkali metals or alkaline earth metals such as lithium hydride, sodium hydride, potassium hydride, calcium hydride; lithium amide, sodium amide, lithium diisopropylamide, lithium dicyclohexylamide, lithium Alkali metal or alkaline earth metal amides such as hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide; alkali metals such as sodium methoxide, sodium ethoxide, potassium tert-butoxide, or alkaline earth Lower metal alkoxides; alkyl lithiums such as butyl lithium, sec-butyl lithium, tert-butyl lithium, methyl lithium; sodium hydroxide, potassium hydroxide, lithium hydroxide, Bali hydroxide Alkali metal or alkaline earth metal hydroxides such as sodium carbonate; alkaline metal or alkaline earth metal carbonates such as sodium carbonate, potassium carbonate and cesium carbonate; alkali metals or alkaline earth such as sodium hydrogen carbonate and potassium hydrogen carbonate Metal carbonates; amines such as triethylamine, N-methylmorpholine, N, N-diisopropylethylamine, N, N-dimethylaniline; quaternary ammonium such as tetra-n-butylammonium fluoride and benzyltrimethylammonium hydroxide Salt; pyridine, imidazole, 2,6-lutidine, 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU), 1,5-diazabicyclo [4.3.0] non-5-ene And basic heterocyclic compounds such as (DBN). These bases are appropriately selected according to various reaction conditions known to those skilled in the art.
「酸」とは例えば、塩酸、臭化水素酸、硫酸、硝酸、リン酸等の無機酸及びp-トルエンスルホン酸、メタンスルホン酸、トリフルオロ酢酸、蟻酸、酢酸等の有機酸である。これらの酸は当業者に公知である種々の反応条件に応じて適宜選択される。
Examples of the “acid” include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, formic acid and acetic acid. These acids are appropriately selected according to various reaction conditions known to those skilled in the art.
〔製造法1〕
本発明化合物[I-I]は以下の方法にて製造することができる。 [Production method 1]
The compound [II] of the present invention can be produced by the following method.
本発明化合物[I-I]は以下の方法にて製造することができる。 [Production method 1]
The compound [II] of the present invention can be produced by the following method.
式中、環A、R1、R2、R3、R4、Y1及びY2は前記と同義である。R5は、メチル基、エチル基、tert-ブチル基、ベンジル基等のカルボキシ基の保護基{プロテクティブ グループズ イン オーガニック シンセシス(Protective Groups in Organic Synthesis)第4版、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}又は水素原子を示す。
工程1:本発明化合物[I-I]は不活性溶媒中、塩基存在下、R5がカルボキシ基の保護基である化合物(1)と化合物(2)の当業者に公知である縮合反応、続く分子内環化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。或いは、本発明化合物[I-I]は不活性溶媒中、R5が水素原子である化合物(1)と化合物(2)の当業者に公知であるアミド化反応後、続く分子内環化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(1)及び化合物(2)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここでアミド化反応とは、例えば、不活性溶媒中、塩基存在下又は非存在下、O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HATU)、O-(ベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HBTU)、N,N’-ジシクロヘキシルカルボジイミド(DCC)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC・HCl)、ジフェニルホスホリルアジド(DPPA)又はカルボニルジイミダゾール(CDI)等の縮合剤を用いた縮合反応、クロロギ酸エチル、クロロギ酸イソブチル又はトリメチルアセチルクロリド等を用いた混合酸無水物経由の縮合反応、塩化チオニル、塩化オキサリル、1-クロロ-N,N,2-トリメチル-1-プロペニルアミン等を用いた酸ハロゲン化物経由の縮合反応等である。またここで、縮合剤を用いたアミド化反応の際、必要に応じて1-ヒドロキシベンゾトリアゾール(HOBt)、ヒドロキシスクシンイミド(HOSu)等の添加剤を使用することができる。
ここで分子内環化反応とは、例えば、不活性溶媒中、加熱または非加熱条件下、必要に応じて酸又は塩基を用いたアミド化合物の環化反応である。 In the formula, ring A, R 1 , R 2 , R 3 , R 4 , Y 1 and Y 2 are as defined above. R 5 is a protecting group of a carboxy group such as a methyl group, an ethyl group, a tert-butyl group, or a benzyl group {Protective Groups in Organic Synthesis 4th edition, John Wiley & Sons (John Wiley & Sons) Sons, INC.)} Or hydrogen atom.
Step 1: Compound [II] of the present invention is a condensation reaction known to those skilled in the art of Compound (1) and Compound (2) in which R 5 is a protecting group for a carboxy group in an inert solvent in the presence of a base. It can be produced by a subsequent intramolecular cyclization reaction {see Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC.}. Alternatively, the compound [II] of the present invention is obtained by subjecting the compound (1) in which R 5 is a hydrogen atom to an amidation reaction known to those skilled in the art in an inert solvent, followed by the subsequent intramolecular cyclization reaction. {See Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC.}. Here, as the compound (1) and the compound (2), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used. Here, the amidation reaction is, for example, O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro in an inert solvent in the presence or absence of a base. Nium hexafluorophosphoric acid (HATU), O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphoric acid (HBTU), N, N′-dicyclohexylcarbodiimide ( DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC · HCl), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and other condensation reactions, chloroformate Condensation reaction via mixed acid anhydride using ethyl, isobutyl chloroformate or trimethylacetyl chloride, thionyl chloride, chloride A condensation reaction via an acid halide using oxalyl, 1-chloro-N, N, 2-trimethyl-1-propenylamine, and the like. Here, in the amidation reaction using the condensing agent, additives such as 1-hydroxybenzotriazole (HOBt) and hydroxysuccinimide (HOSu) can be used as necessary.
Here, the intramolecular cyclization reaction is, for example, a cyclization reaction of an amide compound using an acid or a base as necessary under heating or non-heating conditions in an inert solvent.
工程1:本発明化合物[I-I]は不活性溶媒中、塩基存在下、R5がカルボキシ基の保護基である化合物(1)と化合物(2)の当業者に公知である縮合反応、続く分子内環化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。或いは、本発明化合物[I-I]は不活性溶媒中、R5が水素原子である化合物(1)と化合物(2)の当業者に公知であるアミド化反応後、続く分子内環化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(1)及び化合物(2)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここでアミド化反応とは、例えば、不活性溶媒中、塩基存在下又は非存在下、O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HATU)、O-(ベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HBTU)、N,N’-ジシクロヘキシルカルボジイミド(DCC)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC・HCl)、ジフェニルホスホリルアジド(DPPA)又はカルボニルジイミダゾール(CDI)等の縮合剤を用いた縮合反応、クロロギ酸エチル、クロロギ酸イソブチル又はトリメチルアセチルクロリド等を用いた混合酸無水物経由の縮合反応、塩化チオニル、塩化オキサリル、1-クロロ-N,N,2-トリメチル-1-プロペニルアミン等を用いた酸ハロゲン化物経由の縮合反応等である。またここで、縮合剤を用いたアミド化反応の際、必要に応じて1-ヒドロキシベンゾトリアゾール(HOBt)、ヒドロキシスクシンイミド(HOSu)等の添加剤を使用することができる。
ここで分子内環化反応とは、例えば、不活性溶媒中、加熱または非加熱条件下、必要に応じて酸又は塩基を用いたアミド化合物の環化反応である。 In the formula, ring A, R 1 , R 2 , R 3 , R 4 , Y 1 and Y 2 are as defined above. R 5 is a protecting group of a carboxy group such as a methyl group, an ethyl group, a tert-butyl group, or a benzyl group {Protective Groups in Organic Synthesis 4th edition, John Wiley & Sons (John Wiley & Sons) Sons, INC.)} Or hydrogen atom.
Step 1: Compound [II] of the present invention is a condensation reaction known to those skilled in the art of Compound (1) and Compound (2) in which R 5 is a protecting group for a carboxy group in an inert solvent in the presence of a base. It can be produced by a subsequent intramolecular cyclization reaction {see Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC.}. Alternatively, the compound [II] of the present invention is obtained by subjecting the compound (1) in which R 5 is a hydrogen atom to an amidation reaction known to those skilled in the art in an inert solvent, followed by the subsequent intramolecular cyclization reaction. {See Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC.}. Here, as the compound (1) and the compound (2), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used. Here, the amidation reaction is, for example, O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro in an inert solvent in the presence or absence of a base. Nium hexafluorophosphoric acid (HATU), O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphoric acid (HBTU), N, N′-dicyclohexylcarbodiimide ( DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC · HCl), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and other condensation reactions, chloroformate Condensation reaction via mixed acid anhydride using ethyl, isobutyl chloroformate or trimethylacetyl chloride, thionyl chloride, chloride A condensation reaction via an acid halide using oxalyl, 1-chloro-N, N, 2-trimethyl-1-propenylamine, and the like. Here, in the amidation reaction using the condensing agent, additives such as 1-hydroxybenzotriazole (HOBt) and hydroxysuccinimide (HOSu) can be used as necessary.
Here, the intramolecular cyclization reaction is, for example, a cyclization reaction of an amide compound using an acid or a base as necessary under heating or non-heating conditions in an inert solvent.
〔製造法2〕
本発明化合物[I-II]は以下の方法にて製造することができる。 [Production method 2]
The compound [I-II] of the present invention can be produced by the following method.
本発明化合物[I-II]は以下の方法にて製造することができる。 [Production method 2]
The compound [I-II] of the present invention can be produced by the following method.
式中、環A、R1、R2、R3、R4、R5、Y1及びY2は前記と同義である。
工程2:化合物(4)は不活性溶媒中、R5が水素原子である化合物(1)と化合物(3)の当業者に公知であるアミド化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(1)及び化合物(3)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここでアミド化反応とは、例えば、不活性溶媒中、塩基存在下又は非存在下、O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HATU)、O-(ベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HBTU)、N,N’-ジシクロヘキシルカルボジイミド(DCC)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC・HCl)、ジフェニルホスホリルアジド(DPPA)又はカルボニルジイミダゾール(CDI)等の縮合剤を用いた縮合反応、クロロギ酸エチル、クロロギ酸イソブチル又はトリメチルアセチルクロリド等を用いた混合酸無水物経由の縮合反応、塩化チオニル、塩化オキサリル、1-クロロ-N,N,2-トリメチル-1-プロペニルアミン等を用いた酸ハロゲン化物経由の縮合反応等である。またここで、縮合剤を用いたアミド化反応の際、必要に応じて1-ヒドロキシベンゾトリアゾール(HOBt)、ヒドロキシスクシンイミド(HOSu)等の添加剤を使用することができる。
工程3:本発明化合物[I-II]は不活性溶媒中、化合物(4)の分子内環化反応により製造することができる。本工程において必要に応じて、例えば、塩化トシル、塩化チオニル、塩化ホスホリル、バージェス試薬(Burgess Reagent){カルバミン酸メチル-N-(トリエチルアンモニウムスルホニル)}等の活性化剤を使用することができる。{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。 In the formula, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are as defined above.
Step 2: Compound (4) can be produced by an amidation reaction known to those skilled in the art of Compound (1) and Compound (3) in which R 5 is a hydrogen atom in an inert solvent {Comprehensive Organic Transformations Second Edition (see John Wiley & Sons, INC., 1999)}. Here, as the compound (1) and the compound (3), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used. Here, the amidation reaction is, for example, O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro in an inert solvent in the presence or absence of a base. Nium hexafluorophosphoric acid (HATU), O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphoric acid (HBTU), N, N′-dicyclohexylcarbodiimide ( DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC · HCl), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and other condensation reactions, chloroformate Condensation reaction via mixed acid anhydride using ethyl, isobutyl chloroformate or trimethylacetyl chloride, thionyl chloride, chloride A condensation reaction via an acid halide using oxalyl, 1-chloro-N, N, 2-trimethyl-1-propenylamine, and the like. Here, in the amidation reaction using the condensing agent, additives such as 1-hydroxybenzotriazole (HOBt) and hydroxysuccinimide (HOSu) can be used as necessary.
Step 3: The compound [I-II] of the present invention can be produced by an intramolecular cyclization reaction of the compound (4) in an inert solvent. In this step, for example, an activator such as tosyl chloride, thionyl chloride, phosphoryl chloride, Burgess Reagent {Methyl-N- (triethylammoniumsulfonyl) carbamate} can be used. {See Comprehensive Organic Transformations Second Edition, 1999, John Wiley & Sons, INC.}.
工程2:化合物(4)は不活性溶媒中、R5が水素原子である化合物(1)と化合物(3)の当業者に公知であるアミド化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(1)及び化合物(3)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここでアミド化反応とは、例えば、不活性溶媒中、塩基存在下又は非存在下、O-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HATU)、O-(ベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HBTU)、N,N’-ジシクロヘキシルカルボジイミド(DCC)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(EDC・HCl)、ジフェニルホスホリルアジド(DPPA)又はカルボニルジイミダゾール(CDI)等の縮合剤を用いた縮合反応、クロロギ酸エチル、クロロギ酸イソブチル又はトリメチルアセチルクロリド等を用いた混合酸無水物経由の縮合反応、塩化チオニル、塩化オキサリル、1-クロロ-N,N,2-トリメチル-1-プロペニルアミン等を用いた酸ハロゲン化物経由の縮合反応等である。またここで、縮合剤を用いたアミド化反応の際、必要に応じて1-ヒドロキシベンゾトリアゾール(HOBt)、ヒドロキシスクシンイミド(HOSu)等の添加剤を使用することができる。
工程3:本発明化合物[I-II]は不活性溶媒中、化合物(4)の分子内環化反応により製造することができる。本工程において必要に応じて、例えば、塩化トシル、塩化チオニル、塩化ホスホリル、バージェス試薬(Burgess Reagent){カルバミン酸メチル-N-(トリエチルアンモニウムスルホニル)}等の活性化剤を使用することができる。{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。 In the formula, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are as defined above.
Step 2: Compound (4) can be produced by an amidation reaction known to those skilled in the art of Compound (1) and Compound (3) in which R 5 is a hydrogen atom in an inert solvent {Comprehensive Organic Transformations Second Edition (see John Wiley & Sons, INC., 1999)}. Here, as the compound (1) and the compound (3), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used. Here, the amidation reaction is, for example, O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′-tetramethyluro in an inert solvent in the presence or absence of a base. Nium hexafluorophosphoric acid (HATU), O- (benzotriazol-1-yl) -N, N, N ′, N′-tetramethyluronium hexafluorophosphoric acid (HBTU), N, N′-dicyclohexylcarbodiimide ( DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDC · HCl), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI), and other condensation reactions, chloroformate Condensation reaction via mixed acid anhydride using ethyl, isobutyl chloroformate or trimethylacetyl chloride, thionyl chloride, chloride A condensation reaction via an acid halide using oxalyl, 1-chloro-N, N, 2-trimethyl-1-propenylamine, and the like. Here, in the amidation reaction using the condensing agent, additives such as 1-hydroxybenzotriazole (HOBt) and hydroxysuccinimide (HOSu) can be used as necessary.
Step 3: The compound [I-II] of the present invention can be produced by an intramolecular cyclization reaction of the compound (4) in an inert solvent. In this step, for example, an activator such as tosyl chloride, thionyl chloride, phosphoryl chloride, Burgess Reagent {Methyl-N- (triethylammoniumsulfonyl) carbamate} can be used. {See Comprehensive Organic Transformations Second Edition, 1999, John Wiley & Sons, INC.}.
また例えば、化合物(4)は以下の方法にて製造することができる。
For example, compound (4) can be produced by the following method.
式中、環A、R1、R2、R3、R4、R5、Y1及びY2は前記と同義である。R6 はメトキシメチル基、トリメチルシリルエトキシメチル基、tert-ブトキシカルボニル基、ベンジルオキシカルボニル基、アセチル基、ベンジル基、トリチル基、メタンスルホニル基、ベンゼンスルホニル基、p-トルエンスルホニル基等のアミノ基の保護基{プロテクティブ グループズ イン オーガニック シンセシス(Protective Groups in Organic Synthesis)第4版、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}又は水素原子を示す。
工程4:化合物(6)は<スキーム2>中の工程2と同様の手法により、R5が水素原子である化合物(1)と化合物(5)から製造することができる。ここでR6がアミノ基の保護基である場合は、化合物(6)は保護基R6を当業者に公知である種々の有機合成手法{プロテクティブ グループズ イン オーガニック シンセシス(Protective Groups in Organic Synthesis)第4版、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}を用いて除去することにより製造することができる。または化合物(6)は不活性溶媒中、R5がカルボキシ基の保護基である化合物(1)とR6が水素原子である化合物(5)の当業者に公知である縮合反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(1)及び化合物(5)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。
工程5:化合物(4)は<スキーム2>中の工程2と同様の手法により、化合物(6)と化合物(7)から製造することができる。ここで化合物(7)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are as defined above. R 6 is an amino group such as methoxymethyl group, trimethylsilylethoxymethyl group, tert-butoxycarbonyl group, benzyloxycarbonyl group, acetyl group, benzyl group, trityl group, methanesulfonyl group, benzenesulfonyl group, p-toluenesulfonyl group, etc. Protective group {see Protective Groups in Organic Synthesis 4th Edition, John Wiley & Sons, INC.} Or hydrogen atom.
Step 4: Compound (6) can be produced from Compound (1) and Compound (5) wherein R 5 is a hydrogen atom by the same method as in Step 2 in <Scheme 2>. Here, when R 6 is an amino-protecting group, compound (6) can be prepared by various organic synthesis methods known to those skilled in the art for protecting group R 6 {Protective Groups in Organic Synthesis). 4th edition, see John Wiley & Sons, Inc.}. Alternatively, compound (6) is produced by a condensation reaction known to those skilled in the art of compound (1) in which R 5 is a protecting group for a carboxy group and compound (5) in which R 6 is a hydrogen atom in an inert solvent. {Comprehensive Organic Transformations Second Edition 1999, see John Wiley & Sons, INC.}. Here, as the compound (1) and the compound (5), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
Step 5: Compound (4) can be produced from compound (6) and compound (7) by the same method as in Step 2 in <Scheme 2>. Here, as the compound (7), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
工程4:化合物(6)は<スキーム2>中の工程2と同様の手法により、R5が水素原子である化合物(1)と化合物(5)から製造することができる。ここでR6がアミノ基の保護基である場合は、化合物(6)は保護基R6を当業者に公知である種々の有機合成手法{プロテクティブ グループズ イン オーガニック シンセシス(Protective Groups in Organic Synthesis)第4版、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}を用いて除去することにより製造することができる。または化合物(6)は不活性溶媒中、R5がカルボキシ基の保護基である化合物(1)とR6が水素原子である化合物(5)の当業者に公知である縮合反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(1)及び化合物(5)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。
工程5:化合物(4)は<スキーム2>中の工程2と同様の手法により、化合物(6)と化合物(7)から製造することができる。ここで化合物(7)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , Y 1 and Y 2 are as defined above. R 6 is an amino group such as methoxymethyl group, trimethylsilylethoxymethyl group, tert-butoxycarbonyl group, benzyloxycarbonyl group, acetyl group, benzyl group, trityl group, methanesulfonyl group, benzenesulfonyl group, p-toluenesulfonyl group, etc. Protective group {see Protective Groups in Organic Synthesis 4th Edition, John Wiley & Sons, INC.} Or hydrogen atom.
Step 4: Compound (6) can be produced from Compound (1) and Compound (5) wherein R 5 is a hydrogen atom by the same method as in Step 2 in <Scheme 2>. Here, when R 6 is an amino-protecting group, compound (6) can be prepared by various organic synthesis methods known to those skilled in the art for protecting group R 6 {Protective Groups in Organic Synthesis). 4th edition, see John Wiley & Sons, Inc.}. Alternatively, compound (6) is produced by a condensation reaction known to those skilled in the art of compound (1) in which R 5 is a protecting group for a carboxy group and compound (5) in which R 6 is a hydrogen atom in an inert solvent. {Comprehensive Organic Transformations Second Edition 1999, see John Wiley & Sons, INC.}. Here, as the compound (1) and the compound (5), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
Step 5: Compound (4) can be produced from compound (6) and compound (7) by the same method as in Step 2 in <Scheme 2>. Here, as the compound (7), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
〔製造法3〕
本発明化合物[I-IV]は以下の方法にて製造することができる。 [Production method 3]
The compound [I-IV] of the present invention can be produced by the following method.
本発明化合物[I-IV]は以下の方法にて製造することができる。 [Production method 3]
The compound [I-IV] of the present invention can be produced by the following method.
式中、環A、R1、R2、R3、Ra、Rb、Y1、Y2及びY3は前記と同義である。R7 は結合手、C1-6アルキレン又はC1-6オキシアルキレンを示す。
工程6:本発明化合物[I-IV]は<スキーム2>中の工程2と同様の手法により、本発明化合物[I-III]と化合物(8)から製造することができる。ここで化合物(8)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, ring A, R 1 , R 2 , R 3 , R a , R b , Y 1 , Y 2 and Y 3 are as defined above. R 7 represents a bond, C 1-6 alkylene or C 1-6 oxyalkylene.
Step 6: Compound [I-IV] of the present invention can be produced from compound [I-III] of the present invention and compound (8) by the same method as in Step 2 in <Scheme 2>. Here, as the compound (8), a commercially available compound, a known compound, or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
工程6:本発明化合物[I-IV]は<スキーム2>中の工程2と同様の手法により、本発明化合物[I-III]と化合物(8)から製造することができる。ここで化合物(8)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, ring A, R 1 , R 2 , R 3 , R a , R b , Y 1 , Y 2 and Y 3 are as defined above. R 7 represents a bond, C 1-6 alkylene or C 1-6 oxyalkylene.
Step 6: Compound [I-IV] of the present invention can be produced from compound [I-III] of the present invention and compound (8) by the same method as in Step 2 in <Scheme 2>. Here, as the compound (8), a commercially available compound, a known compound, or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used.
〔製造法4〕
本発明化合物[I-V]は以下の方法にて製造することができる。 [Production Method 4]
The compound [IV] of the present invention can be produced by the following method.
本発明化合物[I-V]は以下の方法にて製造することができる。 [Production Method 4]
The compound [IV] of the present invention can be produced by the following method.
式中、環A、R1、R2、R3、R7、Ra、Rb、Y1、Y2及びY3は前記と同義である。R8はC1-6アルキレン、R9はC1-6アルキル基を示す。
工程7:本発明化合物[I-V]は、不活性溶媒中、酸及び還元剤存在下、化合物(8)と化合物(9)の当業者に公知である還元的アミノ化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(8)及び化合物(9)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここで酸とは、例えば、塩酸、臭化水素酸、硫酸、硝酸、リン酸等の無機酸及びp-トルエンスルホン酸、メタンスルホン酸、トリフルオロ酢酸、蟻酸、酢酸等の有機酸が挙げられる。また、還元的アミノ化反応で用いる還元剤とは、イミノ基を還元してアミノ基に変換することができる試薬であり、例えば、水素化ホウ素ナトリウム、水素化ホウ素トリアセトキシナトリウム、水素化ホウ素シアノナトリウム、ボラン、ボラン-ピリジン、ボラン-ピコリン等が挙げられる。 In the formula, ring A, R 1 , R 2 , R 3 , R 7 , R a , R b , Y 1 , Y 2 and Y 3 are as defined above. R 8 represents C 1-6 alkylene, and R 9 represents a C 1-6 alkyl group.
Step 7: The compound [IV] of the present invention is produced by a reductive amination reaction known to those skilled in the art of the compound (8) and the compound (9) in the presence of an acid and a reducing agent in an inert solvent. {Comprehensive Organic Transformations Second Edition 1999, see John Wiley & Sons, INC.}. Here, as the compound (8) and the compound (9), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used. Examples of the acid herein include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, formic acid, and acetic acid. . The reducing agent used in the reductive amination reaction is a reagent capable of reducing an imino group to convert it to an amino group. For example, sodium borohydride, sodium triacetoxyborohydride, cyanoborohydride Sodium, borane, borane-pyridine, borane-picoline and the like can be mentioned.
工程7:本発明化合物[I-V]は、不活性溶媒中、酸及び還元剤存在下、化合物(8)と化合物(9)の当業者に公知である還元的アミノ化反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(8)及び化合物(9)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここで酸とは、例えば、塩酸、臭化水素酸、硫酸、硝酸、リン酸等の無機酸及びp-トルエンスルホン酸、メタンスルホン酸、トリフルオロ酢酸、蟻酸、酢酸等の有機酸が挙げられる。また、還元的アミノ化反応で用いる還元剤とは、イミノ基を還元してアミノ基に変換することができる試薬であり、例えば、水素化ホウ素ナトリウム、水素化ホウ素トリアセトキシナトリウム、水素化ホウ素シアノナトリウム、ボラン、ボラン-ピリジン、ボラン-ピコリン等が挙げられる。 In the formula, ring A, R 1 , R 2 , R 3 , R 7 , R a , R b , Y 1 , Y 2 and Y 3 are as defined above. R 8 represents C 1-6 alkylene, and R 9 represents a C 1-6 alkyl group.
Step 7: The compound [IV] of the present invention is produced by a reductive amination reaction known to those skilled in the art of the compound (8) and the compound (9) in the presence of an acid and a reducing agent in an inert solvent. {Comprehensive Organic Transformations Second Edition 1999, see John Wiley & Sons, INC.}. Here, as the compound (8) and the compound (9), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used. Examples of the acid herein include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, formic acid, and acetic acid. . The reducing agent used in the reductive amination reaction is a reagent capable of reducing an imino group to convert it to an amino group. For example, sodium borohydride, sodium triacetoxyborohydride, cyanoborohydride Sodium, borane, borane-pyridine, borane-picoline and the like can be mentioned.
〔製造法5〕
本発明化合物[I-VII]は以下の方法にて製造することができる。 [Production Method 5]
The compound [I-VII] of the present invention can be produced by the following method.
本発明化合物[I-VII]は以下の方法にて製造することができる。 [Production Method 5]
The compound [I-VII] of the present invention can be produced by the following method.
式中、環A、R1、R2、R3、R7、Ra、Rb、Y1、Y2及びY3は前記と同義である。
工程8:本発明化合物[I-VII]は、本発明化合物[I-VI]の当業者に公知である水和反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。 In the formula, rings A, R 1 , R 2 , R 3 , R 7 , R a , R b , Y 1 , Y 2 and Y 3 are as defined above.
Step 8: Compound [I-VII] of the present invention can be produced by a hydration reaction known to those skilled in the art of Compound [I-VI] of the present invention {Comprehensive Organic Transformations Second Edition (Comprehensive Organic Transformations Second Edition) See 1999 John Wiley & Sons, INC.}.
工程8:本発明化合物[I-VII]は、本発明化合物[I-VI]の当業者に公知である水和反応により製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。 In the formula, rings A, R 1 , R 2 , R 3 , R 7 , R a , R b , Y 1 , Y 2 and Y 3 are as defined above.
Step 8: Compound [I-VII] of the present invention can be produced by a hydration reaction known to those skilled in the art of Compound [I-VI] of the present invention {Comprehensive Organic Transformations Second Edition (Comprehensive Organic Transformations Second Edition) See 1999 John Wiley & Sons, INC.}.
例えば、化合物(1)が式(1-1)又は式(1-2)で表される化合物は以下の方法にて製造することができる。
For example, a compound in which compound (1) is represented by formula (1-1) or formula (1-2) can be produced by the following method.
式中、n、R1、R2、R5及びY2は前記と同義である。R10、R10’及びR10’’ は同一又は異なって、水素原子、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子を示し、X1は、塩素原子、臭素原子、ヨウ素原子、フッ素原子を示す。
工程9:化合物(1-1)は不活性溶媒中、化合物(10)と化合物(11)の光延反応により製造することができる。ここで化合物(10)及び化合物(11)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。光延反応とは、例えば、トリフェニルホスフィン、トリブチルホスフィン等の有機リン化合物とアゾジカルボン酸ジエチル、アゾジカルボン酸ジイソプロピル、アゾジカルボン酸ジtertブチル等のアゾ化合物を用いる方法、或いはシアノメチルトリブチルホスホラン等のリンイリド試薬を用いる方法が挙げられる(Chem. Rev. 2009. 109,2551-2651参照)。
工程10:化合物(1-2)は不活性溶媒中、塩基存在下、パラジウム触媒存在下又は非存在下、パラジウム触媒配位子の存在下又は非存在下、化合物(10)と化合物(12)を反応させることにより製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(10)及び化合物(12)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここで塩基とは例えば、炭酸ナトリウム、炭酸カリウム、炭酸セシウム、トリエチルアミン、ジイソプロピルエチルアミン、水素化リチウム、水素化ナトリウム、水素化カリウム、リチウムジイソプロピルアミド、リチウムヘキサメチルジシラジド、ナトリウムヘキサメチルジシラジド、ナトリウムメトキシド、ナトリウムエトキシド、カリウム tert-ブトキシド、ブチルリチウム、sec-ブチルリチウム、tert-ブチルリチウム、メチルリチウム、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等が挙げられる。パラジウム触媒とは例えば、酢酸パラジウム(II)、ジクロロビストリフェニルホスフィンパラジウム(II)、ジクロロビスアセトニトリルパラジウム(II)、テトラキストリフェニルホスフィンパラジウム(0)等が挙げられる。配位子とは例えばrac-2-(ジ-t-ブチルホスフィノ)-1,1'-ビナフチル、トリフェニルホスフィン、トリブチルホスフィン、2,2-ビス(ジフェニルホスフィノ)-1,1-ビナフチル(BINAP)、2-(ジ-tert-ブチルホスフィノ)ビフェニル、1,1'-ビス(ジフェニルホスフィノ)フェロセン(dppf)、1,3-ビス(ジフェニルホスフィノ)プロパン(dppp)等が挙げられる。 In the formula, n, R 1 , R 2 , R 5 and Y 2 are as defined above. R 10 , R 10 ′ and R 10 ″ are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), A cyano group and a halogen atom, and X 1 represents a chlorine atom, bromine An atom, an iodine atom, or a fluorine atom is shown.
Step 9: Compound (1-1) can be produced by Mitsunobu reaction of compound (10) and compound (11) in an inert solvent. Here, as the compound (10) and the compound (11), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used. Mitsunobu reaction is, for example, a method using an organic phosphorus compound such as triphenylphosphine or tributylphosphine and an azo compound such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, ditertbutyl azodicarboxylate, or cyanomethyltributylphosphorane. (See Chem. Rev. 2009. 109, 2551-2651).
Step 10: Compound (1-2) is compound (10) and Compound (12) in an inert solvent in the presence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a palladium catalyst ligand. {See Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC.}. Here, as the compound (10) and the compound (12), a commercially available compound, a known compound, or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used. Examples of the base here include sodium carbonate, potassium carbonate, cesium carbonate, triethylamine, diisopropylethylamine, lithium hydride, sodium hydride, potassium hydride, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide. Sodium methoxide, sodium ethoxide, potassium tert-butoxide, butyl lithium, sec-butyl lithium, tert-butyl lithium, methyl lithium, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like. Examples of the palladium catalyst include palladium acetate (II), dichlorobistriphenylphosphine palladium (II), dichlorobisacetonitrile palladium (II), tetrakistriphenylphosphine palladium (0), and the like. Examples of the ligand include rac-2- (di-t-butylphosphino) -1,1′-binaphthyl, triphenylphosphine, tributylphosphine, 2,2-bis (diphenylphosphino) -1,1-binaphthyl. (BINAP), 2- (di-tert-butylphosphino) biphenyl, 1,1′-bis (diphenylphosphino) ferrocene (dppf), 1,3-bis (diphenylphosphino) propane (dppp), etc. It is done.
工程9:化合物(1-1)は不活性溶媒中、化合物(10)と化合物(11)の光延反応により製造することができる。ここで化合物(10)及び化合物(11)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。光延反応とは、例えば、トリフェニルホスフィン、トリブチルホスフィン等の有機リン化合物とアゾジカルボン酸ジエチル、アゾジカルボン酸ジイソプロピル、アゾジカルボン酸ジtertブチル等のアゾ化合物を用いる方法、或いはシアノメチルトリブチルホスホラン等のリンイリド試薬を用いる方法が挙げられる(Chem. Rev. 2009. 109,2551-2651参照)。
工程10:化合物(1-2)は不活性溶媒中、塩基存在下、パラジウム触媒存在下又は非存在下、パラジウム触媒配位子の存在下又は非存在下、化合物(10)と化合物(12)を反応させることにより製造することができる{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで化合物(10)及び化合物(12)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここで塩基とは例えば、炭酸ナトリウム、炭酸カリウム、炭酸セシウム、トリエチルアミン、ジイソプロピルエチルアミン、水素化リチウム、水素化ナトリウム、水素化カリウム、リチウムジイソプロピルアミド、リチウムヘキサメチルジシラジド、ナトリウムヘキサメチルジシラジド、ナトリウムメトキシド、ナトリウムエトキシド、カリウム tert-ブトキシド、ブチルリチウム、sec-ブチルリチウム、tert-ブチルリチウム、メチルリチウム、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等が挙げられる。パラジウム触媒とは例えば、酢酸パラジウム(II)、ジクロロビストリフェニルホスフィンパラジウム(II)、ジクロロビスアセトニトリルパラジウム(II)、テトラキストリフェニルホスフィンパラジウム(0)等が挙げられる。配位子とは例えばrac-2-(ジ-t-ブチルホスフィノ)-1,1'-ビナフチル、トリフェニルホスフィン、トリブチルホスフィン、2,2-ビス(ジフェニルホスフィノ)-1,1-ビナフチル(BINAP)、2-(ジ-tert-ブチルホスフィノ)ビフェニル、1,1'-ビス(ジフェニルホスフィノ)フェロセン(dppf)、1,3-ビス(ジフェニルホスフィノ)プロパン(dppp)等が挙げられる。 In the formula, n, R 1 , R 2 , R 5 and Y 2 are as defined above. R 10 , R 10 ′ and R 10 ″ are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), A cyano group and a halogen atom, and X 1 represents a chlorine atom, bromine An atom, an iodine atom, or a fluorine atom is shown.
Step 9: Compound (1-1) can be produced by Mitsunobu reaction of compound (10) and compound (11) in an inert solvent. Here, as the compound (10) and the compound (11), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used. Mitsunobu reaction is, for example, a method using an organic phosphorus compound such as triphenylphosphine or tributylphosphine and an azo compound such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, ditertbutyl azodicarboxylate, or cyanomethyltributylphosphorane. (See Chem. Rev. 2009. 109, 2551-2651).
Step 10: Compound (1-2) is compound (10) and Compound (12) in an inert solvent in the presence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a palladium catalyst ligand. {See Comprehensive Organic Transformations Second Edition 1999, John Wiley & Sons, INC.}. Here, as the compound (10) and the compound (12), a commercially available compound, a known compound, or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used. Examples of the base here include sodium carbonate, potassium carbonate, cesium carbonate, triethylamine, diisopropylethylamine, lithium hydride, sodium hydride, potassium hydride, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide. Sodium methoxide, sodium ethoxide, potassium tert-butoxide, butyl lithium, sec-butyl lithium, tert-butyl lithium, methyl lithium, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like. Examples of the palladium catalyst include palladium acetate (II), dichlorobistriphenylphosphine palladium (II), dichlorobisacetonitrile palladium (II), tetrakistriphenylphosphine palladium (0), and the like. Examples of the ligand include rac-2- (di-t-butylphosphino) -1,1′-binaphthyl, triphenylphosphine, tributylphosphine, 2,2-bis (diphenylphosphino) -1,1-binaphthyl. (BINAP), 2- (di-tert-butylphosphino) biphenyl, 1,1′-bis (diphenylphosphino) ferrocene (dppf), 1,3-bis (diphenylphosphino) propane (dppp), etc. It is done.
例えば、化合物(10)が式(10-1)で表される化合物は以下の方法にて製造することができる。
For example, a compound in which compound (10) is represented by formula (10-1) can be produced by the following method.
式中、R1、R2及びR5は前記と同義である。
工程11:化合物(14)は不活性溶媒中、塩基存在下、化合物(13)をN,N-ジメチルホルムアミド等と反応させることにより製造することができる。化合物(13)は市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。
工程12:化合物(10-1)は不活性溶媒中、化合物(14)に対し、還元剤を反応させることにより製造することができる。{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで還元剤とは、ホルミル基を還元して水酸基に変換することができる試薬であり、例えば、水素化ホウ素リチウム、水素化ホウ素ナトリウム、水素化ホウ素カルシウム、水素化ホウ素亜鉛、水素化アルミニウムリチウム、水素化アルミニウムナトリウム、水素化ジイソブチルアルミニウム等が挙げられる。 In the formula, R 1 , R 2 and R 5 are as defined above.
Step 11: Compound (14) can be produced by reacting compound (13) with N, N-dimethylformamide or the like in the presence of a base in an inert solvent. Compound (13) may be a commercially available compound, a known compound, or a compound synthesized from a commercially available compound or a known compound using various organic synthesis methods known to those skilled in the art.
Step 12: Compound (10-1) can be produced by reacting compound (14) with a reducing agent in an inert solvent. {See Comprehensive Organic Transformations Second Edition, 1999, John Wiley & Sons, INC.}. Here, the reducing agent is a reagent that can reduce a formyl group and convert it into a hydroxyl group. For example, lithium borohydride, sodium borohydride, calcium borohydride, zinc borohydride, lithium aluminum hydride , Sodium aluminum hydride, diisobutylaluminum hydride and the like.
工程11:化合物(14)は不活性溶媒中、塩基存在下、化合物(13)をN,N-ジメチルホルムアミド等と反応させることにより製造することができる。化合物(13)は市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。
工程12:化合物(10-1)は不活性溶媒中、化合物(14)に対し、還元剤を反応させることにより製造することができる。{コンプリヘンシブ オーガニック トランスフォーメーションズ セカンド エディション (Comprehensive Organic Transformations Second Edition) 1999年、ジョン ウィリー アンド サンズ(John Wiley & Sons, INC.)参照}。ここで還元剤とは、ホルミル基を還元して水酸基に変換することができる試薬であり、例えば、水素化ホウ素リチウム、水素化ホウ素ナトリウム、水素化ホウ素カルシウム、水素化ホウ素亜鉛、水素化アルミニウムリチウム、水素化アルミニウムナトリウム、水素化ジイソブチルアルミニウム等が挙げられる。 In the formula, R 1 , R 2 and R 5 are as defined above.
Step 11: Compound (14) can be produced by reacting compound (13) with N, N-dimethylformamide or the like in the presence of a base in an inert solvent. Compound (13) may be a commercially available compound, a known compound, or a compound synthesized from a commercially available compound or a known compound using various organic synthesis methods known to those skilled in the art.
Step 12: Compound (10-1) can be produced by reacting compound (14) with a reducing agent in an inert solvent. {See Comprehensive Organic Transformations Second Edition, 1999, John Wiley & Sons, INC.}. Here, the reducing agent is a reagent that can reduce a formyl group and convert it into a hydroxyl group. For example, lithium borohydride, sodium borohydride, calcium borohydride, zinc borohydride, lithium aluminum hydride , Sodium aluminum hydride, diisobutylaluminum hydride and the like.
例えば、化合物(2)は、以下の方法にて製造することができる。
For example, compound (2) can be produced by the following method.
式中、環A、X1、R3及びR4は前記と同義である。
工程13:化合物(16)は不活性溶媒中、塩基存在下又は非存在下、パラジウム触媒存在下又は非存在下、パラジウム触媒配位子の存在下又は非存在下、化合物(15)と適当なシアノ化剤との反応により製造することができる。化合物(15)は市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここで、適当なシアノ化剤とは、例えば、シアン化亜鉛、シアン化銅、シアン化カリウム又はシアン化ナトリウムなどが挙げられる。
工程14:化合物(2)は不活性溶媒中、塩基存在下又は非存在下、化合物(16)とヒドロキシアミン又はその塩の付加反応により製造することができる。化合物(16)は化合物(15)から合成する他に、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, rings A, X 1 , R 3 and R 4 are as defined above.
Step 13: Compound (16) is appropriately combined with Compound (15) in an inert solvent in the presence or absence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a palladium catalyst ligand. It can be produced by reaction with a cyanating agent. As the compound (15), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used. Here, suitable cyanating agents include, for example, zinc cyanide, copper cyanide, potassium cyanide or sodium cyanide.
Step 14: Compound (2) can be produced by addition reaction of compound (16) with hydroxyamine or a salt thereof in an inert solvent in the presence or absence of a base. In addition to the compound (16) synthesized from the compound (15), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
工程13:化合物(16)は不活性溶媒中、塩基存在下又は非存在下、パラジウム触媒存在下又は非存在下、パラジウム触媒配位子の存在下又は非存在下、化合物(15)と適当なシアノ化剤との反応により製造することができる。化合物(15)は市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。ここで、適当なシアノ化剤とは、例えば、シアン化亜鉛、シアン化銅、シアン化カリウム又はシアン化ナトリウムなどが挙げられる。
工程14:化合物(2)は不活性溶媒中、塩基存在下又は非存在下、化合物(16)とヒドロキシアミン又はその塩の付加反応により製造することができる。化合物(16)は化合物(15)から合成する他に、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, rings A, X 1 , R 3 and R 4 are as defined above.
Step 13: Compound (16) is appropriately combined with Compound (15) in an inert solvent in the presence or absence of a base, in the presence or absence of a palladium catalyst, in the presence or absence of a palladium catalyst ligand. It can be produced by reaction with a cyanating agent. As the compound (15), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis methods known to those skilled in the art can be used. Here, suitable cyanating agents include, for example, zinc cyanide, copper cyanide, potassium cyanide or sodium cyanide.
Step 14: Compound (2) can be produced by addition reaction of compound (16) with hydroxyamine or a salt thereof in an inert solvent in the presence or absence of a base. In addition to the compound (16) synthesized from the compound (15), a commercially available compound, a known compound or a compound synthesized from a known compound using various organic synthesis techniques known to those skilled in the art can be used.
例えば、化合物(3)は、以下の方法にて製造することができる。
For example, compound (3) can be produced by the following method.
式中、環A、R3、R4、R5及びR6は前記と同義である。
工程15:化合物(3)は<スキーム3>中の工程4と同様の手法により、化合物(17)と化合物(5)から製造することができる。ここで化合物(17)及び化合物(5)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, rings A, R 3 , R 4 , R 5 and R 6 are as defined above.
Step 15: Compound (3) can be produced from compound (17) and compound (5) by the same method as in Step 4 in <Scheme 3>. Here, as the compound (17) and the compound (5), a commercially available compound, a known compound or a compound synthesized from a known compound by using various organic synthesis methods known to those skilled in the art can be used.
工程15:化合物(3)は<スキーム3>中の工程4と同様の手法により、化合物(17)と化合物(5)から製造することができる。ここで化合物(17)及び化合物(5)は、市販化合物、公知化合物或いは当業者に公知である種々の有機合成手法を用いて市販化合物又は公知化合物より合成した化合物を用いることができる。 In the formula, rings A, R 3 , R 4 , R 5 and R 6 are as defined above.
Step 15: Compound (3) can be produced from compound (17) and compound (5) by the same method as in Step 4 in <Scheme 3>. Here, as the compound (17) and the compound (5), a commercially available compound, a known compound or a compound synthesized from a known compound by using various organic synthesis methods known to those skilled in the art can be used.
次に、製造例、実施例及び試験例により本発明をさらに詳細に説明するが、本発明はこれらの製造例、実施例及び試験例に限定されるものではなく、また、本発明の範囲を逸脱しない範囲で変化させてもよい。
Next, the present invention will be described in more detail with reference to production examples, examples and test examples. However, the present invention is not limited to these production examples, examples and test examples, and the scope of the present invention is not limited thereto. You may change in the range which does not deviate.
製造例及び実施例中で、カラムクロマトグラフィーを使用して精製した際の「NHシリカゲルカートリッジ」にはバイオタージ社製Biotage(登録商標)SNAPCartridge KP-NH、「シリカゲルカートリッジ」にはバイオタージ社製Biotage(登録商標)SNAPCartridge KP-Sil及びHP-Sil、「シリカゲル 60 N」には関東化学社製シリカゲル 60 N、「クロマトレックスNH」には富士シリシア化学社製クロマトレックス(登録商標)NHをそれぞれ市販されているものを使用した。逆相カラムクロマトグラフィーを使用して精製した際の「CAPCELL PAK」には資生堂社製のCAPCELL PAK(登録商標)C18 TYPE MGIIを使用した。TLCを使用して精製した際のTLC(シリカゲルプレート)にはSilica gel 60F254(メルク)、TLC(NHシリカゲルプレート)にはTLCプレートNH(Fuji Silysia)を使用した。
In the production examples and examples, Biotage (registered trademark) SNAP cartridge KP-NH manufactured by Biotage was used for “NH silica gel cartridge” when purified using column chromatography, and Biotage was manufactured for “silica gel cartridge”. Biotage (registered trademark) SNAPCartridge KP-Sil and HP-Sil, "Silica gel 60 N" is silica gel 60 N manufactured by Kanto Chemical Co., and "Chromatolex NH" is Chromatrex (registered trademark) NH manufactured by Fuji Silysia Chemical Ltd. A commercially available product was used. CAPCELL PAK (registered trademark) C18 TYPE MGII manufactured by Shiseido Co., Ltd. was used for “CAPCELL PAK” when purified using reverse phase column chromatography. Silica gel 60F254 (Merck) was used for TLC (silica gel plate) when purified using TLC, and TLC plate NH (Fuji Silysia) was used for TLC (NH silica gel plate).
製造例及び実施例中記載の各機器データは以下の測定機器で測定した。
マイクロウェーブ反応装置:Initiator(Biotage AB)
LCMSスペクトル:島津LCMS-IT-TOF、島津LCMS-2010EV、micromass Platform LC、micromass GCT、Agilent 6150、Agilent 1290Infinity及びAgilent1100
NMRスペクトル:[1H-NMR]600MHz:JNM-ECA600(日本電子)、500MHz:JNM-ECA500(日本電子)、300MHz:UNITYNOVA300(Varian Inc.)、200MHz:GEMINI2000/200(Varian Inc.)
製造例及び実施例中の化合物名はACD/Name (ACD/Labs 12.0, Advanced Chemistry Development Inc.)により命名した。 Each instrument data described in the production examples and examples was measured with the following measuring instruments.
Microwave reactor: Initiator (Biotage AB)
LCMS spectrum: Shimadzu LCMS-IT-TOF, Shimadzu LCMS-2010EV, micromass platform LC, micromass GCT, Agilent 6150, Agilent 1290 Infinity and Agilent 1100
NMR spectrum: [ 1 H-NMR] 600 MHz: JNM-ECA600 (JEOL), 500 MHz: JNM-ECA500 (JEOL), 300 MHz: UNITYNOVA300 (Varian Inc.), 200 MHz: GEMINI 2000/200 (Varian Inc.)
The compound name in a manufacture example and an Example was named by ACD / Name (ACD / Labs 12.0, Advanced Chemistry Development Inc.).
マイクロウェーブ反応装置:Initiator(Biotage AB)
LCMSスペクトル:島津LCMS-IT-TOF、島津LCMS-2010EV、micromass Platform LC、micromass GCT、Agilent 6150、Agilent 1290Infinity及びAgilent1100
NMRスペクトル:[1H-NMR]600MHz:JNM-ECA600(日本電子)、500MHz:JNM-ECA500(日本電子)、300MHz:UNITYNOVA300(Varian Inc.)、200MHz:GEMINI2000/200(Varian Inc.)
製造例及び実施例中の化合物名はACD/Name (ACD/Labs 12.0, Advanced Chemistry Development Inc.)により命名した。 Each instrument data described in the production examples and examples was measured with the following measuring instruments.
Microwave reactor: Initiator (Biotage AB)
LCMS spectrum: Shimadzu LCMS-IT-TOF, Shimadzu LCMS-2010EV, micromass platform LC, micromass GCT, Agilent 6150, Agilent 1290 Infinity and Agilent 1100
NMR spectrum: [ 1 H-NMR] 600 MHz: JNM-ECA600 (JEOL), 500 MHz: JNM-ECA500 (JEOL), 300 MHz: UNITYNOVA300 (Varian Inc.), 200 MHz: GEMINI 2000/200 (Varian Inc.)
The compound name in a manufacture example and an Example was named by ACD / Name (ACD / Labs 12.0, Advanced Chemistry Development Inc.).
製造例及び実施例中のLCMSのRT(保持時間)は以下に示す何れかの条件で測定した値を用いた。
Condition A
測定機械:Agilent社 Agilent 1290Infinity及びAgilent 6150
カラム:Waters社 Acquity CSH C18,1.7μm,φ2.1x50mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=80/20)、1.2-1.4分(A液/B液=1/99)
流速:0.8mL/min、検出法:254nm
Condition B
測定機械:Shimadzu社 LCMS-2010EV
カラム:Shimpack XR-ODS,2.2μm,φ2.0x30mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、3分(A液/B液=0/100)
流速:0.6mL/min、検出法:254nm
Condition C
測定機器:Agilent社 Agilent 1100及びmicromass社 Platform LC
カラム:Waters社 SunFire C18,2.5μm,φ4.6x50mm
溶媒:A液;0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、0.5分(A液/B液=90/10)、5.5分(A液/B液=20/80)、6.0分(A液/B液=1/99)、6.3分(A液/B液=1/99)
流速:1mL/min、検出法:254nm For the RT (retention time) of LCMS in the production examples and examples, values measured under any of the following conditions were used.
Condition A
Measuring machine: Agilent Agilent 1290 Infinity and Agilent 6150
Column: Waters Acquity CSH C18, 1.7 μm, φ2.1 × 50 mm
Solvent: Solution A; 0.1% formic acid-containing water, Solution B; 0.1% formic acid-containing acetonitrile gradient: 0 minutes (A solution / B solution = 80/20), 1.2-1.4 minutes (A solution / B liquid = 1/99)
Flow rate: 0.8 mL / min, detection method: 254 nm
Condition B
Measuring machine: Shimadzu LCMS-2010EV
Column: Shimpack XR-ODS, 2.2 μm, φ2.0 × 30 mm
Solvent: A solution; 0.1% formic acid-containing water, B solution; 0.1% formic acid-containing acetonitrile gradient: 0 minutes (A solution / B solution = 90/10), 3 minutes (A solution / B solution = 0 / 100)
Flow rate: 0.6 mL / min, detection method: 254 nm
Condition C
Measuring instrument: Agilent Agilent 1100 and micromass Platform LC
Column: Waters SunFire C18, 2.5 μm, φ4.6 × 50 mm
Solvent: A liquid; 0.1% trifluoroacetic acid-containing water, B liquid; 0.1% trifluoroacetic acid-containing acetonitrile gradient: 0 minutes (A liquid / B liquid = 90/10), 0.5 minutes (A liquid / B liquid = 90/10), 5.5 minutes (A liquid / B liquid = 20/80), 6.0 minutes (A liquid / B liquid = 1/99), 6.3 minutes (A liquid / B Liquid = 1/99)
Flow rate: 1 mL / min, detection method: 254 nm
Condition A
測定機械:Agilent社 Agilent 1290Infinity及びAgilent 6150
カラム:Waters社 Acquity CSH C18,1.7μm,φ2.1x50mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=80/20)、1.2-1.4分(A液/B液=1/99)
流速:0.8mL/min、検出法:254nm
Condition B
測定機械:Shimadzu社 LCMS-2010EV
カラム:Shimpack XR-ODS,2.2μm,φ2.0x30mm
溶媒:A液;0.1%ギ酸含有水、B液;0.1%ギ酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、3分(A液/B液=0/100)
流速:0.6mL/min、検出法:254nm
Condition C
測定機器:Agilent社 Agilent 1100及びmicromass社 Platform LC
カラム:Waters社 SunFire C18,2.5μm,φ4.6x50mm
溶媒:A液;0.1%トリフルオロ酢酸含有水、B液;0.1%トリフルオロ酢酸含有アセトニトリル
グラジエント:0分(A液/B液=90/10)、0.5分(A液/B液=90/10)、5.5分(A液/B液=20/80)、6.0分(A液/B液=1/99)、6.3分(A液/B液=1/99)
流速:1mL/min、検出法:254nm For the RT (retention time) of LCMS in the production examples and examples, values measured under any of the following conditions were used.
Condition A
Measuring machine: Agilent Agilent 1290 Infinity and Agilent 6150
Column: Waters Acquity CSH C18, 1.7 μm, φ2.1 × 50 mm
Solvent: Solution A; 0.1% formic acid-containing water, Solution B; 0.1% formic acid-containing acetonitrile gradient: 0 minutes (A solution / B solution = 80/20), 1.2-1.4 minutes (A solution / B liquid = 1/99)
Flow rate: 0.8 mL / min, detection method: 254 nm
Condition B
Measuring machine: Shimadzu LCMS-2010EV
Column: Shimpack XR-ODS, 2.2 μm, φ2.0 × 30 mm
Solvent: A solution; 0.1% formic acid-containing water, B solution; 0.1% formic acid-containing acetonitrile gradient: 0 minutes (A solution / B solution = 90/10), 3 minutes (A solution / B solution = 0 / 100)
Flow rate: 0.6 mL / min, detection method: 254 nm
Condition C
Measuring instrument: Agilent Agilent 1100 and micromass Platform LC
Column: Waters SunFire C18, 2.5 μm, φ4.6 × 50 mm
Solvent: A liquid; 0.1% trifluoroacetic acid-containing water, B liquid; 0.1% trifluoroacetic acid-containing acetonitrile gradient: 0 minutes (A liquid / B liquid = 90/10), 0.5 minutes (A liquid / B liquid = 90/10), 5.5 minutes (A liquid / B liquid = 20/80), 6.0 minutes (A liquid / B liquid = 1/99), 6.3 minutes (A liquid / B Liquid = 1/99)
Flow rate: 1 mL / min, detection method: 254 nm
製造例及び実施例中で使用した核磁気共鳴(NMR)スペクトルに於ける略語を以下に示す。
s:シングレット(singlet)、d:ダブレット(doublet)、t:トリプレット(triplet)、q:カルテット(quartet)、d d:ダブルダブレット(double doublet)、d t:ダブルトリプレット(double triplet)、d q:ダブルカルテット(double quartet)、d d d:ダブルダブルダブレット(double double doublet)、m:マルチプレット(multiplet)、br:ブロード(broad)、J:カップリング定数、Hz:ヘルツ、DMSO-d6:重水素化ジメチルスルホキシド Abbreviations in the nuclear magnetic resonance (NMR) spectra used in the production examples and examples are shown below.
s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, dt: double triplet, dq: double triplet, dq: double triplet, dq: double triplet (Double quartz), ddd: double doublet, m: multiplet, br: broad, J: coupling constant, Hz: Hertz, DMSO-d 6 : deuterated dimethyl Sulfoxide
s:シングレット(singlet)、d:ダブレット(doublet)、t:トリプレット(triplet)、q:カルテット(quartet)、d d:ダブルダブレット(double doublet)、d t:ダブルトリプレット(double triplet)、d q:ダブルカルテット(double quartet)、d d d:ダブルダブルダブレット(double double doublet)、m:マルチプレット(multiplet)、br:ブロード(broad)、J:カップリング定数、Hz:ヘルツ、DMSO-d6:重水素化ジメチルスルホキシド Abbreviations in the nuclear magnetic resonance (NMR) spectra used in the production examples and examples are shown below.
s: singlet, d: doublet, t: triplet, q: quartet, dd: double doublet, dt: double triplet, dq: double triplet, dq: double triplet, dq: double triplet (Double quartz), ddd: double doublet, m: multiplet, br: broad, J: coupling constant, Hz: Hertz, DMSO-d 6 : deuterated dimethyl Sulfoxide
製造例1 エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート
1)エチル 5-ホルミル-1-メチル-1H-ピラゾール-4-カルボキシラート
窒素雰囲気下、ジイソプロピルアミン(27.6 g)のテトラヒドロフラン(400 mL)溶液に、氷浴冷却下にてn-ブチルリチウム(105 mL、2.60M ヘキサン溶液)を滴下し、1時間撹拌した。反応液を-78 ℃に冷却後、エチル 1-メチル-1H-ピラゾール-4-カルボキシラート(20.0 g)のテトラヒドロフラン(100 mL)溶液を滴下し、2時間撹拌した。反応液に-78 ℃にてN,N-ジメチルホルムアミド(79.7 g)を滴下し1時間撹拌した後、2M 塩化水素水溶液を加えた。反応液を5M 塩化水素水溶液にて酸性とした後、酢酸エチルにて3回抽出した。合わせた有機層を水にて2回洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~50:50)にて精製し、表題化合物(17.0 g)を淡黄色固体として得た。
2)エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート
氷浴冷却下、エチル 5-ホルミル-1-メチル-1H-ピラゾール-4-カルボキシラート(23.0 g)のメタノール(300 mL)溶液に、水素化ホウ素ナトリウム(5.25 g)を加え、1時間撹拌した。反応液に塩化アンモニウム水溶液を加え、水にて希釈した後、酢酸エチルにて3回抽出した。合わせた有機層を水にて洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮して表題化合物(22.8 g)を淡黄色固体として得た。
1H NMR (200 MHz, DMSO-d6) δ ppm 1.27 (t, J=7.03 Hz, 3 H) 3.87 (s, 3 H) 4.21 (q, J=7.03 Hz, 2 H) 4.81 (d, J=5.71 Hz, 2 H) 5.26 - 5.41 (m, 1 H) 7.75 (s, 1 H) Production Example 1 Ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4-carboxylate 1) Ethyl 5-formyl-1-methyl-1H-pyrazole-4-carboxylate Diisopropylamine (27 1.6 g) in tetrahydrofuran (400 mL) was added dropwise n-butyllithium (105 mL, 2.60 M hexane solution) under ice bath cooling, and the mixture was stirred for 1 hour. The reaction mixture was cooled to −78 ° C., a solution of ethyl 1-methyl-1H-pyrazole-4-carboxylate (20.0 g) in tetrahydrofuran (100 mL) was added dropwise, and the mixture was stirred for 2 hr. N, N-dimethylformamide (79.7 g) was added dropwise to the reaction solution at −78 ° C., and the mixture was stirred for 1 hour, and then 2M aqueous hydrogen chloride solution was added. The reaction mixture was acidified with 5M aqueous hydrogen chloride solution and extracted three times with ethyl acetate. The combined organic layers were washed twice with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 90: 10-50: 50) to give the title compound (17.0 g) as a pale yellow solid.
2) Ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5-formyl-1-methyl-1H-pyrazole-4-carboxylate (23.0 g) under ice bath cooling Sodium borohydride (5.25 g) was added to a methanol (300 mL) solution and stirred for 1 hour. An aqueous ammonium chloride solution was added to the reaction solution, diluted with water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title compound (22.8 g) as a pale yellow solid.
1H NMR (200 MHz, DMSO-d6) δ ppm 1.27 (t, J = 7.03 Hz, 3 H) 3.87 (s, 3 H) 4.21 (q, J = 7.03 Hz, 2 H) 4.81 (d, J = 5.71 Hz, 2 H) 5.26-5.41 (m, 1 H) 7.75 (s, 1 H)
1)エチル 5-ホルミル-1-メチル-1H-ピラゾール-4-カルボキシラート
窒素雰囲気下、ジイソプロピルアミン(27.6 g)のテトラヒドロフラン(400 mL)溶液に、氷浴冷却下にてn-ブチルリチウム(105 mL、2.60M ヘキサン溶液)を滴下し、1時間撹拌した。反応液を-78 ℃に冷却後、エチル 1-メチル-1H-ピラゾール-4-カルボキシラート(20.0 g)のテトラヒドロフラン(100 mL)溶液を滴下し、2時間撹拌した。反応液に-78 ℃にてN,N-ジメチルホルムアミド(79.7 g)を滴下し1時間撹拌した後、2M 塩化水素水溶液を加えた。反応液を5M 塩化水素水溶液にて酸性とした後、酢酸エチルにて3回抽出した。合わせた有機層を水にて2回洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~50:50)にて精製し、表題化合物(17.0 g)を淡黄色固体として得た。
2)エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート
氷浴冷却下、エチル 5-ホルミル-1-メチル-1H-ピラゾール-4-カルボキシラート(23.0 g)のメタノール(300 mL)溶液に、水素化ホウ素ナトリウム(5.25 g)を加え、1時間撹拌した。反応液に塩化アンモニウム水溶液を加え、水にて希釈した後、酢酸エチルにて3回抽出した。合わせた有機層を水にて洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮して表題化合物(22.8 g)を淡黄色固体として得た。
1H NMR (200 MHz, DMSO-d6) δ ppm 1.27 (t, J=7.03 Hz, 3 H) 3.87 (s, 3 H) 4.21 (q, J=7.03 Hz, 2 H) 4.81 (d, J=5.71 Hz, 2 H) 5.26 - 5.41 (m, 1 H) 7.75 (s, 1 H) Production Example 1 Ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4-carboxylate 1) Ethyl 5-formyl-1-methyl-1H-pyrazole-4-carboxylate Diisopropylamine (27 1.6 g) in tetrahydrofuran (400 mL) was added dropwise n-butyllithium (105 mL, 2.60 M hexane solution) under ice bath cooling, and the mixture was stirred for 1 hour. The reaction mixture was cooled to −78 ° C., a solution of ethyl 1-methyl-1H-pyrazole-4-carboxylate (20.0 g) in tetrahydrofuran (100 mL) was added dropwise, and the mixture was stirred for 2 hr. N, N-dimethylformamide (79.7 g) was added dropwise to the reaction solution at −78 ° C., and the mixture was stirred for 1 hour, and then 2M aqueous hydrogen chloride solution was added. The reaction mixture was acidified with 5M aqueous hydrogen chloride solution and extracted three times with ethyl acetate. The combined organic layers were washed twice with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 90: 10-50: 50) to give the title compound (17.0 g) as a pale yellow solid.
2) Ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5-formyl-1-methyl-1H-pyrazole-4-carboxylate (23.0 g) under ice bath cooling Sodium borohydride (5.25 g) was added to a methanol (300 mL) solution and stirred for 1 hour. An aqueous ammonium chloride solution was added to the reaction solution, diluted with water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title compound (22.8 g) as a pale yellow solid.
1H NMR (200 MHz, DMSO-d6) δ ppm 1.27 (t, J = 7.03 Hz, 3 H) 3.87 (s, 3 H) 4.21 (q, J = 7.03 Hz, 2 H) 4.81 (d, J = 5.71 Hz, 2 H) 5.26-5.41 (m, 1 H) 7.75 (s, 1 H)
製造例2 エチル 1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボキシラート
エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート(5.00 g)、4-ヒドロキシベンゾトリフルオリド(6.60 g)及びトリフェニルホスフィン(9.61 g)のテトラヒドロフラン(250 mL)溶液に、室温にてアゾジカルボン酸ジイソプロピル(7.60 mL)を滴下し、3時間撹拌した。溶媒を減圧下留去した後、酢酸エチルにて希釈し、食塩水にて洗浄した。有機層を無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣をカラムクロマトグラフィー{(NHシリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~75:25)及び(シリカゲルカートリッジ、ヘキサン:酢酸エチル=80:20)}にて精製し、表題化合物(7.36 g)を無色固体として得た。
1H NMR (200 MHz, CHLOROFORM-d) δppm 1.35 (t, J=7.25 Hz, 3 H) 3.97 (s, 3 H) 4.32 (q, J=7.03 Hz, 2 H) 5.54 (s, 2 H) 7.10 (d, J=8.79 Hz, 2 H) 7.56 (d, J=8.35 Hz, 2 H) 7.88 (s, 1 H); MS (ESI neg.) m/z: 327 [M-H]- Production Example 2 Ethyl 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carboxylate ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4- A solution of carboxylate (5.00 g), 4-hydroxybenzotrifluoride (6.60 g) and triphenylphosphine (9.61 g) in tetrahydrofuran (250 mL) at room temperature with diisopropyl azodicarboxylate (7. 60 mL) was added dropwise and stirred for 3 hours. The solvent was evaporated under reduced pressure, diluted with ethyl acetate, and washed with brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography {(NH silica gel cartridge, hexane: ethyl acetate = 90: 10 to 75:25) and (silica gel cartridge, hexane: ethyl acetate = 80: 20)} to give the title compound (7.36 g) was obtained as a colorless solid.
1H NMR (200 MHz, CHLOROFORM-d) δppm 1.35 (t, J = 7.25 Hz, 3 H) 3.97 (s, 3 H) 4.32 (q, J = 7.03 Hz, 2 H) 5.54 (s, 2 H) 7.10 (d, J = 8.79 Hz, 2 H) 7.56 (d, J = 8.35 Hz, 2 H) 7.88 (s, 1 H); MS (ESI neg.) m / z: 327 [MH]-
エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート(5.00 g)、4-ヒドロキシベンゾトリフルオリド(6.60 g)及びトリフェニルホスフィン(9.61 g)のテトラヒドロフラン(250 mL)溶液に、室温にてアゾジカルボン酸ジイソプロピル(7.60 mL)を滴下し、3時間撹拌した。溶媒を減圧下留去した後、酢酸エチルにて希釈し、食塩水にて洗浄した。有機層を無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣をカラムクロマトグラフィー{(NHシリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~75:25)及び(シリカゲルカートリッジ、ヘキサン:酢酸エチル=80:20)}にて精製し、表題化合物(7.36 g)を無色固体として得た。
1H NMR (200 MHz, CHLOROFORM-d) δppm 1.35 (t, J=7.25 Hz, 3 H) 3.97 (s, 3 H) 4.32 (q, J=7.03 Hz, 2 H) 5.54 (s, 2 H) 7.10 (d, J=8.79 Hz, 2 H) 7.56 (d, J=8.35 Hz, 2 H) 7.88 (s, 1 H); MS (ESI neg.) m/z: 327 [M-H]- Production Example 2 Ethyl 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carboxylate ethyl 5- (hydroxymethyl) -1-methyl-1H-pyrazole-4- A solution of carboxylate (5.00 g), 4-hydroxybenzotrifluoride (6.60 g) and triphenylphosphine (9.61 g) in tetrahydrofuran (250 mL) at room temperature with diisopropyl azodicarboxylate (7. 60 mL) was added dropwise and stirred for 3 hours. The solvent was evaporated under reduced pressure, diluted with ethyl acetate, and washed with brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography {(NH silica gel cartridge, hexane: ethyl acetate = 90: 10 to 75:25) and (silica gel cartridge, hexane: ethyl acetate = 80: 20)} to give the title compound (7.36 g) was obtained as a colorless solid.
1H NMR (200 MHz, CHLOROFORM-d) δppm 1.35 (t, J = 7.25 Hz, 3 H) 3.97 (s, 3 H) 4.32 (q, J = 7.03 Hz, 2 H) 5.54 (s, 2 H) 7.10 (d, J = 8.79 Hz, 2 H) 7.56 (d, J = 8.35 Hz, 2 H) 7.88 (s, 1 H); MS (ESI neg.) m / z: 327 [MH]-
同様にして以下の化合物を合成した。
エチル 5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボキシラート
1H NMR (600 MHz, CHLOROFORM-d) δppm 1.33 (t, J=7.30 Hz, 3 H) 3.96 (s, 3 H) 4.30 (q, J=6.88 Hz, 2 H) 5.44 (s, 2 H) 6.88 - 7.00 (m, 4 H) 7.86 (s, 1 H)
エチル 5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 297 [M+H]+
エチル 5-{[(6-フルオロピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 280 [M+H]+ The following compounds were synthesized in the same manner.
Ethyl 5-[(4-fluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylate
1H NMR (600 MHz, CHLOROFORM-d) δppm 1.33 (t, J = 7.30 Hz, 3 H) 3.96 (s, 3 H) 4.30 (q, J = 6.88 Hz, 2 H) 5.44 (s, 2 H) 6.88 -7.00 (m, 4 H) 7.86 (s, 1 H)
Ethyl 5-[(3,4-difluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 297 [M + H] +
Ethyl 5-{[(6-fluoropyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 280 [M + H] +
エチル 5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボキシラート
1H NMR (600 MHz, CHLOROFORM-d) δppm 1.33 (t, J=7.30 Hz, 3 H) 3.96 (s, 3 H) 4.30 (q, J=6.88 Hz, 2 H) 5.44 (s, 2 H) 6.88 - 7.00 (m, 4 H) 7.86 (s, 1 H)
エチル 5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 297 [M+H]+
エチル 5-{[(6-フルオロピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 280 [M+H]+ The following compounds were synthesized in the same manner.
Ethyl 5-[(4-fluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylate
1H NMR (600 MHz, CHLOROFORM-d) δppm 1.33 (t, J = 7.30 Hz, 3 H) 3.96 (s, 3 H) 4.30 (q, J = 6.88 Hz, 2 H) 5.44 (s, 2 H) 6.88 -7.00 (m, 4 H) 7.86 (s, 1 H)
Ethyl 5-[(3,4-difluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 297 [M + H] +
Ethyl 5-{[(6-fluoropyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 280 [M + H] +
製造例3 エチル 5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
窒素雰囲気下、エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート(300 mg)、2-クロロ-5-フルオロピリジン(322 mg)、酢酸パラジウム(II)(37 mg)、炭酸セシウム (797 mg)、rac-2-(ジ-t-ブチルホスフィノ)-1,1'-ビナフチル(65 mg)及び1,4-ジオキサン(16 mL)の混合物を100 ℃にて1時間攪拌した。反応液を酢酸エチルにて希釈し、セライト濾過後、濾液を減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~50:50)にて精製し、表題化合物(149 mg)を無色固体として得た。
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.26 - 1.38 (m, 3 H) 3.95 (s, 3 H) 4.29 (q, J=7.18 Hz, 2 H) 5.68 (s, 2 H) 6.75 (dd, J=9.67, 3.52 Hz, 1 H) 7.36 (ddd, J=9.12, 7.58, 3.08 Hz, 1 H) 7.90 (s, 1 H) 8.01 (d, J=3.08 Hz, 1 H); MS (ESI pos.) m/z: 280 [M+H]+ Production Example 3 Ethyl 5-{[(5-fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5- (hydroxymethyl) -1-methyl under nitrogen atmosphere -1H-pyrazole-4-carboxylate (300 mg), 2-chloro-5-fluoropyridine (322 mg), palladium (II) acetate (37 mg), cesium carbonate (797 mg), rac-2- (di A mixture of -t-butylphosphino) -1,1′-binaphthyl (65 mg) and 1,4-dioxane (16 mL) was stirred at 100 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 90: 10-50: 50) to give the title compound (149 mg) as a colorless solid.
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.26-1.38 (m, 3 H) 3.95 (s, 3 H) 4.29 (q, J = 7.18 Hz, 2 H) 5.68 (s, 2 H) 6.75 (dd , J = 9.67, 3.52 Hz, 1 H) 7.36 (ddd, J = 9.12, 7.58, 3.08 Hz, 1 H) 7.90 (s, 1 H) 8.01 (d, J = 3.08 Hz, 1 H); MS (ESI pos.) m / z: 280 [M + H] +
窒素雰囲気下、エチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート(300 mg)、2-クロロ-5-フルオロピリジン(322 mg)、酢酸パラジウム(II)(37 mg)、炭酸セシウム (797 mg)、rac-2-(ジ-t-ブチルホスフィノ)-1,1'-ビナフチル(65 mg)及び1,4-ジオキサン(16 mL)の混合物を100 ℃にて1時間攪拌した。反応液を酢酸エチルにて希釈し、セライト濾過後、濾液を減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~50:50)にて精製し、表題化合物(149 mg)を無色固体として得た。
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.26 - 1.38 (m, 3 H) 3.95 (s, 3 H) 4.29 (q, J=7.18 Hz, 2 H) 5.68 (s, 2 H) 6.75 (dd, J=9.67, 3.52 Hz, 1 H) 7.36 (ddd, J=9.12, 7.58, 3.08 Hz, 1 H) 7.90 (s, 1 H) 8.01 (d, J=3.08 Hz, 1 H); MS (ESI pos.) m/z: 280 [M+H]+ Production Example 3 Ethyl 5-{[(5-fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5- (hydroxymethyl) -1-methyl under nitrogen atmosphere -1H-pyrazole-4-carboxylate (300 mg), 2-chloro-5-fluoropyridine (322 mg), palladium (II) acetate (37 mg), cesium carbonate (797 mg), rac-2- (di A mixture of -t-butylphosphino) -1,1′-binaphthyl (65 mg) and 1,4-dioxane (16 mL) was stirred at 100 ° C. for 1 hour. The reaction mixture was diluted with ethyl acetate, filtered through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 90: 10-50: 50) to give the title compound (149 mg) as a colorless solid.
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.26-1.38 (m, 3 H) 3.95 (s, 3 H) 4.29 (q, J = 7.18 Hz, 2 H) 5.68 (s, 2 H) 6.75 (dd , J = 9.67, 3.52 Hz, 1 H) 7.36 (ddd, J = 9.12, 7.58, 3.08 Hz, 1 H) 7.90 (s, 1 H) 8.01 (d, J = 3.08 Hz, 1 H); MS (ESI pos.) m / z: 280 [M + H] +
同様にして以下の化合物を合成した。
エチル 1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボキシラート
MS (ESI pos.) m/z: 330 [M+H]+
エチル 1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 330 [M+H]+
エチル 1-メチル-5-{[(5-メチルピリジン-2-イル)オキシ]メチル}-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 276 [M+H]+ The following compounds were synthesized in the same manner.
Ethyl 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate
MS (ESI pos.) M / z: 330 [M + H] +
Ethyl 1-methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 330 [M + H] +
Ethyl 1-methyl-5-{[(5-methylpyridin-2-yl) oxy] methyl} -1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 276 [M + H] +
エチル 1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボキシラート
MS (ESI pos.) m/z: 330 [M+H]+
エチル 1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 330 [M+H]+
エチル 1-メチル-5-{[(5-メチルピリジン-2-イル)オキシ]メチル}-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 276 [M+H]+ The following compounds were synthesized in the same manner.
Ethyl 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate
MS (ESI pos.) M / z: 330 [M + H] +
Ethyl 1-methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 330 [M + H] +
Ethyl 1-methyl-5-{[(5-methylpyridin-2-yl) oxy] methyl} -1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 276 [M + H] +
製造例4 1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸
エチル 1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボキシラート(249 mg)、2M 水酸化ナトリウム水溶液(1.13 mL)、テトラヒドロフラン(4.0 mL)及びメタノール(2.0 mL)の混合物を1時間加熱還流した。クエン酸水溶液にて約pH6に調整した後、クロロホルムにて3回抽出した。合わせた有機層を飽和食塩水にて洗浄し、無水硫酸マグネシウムにて乾燥した後、減圧下濃縮して表題化合物(188 mg)を無色固体として得た。
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.97 (s, 3 H) 5.74 (s, 2 H) 6.87 (d, J=8.67 Hz, 1 H) 7.82 (dd, J=8.67, 2.48 Hz, 1 H) 7.96 (s, 1 H) 8.46 (s, 1 H); MS (ESI neg.) m/z: 300 [M-H]- Production Example 4 Ethyl 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate 1-methyl-5-({[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate (249 mg), 2M aqueous sodium hydroxide (1.13 mL), tetrahydrofuran (4.0 mL) and methanol (2.0 mL) was heated to reflux for 1 hour. The pH was adjusted to about pH 6 with an aqueous citric acid solution, followed by extraction with chloroform three times. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (188 mg) as a colorless solid.
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.97 (s, 3 H) 5.74 (s, 2 H) 6.87 (d, J = 8.67 Hz, 1 H) 7.82 (dd, J = 8.67, 2.48 Hz, 1 H) 7.96 (s, 1 H) 8.46 (s, 1 H); MS (ESI neg.) M / z: 300 [MH]-
エチル 1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボキシラート(249 mg)、2M 水酸化ナトリウム水溶液(1.13 mL)、テトラヒドロフラン(4.0 mL)及びメタノール(2.0 mL)の混合物を1時間加熱還流した。クエン酸水溶液にて約pH6に調整した後、クロロホルムにて3回抽出した。合わせた有機層を飽和食塩水にて洗浄し、無水硫酸マグネシウムにて乾燥した後、減圧下濃縮して表題化合物(188 mg)を無色固体として得た。
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.97 (s, 3 H) 5.74 (s, 2 H) 6.87 (d, J=8.67 Hz, 1 H) 7.82 (dd, J=8.67, 2.48 Hz, 1 H) 7.96 (s, 1 H) 8.46 (s, 1 H); MS (ESI neg.) m/z: 300 [M-H]- Production Example 4 Ethyl 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate 1-methyl-5-({[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylate (249 mg), 2M aqueous sodium hydroxide (1.13 mL), tetrahydrofuran (4.0 mL) and methanol (2.0 mL) was heated to reflux for 1 hour. The pH was adjusted to about pH 6 with an aqueous citric acid solution, followed by extraction with chloroform three times. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (188 mg) as a colorless solid.
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.97 (s, 3 H) 5.74 (s, 2 H) 6.87 (d, J = 8.67 Hz, 1 H) 7.82 (dd, J = 8.67, 2.48 Hz, 1 H) 7.96 (s, 1 H) 8.46 (s, 1 H); MS (ESI neg.) M / z: 300 [MH]-
同様にして以下の化合物を合成した。
1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボン酸
MS (ESI pos.) m/z: 301 [M+H]+
5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI pos.) m/z: 251 [M+H]+
5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI pos.) m/z: 252 [M+H]+
5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 269 [M+H]+
1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 302 [M+H]+
5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 290 [M+Na]+
5-{[(6-メトキシピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual neg.) m/z: 262 [M-H]-
5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual neg.) m/z: 282 [M-H]-
1-メチル-5-{[(5-メチルピリジン-2-イル)オキシ]メチル}-1H-ピラゾール-4-カルボン酸
1H NMR (600 MHz, DMSO-d6) δ ppm 2.19 - 2.25 (m, 3 H) 3.86 - 3.90 (m, 3 H) 5.60 (s, 2 H) 6.79 (d, J=8.26 Hz, 1 H) 7.57 (dd, J=8.46, 2.27 Hz, 1 H) 7.81 (s, 1 H) 8.02 (dd, J=1.65, 0.83 Hz, 1 H) 12.42 - 12.57 (m, 1 H)
5-{[(5-シクロプロピルピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 274 [M+H]+ The following compounds were synthesized in the same manner.
1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carboxylic acid
MS (ESI pos.) M / z: 301 [M + H] +
5-[(4-Fluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI pos.) M / z: 251 [M + H] +
5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI pos.) M / z: 252 [M + H] +
5-[(3,4-Difluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 269 [M + H] +
1-methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 302 [M + H] +
5-{[(5-chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 290 [M + Na] +
5-{[(6-Methoxypyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual neg.) M / z: 262 [MH]-
5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual neg.) M / z: 282 [MH]-
1-methyl-5-{[(5-methylpyridin-2-yl) oxy] methyl} -1H-pyrazole-4-carboxylic acid
1H NMR (600 MHz, DMSO-d6) δ ppm 2.19-2.25 (m, 3 H) 3.86-3.90 (m, 3 H) 5.60 (s, 2 H) 6.79 (d, J = 8.26 Hz, 1 H) 7.57 (dd, J = 8.46, 2.27 Hz, 1 H) 7.81 (s, 1 H) 8.02 (dd, J = 1.65, 0.83 Hz, 1 H) 12.42-12.57 (m, 1 H)
5-{[(5-Cyclopropylpyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 274 [M + H] +
1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボン酸
MS (ESI pos.) m/z: 301 [M+H]+
5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI pos.) m/z: 251 [M+H]+
5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI pos.) m/z: 252 [M+H]+
5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 269 [M+H]+
1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 302 [M+H]+
5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 290 [M+Na]+
5-{[(6-メトキシピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual neg.) m/z: 262 [M-H]-
5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual neg.) m/z: 282 [M-H]-
1-メチル-5-{[(5-メチルピリジン-2-イル)オキシ]メチル}-1H-ピラゾール-4-カルボン酸
1H NMR (600 MHz, DMSO-d6) δ ppm 2.19 - 2.25 (m, 3 H) 3.86 - 3.90 (m, 3 H) 5.60 (s, 2 H) 6.79 (d, J=8.26 Hz, 1 H) 7.57 (dd, J=8.46, 2.27 Hz, 1 H) 7.81 (s, 1 H) 8.02 (dd, J=1.65, 0.83 Hz, 1 H) 12.42 - 12.57 (m, 1 H)
5-{[(5-シクロプロピルピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボン酸
MS (ESI/APCI Dual pos.) m/z: 274 [M+H]+ The following compounds were synthesized in the same manner.
1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carboxylic acid
MS (ESI pos.) M / z: 301 [M + H] +
5-[(4-Fluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI pos.) M / z: 251 [M + H] +
5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI pos.) M / z: 252 [M + H] +
5-[(3,4-Difluorophenoxy) methyl] -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 269 [M + H] +
1-methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 302 [M + H] +
5-{[(5-chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 290 [M + Na] +
5-{[(6-Methoxypyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual neg.) M / z: 262 [MH]-
5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual neg.) M / z: 282 [MH]-
1-methyl-5-{[(5-methylpyridin-2-yl) oxy] methyl} -1H-pyrazole-4-carboxylic acid
1H NMR (600 MHz, DMSO-d6) δ ppm 2.19-2.25 (m, 3 H) 3.86-3.90 (m, 3 H) 5.60 (s, 2 H) 6.79 (d, J = 8.26 Hz, 1 H) 7.57 (dd, J = 8.46, 2.27 Hz, 1 H) 7.81 (s, 1 H) 8.02 (dd, J = 1.65, 0.83 Hz, 1 H) 12.42-12.57 (m, 1 H)
5-{[(5-Cyclopropylpyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylic acid
MS (ESI / APCI Dual pos.) M / z: 274 [M + H] +
製造例5 2-[4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
1)2-(4-シアノフェニル)アセトアミド
窒素雰囲気下、(4-シアノフェニル)酢酸(500 mg)のクロロホルム(6.0 mL)溶液に、氷浴冷却下、塩化オキサリル(620 mg)及びN,N-ジメチルホルムアミド(1滴)を加えた後、室温にて1時間攪拌した。 反応液を減圧下濃縮した。残渣のテトラヒドロフラン(7.0 mL)懸濁液に氷浴冷却下、28%アンモニア水(3.00 mL)を加えた後、室温にて1時間攪拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルにて抽出した。有機層を飽和炭酸水素ナトリウム水溶液及び飽和食塩水にて洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。得られた固体をジイソプロピルエーテルにて洗浄し、表題化合物(350 mg)を淡黄色固体として得た。
2)2-[4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
2-(4-シアノフェニル)アセトアミド(350 mg)、50%ヒドロキシアミン水溶液(160 μL)及びエタノール(1.5 mL)の混合物を12時間加熱還流した。反応液を減圧下濃縮して表題化合物(400 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 5.72 (s, 2 H) 6.85 (br. s., 1 H) 7.22 (d, J=8.25 Hz, 2 H) 7.43 (br. s., 1 H) 7.56 (d, J=8.25 Hz, 2 H) 9.53 (s, 1 H) Production Example 5 2- [4- (N′-Hydroxycarbamimidoyl) phenyl] acetamide 1) 2- (4-Cyanophenyl) acetamide In a nitrogen atmosphere, (4-cyanophenyl) acetic acid (500 mg) in chloroform ( To the 6.0 mL solution, oxalyl chloride (620 mg) and N, N-dimethylformamide (1 drop) were added while cooling in an ice bath, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure. To a suspension of the residue in tetrahydrofuran (7.0 mL) was added 28% aqueous ammonia (3.00 mL) with cooling in an ice bath, and the mixture was stirred at room temperature for 1 hr. The reaction mixture saturated aqueous solution of sodium hydrogen carbonate was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained solid was washed with diisopropyl ether to give the title compound (350 mg) as a pale yellow solid.
2) 2- [4- (N′-hydroxycarbamimidoyl) phenyl] acetamide 2- (4-cyanophenyl) acetamide (350 mg), 50% aqueous hydroxyamine solution (160 μL) and ethanol (1.5 mL) ) Was heated to reflux for 12 hours. The reaction was concentrated under reduced pressure to give the title compound (400 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δppm 5.72 (s, 2 H) 6.85 (br. S., 1 H) 7.22 (d, J = 8.25 Hz, 2 H) 7.43 (br. S., 1 H) 7.56 (d, J = 8.25 Hz, 2 H) 9.53 (s, 1 H)
1)2-(4-シアノフェニル)アセトアミド
窒素雰囲気下、(4-シアノフェニル)酢酸(500 mg)のクロロホルム(6.0 mL)溶液に、氷浴冷却下、塩化オキサリル(620 mg)及びN,N-ジメチルホルムアミド(1滴)を加えた後、室温にて1時間攪拌した。 反応液を減圧下濃縮した。残渣のテトラヒドロフラン(7.0 mL)懸濁液に氷浴冷却下、28%アンモニア水(3.00 mL)を加えた後、室温にて1時間攪拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルにて抽出した。有機層を飽和炭酸水素ナトリウム水溶液及び飽和食塩水にて洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。得られた固体をジイソプロピルエーテルにて洗浄し、表題化合物(350 mg)を淡黄色固体として得た。
2)2-[4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
2-(4-シアノフェニル)アセトアミド(350 mg)、50%ヒドロキシアミン水溶液(160 μL)及びエタノール(1.5 mL)の混合物を12時間加熱還流した。反応液を減圧下濃縮して表題化合物(400 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 5.72 (s, 2 H) 6.85 (br. s., 1 H) 7.22 (d, J=8.25 Hz, 2 H) 7.43 (br. s., 1 H) 7.56 (d, J=8.25 Hz, 2 H) 9.53 (s, 1 H) Production Example 5 2- [4- (N′-Hydroxycarbamimidoyl) phenyl] acetamide 1) 2- (4-Cyanophenyl) acetamide In a nitrogen atmosphere, (4-cyanophenyl) acetic acid (500 mg) in chloroform ( To the 6.0 mL solution, oxalyl chloride (620 mg) and N, N-dimethylformamide (1 drop) were added while cooling in an ice bath, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure. To a suspension of the residue in tetrahydrofuran (7.0 mL) was added 28% aqueous ammonia (3.00 mL) with cooling in an ice bath, and the mixture was stirred at room temperature for 1 hr. The reaction mixture saturated aqueous solution of sodium hydrogen carbonate was added, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained solid was washed with diisopropyl ether to give the title compound (350 mg) as a pale yellow solid.
2) 2- [4- (N′-hydroxycarbamimidoyl) phenyl] acetamide 2- (4-cyanophenyl) acetamide (350 mg), 50% aqueous hydroxyamine solution (160 μL) and ethanol (1.5 mL) ) Was heated to reflux for 12 hours. The reaction was concentrated under reduced pressure to give the title compound (400 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δppm 5.72 (s, 2 H) 6.85 (br. S., 1 H) 7.22 (d, J = 8.25 Hz, 2 H) 7.43 (br. S., 1 H) 7.56 (d, J = 8.25 Hz, 2 H) 9.53 (s, 1 H)
同様にして以下の化合物を合成した。
2-[3-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI pos.) m/z : 194 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δppm 5.88 (s, 2 H) 7.38 (br. s., 1 H) 7.73 (d, J=8.35 Hz, 2 H) 7.86 (d, J=8.35 Hz, 2 H) 7.97 (br. s., 1 H) 9.78 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 5.85 (s, 2 H) 7.26 - 7.52 (m, 2 H) 7.72 - 7.89 (m, 2 H) 7.96 (br. s., 1 H) 8.15 (s, 1 H) 9.68 (s, 1 H)
4-(N'-ヒドロキシカルバムイミドイル)-3-メチルベンズアミド
MS (ESI pos.) m/z: 194 [M+H]+
4-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI pos.) m/z: 198 [M+H]+
N-[2-(ジメチルアミノ)エチル]-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.18 (s, 6 H) 2.40 (t, J=6.81 Hz, 2 H) 3.32 - 3.43 (m, 2 H) 5.86 (s, 2 H) 7.39 - 7.51 (m, 1 H) 7.74 - 7.84 (m, 2 H) 8.12 (s, 1 H) 8.33 - 8.43 (m, 1 H) 9.69 (s, 1 H)
2-[3-(N'-ヒドロキシカルバムイミドイル)フェノキシ]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.40 (s, 2 H) 5.75 (s, 2 H) 6.86 - 6.96 (m, 1 H) 7.19 - 7.28 (m, 3 H) 7.33 (br. s., 1 H) 7.47 (br. s., 1 H) 9.59 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-N-(オキセタン-3-イル)ベンズアミド
MS (ESI pos.) m/z: 236 [M+H]+
6-(N'-ヒドロキシカルバムイミドイル)ピリジン-3-カルボキサミド
MS (ESI/APCI Dual pos.) m/z: 181 [M+H]+
N-[2-(ジメチルアミノ)エチル]-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.12 (s, 9 H) 2.28 - 2.44 (m, 2 H) 3.18 - 3.53 (m, 2 H) 5.86 (s, 2 H) 7.32 - 8.54 (m, 5 H) 9.69 (s, 1 H)
3-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
3-(N'-ヒドロキシカルバムイミドイル)-4-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)-N-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)安息香酸
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67 - 8.25 (m, 7 H)
3-(N'-ヒドロキシカルバムイミドイル)安息香酸
1H NMR (200 MHz, DMSO-d6) δ ppm 5.65 - 8.32 (m, 7 H)
[4-(N'-ヒドロキシカルバムイミドイル)フェニル]酢酸
[3-(N'-ヒドロキシカルバムイミドイル)フェニル]酢酸
6-(N'-ヒドロキシカルバムイミドイル)ピリジン-2-カルボキサミド
1H NMR (200 MHz, DMSO-d6) δ ppm 6.39 (br. s., 2 H) 7.52 - 7.70 (m, 1 H) 7.86 - 8.09 (m, 3 H) 8.82 (br. s., 1 H) 9.93 (s, 1 H)
4-(N'-ヒドロキシカルバムイミドイル)フェニル カルバマート
1H NMR (200 MHz, DMSO-d6) δ ppm 5.56 - 9.69 (m, 9 H)
3-(N'-ヒドロキシカルバムイミドイル)-N-メチルベンズアミド
2-[3-(N'-ヒドロキシカルバムイミドイル)フェノキシ]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.20 - 4.62 (m, 2 H) 5.75 (s, 2 H) 6.78 - 7.59 (m, 6 H) 9.59 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-N-(2-ヒドロキシエチル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 3.42 - 3.61 (m, 2 H) 4.59 - 4.91 (m, 1 H) 5.86 (s, 2 H) 7.32 - 8.48 (m, 7 H) 9.69 (s, 1 H)
tert-ブチル 3-(N'-ヒドロキシカルバムイミドイル)ベンゾエ-ト
1H NMR (200 MHz, DMSO-d6) δ ppm 1.56 (s, 9 H) 5.72 - 9.84 (m, 7 H)
5-(N'-ヒドロキシカルバムイミドイル)ピリジン-3-カルボキサミド
MS (ESI/APCI Dual pos.) m/z: 181 [M+H]+
2-[2-ブロモ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 5.75 - 5.92 (m, 2 H) 6.88 - 8.10 (m, 7 H) 9.68 (s, 1 H)
2-[4-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 3.33 (s, 2 H) 6.73 - 8.20 (m, 8 H)
2-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
2-[3-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 234 [M+Na]+
2-[3-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
5-(N'-ヒドロキシカルバムイミドイル)ピリジン-2-カルボキサミド
MS (ESI/APCI Dual pos.) m/z: 181 [M+H]+
2-[2-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
2-[2-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
2-[2-クロロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 228 [M+H]+
5-(N'-ヒドロキシカルバムイミドイル)-2-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
2-[5-(N'-ヒドロキシカルバムイミドイル)-2-メチルフェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 208 [M+H]
2-クロロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 214 [M+H]+
3-クロロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 214 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)-2-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
2-[2-クロロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 228 [M+H]+
2-[4-(N'-ヒドロキシカルバムイミドイル)-2-メチルフェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 208 [M+H]+
2-[4-(N'-ヒドロキシカルバムイミドイル)-3-メチルフェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 208 [M+H]+
N'-ヒドロキシ-3-[(3-オキソピペラジン-1-イル)カルボニル]ベンゼンカルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 263 [M+H]+
2-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
3-[3-(N'-ヒドロキシカルバムイミドイル)フェニル]プロパンアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.68 - 2.91 (m, 3 H) 3.33 (br. s., 1 H) 5.75 (s, 2 H) 6.76 (br. s., 1 H) 7.10 - 7.62 (m, 5 H) 9.57 (s, 1 H)
2-[4-(N'-ヒドロキシカルバムイミドイル)フェニル]-2-メチルプロパンアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 1.43 (s, 6 H) 5.76 (s, 2 H) 6.90 (s, 2 H) 7.32 (d, J=8.4 Hz, 2 H) 7.61 (d, J=8.4 Hz, 2 H) 9.57 (s, 1 H)
3-アセチル-N'-ヒドロキシベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.51 (dt, J=3.7, 1.9 Hz, 3 H) 5.68 (s, 2 H) 6.69 (s, 2 H) 6.92 (d, J=5.0 Hz, 1 H) 8.20 (d, J=5.4 Hz, 1 H) 10.14 (s, 1 H)
2-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
3-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI pos.) m/z: 198 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)-3-メトキシベンズアミド
MS (ESI pos.) m/z: 210 [M+H]+
5-(N'-ヒドロキシカルバムイミドイル)-2-メトキシベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.90 (s, 3 H) 5.77 (s, 2 H) 7.12 (d, J=9.1 Hz, 1 H) 7.49 - 7.58 (m, 1 H) 7.59 - 7.67 (m, 1 H) 7.74 (dd, J=8.7, 2.48 Hz, 1 H) 8.11 (d, J=2.5 Hz, 1 H) 9.51 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-4-メトキシベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H) 5.54 - 5.69 (m, 2 H) 7.06 - 7.22 (m, 2 H) 7.81 - 7.95 (m, 3 H) 9.39 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-2-メトキシベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.05 (s, 2 H) 5.91 - 5.97 (m, 1 H) 7.06 - 8.29 (m, 7 H) 8.63 - 8.72 (m, 1 H)
N-(2-アミノ-2-オキソエチル)-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.83 (d, J=5.78 Hz, 2 H) 5.86 (s, 2 H) 7.04 (br. s., 1 H) 7.38 (br. s., 1 H) 7.47 (t, J=7.8 Hz, 1 H) 7.74 - 7.90 (m, 2 H) 8.18 (t, J=1.7 Hz, 1 H) 8.65 (t, J=5.8 Hz, 1 H) 9.70 (s, 1 H)
N-(2-アミノ-2-オキソエチル)-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.79 - 3.85 (m, 2 H) 5.89 (s, 2 H) 7.37 (br. s., 1 H) 7.73 - 7.81 (m, 2 H) 7.87 (d, J=8.7 Hz, 2 H) 7.94 - 8.06 (m, 1 H) 8.68 (s, 1 H) 9.78 (s, 1 H)
2-[3-クロロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
2-[3-クロロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
3-クロロ-5-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
2-[6-(N'-ヒドロキシカルバムイミドイル)ピリジン-3-イル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 195 [M+H]+
2-[2-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
2-[5-(N'-ヒドロキシカルバムイミドイル)ピリジン-2-イル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 195 [M+H]+
N'-ヒドロキシ-4-(2-ヒドロキシエチル)ベンゼンカルボキシミドアミド
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.27 - 1.44 (m, 2 H) 4.21 - 4.49 (m, 2 H) 5.57 (s, 1 H) 6.98 - 8.00 (m, 7 H)
N'-ヒドロキシ-2-(ヒドロキシメチル)ピリジン-4-カルボキシミドアミド
N'-ヒドロキシ-3-(2-ヒドロキシプロパン-2-イル)ベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.32 (s, 1 H) 5.01 (s, 1 H) 5.76 (s, 1 H) 7.19 - 7.37 (m, 1 H) 7.41 - 7.56 (m, 2 H) 7.76 (t, J=1.5 Hz, 1 H) 9.55 (s, 1 H)
N'-ヒドロキシ-4-(2-ヒドロキシプロパン-2-イル)ベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.33 (s, 1 H) 5.02 (s, 1 H) 5.74 (s, 1 H) 7.32 - 7.49 (m, 2 H) 7.52 - 7.66 (m, 2 H) 9.54 (s, 1 H)
N'-ヒドロキシ-4-(ヒドロキシメチル)ベンゼンカルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 167 [M+H]+
4-[カルバモイル(メチル)アミノ]-N'-ヒドロキシベンゼンカルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 209 [M+H]+
4-(カルバモイルアミノ)-N'-ヒドロキシベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67 (s, 2 H) 5.87 (s, 2 H) 7.26 - 7.62 (m, 4 H) 8.60 (s, 1 H) 9.42 (s, 1 H)
3-(カルバモイルアミノ)-N'-ヒドロキシベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.08 (d, J=5.4 Hz, 1 H) 5.59 (s, 2 H) 5.74 (s, 1 H) 7.01 - 7.17 (m, 2 H) 7.31 - 7.40 (m, 1 H) 7.57 (t, J=1.9 Hz, 1 H) 8.45 (s, 1 H) 9.47 (s, 1 H)
N'-ヒドロキシ-4-[(メチルカルバモイル)アミノ]ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.64 (d, J=4.5 Hz, 3 H) 5.66 (s, 2 H) 6.03 (d, J=4.5 Hz, 1 H) 7.37 (d, J=8.7 Hz, 2 H) 7.47 - 7.55 (m, 2 H) 8.58 (s, 1 H) 9.41 (s, 1 H)
N'-ヒドロキシ-3-[(メチルカルバモイル)アミノ]ベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.63 (d, J=4.4 Hz, 3 H) 5.68 (s, 2 H) 5.99 (d, J=4.4 Hz, 1 H) 7.05 - 7.28 (m, 2 H) 7.47 (dt, J=7.5, 2.0 Hz, 1 H) 7.56 - 7.68 (m, 1 H) 8.52 (s, 1 H) 9.55 (s, 1 H)
メチル [4-(N'-ヒドロキシカルバムイミドイル)フェニル]カルバマート
N'-ヒドロキシ-1-オキソ-2,3-ジヒドロ-1H-イソインドール-5-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 192 [M+H]+
N'-ヒドロキシ-3-オキソ-2,3-ジヒドロ-1H-イソインドール-5-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 192 [M+H]+
N'-ヒドロキシ-2-オキソ-2,3-ジヒドロ-1H-インドール-5-カルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.48 (s, 2 H) 5.68 (s, 2 H) 6.78 (d, J=8.3 Hz, 1 H) 7.42 - 7.61 (m, 2 H) 9.43 (s, 1 H) 10.45 (s, 1 H)
N'-ヒドロキシ-2-オキソ-2,3-ジヒドロ-1H-ベンゾイミダゾール-5-カルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 4.34 (br. s., 2 H) 5.69 (s, 2 H) 6.77 - 7.01 (m, 1 H) 7.15 - 7.63 (m, 3 H) 10.69 (br. s., 2 H)
N'-ヒドロキシ-4-(2-オキソイミダゾリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.37 - 3.50 (m, 2 H) 3.85 (dd, J=8.9, 7.22 Hz, 2 H) 5.72 (s, 2 H) 7.00 (s, 1 H) 7.47 - 7.65 (m, 4 H) 9.47 (s, 1 H)
N'-ヒドロキシ-3-(2-オキソイミダゾリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.36 - 3.45 (m, 2 H) 3.81 - 3.92 (m, 2 H) 5.76 (s, 2 H) 6.96 (s, 1 H) 7.24 - 7.32 (m, 2 H) 7.63 - 7.78 (m, 2 H) 9.60 (s, 1 H)
N'-ヒドロキシ-4-(2-オキソピロリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.06 (quin, J=7.53 Hz, 2 H) 2.40 - 2.57 (m, 2 H) 3.84 (t, J=7.02 Hz, 2 H) 5.77 (s, 2 H) 7.56 - 7.76 (m, 4 H) 9.56 (s, 1 H)
N'-ヒドロキシ-3-(2-オキソピロリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.03 - 2.12 (m, 2 H) 2.46 - 2.55 (m, 2 H) 3.80 - 3.90 (m, 2 H) 5.81 (s, 2 H) 7.32 - 8.04 (m, 4 H) 9.65 (s, 1 H)
N-(2,2-ジメトキシエチル)-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 268 [M+H]+
N'-ヒドロキシ-2-オキソ-1,2-ジヒドロピリジン-4-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 154 [M+H]+
N'-ヒドロキシ-6-オキソ-1,6-ジヒドロピリジン-3-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 154 [M+H]+
3-アミノ-N'-ヒドロキシベンゼンカルボキシミドアミド The following compounds were synthesized in the same manner.
2- [3- (N'-Hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI pos.) M / z: 194 [M + H] +
4- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δppm 5.88 (s, 2 H) 7.38 (br. S., 1 H) 7.73 (d, J = 8.35 Hz, 2 H) 7.86 (d, J = 8.35 Hz, 2 H) 7.97 (br. S., 1 H) 9.78 (s, 1 H)
3- (N'-Hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 5.85 (s, 2 H) 7.26-7.52 (m, 2 H) 7.72-7.89 (m, 2 H) 7.96 (br. S., 1 H) 8.15 (s , 1 H) 9.68 (s, 1 H)
4- (N'-hydroxycarbamimidoyl) -3-methylbenzamide
MS (ESI pos.) M / z: 194 [M + H] +
4-Fluoro-3- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI pos.) M / z: 198 [M + H] +
N- [2- (Dimethylamino) ethyl] -3- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.18 (s, 6 H) 2.40 (t, J = 6.81 Hz, 2 H) 3.32-3.43 (m, 2 H) 5.86 (s, 2 H) 7.39-7.51 (m, 1 H) 7.74-7.84 (m, 2 H) 8.12 (s, 1 H) 8.33-8.43 (m, 1 H) 9.69 (s, 1 H)
2- [3- (N'-Hydroxycarbamimidoyl) phenoxy] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.40 (s, 2 H) 5.75 (s, 2 H) 6.86-6.96 (m, 1 H) 7.19-7.28 (m, 3 H) 7.33 (br. S. , 1 H) 7.47 (br. S., 1 H) 9.59 (s, 1 H)
3- (N'-Hydroxycarbamimidoyl) -N- (oxetan-3-yl) benzamide
MS (ESI pos.) M / z: 236 [M + H] +
6- (N'-Hydroxycarbamimidoyl) pyridine-3-carboxamide
MS (ESI / APCI Dual pos.) M / z: 181 [M + H] +
N- [2- (Dimethylamino) ethyl] -4- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.12 (s, 9 H) 2.28-2.44 (m, 2 H) 3.18-3.53 (m, 2 H) 5.86 (s, 2 H) 7.32-8.54 (m, 5 H) 9.69 (s, 1 H)
3-Fluoro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
3- (N'-hydroxycarbamimidoyl) -4-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
4- (N'-hydroxycarbamimidoyl) -N-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
4- (N'-hydroxycarbamimidoyl) benzoic acid
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67-8.25 (m, 7 H)
3- (N'-Hydroxycarbamimidoyl) benzoic acid
1H NMR (200 MHz, DMSO-d6) δ ppm 5.65-8.32 (m, 7 H)
[4- (N'-Hydroxycarbamimidoyl) phenyl] acetic acid
[3- (N'-Hydroxycarbamimidoyl) phenyl] acetic acid
6- (N'-hydroxycarbamimidoyl) pyridine-2-carboxamide
1H NMR (200 MHz, DMSO-d6) δ ppm 6.39 (br. S., 2 H) 7.52-7.70 (m, 1 H) 7.86-8.09 (m, 3 H) 8.82 (br. S., 1 H) 9.93 (s, 1 H)
4- (N'-hydroxycarbamimidoyl) phenyl carbamate
1H NMR (200 MHz, DMSO-d6) δ ppm 5.56-9.69 (m, 9 H)
3- (N'-Hydroxycarbamimidoyl) -N-methylbenzamide
2- [3- (N'-Hydroxycarbamimidoyl) phenoxy] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.20-4.62 (m, 2 H) 5.75 (s, 2 H) 6.78-7.59 (m, 6 H) 9.59 (s, 1 H)
3- (N'-hydroxycarbamimidoyl) -N- (2-hydroxyethyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 3.42-3.61 (m, 2 H) 4.59-4.91 (m, 1 H) 5.86 (s, 2 H) 7.32-8.48 (m, 7 H) 9.69 (s, 1 H)
tert-Butyl 3- (N'-hydroxycarbamimidoyl) benzoate
1H NMR (200 MHz, DMSO-d6) δ ppm 1.56 (s, 9 H) 5.72-9.84 (m, 7 H)
5- (N'-Hydroxycarbamimidoyl) pyridine-3-carboxamide
MS (ESI / APCI Dual pos.) M / z: 181 [M + H] +
2- [2-Bromo-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 5.75-5.92 (m, 2 H) 6.88-8.10 (m, 7 H) 9.68 (s, 1 H)
2- [4-Fluoro-3- (N'-hydroxycarbamimidoyl) phenyl] acetamide
1H NMR (200 MHz, DMSO-d6) δ ppm 3.33 (s, 2 H) 6.73-8.20 (m, 8 H)
2-Fluoro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
2- [3-Fluoro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 234 [M + Na] +
2- [3-Fluoro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
5- (N'-hydroxycarbamimidoyl) pyridine-2-carboxamide
MS (ESI / APCI Dual pos.) M / z: 181 [M + H] +
2- [2-Fluoro-3- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
2- [2-Fluoro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
2- [2-Chloro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 228 [M + H] +
5- (N'-hydroxycarbamimidoyl) -2-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
2- [5- (N'-Hydroxycarbamimidoyl) -2-methylphenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 208 [M + H]
2-Chloro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 214 [M + H] +
3-Chloro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 214 [M + H] +
4- (N'-hydroxycarbamimidoyl) -2-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
2- [2-Chloro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 228 [M + H] +
2- [4- (N'-Hydroxycarbamimidoyl) -2-methylphenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 208 [M + H] +
2- [4- (N'-Hydroxycarbamimidoyl) -3-methylphenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 208 [M + H] +
N'-hydroxy-3-[(3-oxopiperazin-1-yl) carbonyl] benzenecarboximidamide
MS (ESI / APCI Dual pos.) M / z: 263 [M + H] +
2-Fluoro-3- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
3- [3- (N'-Hydroxycarbamimidoyl) phenyl] propanamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.68-2.91 (m, 3 H) 3.33 (br. S., 1 H) 5.75 (s, 2 H) 6.76 (br. S., 1 H) 7.10- 7.62 (m, 5 H) 9.57 (s, 1 H)
2- [4- (N'-Hydroxycarbamimidoyl) phenyl] -2-methylpropanamide
1H NMR (200 MHz, DMSO-d6) δ ppm 1.43 (s, 6 H) 5.76 (s, 2 H) 6.90 (s, 2 H) 7.32 (d, J = 8.4 Hz, 2 H) 7.61 (d, J = 8.4 Hz, 2 H) 9.57 (s, 1 H)
3-acetyl-N'-hydroxybenzenecarboximidoamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.51 (dt, J = 3.7, 1.9 Hz, 3 H) 5.68 (s, 2 H) 6.69 (s, 2 H) 6.92 (d, J = 5.0 Hz, 1 H) 8.20 (d, J = 5.4 Hz, 1 H) 10.14 (s, 1 H)
2-Fluoro-5- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
3-Fluoro-5- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI pos.) M / z: 198 [M + H] +
4- (N'-hydroxycarbamimidoyl) -3-methoxybenzamide
MS (ESI pos.) M / z: 210 [M + H] +
5- (N'-hydroxycarbamimidoyl) -2-methoxybenzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.90 (s, 3 H) 5.77 (s, 2 H) 7.12 (d, J = 9.1 Hz, 1 H) 7.49-7.58 (m, 1 H) 7.59-7.67 (m, 1 H) 7.74 (dd, J = 8.7, 2.48 Hz, 1 H) 8.11 (d, J = 2.5 Hz, 1 H) 9.51 (s, 1 H)
3- (N'-hydroxycarbamimidoyl) -4-methoxybenzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H) 5.54-5.69 (m, 2 H) 7.06-7.22 (m, 2 H) 7.81-7.95 (m, 3 H) 9.39 (s, 1 H)
3- (N'-hydroxycarbamimidoyl) -2-methoxybenzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.05 (s, 2 H) 5.91-5.97 (m, 1 H) 7.06-8.29 (m, 7 H) 8.63-8.72 (m, 1 H)
N- (2-amino-2-oxoethyl) -3- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.83 (d, J = 5.78 Hz, 2 H) 5.86 (s, 2 H) 7.04 (br. S., 1 H) 7.38 (br. S., 1 H ) 7.47 (t, J = 7.8 Hz, 1 H) 7.74-7.90 (m, 2 H) 8.18 (t, J = 1.7 Hz, 1 H) 8.65 (t, J = 5.8 Hz, 1 H) 9.70 (s, 1 H)
N- (2-amino-2-oxoethyl) -4- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.79-3.85 (m, 2 H) 5.89 (s, 2 H) 7.37 (br. S., 1 H) 7.73-7.81 (m, 2 H) 7.87 (d , J = 8.7 Hz, 2 H) 7.94-8.06 (m, 1 H) 8.68 (s, 1 H) 9.78 (s, 1 H)
2- [3-Chloro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
2- [3-Chloro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
3-Chloro-5- (N'-hydroxycarbamimidoyl) benzamide
2- [6- (N'-Hydroxycarbamimidoyl) pyridin-3-yl] acetamide
MS (ESI / APCI Dual pos.) M / z: 195 [M + H] +
2- [2-Fluoro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
2- [5- (N'-Hydroxycarbamimidoyl) pyridin-2-yl] acetamide
MS (ESI / APCI Dual pos.) M / z: 195 [M + H] +
N'-hydroxy-4- (2-hydroxyethyl) benzenecarboximidamide
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.27-1.44 (m, 2 H) 4.21-4.49 (m, 2 H) 5.57 (s, 1 H) 6.98-8.00 (m, 7 H)
N'-hydroxy-2- (hydroxymethyl) pyridine-4-carboximidamide
N'-hydroxy-3- (2-hydroxypropan-2-yl) benzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.32 (s, 1 H) 5.01 (s, 1 H) 5.76 (s, 1 H) 7.19-7.37 (m, 1 H) 7.41 -7.56 (m, 2 H) 7.76 (t, J = 1.5 Hz, 1 H) 9.55 (s, 1 H)
N'-hydroxy-4- (2-hydroxypropan-2-yl) benzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.33 (s, 1 H) 5.02 (s, 1 H) 5.74 (s, 1 H) 7.32-7.49 (m, 2 H) 7.52 -7.66 (m, 2 H) 9.54 (s, 1 H)
N'-hydroxy-4- (hydroxymethyl) benzenecarboximidamide
MS (ESI / APCI Dual pos.) M / z: 167 [M + H] +
4- [Carbamoyl (methyl) amino] -N'-hydroxybenzenecarboximidamide
MS (ESI / APCI Dual pos.) M / z: 209 [M + H] +
4- (Carbamoylamino) -N'-hydroxybenzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67 (s, 2 H) 5.87 (s, 2 H) 7.26-7.62 (m, 4 H) 8.60 (s, 1 H) 9.42 (s, 1 H)
3- (Carbamoylamino) -N'-hydroxybenzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.08 (d, J = 5.4 Hz, 1 H) 5.59 (s, 2 H) 5.74 (s, 1 H) 7.01-7.17 (m, 2 H) 7.31-7.40 (m, 1 H) 7.57 (t, J = 1.9 Hz, 1 H) 8.45 (s, 1 H) 9.47 (s, 1 H)
N'-hydroxy-4-[(methylcarbamoyl) amino] benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.64 (d, J = 4.5 Hz, 3 H) 5.66 (s, 2 H) 6.03 (d, J = 4.5 Hz, 1 H) 7.37 (d, J = 8.7 Hz, 2 H) 7.47-7.55 (m, 2 H) 8.58 (s, 1 H) 9.41 (s, 1 H)
N'-hydroxy-3-[(methylcarbamoyl) amino] benzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.63 (d, J = 4.4 Hz, 3 H) 5.68 (s, 2 H) 5.99 (d, J = 4.4 Hz, 1 H) 7.05-7.28 (m, 2 H) 7.47 (dt, J = 7.5, 2.0 Hz, 1 H) 7.56-7.68 (m, 1 H) 8.52 (s, 1 H) 9.55 (s, 1 H)
Methyl [4- (N'-hydroxycarbamimidoyl) phenyl] carbamate
N'-hydroxy-1-oxo-2,3-dihydro-1H-isoindole-5-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 192 [M + H] +
N'-hydroxy-3-oxo-2,3-dihydro-1H-isoindole-5-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 192 [M + H] +
N'-hydroxy-2-oxo-2,3-dihydro-1H-indole-5-carboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.48 (s, 2 H) 5.68 (s, 2 H) 6.78 (d, J = 8.3 Hz, 1 H) 7.42-7.61 (m, 2 H) 9.43 (s , 1 H) 10.45 (s, 1 H)
N'-hydroxy-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 4.34 (br.s., 2 H) 5.69 (s, 2 H) 6.77-7.01 (m, 1 H) 7.15-7.63 (m, 3 H) 10.69 (br s., 2 H)
N'-hydroxy-4- (2-oxoimidazolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.37-3.50 (m, 2 H) 3.85 (dd, J = 8.9, 7.22 Hz, 2 H) 5.72 (s, 2 H) 7.00 (s, 1 H) 7.47 -7.65 (m, 4 H) 9.47 (s, 1 H)
N'-hydroxy-3- (2-oxoimidazolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.36-3.45 (m, 2 H) 3.81-3.92 (m, 2 H) 5.76 (s, 2 H) 6.96 (s, 1 H) 7.24-7.32 (m, 2 H) 7.63-7.78 (m, 2 H) 9.60 (s, 1 H)
N'-hydroxy-4- (2-oxopyrrolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.06 (quin, J = 7.53 Hz, 2 H) 2.40-2.57 (m, 2 H) 3.84 (t, J = 7.02 Hz, 2 H) 5.77 (s, 2 H) 7.56-7.76 (m, 4 H) 9.56 (s, 1 H)
N'-hydroxy-3- (2-oxopyrrolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.03-2.12 (m, 2 H) 2.46-2.55 (m, 2 H) 3.80-3.90 (m, 2 H) 5.81 (s, 2 H) 7.32-8.04 ( m, 4 H) 9.65 (s, 1 H)
N- (2,2-dimethoxyethyl) -3- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 268 [M + H] +
N'-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 154 [M + H] +
N'-hydroxy-6-oxo-1,6-dihydropyridine-3-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 154 [M + H] +
3-Amino-N'-hydroxybenzenecarboximidamide
2-[3-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI pos.) m/z : 194 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δppm 5.88 (s, 2 H) 7.38 (br. s., 1 H) 7.73 (d, J=8.35 Hz, 2 H) 7.86 (d, J=8.35 Hz, 2 H) 7.97 (br. s., 1 H) 9.78 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 5.85 (s, 2 H) 7.26 - 7.52 (m, 2 H) 7.72 - 7.89 (m, 2 H) 7.96 (br. s., 1 H) 8.15 (s, 1 H) 9.68 (s, 1 H)
4-(N'-ヒドロキシカルバムイミドイル)-3-メチルベンズアミド
MS (ESI pos.) m/z: 194 [M+H]+
4-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI pos.) m/z: 198 [M+H]+
N-[2-(ジメチルアミノ)エチル]-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.18 (s, 6 H) 2.40 (t, J=6.81 Hz, 2 H) 3.32 - 3.43 (m, 2 H) 5.86 (s, 2 H) 7.39 - 7.51 (m, 1 H) 7.74 - 7.84 (m, 2 H) 8.12 (s, 1 H) 8.33 - 8.43 (m, 1 H) 9.69 (s, 1 H)
2-[3-(N'-ヒドロキシカルバムイミドイル)フェノキシ]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.40 (s, 2 H) 5.75 (s, 2 H) 6.86 - 6.96 (m, 1 H) 7.19 - 7.28 (m, 3 H) 7.33 (br. s., 1 H) 7.47 (br. s., 1 H) 9.59 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-N-(オキセタン-3-イル)ベンズアミド
MS (ESI pos.) m/z: 236 [M+H]+
6-(N'-ヒドロキシカルバムイミドイル)ピリジン-3-カルボキサミド
MS (ESI/APCI Dual pos.) m/z: 181 [M+H]+
N-[2-(ジメチルアミノ)エチル]-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.12 (s, 9 H) 2.28 - 2.44 (m, 2 H) 3.18 - 3.53 (m, 2 H) 5.86 (s, 2 H) 7.32 - 8.54 (m, 5 H) 9.69 (s, 1 H)
3-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
3-(N'-ヒドロキシカルバムイミドイル)-4-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)-N-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)安息香酸
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67 - 8.25 (m, 7 H)
3-(N'-ヒドロキシカルバムイミドイル)安息香酸
1H NMR (200 MHz, DMSO-d6) δ ppm 5.65 - 8.32 (m, 7 H)
[4-(N'-ヒドロキシカルバムイミドイル)フェニル]酢酸
[3-(N'-ヒドロキシカルバムイミドイル)フェニル]酢酸
6-(N'-ヒドロキシカルバムイミドイル)ピリジン-2-カルボキサミド
1H NMR (200 MHz, DMSO-d6) δ ppm 6.39 (br. s., 2 H) 7.52 - 7.70 (m, 1 H) 7.86 - 8.09 (m, 3 H) 8.82 (br. s., 1 H) 9.93 (s, 1 H)
4-(N'-ヒドロキシカルバムイミドイル)フェニル カルバマート
1H NMR (200 MHz, DMSO-d6) δ ppm 5.56 - 9.69 (m, 9 H)
3-(N'-ヒドロキシカルバムイミドイル)-N-メチルベンズアミド
2-[3-(N'-ヒドロキシカルバムイミドイル)フェノキシ]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.20 - 4.62 (m, 2 H) 5.75 (s, 2 H) 6.78 - 7.59 (m, 6 H) 9.59 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-N-(2-ヒドロキシエチル)ベンズアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 3.42 - 3.61 (m, 2 H) 4.59 - 4.91 (m, 1 H) 5.86 (s, 2 H) 7.32 - 8.48 (m, 7 H) 9.69 (s, 1 H)
tert-ブチル 3-(N'-ヒドロキシカルバムイミドイル)ベンゾエ-ト
1H NMR (200 MHz, DMSO-d6) δ ppm 1.56 (s, 9 H) 5.72 - 9.84 (m, 7 H)
5-(N'-ヒドロキシカルバムイミドイル)ピリジン-3-カルボキサミド
MS (ESI/APCI Dual pos.) m/z: 181 [M+H]+
2-[2-ブロモ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 5.75 - 5.92 (m, 2 H) 6.88 - 8.10 (m, 7 H) 9.68 (s, 1 H)
2-[4-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 3.33 (s, 2 H) 6.73 - 8.20 (m, 8 H)
2-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
2-[3-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 234 [M+Na]+
2-[3-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
5-(N'-ヒドロキシカルバムイミドイル)ピリジン-2-カルボキサミド
MS (ESI/APCI Dual pos.) m/z: 181 [M+H]+
2-[2-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
2-[2-フルオロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
2-[2-クロロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 228 [M+H]+
5-(N'-ヒドロキシカルバムイミドイル)-2-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
2-[5-(N'-ヒドロキシカルバムイミドイル)-2-メチルフェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 208 [M+H]
2-クロロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 214 [M+H]+
3-クロロ-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 214 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)-2-メチルベンズアミド
MS (ESI/APCI Dual pos.) m/z: 194 [M+H]+
2-[2-クロロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 228 [M+H]+
2-[4-(N'-ヒドロキシカルバムイミドイル)-2-メチルフェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 208 [M+H]+
2-[4-(N'-ヒドロキシカルバムイミドイル)-3-メチルフェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 208 [M+H]+
N'-ヒドロキシ-3-[(3-オキソピペラジン-1-イル)カルボニル]ベンゼンカルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 263 [M+H]+
2-フルオロ-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
3-[3-(N'-ヒドロキシカルバムイミドイル)フェニル]プロパンアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.68 - 2.91 (m, 3 H) 3.33 (br. s., 1 H) 5.75 (s, 2 H) 6.76 (br. s., 1 H) 7.10 - 7.62 (m, 5 H) 9.57 (s, 1 H)
2-[4-(N'-ヒドロキシカルバムイミドイル)フェニル]-2-メチルプロパンアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 1.43 (s, 6 H) 5.76 (s, 2 H) 6.90 (s, 2 H) 7.32 (d, J=8.4 Hz, 2 H) 7.61 (d, J=8.4 Hz, 2 H) 9.57 (s, 1 H)
3-アセチル-N'-ヒドロキシベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.51 (dt, J=3.7, 1.9 Hz, 3 H) 5.68 (s, 2 H) 6.69 (s, 2 H) 6.92 (d, J=5.0 Hz, 1 H) 8.20 (d, J=5.4 Hz, 1 H) 10.14 (s, 1 H)
2-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 198 [M+H]+
3-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI pos.) m/z: 198 [M+H]+
4-(N'-ヒドロキシカルバムイミドイル)-3-メトキシベンズアミド
MS (ESI pos.) m/z: 210 [M+H]+
5-(N'-ヒドロキシカルバムイミドイル)-2-メトキシベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.90 (s, 3 H) 5.77 (s, 2 H) 7.12 (d, J=9.1 Hz, 1 H) 7.49 - 7.58 (m, 1 H) 7.59 - 7.67 (m, 1 H) 7.74 (dd, J=8.7, 2.48 Hz, 1 H) 8.11 (d, J=2.5 Hz, 1 H) 9.51 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-4-メトキシベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H) 5.54 - 5.69 (m, 2 H) 7.06 - 7.22 (m, 2 H) 7.81 - 7.95 (m, 3 H) 9.39 (s, 1 H)
3-(N'-ヒドロキシカルバムイミドイル)-2-メトキシベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.05 (s, 2 H) 5.91 - 5.97 (m, 1 H) 7.06 - 8.29 (m, 7 H) 8.63 - 8.72 (m, 1 H)
N-(2-アミノ-2-オキソエチル)-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.83 (d, J=5.78 Hz, 2 H) 5.86 (s, 2 H) 7.04 (br. s., 1 H) 7.38 (br. s., 1 H) 7.47 (t, J=7.8 Hz, 1 H) 7.74 - 7.90 (m, 2 H) 8.18 (t, J=1.7 Hz, 1 H) 8.65 (t, J=5.8 Hz, 1 H) 9.70 (s, 1 H)
N-(2-アミノ-2-オキソエチル)-4-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.79 - 3.85 (m, 2 H) 5.89 (s, 2 H) 7.37 (br. s., 1 H) 7.73 - 7.81 (m, 2 H) 7.87 (d, J=8.7 Hz, 2 H) 7.94 - 8.06 (m, 1 H) 8.68 (s, 1 H) 9.78 (s, 1 H)
2-[3-クロロ-4-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
2-[3-クロロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
3-クロロ-5-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
2-[6-(N'-ヒドロキシカルバムイミドイル)ピリジン-3-イル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 195 [M+H]+
2-[2-フルオロ-5-(N'-ヒドロキシカルバムイミドイル)フェニル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 212 [M+H]+
2-[5-(N'-ヒドロキシカルバムイミドイル)ピリジン-2-イル]アセトアミド
MS (ESI/APCI Dual pos.) m/z: 195 [M+H]+
N'-ヒドロキシ-4-(2-ヒドロキシエチル)ベンゼンカルボキシミドアミド
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.27 - 1.44 (m, 2 H) 4.21 - 4.49 (m, 2 H) 5.57 (s, 1 H) 6.98 - 8.00 (m, 7 H)
N'-ヒドロキシ-2-(ヒドロキシメチル)ピリジン-4-カルボキシミドアミド
N'-ヒドロキシ-3-(2-ヒドロキシプロパン-2-イル)ベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.32 (s, 1 H) 5.01 (s, 1 H) 5.76 (s, 1 H) 7.19 - 7.37 (m, 1 H) 7.41 - 7.56 (m, 2 H) 7.76 (t, J=1.5 Hz, 1 H) 9.55 (s, 1 H)
N'-ヒドロキシ-4-(2-ヒドロキシプロパン-2-イル)ベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.33 (s, 1 H) 5.02 (s, 1 H) 5.74 (s, 1 H) 7.32 - 7.49 (m, 2 H) 7.52 - 7.66 (m, 2 H) 9.54 (s, 1 H)
N'-ヒドロキシ-4-(ヒドロキシメチル)ベンゼンカルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 167 [M+H]+
4-[カルバモイル(メチル)アミノ]-N'-ヒドロキシベンゼンカルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 209 [M+H]+
4-(カルバモイルアミノ)-N'-ヒドロキシベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67 (s, 2 H) 5.87 (s, 2 H) 7.26 - 7.62 (m, 4 H) 8.60 (s, 1 H) 9.42 (s, 1 H)
3-(カルバモイルアミノ)-N'-ヒドロキシベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.08 (d, J=5.4 Hz, 1 H) 5.59 (s, 2 H) 5.74 (s, 1 H) 7.01 - 7.17 (m, 2 H) 7.31 - 7.40 (m, 1 H) 7.57 (t, J=1.9 Hz, 1 H) 8.45 (s, 1 H) 9.47 (s, 1 H)
N'-ヒドロキシ-4-[(メチルカルバモイル)アミノ]ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.64 (d, J=4.5 Hz, 3 H) 5.66 (s, 2 H) 6.03 (d, J=4.5 Hz, 1 H) 7.37 (d, J=8.7 Hz, 2 H) 7.47 - 7.55 (m, 2 H) 8.58 (s, 1 H) 9.41 (s, 1 H)
N'-ヒドロキシ-3-[(メチルカルバモイル)アミノ]ベンゼンカルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 2.63 (d, J=4.4 Hz, 3 H) 5.68 (s, 2 H) 5.99 (d, J=4.4 Hz, 1 H) 7.05 - 7.28 (m, 2 H) 7.47 (dt, J=7.5, 2.0 Hz, 1 H) 7.56 - 7.68 (m, 1 H) 8.52 (s, 1 H) 9.55 (s, 1 H)
メチル [4-(N'-ヒドロキシカルバムイミドイル)フェニル]カルバマート
N'-ヒドロキシ-1-オキソ-2,3-ジヒドロ-1H-イソインドール-5-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 192 [M+H]+
N'-ヒドロキシ-3-オキソ-2,3-ジヒドロ-1H-イソインドール-5-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 192 [M+H]+
N'-ヒドロキシ-2-オキソ-2,3-ジヒドロ-1H-インドール-5-カルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.48 (s, 2 H) 5.68 (s, 2 H) 6.78 (d, J=8.3 Hz, 1 H) 7.42 - 7.61 (m, 2 H) 9.43 (s, 1 H) 10.45 (s, 1 H)
N'-ヒドロキシ-2-オキソ-2,3-ジヒドロ-1H-ベンゾイミダゾール-5-カルボキシミドアミド
1H NMR (200 MHz, DMSO-d6) δ ppm 4.34 (br. s., 2 H) 5.69 (s, 2 H) 6.77 - 7.01 (m, 1 H) 7.15 - 7.63 (m, 3 H) 10.69 (br. s., 2 H)
N'-ヒドロキシ-4-(2-オキソイミダゾリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.37 - 3.50 (m, 2 H) 3.85 (dd, J=8.9, 7.22 Hz, 2 H) 5.72 (s, 2 H) 7.00 (s, 1 H) 7.47 - 7.65 (m, 4 H) 9.47 (s, 1 H)
N'-ヒドロキシ-3-(2-オキソイミダゾリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 3.36 - 3.45 (m, 2 H) 3.81 - 3.92 (m, 2 H) 5.76 (s, 2 H) 6.96 (s, 1 H) 7.24 - 7.32 (m, 2 H) 7.63 - 7.78 (m, 2 H) 9.60 (s, 1 H)
N'-ヒドロキシ-4-(2-オキソピロリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.06 (quin, J=7.53 Hz, 2 H) 2.40 - 2.57 (m, 2 H) 3.84 (t, J=7.02 Hz, 2 H) 5.77 (s, 2 H) 7.56 - 7.76 (m, 4 H) 9.56 (s, 1 H)
N'-ヒドロキシ-3-(2-オキソピロリジン-1-イル)ベンゼンカルボキシミドアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 2.03 - 2.12 (m, 2 H) 2.46 - 2.55 (m, 2 H) 3.80 - 3.90 (m, 2 H) 5.81 (s, 2 H) 7.32 - 8.04 (m, 4 H) 9.65 (s, 1 H)
N-(2,2-ジメトキシエチル)-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド
MS (ESI/APCI Dual pos.) m/z: 268 [M+H]+
N'-ヒドロキシ-2-オキソ-1,2-ジヒドロピリジン-4-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 154 [M+H]+
N'-ヒドロキシ-6-オキソ-1,6-ジヒドロピリジン-3-カルボキシミドアミド
MS (ESI/APCI Dual pos.) m/z: 154 [M+H]+
3-アミノ-N'-ヒドロキシベンゼンカルボキシミドアミド The following compounds were synthesized in the same manner.
2- [3- (N'-Hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI pos.) M / z: 194 [M + H] +
4- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δppm 5.88 (s, 2 H) 7.38 (br. S., 1 H) 7.73 (d, J = 8.35 Hz, 2 H) 7.86 (d, J = 8.35 Hz, 2 H) 7.97 (br. S., 1 H) 9.78 (s, 1 H)
3- (N'-Hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 5.85 (s, 2 H) 7.26-7.52 (m, 2 H) 7.72-7.89 (m, 2 H) 7.96 (br. S., 1 H) 8.15 (s , 1 H) 9.68 (s, 1 H)
4- (N'-hydroxycarbamimidoyl) -3-methylbenzamide
MS (ESI pos.) M / z: 194 [M + H] +
4-Fluoro-3- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI pos.) M / z: 198 [M + H] +
N- [2- (Dimethylamino) ethyl] -3- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.18 (s, 6 H) 2.40 (t, J = 6.81 Hz, 2 H) 3.32-3.43 (m, 2 H) 5.86 (s, 2 H) 7.39-7.51 (m, 1 H) 7.74-7.84 (m, 2 H) 8.12 (s, 1 H) 8.33-8.43 (m, 1 H) 9.69 (s, 1 H)
2- [3- (N'-Hydroxycarbamimidoyl) phenoxy] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.40 (s, 2 H) 5.75 (s, 2 H) 6.86-6.96 (m, 1 H) 7.19-7.28 (m, 3 H) 7.33 (br. S. , 1 H) 7.47 (br. S., 1 H) 9.59 (s, 1 H)
3- (N'-Hydroxycarbamimidoyl) -N- (oxetan-3-yl) benzamide
MS (ESI pos.) M / z: 236 [M + H] +
6- (N'-Hydroxycarbamimidoyl) pyridine-3-carboxamide
MS (ESI / APCI Dual pos.) M / z: 181 [M + H] +
N- [2- (Dimethylamino) ethyl] -4- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.12 (s, 9 H) 2.28-2.44 (m, 2 H) 3.18-3.53 (m, 2 H) 5.86 (s, 2 H) 7.32-8.54 (m, 5 H) 9.69 (s, 1 H)
3-Fluoro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
3- (N'-hydroxycarbamimidoyl) -4-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
4- (N'-hydroxycarbamimidoyl) -N-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
4- (N'-hydroxycarbamimidoyl) benzoic acid
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67-8.25 (m, 7 H)
3- (N'-Hydroxycarbamimidoyl) benzoic acid
1H NMR (200 MHz, DMSO-d6) δ ppm 5.65-8.32 (m, 7 H)
[4- (N'-Hydroxycarbamimidoyl) phenyl] acetic acid
[3- (N'-Hydroxycarbamimidoyl) phenyl] acetic acid
6- (N'-hydroxycarbamimidoyl) pyridine-2-carboxamide
1H NMR (200 MHz, DMSO-d6) δ ppm 6.39 (br. S., 2 H) 7.52-7.70 (m, 1 H) 7.86-8.09 (m, 3 H) 8.82 (br. S., 1 H) 9.93 (s, 1 H)
4- (N'-hydroxycarbamimidoyl) phenyl carbamate
1H NMR (200 MHz, DMSO-d6) δ ppm 5.56-9.69 (m, 9 H)
3- (N'-Hydroxycarbamimidoyl) -N-methylbenzamide
2- [3- (N'-Hydroxycarbamimidoyl) phenoxy] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.20-4.62 (m, 2 H) 5.75 (s, 2 H) 6.78-7.59 (m, 6 H) 9.59 (s, 1 H)
3- (N'-hydroxycarbamimidoyl) -N- (2-hydroxyethyl) benzamide
1H NMR (200 MHz, DMSO-d6) δ ppm 3.42-3.61 (m, 2 H) 4.59-4.91 (m, 1 H) 5.86 (s, 2 H) 7.32-8.48 (m, 7 H) 9.69 (s, 1 H)
tert-Butyl 3- (N'-hydroxycarbamimidoyl) benzoate
1H NMR (200 MHz, DMSO-d6) δ ppm 1.56 (s, 9 H) 5.72-9.84 (m, 7 H)
5- (N'-Hydroxycarbamimidoyl) pyridine-3-carboxamide
MS (ESI / APCI Dual pos.) M / z: 181 [M + H] +
2- [2-Bromo-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 5.75-5.92 (m, 2 H) 6.88-8.10 (m, 7 H) 9.68 (s, 1 H)
2- [4-Fluoro-3- (N'-hydroxycarbamimidoyl) phenyl] acetamide
1H NMR (200 MHz, DMSO-d6) δ ppm 3.33 (s, 2 H) 6.73-8.20 (m, 8 H)
2-Fluoro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
2- [3-Fluoro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 234 [M + Na] +
2- [3-Fluoro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
5- (N'-hydroxycarbamimidoyl) pyridine-2-carboxamide
MS (ESI / APCI Dual pos.) M / z: 181 [M + H] +
2- [2-Fluoro-3- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
2- [2-Fluoro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
2- [2-Chloro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 228 [M + H] +
5- (N'-hydroxycarbamimidoyl) -2-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
2- [5- (N'-Hydroxycarbamimidoyl) -2-methylphenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 208 [M + H]
2-Chloro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 214 [M + H] +
3-Chloro-4- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 214 [M + H] +
4- (N'-hydroxycarbamimidoyl) -2-methylbenzamide
MS (ESI / APCI Dual pos.) M / z: 194 [M + H] +
2- [2-Chloro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 228 [M + H] +
2- [4- (N'-Hydroxycarbamimidoyl) -2-methylphenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 208 [M + H] +
2- [4- (N'-Hydroxycarbamimidoyl) -3-methylphenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 208 [M + H] +
N'-hydroxy-3-[(3-oxopiperazin-1-yl) carbonyl] benzenecarboximidamide
MS (ESI / APCI Dual pos.) M / z: 263 [M + H] +
2-Fluoro-3- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
3- [3- (N'-Hydroxycarbamimidoyl) phenyl] propanamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.68-2.91 (m, 3 H) 3.33 (br. S., 1 H) 5.75 (s, 2 H) 6.76 (br. S., 1 H) 7.10- 7.62 (m, 5 H) 9.57 (s, 1 H)
2- [4- (N'-Hydroxycarbamimidoyl) phenyl] -2-methylpropanamide
1H NMR (200 MHz, DMSO-d6) δ ppm 1.43 (s, 6 H) 5.76 (s, 2 H) 6.90 (s, 2 H) 7.32 (d, J = 8.4 Hz, 2 H) 7.61 (d, J = 8.4 Hz, 2 H) 9.57 (s, 1 H)
3-acetyl-N'-hydroxybenzenecarboximidoamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.51 (dt, J = 3.7, 1.9 Hz, 3 H) 5.68 (s, 2 H) 6.69 (s, 2 H) 6.92 (d, J = 5.0 Hz, 1 H) 8.20 (d, J = 5.4 Hz, 1 H) 10.14 (s, 1 H)
2-Fluoro-5- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 198 [M + H] +
3-Fluoro-5- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI pos.) M / z: 198 [M + H] +
4- (N'-hydroxycarbamimidoyl) -3-methoxybenzamide
MS (ESI pos.) M / z: 210 [M + H] +
5- (N'-hydroxycarbamimidoyl) -2-methoxybenzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.90 (s, 3 H) 5.77 (s, 2 H) 7.12 (d, J = 9.1 Hz, 1 H) 7.49-7.58 (m, 1 H) 7.59-7.67 (m, 1 H) 7.74 (dd, J = 8.7, 2.48 Hz, 1 H) 8.11 (d, J = 2.5 Hz, 1 H) 9.51 (s, 1 H)
3- (N'-hydroxycarbamimidoyl) -4-methoxybenzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.84 (s, 3 H) 5.54-5.69 (m, 2 H) 7.06-7.22 (m, 2 H) 7.81-7.95 (m, 3 H) 9.39 (s, 1 H)
3- (N'-hydroxycarbamimidoyl) -2-methoxybenzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.05 (s, 2 H) 5.91-5.97 (m, 1 H) 7.06-8.29 (m, 7 H) 8.63-8.72 (m, 1 H)
N- (2-amino-2-oxoethyl) -3- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.83 (d, J = 5.78 Hz, 2 H) 5.86 (s, 2 H) 7.04 (br. S., 1 H) 7.38 (br. S., 1 H ) 7.47 (t, J = 7.8 Hz, 1 H) 7.74-7.90 (m, 2 H) 8.18 (t, J = 1.7 Hz, 1 H) 8.65 (t, J = 5.8 Hz, 1 H) 9.70 (s, 1 H)
N- (2-amino-2-oxoethyl) -4- (N'-hydroxycarbamimidoyl) benzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.79-3.85 (m, 2 H) 5.89 (s, 2 H) 7.37 (br. S., 1 H) 7.73-7.81 (m, 2 H) 7.87 (d , J = 8.7 Hz, 2 H) 7.94-8.06 (m, 1 H) 8.68 (s, 1 H) 9.78 (s, 1 H)
2- [3-Chloro-4- (N'-hydroxycarbamimidoyl) phenyl] acetamide
2- [3-Chloro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
3-Chloro-5- (N'-hydroxycarbamimidoyl) benzamide
2- [6- (N'-Hydroxycarbamimidoyl) pyridin-3-yl] acetamide
MS (ESI / APCI Dual pos.) M / z: 195 [M + H] +
2- [2-Fluoro-5- (N'-hydroxycarbamimidoyl) phenyl] acetamide
MS (ESI / APCI Dual pos.) M / z: 212 [M + H] +
2- [5- (N'-Hydroxycarbamimidoyl) pyridin-2-yl] acetamide
MS (ESI / APCI Dual pos.) M / z: 195 [M + H] +
N'-hydroxy-4- (2-hydroxyethyl) benzenecarboximidamide
1H NMR (200 MHz, CHLOROFORM-d) δ ppm 1.27-1.44 (m, 2 H) 4.21-4.49 (m, 2 H) 5.57 (s, 1 H) 6.98-8.00 (m, 7 H)
N'-hydroxy-2- (hydroxymethyl) pyridine-4-carboximidamide
N'-hydroxy-3- (2-hydroxypropan-2-yl) benzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.32 (s, 1 H) 5.01 (s, 1 H) 5.76 (s, 1 H) 7.19-7.37 (m, 1 H) 7.41 -7.56 (m, 2 H) 7.76 (t, J = 1.5 Hz, 1 H) 9.55 (s, 1 H)
N'-hydroxy-4- (2-hydroxypropan-2-yl) benzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 1.42 (s, 6 H) 3.33 (s, 1 H) 5.02 (s, 1 H) 5.74 (s, 1 H) 7.32-7.49 (m, 2 H) 7.52 -7.66 (m, 2 H) 9.54 (s, 1 H)
N'-hydroxy-4- (hydroxymethyl) benzenecarboximidamide
MS (ESI / APCI Dual pos.) M / z: 167 [M + H] +
4- [Carbamoyl (methyl) amino] -N'-hydroxybenzenecarboximidamide
MS (ESI / APCI Dual pos.) M / z: 209 [M + H] +
4- (Carbamoylamino) -N'-hydroxybenzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 5.67 (s, 2 H) 5.87 (s, 2 H) 7.26-7.62 (m, 4 H) 8.60 (s, 1 H) 9.42 (s, 1 H)
3- (Carbamoylamino) -N'-hydroxybenzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.08 (d, J = 5.4 Hz, 1 H) 5.59 (s, 2 H) 5.74 (s, 1 H) 7.01-7.17 (m, 2 H) 7.31-7.40 (m, 1 H) 7.57 (t, J = 1.9 Hz, 1 H) 8.45 (s, 1 H) 9.47 (s, 1 H)
N'-hydroxy-4-[(methylcarbamoyl) amino] benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.64 (d, J = 4.5 Hz, 3 H) 5.66 (s, 2 H) 6.03 (d, J = 4.5 Hz, 1 H) 7.37 (d, J = 8.7 Hz, 2 H) 7.47-7.55 (m, 2 H) 8.58 (s, 1 H) 9.41 (s, 1 H)
N'-hydroxy-3-[(methylcarbamoyl) amino] benzenecarboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 2.63 (d, J = 4.4 Hz, 3 H) 5.68 (s, 2 H) 5.99 (d, J = 4.4 Hz, 1 H) 7.05-7.28 (m, 2 H) 7.47 (dt, J = 7.5, 2.0 Hz, 1 H) 7.56-7.68 (m, 1 H) 8.52 (s, 1 H) 9.55 (s, 1 H)
Methyl [4- (N'-hydroxycarbamimidoyl) phenyl] carbamate
N'-hydroxy-1-oxo-2,3-dihydro-1H-isoindole-5-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 192 [M + H] +
N'-hydroxy-3-oxo-2,3-dihydro-1H-isoindole-5-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 192 [M + H] +
N'-hydroxy-2-oxo-2,3-dihydro-1H-indole-5-carboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.48 (s, 2 H) 5.68 (s, 2 H) 6.78 (d, J = 8.3 Hz, 1 H) 7.42-7.61 (m, 2 H) 9.43 (s , 1 H) 10.45 (s, 1 H)
N'-hydroxy-2-oxo-2,3-dihydro-1H-benzimidazole-5-carboximidamide
1H NMR (200 MHz, DMSO-d6) δ ppm 4.34 (br.s., 2 H) 5.69 (s, 2 H) 6.77-7.01 (m, 1 H) 7.15-7.63 (m, 3 H) 10.69 (br s., 2 H)
N'-hydroxy-4- (2-oxoimidazolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.37-3.50 (m, 2 H) 3.85 (dd, J = 8.9, 7.22 Hz, 2 H) 5.72 (s, 2 H) 7.00 (s, 1 H) 7.47 -7.65 (m, 4 H) 9.47 (s, 1 H)
N'-hydroxy-3- (2-oxoimidazolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.36-3.45 (m, 2 H) 3.81-3.92 (m, 2 H) 5.76 (s, 2 H) 6.96 (s, 1 H) 7.24-7.32 (m, 2 H) 7.63-7.78 (m, 2 H) 9.60 (s, 1 H)
N'-hydroxy-4- (2-oxopyrrolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.06 (quin, J = 7.53 Hz, 2 H) 2.40-2.57 (m, 2 H) 3.84 (t, J = 7.02 Hz, 2 H) 5.77 (s, 2 H) 7.56-7.76 (m, 4 H) 9.56 (s, 1 H)
N'-hydroxy-3- (2-oxopyrrolidin-1-yl) benzenecarboximidamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.03-2.12 (m, 2 H) 2.46-2.55 (m, 2 H) 3.80-3.90 (m, 2 H) 5.81 (s, 2 H) 7.32-8.04 ( m, 4 H) 9.65 (s, 1 H)
N- (2,2-dimethoxyethyl) -3- (N'-hydroxycarbamimidoyl) benzamide
MS (ESI / APCI Dual pos.) M / z: 268 [M + H] +
N'-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 154 [M + H] +
N'-hydroxy-6-oxo-1,6-dihydropyridine-3-carboximidamide
MS (ESI / APCI Dual pos.) M / z: 154 [M + H] +
3-Amino-N'-hydroxybenzenecarboximidamide
製造例6 4-(シアノメチル)ベンゾヒドラジド
メチル 4-(シアノメチル)ベンゾアート(1.00 g)、ヒドラジン一水和物(2.86 g)及びメタノール(20 mL)の混合物を2時間加熱還流した。反応液を氷浴冷却下にて15分間攪拌した後、生じた固体をろ取し、メタノールにて洗浄して表題化合物(527 mg)を淡茶色固体として得た。
1H NMR (200 MHz, DMSO-d6) δ ppm 4.11 (s, 2 H) 4.49 (br. s., 2 H) 7.42 (d, J=7.91 Hz, 2 H) 7.84 (d, J=7.91 Hz, 2 H) 9.79 (s, 1 H); MS (ESI neg.) m/z: 174 [M-H]- Production Example 6 4- (Cyanomethyl) benzohydrazide Methyl A mixture of 4- (cyanomethyl) benzoate (1.00 g), hydrazine monohydrate (2.86 g) and methanol (20 mL) was heated to reflux for 2 hours. . The reaction mixture was stirred for 15 minutes under ice bath cooling, and the resulting solid was collected by filtration and washed with methanol to give the title compound (527 mg) as a pale brown solid.
1H NMR (200 MHz, DMSO-d6) δ ppm 4.11 (s, 2 H) 4.49 (br. S., 2 H) 7.42 (d, J = 7.91 Hz, 2 H) 7.84 (d, J = 7.91 Hz, 2 H) 9.79 (s, 1 H); MS (ESI neg.) M / z: 174 [MH]-
メチル 4-(シアノメチル)ベンゾアート(1.00 g)、ヒドラジン一水和物(2.86 g)及びメタノール(20 mL)の混合物を2時間加熱還流した。反応液を氷浴冷却下にて15分間攪拌した後、生じた固体をろ取し、メタノールにて洗浄して表題化合物(527 mg)を淡茶色固体として得た。
1H NMR (200 MHz, DMSO-d6) δ ppm 4.11 (s, 2 H) 4.49 (br. s., 2 H) 7.42 (d, J=7.91 Hz, 2 H) 7.84 (d, J=7.91 Hz, 2 H) 9.79 (s, 1 H); MS (ESI neg.) m/z: 174 [M-H]- Production Example 6 4- (Cyanomethyl) benzohydrazide Methyl A mixture of 4- (cyanomethyl) benzoate (1.00 g), hydrazine monohydrate (2.86 g) and methanol (20 mL) was heated to reflux for 2 hours. . The reaction mixture was stirred for 15 minutes under ice bath cooling, and the resulting solid was collected by filtration and washed with methanol to give the title compound (527 mg) as a pale brown solid.
1H NMR (200 MHz, DMSO-d6) δ ppm 4.11 (s, 2 H) 4.49 (br. S., 2 H) 7.42 (d, J = 7.91 Hz, 2 H) 7.84 (d, J = 7.91 Hz, 2 H) 9.79 (s, 1 H); MS (ESI neg.) M / z: 174 [MH]-
同様にして以下の化合物を合成した。
3-(シアノメチル)ベンゾヒドラジド
MS (ESI neg.) m/z: 174 [M-H]-
4-シアノベンゾヒドラジド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.56 (br. s., 2 H) 7.87 - 7.95 (m, 4 H) 10.00 (br. s., 1 H)
3-シアノベンゾヒドラジド
MS (ESI neg.) m/z: 160 [M-H]- The following compounds were synthesized in the same manner.
3- (Cyanomethyl) benzohydrazide
MS (ESI neg.) M / z: 174 [MH]-
4-cyanobenzohydrazide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.56 (br. S., 2 H) 7.87-7.95 (m, 4 H) 10.00 (br. S., 1 H)
3-Cyanobenzohydrazide
MS (ESI neg.) M / z: 160 [MH]-
3-(シアノメチル)ベンゾヒドラジド
MS (ESI neg.) m/z: 174 [M-H]-
4-シアノベンゾヒドラジド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.56 (br. s., 2 H) 7.87 - 7.95 (m, 4 H) 10.00 (br. s., 1 H)
3-シアノベンゾヒドラジド
MS (ESI neg.) m/z: 160 [M-H]- The following compounds were synthesized in the same manner.
3- (Cyanomethyl) benzohydrazide
MS (ESI neg.) M / z: 174 [MH]-
4-cyanobenzohydrazide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.56 (br. S., 2 H) 7.87-7.95 (m, 4 H) 10.00 (br. S., 1 H)
3-Cyanobenzohydrazide
MS (ESI neg.) M / z: 160 [MH]-
製造例7 N'-[4-(シアノメチル)ベンゾイル]-1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボヒドラジド
窒素雰囲気下、1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸(26 mg)のテトラヒドロフラン(0.40 mL)溶液に、室温にて4-(シアノメチル)ベンゾヒドラジド(23 mg)、ジイソプロピルエチルアミン(31 μL)及びO-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HATU)(49 mg)を加えて14時間撹拌した。反応液に水を加え、クロロホルム/メタノール(5/1)にて抽出した。有機層を無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=99:1~97:3)にて精製して、表題化合物(36 mg)を無色固体として得た。
1H NMR (600 MHz, METHANOL-d3) δ ppm 3.98 (s, 3 H) 3.99 (s, 2 H) 5.83 (s, 2 H) 6.99 (d, J=9.08 Hz, 1 H) 7.49 (d, J=8.26 Hz, 2 H) 7.90 - 7.97 (m, 4 H) 8.53 (s, 1 H); MS (ESI pos.) m/z: 459 [M+H]+ Production Example 7 N ′-[4- (Cyanomethyl) benzoyl] -1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carbohydrazide Under a nitrogen atmosphere, 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylic acid (26 mg) in tetrahydrofuran (0.40 mL) ) Solution of 4- (cyanomethyl) benzohydrazide (23 mg), diisopropylethylamine (31 μL) and O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′- at room temperature. Tetramethyluronium hexafluorophosphoric acid (HATU) (49 mg) was added and stirred for 14 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform / methanol (5/1). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 99: 1 to 97: 3) to give the title compound (36 mg) as a colorless solid.
1H NMR (600 MHz, METHANOL-d3) δ ppm 3.98 (s, 3 H) 3.99 (s, 2 H) 5.83 (s, 2 H) 6.99 (d, J = 9.08 Hz, 1 H) 7.49 (d, J = 8.26 Hz, 2 H) 7.90-7.97 (m, 4 H) 8.53 (s, 1 H); MS (ESI pos.) M / z: 459 [M + H] +
窒素雰囲気下、1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸(26 mg)のテトラヒドロフラン(0.40 mL)溶液に、室温にて4-(シアノメチル)ベンゾヒドラジド(23 mg)、ジイソプロピルエチルアミン(31 μL)及びO-(7-アザベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウム ヘキサフルオロリン酸(HATU)(49 mg)を加えて14時間撹拌した。反応液に水を加え、クロロホルム/メタノール(5/1)にて抽出した。有機層を無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=99:1~97:3)にて精製して、表題化合物(36 mg)を無色固体として得た。
1H NMR (600 MHz, METHANOL-d3) δ ppm 3.98 (s, 3 H) 3.99 (s, 2 H) 5.83 (s, 2 H) 6.99 (d, J=9.08 Hz, 1 H) 7.49 (d, J=8.26 Hz, 2 H) 7.90 - 7.97 (m, 4 H) 8.53 (s, 1 H); MS (ESI pos.) m/z: 459 [M+H]+ Production Example 7 N ′-[4- (Cyanomethyl) benzoyl] -1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carbohydrazide Under a nitrogen atmosphere, 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylic acid (26 mg) in tetrahydrofuran (0.40 mL) ) Solution of 4- (cyanomethyl) benzohydrazide (23 mg), diisopropylethylamine (31 μL) and O- (7-azabenzotriazol-1-yl) -N, N, N ′, N′- at room temperature. Tetramethyluronium hexafluorophosphoric acid (HATU) (49 mg) was added and stirred for 14 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform / methanol (5/1). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 99: 1 to 97: 3) to give the title compound (36 mg) as a colorless solid.
1H NMR (600 MHz, METHANOL-d3) δ ppm 3.98 (s, 3 H) 3.99 (s, 2 H) 5.83 (s, 2 H) 6.99 (d, J = 9.08 Hz, 1 H) 7.49 (d, J = 8.26 Hz, 2 H) 7.90-7.97 (m, 4 H) 8.53 (s, 1 H); MS (ESI pos.) M / z: 459 [M + H] +
同様にして以下の化合物を合成した。
N'-[3-(シアノメチル)ベンゾイル]-1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボヒドラジド
MS (ESI neg.) m/z : 457 [M-H]- The following compounds were synthesized in the same manner.
N '-[3- (cyanomethyl) benzoyl] -1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carbohydrazide
MS (ESI neg.) M / z: 457 [MH]-
N'-[3-(シアノメチル)ベンゾイル]-1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボヒドラジド
MS (ESI neg.) m/z : 457 [M-H]- The following compounds were synthesized in the same manner.
N '-[3- (cyanomethyl) benzoyl] -1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carbohydrazide
MS (ESI neg.) M / z: 457 [MH]-
製造例8 メチル ({4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)-1,3,4-オキサジアゾール-2-イル]フェニル}アセチル)カルバマート
1)tert-ブチル 2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジンカルボキシラート
1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボン酸(500 mg)のクロロホルム(5.0 mL)溶液に、氷浴冷却下、塩化オキサリル(254 mg)及びN,N-ジメチルホルムアミド(1滴)を加えた後、室温にて1時間攪拌した。 反応液を減圧下濃縮した。残渣のテトラヒドロフラン(5.0 mL)懸濁液に氷浴冷却下、ピリジン(260 mg)及びtert-ブチル ヒドラジンカルボキシラート(264 mg)を加えた後、室温にて1時間攪拌した。反応液を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム~クロロホルム:メタノール=90:10)にて精製して、表題化合物(730 mg)を無色固体として得た。
2)1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボヒドラジド 塩酸塩
tert-ブチル 2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジンカルボキシラート(690 mg)、クロロホルム(7.0 mL)及び塩化水素溶液(1.25 mL、4M ジオキサン溶液)の混合物を室温にて20時間攪拌した。反応液を減圧下濃縮した後、酢酸エチルにて洗浄して、表題化合物(550 mg)を無色固体として得た。
3)2-[4-({2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジニル}カルボニル)フェニル]アセトアミド
4-(2-アミノ-2-オキソエチル)安息香酸(188 mg)のN,N-ジメチルホルムアミド(3.0 mL)溶液に、室温にて1,1’-カルボニルジイミダゾール(193 mg)を加えた後、40 ℃にて1時間攪拌した。反応液に1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボヒドラジド 塩酸塩(300 mg)を加え、40 ℃にて5時間攪拌した。反応液に水を加え、クロロホルムにて抽出した。有機層を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム~クロロホルム:メタノール=90:10)にて精製して、表題化合物(180 mg)を無色固体として得た。
4)メチル ({4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)-1,3,4-オキサジアゾール-2-イル]フェニル}アセチル)カルバマート
窒素雰囲気下、2-[4-({2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジニル}カルボニル)フェニル]アセトアミド(180 mg)、テトラヒドロフラン(3.8 mL)及びBurgess試薬(451 mg)の混合物を70 ℃にて2時間撹拌した。反応液を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム~クロロホルム:メタノール=95:5)にて精製して、表題化合物(120 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 3.68 (s, 3 H) 3.92 (s, 3 H) 4.35 (s, 2 H) 5.54 (s, 2 H) 7.20 (d, J=8.67 Hz, 2 H) 7.40 (d, J=8.67 Hz, 2 H) 7.65 (d, J=8.67 Hz, 2 H) 7.78 (d, J=8.26 Hz, 2 H) 7.97 (s, 1 H) 10.92 (s, 1 H) ; MS (ESI pos.) m/z : 516 [M+H]+ Production Example 8 Methyl ({4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazole -2-yl] phenyl} acetyl) carbamate 1) tert-butyl 2-[(1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) carbonyl] hydrazine Carboxylate 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carboxylic acid (500 mg) in chloroform (5.0 mL) was cooled with an ice bath. Oxalyl chloride (254 mg) and N, N-dimethylformamide (1 drop) were added, and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated under reduced pressure. To a suspension of the residue in tetrahydrofuran (5.0 mL), pyridine (260 mg) and tert-butyl hydrazinecarboxylate (264 mg) were added while cooling in an ice bath, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform to chloroform: methanol = 90: 10) to give the title compound (730 mg) as a colorless solid.
2) 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carbohydrazide hydrochloride tert-butyl 2-[(1-methyl-5-{[4- ( Trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) carbonyl] hydrazinecarboxylate (690 mg), chloroform (7.0 mL) and hydrogen chloride solution (1.25 mL, 4M dioxane solution) Was stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure and washed with ethyl acetate to give the title compound (550 mg) as a colorless solid.
3) 2- [4-({2-[(1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) carbonyl] hydrazinyl} carbonyl) phenyl] acetamide To a solution of 4- (2-amino-2-oxoethyl) benzoic acid (188 mg) in N, N-dimethylformamide (3.0 mL) was added 1,1′-carbonyldiimidazole (193 mg) at room temperature. After that, the mixture was stirred at 40 ° C. for 1 hour. 1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carbohydrazide hydrochloride (300 mg) was added to the reaction solution, and the mixture was stirred at 40 ° C. for 5 hours. Water was added to the reaction solution and extracted with chloroform. The organic layer was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform to chloroform: methanol = 90: 10) to give the title compound (180 mg) as a colorless solid.
4) Methyl ({4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazole- 2-yl] phenyl} acetyl) carbamate Under nitrogen atmosphere 2- [4-({2-[(1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4- Yl) carbonyl] hydrazinyl} carbonyl) phenyl] acetamide (180 mg), tetrahydrofuran (3.8 mL) and Burgess reagent (451 mg) were stirred at 70 ° C. for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform to chloroform: methanol = 95: 5) to give the title compound (120 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δppm 3.68 (s, 3 H) 3.92 (s, 3 H) 4.35 (s, 2 H) 5.54 (s, 2 H) 7.20 (d, J = 8.67 Hz, 2 H ) 7.40 (d, J = 8.67 Hz, 2 H) 7.65 (d, J = 8.67 Hz, 2 H) 7.78 (d, J = 8.26 Hz, 2 H) 7.97 (s, 1 H) 10.92 (s, 1 H ); MS (ESI pos.) M / z: 516 [M + H] +
1)tert-ブチル 2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジンカルボキシラート
1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボン酸(500 mg)のクロロホルム(5.0 mL)溶液に、氷浴冷却下、塩化オキサリル(254 mg)及びN,N-ジメチルホルムアミド(1滴)を加えた後、室温にて1時間攪拌した。 反応液を減圧下濃縮した。残渣のテトラヒドロフラン(5.0 mL)懸濁液に氷浴冷却下、ピリジン(260 mg)及びtert-ブチル ヒドラジンカルボキシラート(264 mg)を加えた後、室温にて1時間攪拌した。反応液を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム~クロロホルム:メタノール=90:10)にて精製して、表題化合物(730 mg)を無色固体として得た。
2)1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボヒドラジド 塩酸塩
tert-ブチル 2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジンカルボキシラート(690 mg)、クロロホルム(7.0 mL)及び塩化水素溶液(1.25 mL、4M ジオキサン溶液)の混合物を室温にて20時間攪拌した。反応液を減圧下濃縮した後、酢酸エチルにて洗浄して、表題化合物(550 mg)を無色固体として得た。
3)2-[4-({2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジニル}カルボニル)フェニル]アセトアミド
4-(2-アミノ-2-オキソエチル)安息香酸(188 mg)のN,N-ジメチルホルムアミド(3.0 mL)溶液に、室温にて1,1’-カルボニルジイミダゾール(193 mg)を加えた後、40 ℃にて1時間攪拌した。反応液に1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-カルボヒドラジド 塩酸塩(300 mg)を加え、40 ℃にて5時間攪拌した。反応液に水を加え、クロロホルムにて抽出した。有機層を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム~クロロホルム:メタノール=90:10)にて精製して、表題化合物(180 mg)を無色固体として得た。
4)メチル ({4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)-1,3,4-オキサジアゾール-2-イル]フェニル}アセチル)カルバマート
窒素雰囲気下、2-[4-({2-[(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾール-4-イル)カルボニル]ヒドラジニル}カルボニル)フェニル]アセトアミド(180 mg)、テトラヒドロフラン(3.8 mL)及びBurgess試薬(451 mg)の混合物を70 ℃にて2時間撹拌した。反応液を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム~クロロホルム:メタノール=95:5)にて精製して、表題化合物(120 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 3.68 (s, 3 H) 3.92 (s, 3 H) 4.35 (s, 2 H) 5.54 (s, 2 H) 7.20 (d, J=8.67 Hz, 2 H) 7.40 (d, J=8.67 Hz, 2 H) 7.65 (d, J=8.67 Hz, 2 H) 7.78 (d, J=8.26 Hz, 2 H) 7.97 (s, 1 H) 10.92 (s, 1 H) ; MS (ESI pos.) m/z : 516 [M+H]+ Production Example 8 Methyl ({4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazole -2-yl] phenyl} acetyl) carbamate 1) tert-butyl 2-[(1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) carbonyl] hydrazine Carboxylate 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carboxylic acid (500 mg) in chloroform (5.0 mL) was cooled with an ice bath. Oxalyl chloride (254 mg) and N, N-dimethylformamide (1 drop) were added, and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated under reduced pressure. To a suspension of the residue in tetrahydrofuran (5.0 mL), pyridine (260 mg) and tert-butyl hydrazinecarboxylate (264 mg) were added while cooling in an ice bath, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform to chloroform: methanol = 90: 10) to give the title compound (730 mg) as a colorless solid.
2) 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carbohydrazide hydrochloride tert-butyl 2-[(1-methyl-5-{[4- ( Trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) carbonyl] hydrazinecarboxylate (690 mg), chloroform (7.0 mL) and hydrogen chloride solution (1.25 mL, 4M dioxane solution) Was stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure and washed with ethyl acetate to give the title compound (550 mg) as a colorless solid.
3) 2- [4-({2-[(1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) carbonyl] hydrazinyl} carbonyl) phenyl] acetamide To a solution of 4- (2-amino-2-oxoethyl) benzoic acid (188 mg) in N, N-dimethylformamide (3.0 mL) was added 1,1′-carbonyldiimidazole (193 mg) at room temperature. After that, the mixture was stirred at 40 ° C. for 1 hour. 1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4-carbohydrazide hydrochloride (300 mg) was added to the reaction solution, and the mixture was stirred at 40 ° C. for 5 hours. Water was added to the reaction solution and extracted with chloroform. The organic layer was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform to chloroform: methanol = 90: 10) to give the title compound (180 mg) as a colorless solid.
4) Methyl ({4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazole- 2-yl] phenyl} acetyl) carbamate Under nitrogen atmosphere 2- [4-({2-[(1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole-4- Yl) carbonyl] hydrazinyl} carbonyl) phenyl] acetamide (180 mg), tetrahydrofuran (3.8 mL) and Burgess reagent (451 mg) were stirred at 70 ° C. for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform to chloroform: methanol = 95: 5) to give the title compound (120 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δppm 3.68 (s, 3 H) 3.92 (s, 3 H) 4.35 (s, 2 H) 5.54 (s, 2 H) 7.20 (d, J = 8.67 Hz, 2 H ) 7.40 (d, J = 8.67 Hz, 2 H) 7.65 (d, J = 8.67 Hz, 2 H) 7.78 (d, J = 8.26 Hz, 2 H) 7.97 (s, 1 H) 10.92 (s, 1 H ); MS (ESI pos.) M / z: 516 [M + H] +
製造例9 エチル 5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾール-4-カルボキシラート
製造例1で得られたエチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート(1.69 g)及び2-クロロ-5-(ジフルオロメチル)ピリジン(1.32 g)のN,N-ジメチルホルムアミド(20 mL)溶液に、氷浴冷却下、水素化ナトリウム(60%、387 mgを少しずつ加えた後、同温にて10分間、室温にて18時間攪拌した。 反応液に水(100 mL)を加え、析出した結晶をろ取し、表題化合物(1.99 g)を無色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 312 [M+H]+ Production Example 9 Ethyl 5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5- (hydroxy) obtained in Production Example 1 Methyl) -1-methyl-1H-pyrazole-4-carboxylate (1.69 g) and 2-chloro-5- (difluoromethyl) pyridine (1.32 g) in N, N-dimethylformamide (20 mL) To the solution, sodium hydride (60%, 387 mg) was added little by little with cooling in an ice bath, and the mixture was stirred at the same temperature for 10 minutes and at room temperature for 18 hours. The precipitated crystals were collected by filtration to give the title compound (1.99 g) as a colorless solid.
MS (ESI / APCI Dual pos.) M / z: 312 [M + H] +
製造例1で得られたエチル 5-(ヒドロキシメチル)-1-メチル-1H-ピラゾール-4-カルボキシラート(1.69 g)及び2-クロロ-5-(ジフルオロメチル)ピリジン(1.32 g)のN,N-ジメチルホルムアミド(20 mL)溶液に、氷浴冷却下、水素化ナトリウム(60%、387 mgを少しずつ加えた後、同温にて10分間、室温にて18時間攪拌した。 反応液に水(100 mL)を加え、析出した結晶をろ取し、表題化合物(1.99 g)を無色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 312 [M+H]+ Production Example 9 Ethyl 5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5- (hydroxy) obtained in Production Example 1 Methyl) -1-methyl-1H-pyrazole-4-carboxylate (1.69 g) and 2-chloro-5- (difluoromethyl) pyridine (1.32 g) in N, N-dimethylformamide (20 mL) To the solution, sodium hydride (60%, 387 mg) was added little by little with cooling in an ice bath, and the mixture was stirred at the same temperature for 10 minutes and at room temperature for 18 hours. The precipitated crystals were collected by filtration to give the title compound (1.99 g) as a colorless solid.
MS (ESI / APCI Dual pos.) M / z: 312 [M + H] +
同様にして以下の化合物を合成した。
エチル 5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
エチル 5-{[(5-ヨードピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 388 [M+H]+ The following compounds were synthesized in the same manner.
Ethyl 5-{[(5-chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate ethyl 5-{[(5-iodopyridin-2-yl) oxy] methyl } -1-Methyl-1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 388 [M + H] +
エチル 5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
エチル 5-{[(5-ヨードピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
MS (ESI/APCI Dual pos.) m/z: 388 [M+H]+ The following compounds were synthesized in the same manner.
Ethyl 5-{[(5-chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate ethyl 5-{[(5-iodopyridin-2-yl) oxy] methyl } -1-Methyl-1H-pyrazole-4-carboxylate
MS (ESI / APCI Dual pos.) M / z: 388 [M + H] +
製造例10 メチル 5-{[(6-メトキシピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
Production Example 10 Methyl 5-{[(6-methoxypyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate
製造例2で得られたエチル 5-{[(6-フルオロピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート(266 mg)、ナトリウムメトキシド(28%/メタノール、550 μL)及びメタノール(2.0 mL)の混合物を、マイクロウェーブ照射下150 ℃にて1時間撹拌した。反応液を減圧下濃縮した後、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=95:5~90:10)にて精製し、表題化合物(150 mg)を無色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 278 [M+H]+ Ethyl 5-{[(6-fluoropyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate (266 mg) obtained in Preparation Example 2, sodium methoxide (28% / Methanol, 550 μL) and methanol (2.0 mL) were stirred at 150 ° C. for 1 hour under microwave irradiation. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 95: 5 to 90:10) to give the title compound (150 mg) as a colorless solid.
MS (ESI / APCI Dual pos.) M / z: 278 [M + H] +
MS (ESI/APCI Dual pos.) m/z: 278 [M+H]+ Ethyl 5-{[(6-fluoropyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate (266 mg) obtained in Preparation Example 2, sodium methoxide (28% / Methanol, 550 μL) and methanol (2.0 mL) were stirred at 150 ° C. for 1 hour under microwave irradiation. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 95: 5 to 90:10) to give the title compound (150 mg) as a colorless solid.
MS (ESI / APCI Dual pos.) M / z: 278 [M + H] +
製造例11 エチル 5-{[(5-シクロプロピルピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート
製造例9で得られたエチル 5-{[(5-ヨードピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート(2.00 g)、シクロプロピルジンク(II) ブロミド(0.5M/テトラヒドロフラン,15.5 mL)、テトラキストリフェニルホスフィンパラジウム(497 mg)及びテトラヒドロフラン(20 mL)の混合物を、窒素雰囲気下、60 ℃にて1時間攪拌した。反応液に水を加え、反応液を減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~50:50)にて精製し、表題化合物(510 mg)を黄色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 302 [M+H]+ Production Example 11 Ethyl 5-{[(5-Cyclopropylpyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5-{[(5 -Iodopyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate (2.00 g), cyclopropylzinc (II) bromide (0.5M / tetrahydrofuran, 15.5 mL) ), Tetrakistriphenylphosphine palladium (497 mg) and tetrahydrofuran (20 mL) were stirred at 60 ° C. for 1 hour under a nitrogen atmosphere. Water was added to the reaction solution, and the reaction solution was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 90: 10-50: 50) to give the title compound (510 mg) as a yellow solid.
MS (ESI / APCI Dual pos.) M / z: 302 [M + H] +
製造例9で得られたエチル 5-{[(5-ヨードピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾール-4-カルボキシラート(2.00 g)、シクロプロピルジンク(II) ブロミド(0.5M/テトラヒドロフラン,15.5 mL)、テトラキストリフェニルホスフィンパラジウム(497 mg)及びテトラヒドロフラン(20 mL)の混合物を、窒素雰囲気下、60 ℃にて1時間攪拌した。反応液に水を加え、反応液を減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=90:10~50:50)にて精製し、表題化合物(510 mg)を黄色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 302 [M+H]+ Production Example 11 Ethyl 5-{[(5-Cyclopropylpyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate Ethyl 5-{[(5 -Iodopyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazole-4-carboxylate (2.00 g), cyclopropylzinc (II) bromide (0.5M / tetrahydrofuran, 15.5 mL) ), Tetrakistriphenylphosphine palladium (497 mg) and tetrahydrofuran (20 mL) were stirred at 60 ° C. for 1 hour under a nitrogen atmosphere. Water was added to the reaction solution, and the reaction solution was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 90: 10-50: 50) to give the title compound (510 mg) as a yellow solid.
MS (ESI / APCI Dual pos.) M / z: 302 [M + H] +
実施例1 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
Example 1 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) acetamide
1H NMR (600 MHz, DMSO-d6) δppm 3.38 (s, 2 H) 3.96 (s, 3 H) 5.85 (s, 2 H) 6.85 (br. s., 1 H) 7.02 (d, J=8.67 Hz, 1 H) 7.32 (d, J=8.26 Hz, 2 H) 7.44 (br. s., 1 H) 7.76 (d, J=8.26 Hz, 2 H) 8.04 (dd, J=9.08, 2.48 Hz, 1 H) 8.16 (s, 1 H) 8.61 (s, 1 H); MS (ESI pos.) m/z : 459 [M+H]+
1H NMR (600 MHz, DMSO-d6) δppm 3.38 (s, 2 H) 3.96 (s, 3 H) 5.85 (s, 2 H) 6.85 (br. S., 1 H) 7.02 (d, J = 8.67 Hz , 1 H) 7.32 (d, J = 8.26 Hz, 2 H) 7.44 (br. S., 1 H) 7.76 (d, J = 8.26 Hz, 2 H) 8.04 (dd, J = 9.08, 2.48 Hz, 1 H) 8.16 (s, 1 H) 8.61 (s, 1 H); MS (ESI pos.) M / z: 459 [M + H] +
実施例1と同様の手法を用いて、表1-1から表1-3に記載した実施例2から実施例14の化合物を得た。
Using the same method as in Example 1, the compounds of Examples 2 to 14 listed in Table 1-1 to Table 1-3 were obtained.
実施例2 4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例3 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例4 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例5 6-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ピリジン-3-カルボキサミド
実施例6 N-[2-(ジメチルアミノ)エチル]-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例7 3-メチル-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例8 3-フルオロ-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例9 4-フルオロ-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例10 4-メチル-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例11 N-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例12 4-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例13 3-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例14 4-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド Example 2 4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl} benzamide Example 3 3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} benzamide Example 4 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 5 6- [5- (1-Methyl-5-{[4- (tri Fluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] pyridine-3-carboxamide Example 6 N- [2- (dimethylamino) ethyl] -4 -[5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 7 3-Methyl-4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3 -Yl] benzamide Example 8 3-Fluoro-4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2, 4-oxadiazol-3-yl] benzamide Example 9 4-Fluoro-3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 10 4-Methyl-3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole -4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 11 N-methyl-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine- 2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 12 4-methyl-3- {5- [1-methyl-5 -({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 13 3-methyl -4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol -3-yl} benzamide Example 14 4-Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole- 4-yl] -1,2,4-oxadiazol-3-yl} benzamide
実施例3 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例4 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例5 6-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ピリジン-3-カルボキサミド
実施例6 N-[2-(ジメチルアミノ)エチル]-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例7 3-メチル-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例8 3-フルオロ-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例9 4-フルオロ-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例10 4-メチル-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例11 N-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例12 4-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例13 3-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例14 4-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド Example 2 4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl} benzamide Example 3 3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} benzamide Example 4 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 5 6- [5- (1-Methyl-5-{[4- (tri Fluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] pyridine-3-carboxamide Example 6 N- [2- (dimethylamino) ethyl] -4 -[5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 7 3-Methyl-4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3 -Yl] benzamide Example 8 3-Fluoro-4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2, 4-oxadiazol-3-yl] benzamide Example 9 4-Fluoro-3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 10 4-Methyl-3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazole -4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 11 N-methyl-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine- 2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 12 4-methyl-3- {5- [1-methyl-5 -({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 13 3-methyl -4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol -3-yl} benzamide Example 14 4-Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole- 4-yl] -1,2,4-oxadiazol-3-yl} benzamide
実施例15 2-{3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
Example 15 2- {3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3 -Il] phenyl} acetamide
1H NMR (500 MHz, DMSO-d6) δ ppm 3.43 (s, 2 H) 3.99 (s, 3 H) 5.72 (s, 2 H) 6.90 (br. s., 1 H) 7.30 (d, J=8.79 Hz, 2 H) 7.41 - 7.45 (m, 2 H) 7.52 (br. s., 1 H) 7.69 (d, J=8.79 Hz, 2 H) 7.76 - 7.80 (m, 1 H) 7.90 (s, 1 H) 8.24 (s, 1 H) ; MS (ESI pos.) m/z : 458 [M+H]+
1H NMR (500 MHz, DMSO-d6) δ ppm 3.43 (s, 2 H) 3.99 (s, 3 H) 5.72 (s, 2 H) 6.90 (br. S., 1 H) 7.30 (d, J = 8.79 Hz, 2 H) 7.41-7.45 (m, 2 H) 7.52 (br. S., 1 H) 7.69 (d, J = 8.79 Hz, 2 H) 7.76-7.80 (m, 1 H) 7.90 (s, 1 H) 8.24 (s, 1 H); MS (ESI pos.) M / z: 458 [M + H] +
実施例15と同様の手法を用いて、表2-1から表2-3に記載した実施例16から実施例31の化合物を得た。
Using the same method as in Example 15, the compounds of Example 16 to Example 31 described in Tables 2-1 to 2-3 were obtained.
実施例16 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]安息香酸
実施例17 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]安息香酸
実施例18 2-{4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例19 {4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}酢酸
実施例20 {3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}酢酸
実施例21 6-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ピリジン-2-カルボキサミド
実施例22 2-[3-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例23 2-[4-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例24 2-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例25 2-{4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例26 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル カルバマート
実施例27 N-[2-(ジメチルアミノ)エチル]-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例28 N-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例29 2-{3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェノキシ}アセトアミド
実施例30 N-(2-ヒドロキシエチル)-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例31 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]-N-(オキセタン-3-イル)ベンズアミド Example 16 4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] Benzoic acid Example 17 3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3- yl] benzoic acid example 18 2- {4- [5- (1-methyl-5 - {[4- (trifluoromethyl) phenoxy] methyl}-1H-pyrazol-4-yl) -1,2,4 -Oxadiazol-3-yl] phenyl} acetamide Example 19 {4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1 , 2,4-oxadiazol-3-yl] phenyl} acetic acid Example 20 {3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4- Yl) -1,2,4-oxadiazol-3-yl] phenyl} acetic acid EXAMPLE 21 6- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyra Le-4-yl) -1,2,4-oxadiazol-3-yl] pyridine-2-carboxamide Example 22 2- [3- (5- {5 - [(4-fluorophenoxy) methyl] -1 Methyl-1H-pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 23 2- [4- (5- {5-[(4-fluorophenoxy) methyl]- 1-methyl-1H-pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 24 2- {3- [5- (5-{[(5-fluoropyridine- 2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 25 2- {4- [5- (5 -{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 26 4 -[5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl Rubamate Example 27 N- [2- (Dimethylamino) ethyl] -3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide example 28 N-methyl-3- {5- [1-methyl-5 - ({[5- (trifluoromethyl) pyridin-2-yl] oxy } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 29 2- {3- [5- (1-methyl-5-{[4- (tri Fluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenoxy} acetamide Example 30 N- (2-hydroxyethyl) -3- [5- ( 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 31 3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl ] -N- (Oxetane-3-yl) benzamide
実施例17 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]安息香酸
実施例18 2-{4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例19 {4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}酢酸
実施例20 {3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}酢酸
実施例21 6-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ピリジン-2-カルボキサミド
実施例22 2-[3-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例23 2-[4-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例24 2-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例25 2-{4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例26 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル カルバマート
実施例27 N-[2-(ジメチルアミノ)エチル]-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例28 N-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例29 2-{3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェノキシ}アセトアミド
実施例30 N-(2-ヒドロキシエチル)-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例31 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]-N-(オキセタン-3-イル)ベンズアミド Example 16 4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] Benzoic acid Example 17 3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3- yl] benzoic acid example 18 2- {4- [5- (1-methyl-5 - {[4- (trifluoromethyl) phenoxy] methyl}-1H-pyrazol-4-yl) -1,2,4 -Oxadiazol-3-yl] phenyl} acetamide Example 19 {4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1 , 2,4-oxadiazol-3-yl] phenyl} acetic acid Example 20 {3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4- Yl) -1,2,4-oxadiazol-3-yl] phenyl} acetic acid EXAMPLE 21 6- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyra Le-4-yl) -1,2,4-oxadiazol-3-yl] pyridine-2-carboxamide Example 22 2- [3- (5- {5 - [(4-fluorophenoxy) methyl] -1 Methyl-1H-pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 23 2- [4- (5- {5-[(4-fluorophenoxy) methyl]- 1-methyl-1H-pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 24 2- {3- [5- (5-{[(5-fluoropyridine- 2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 25 2- {4- [5- (5 -{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 26 4 -[5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl Rubamate Example 27 N- [2- (Dimethylamino) ethyl] -3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide example 28 N-methyl-3- {5- [1-methyl-5 - ({[5- (trifluoromethyl) pyridin-2-yl] oxy } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 29 2- {3- [5- (1-methyl-5-{[4- (tri Fluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenoxy} acetamide Example 30 N- (2-hydroxyethyl) -3- [5- ( 1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 31 3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl ] -N- (Oxetane-3-yl) benzamide
実施例32 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
Example 32 3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] Benzamide
1H NMR (600 MHz, DMSO-d6) δppm 4.00 (s, 3 H) 5.73 (s, 2 H) 7.23 - 7.36 (m, 2 H) 7.49 (br. s., 1 H) 7.62 - 7.77 (m, 2 H) 7.93 - 8.04 (m, 4 H) 8.08 (s, 1 H) 8.25 (s, 1 H) ; MS (ESI pos.) m/z : 444 [M+H]+
1H NMR (600 MHz, DMSO-d6) δppm 4.00 (s, 3 H) 5.73 (s, 2 H) 7.23-7.36 (m, 2 H) 7.49 (br. S., 1 H) 7.62-7.77 (m, 2 H) 7.93-8.04 (m, 4 H) 8.08 (s, 1 H) 8.25 (s, 1 H); MS (ESI pos.) M / z: 444 [M + H] +
実施例32と同様の手法を用いて、表3-1から表3-2に記載した実施例33から実施例41の化合物を得た。
Using the same method as in Example 32, the compounds of Example 33 to Example 41 described in Table 3-1 to Table 3-2 were obtained.
実施例33 tert-ブチル 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンゾアート
実施例34 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例35 3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例36 4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例37 4-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)ベンズアミド
実施例38 3-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)ベンズアミド
実施例39 5-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ピリジン-3-カルボキサミド
実施例40 N-メチル-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例41 N-メチル-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド Example 33 tert-butyl 3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3 -Yl] benzoate Example 34 4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol -3-yl] benzamide Example 35 3- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2 , 4-Oxadiazol-3-yl] benzamide Example 36 4- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 37 4- (5- {5-[(4-fluorophenoxy) methyl] -1-methyl-1H-pyrazol-4-yl} -1, 2,4-oxadiazol-3-yl) benzamide Example 38 3- (5- {5-[(4-fluorophenoxy) methyl] -1-methyl-1H-pyrazol-4-yl} -1,2,4 -Oki Sadiazol-3-yl) benzamide Example 39 5- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4 -Oxadiazol-3-yl] pyridine-3-carboxamide Example 40 N-methyl-3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4 -Yl) -1,2,4-oxadiazol-3-yl] benzamide Example 41 N-methyl-4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl}- 1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide
実施例34 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例35 3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例36 4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例37 4-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)ベンズアミド
実施例38 3-(5-{5-[(4-フルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)ベンズアミド
実施例39 5-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ピリジン-3-カルボキサミド
実施例40 N-メチル-3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例41 N-メチル-4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド Example 33 tert-butyl 3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3 -Yl] benzoate Example 34 4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol -3-yl] benzamide Example 35 3- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2 , 4-Oxadiazol-3-yl] benzamide Example 36 4- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 37 4- (5- {5-[(4-fluorophenoxy) methyl] -1-methyl-1H-pyrazol-4-yl} -1, 2,4-oxadiazol-3-yl) benzamide Example 38 3- (5- {5-[(4-fluorophenoxy) methyl] -1-methyl-1H-pyrazol-4-yl} -1,2,4 -Oki Sadiazol-3-yl) benzamide Example 39 5- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4 -Oxadiazol-3-yl] pyridine-3-carboxamide Example 40 N-methyl-3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4 -Yl) -1,2,4-oxadiazol-3-yl] benzamide Example 41 N-methyl-4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl}- 1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide
実施例42 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}フェニル)アセトニトリル
Example 42 (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,3, 4-oxadiazol-2-yl} phenyl) acetonitrile
1H NMR (600 MHz, CHLOROFORM-d) δppm 3.83 (s, 2 H) 4.06 (s, 3 H) 5.92 (s, 2 H) 6.86 (d, J=8.67 Hz, 1 H) 7.48 (d, J=8.67 Hz, 2 H) 7.80 (dd, J=8.67, 2.06 Hz, 1 H) 8.05 (s, 1 H) 8.07 (d, J=8.67 Hz, 2 H) 8.42 - 8.47 (m, 1 H); MS (ESI pos.) m/z : 441 [M+H]+
1H NMR (600 MHz, CHLOROFORM-d) δppm 3.83 (s, 2 H) 4.06 (s, 3 H) 5.92 (s, 2 H) 6.86 (d, J = 8.67 Hz, 1 H) 7.48 (d, J = 8.67 Hz, 2 H) 7.80 (dd, J = 8.67, 2.06 Hz, 1 H) 8.05 (s, 1 H) 8.07 (d, J = 8.67 Hz, 2 H) 8.42-8.47 (m, 1 H); MS (ESI pos.) M / z: 441 [M + H] +
実施例43 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}フェニル)アセトアミド
Example 43 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 3,4-oxadiazol-2-yl} phenyl) acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.44 (s, 2 H) 4.00 (s, 3 H) 5.86 (s, 2 H) 6.91 (br. s., 1 H) 7.07 (d, J=8.67 Hz, 1 H) 7.41 (d, J=8.26 Hz, 2 H) 7.50 (br. s., 1 H) 7.86 (d, J=8.26 Hz, 2 H) 8.09 (dd, J=8.67, 2.48 Hz, 1 H) 8.13 (s, 1 H) 8.63 (s, 1 H); MS (ESI pos.) m/z : 459 [M+H]+
1H NMR (600 MHz, DMSO-d6) δ ppm 3.44 (s, 2 H) 4.00 (s, 3 H) 5.86 (s, 2 H) 6.91 (br. S., 1 H) 7.07 (d, J = 8.67 Hz, 1 H) 7.41 (d, J = 8.26 Hz, 2 H) 7.50 (br. S., 1 H) 7.86 (d, J = 8.26 Hz, 2 H) 8.09 (dd, J = 8.67, 2.48 Hz, 1 H) 8.13 (s, 1 H) 8.63 (s, 1 H); MS (ESI pos.) M / z: 459 [M + H] +
実施例44 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}フェニル)アセトアミド
Example 44 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 3,4-oxadiazol-2-yl} phenyl) acetamide
実施例42と同様の手法を用いて、製造例7で得られたN'-[3-(シアノメチル)ベンゾイル]-1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボヒドラジド(367mg)より、表題化合物(225 mg)を無色固体として得た。
MS (ESI neg.) m/z : 439 [M-H]-
2)2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}フェニル)アセトアミド
(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}フェニル)アセトニトリル(119 mg)のN,N-ジメチルホルムアミド(3.0 mL)溶液に室温にて35%過酸化水素水(261 μL)を加え1時間撹拌した後、40 ℃にて4時間、室温にて12時間攪拌した。反応液に室温にて35%過酸化水素水(261 μL)を加えた後、60 ℃にて2時間攪拌した。反応液に水及び10%チオ硫酸ナトリウム水溶液を加え、生じた固体をろ取した。得られた固体を逆相カラムクロマトグラフィー(CAPCELL PAK MG II、0.1%トリフルオロ酢酸含有水:0.1%トリフルオロ酢酸含有アセトニトリル=90:10~10:90)にて精製して、表題化合物(56 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 3.44 (s, 2 H) 4.00 (s, 3 H) 5.86 (s, 2 H) 6.91 (br. s., 1 H) 7.07 (d, J=8.67 Hz, 1 H) 7.41 - 7.48 (m, 2 H) 7.52 (br. s., 1 H) 7.76 (dt, J=6.71, 2.01 Hz, 1 H) 7.90 (s, 1 H) 8.08 (dd, J=8.67, 2.48 Hz, 1 H) 8.13 (s, 1 H) 8.63 (d, J=2.48 Hz, 1 H) ; MS (ESI pos.) m/z : 459 [M+H]+
MS (ESI neg.) M / z: 439 [MH]-
2) 2- (3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,3 , 4-Oxadiazol-2-yl} phenyl) acetamide (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol- 4-yl] -1,3,4-oxadiazol-2-yl} phenyl) acetonitrile (119 mg) in N, N-dimethylformamide (3.0 mL) at room temperature with 35% hydrogen peroxide (261) μL) was added and stirred for 1 hour, followed by stirring at 40 ° C. for 4 hours and at room temperature for 12 hours. 35% hydrogen peroxide (261 μL) was added to the reaction solution at room temperature, and the mixture was stirred at 60 ° C. for 2 hours. Water and a 10% aqueous sodium thiosulfate solution were added to the reaction solution, and the resulting solid was collected by filtration. The obtained solid was purified by reverse phase column chromatography (CAPCELL PAK MG II, water containing 0.1% trifluoroacetic acid: acetonitrile containing 0.1% trifluoroacetic acid = 90: 10 to 10:90), The title compound (56 mg) was obtained as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δppm 3.44 (s, 2 H) 4.00 (s, 3 H) 5.86 (s, 2 H) 6.91 (br. S., 1 H) 7.07 (d, J = 8.67 Hz , 1 H) 7.41-7.48 (m, 2 H) 7.52 (br. S., 1 H) 7.76 (dt, J = 6.71, 2.01 Hz, 1 H) 7.90 (s, 1 H) 8.08 (dd, J = 8.67, 2.48 Hz, 1 H) 8.13 (s, 1 H) 8.63 (d, J = 2.48 Hz, 1 H); MS (ESI pos.) M / z: 459 [M + H] +
実施例44と同様の手法を用いて、表4に記載した実施例45から実施例49の化合物を得た。
Using the same method as in Example 44, the compounds of Example 45 to Example 49 listed in Table 4 were obtained.
実施例45 2-{3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,3,4-オキサジアゾル-2-イル]フェニル}アセトアミド
実施例46 4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}ベンズアミド
実施例47 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,3,4-オキサジアゾル-2-イル]ベンズアミド
実施例48 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,3,4-オキサジアゾル-2-イル]ベンズアミド
実施例49 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}ベンズアミド Example 45 2- {3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazol-2 -Yl] phenyl} acetamide Example 46 4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,3,4-oxadiazol-2-yl} benzamide Example 47 3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl ) -1,3,4-oxadiazol-2-yl] benzamide Example 48 4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4- Yl) -1,3,4-oxadiazol-2-yl] benzamide Example 49 3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,3,4-oxadiazol-2-yl} benzamide
実施例46 4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}ベンズアミド
実施例47 3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,3,4-オキサジアゾル-2-イル]ベンズアミド
実施例48 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,3,4-オキサジアゾル-2-イル]ベンズアミド
実施例49 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,3,4-オキサジアゾル-2-イル}ベンズアミド Example 45 2- {3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazol-2 -Yl] phenyl} acetamide Example 46 4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,3,4-oxadiazol-2-yl} benzamide Example 47 3- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl ) -1,3,4-oxadiazol-2-yl] benzamide Example 48 4- [5- (1-Methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4- Yl) -1,3,4-oxadiazol-2-yl] benzamide Example 49 3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,3,4-oxadiazol-2-yl} benzamide
実施例50 4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]-N-(オキセタン-3-イル)ベンズアミド
Example 50 4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] -N- (Oxetane-3-yl) benzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.99 (s, 3 H) 4.57 (t, J=6.61 Hz, 2 H) 4.75 (t, J=7.02 Hz, 2 H) 4.92 - 5.07 (m, 1 H) 5.73 (s, 2 H) 7.30 (d, J=8.67 Hz, 2 H) 7.69 (d, J=8.67 Hz, 2 H) 7.98 - 8.01 (m, 2 H) 8.02 - 8.05 (m, 2 H) 8.25 (s, 1 H) 9.23 (d, J=6.61 Hz, 1 H) ; MS (ESI pos.) m/z : 500 [M+H]+
1H NMR (600 MHz, DMSO-d6) δ ppm 3.99 (s, 3 H) 4.57 (t, J = 6.61 Hz, 2 H) 4.75 (t, J = 7.02 Hz, 2 H) 4.92-5.07 (m, 1 H) 5.73 (s, 2 H) 7.30 (d, J = 8.67 Hz, 2 H) 7.69 (d, J = 8.67 Hz, 2 H) 7.98-8.01 (m, 2 H) 8.02-8.05 (m, 2 H ) 8.25 (s, 1 H) 9.23 (d, J = 6.61 Hz, 1 H); MS (ESI pos.) M / z: 500 [M + H] +
実施例51 N-メチル-2-{3-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
Example 51 N-methyl-2- {3- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,2,4 -Oxadiazol-3-yl] phenyl} acetamide
1H NMR (600 MHz, DMSO-d6) δppm 2.53 (d, J=4.54 Hz, 3 H) 3.45 (s, 2 H) 3.99 (s, 3H) 5.72 (s, 2 H) 7.30 (d, J=8.67 Hz, 2 H) 7.39 - 7.44 (m, 2 H) 7.69 (d, J=8.67 Hz, 2 H) 7.75 - 7.79 (m, 1 H) 7.89 (s, 1 H) 7.98 (d, J=4.54 Hz, 1 H) 8.23 (s, 1 H); MS (ESI neg.) m/z : 470 [M-H]-
1H NMR (600 MHz, DMSO-d6) δppm 2.53 (d, J = 4.54 Hz, 3 H) 3.45 (s, 2 H) 3.99 (s, 3H) 5.72 (s, 2 H) 7.30 (d, J = 8.67 Hz, 2 H) 7.39-7.44 (m, 2 H) 7.69 (d, J = 8.67 Hz, 2 H) 7.75-7.79 (m, 1 H) 7.89 (s, 1 H) 7.98 (d, J = 4.54 Hz , 1 H) 8.23 (s, 1 H); MS (ESI neg.) M / z: 470 [MH]-
実施例52 2-{4-[5-(1-メチル-5-{[4-(トリフルオロメチル)フェノキシ]メチル}-1H-ピラゾル-4-イル)-1,3,4-オキサジアゾル-2-イル]フェニル}アセトアミド
Example 52 2- {4- [5- (1-methyl-5-{[4- (trifluoromethyl) phenoxy] methyl} -1H-pyrazol-4-yl) -1,3,4-oxadiazol-2 -Il] phenyl} acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 3.96 (s, 3 H) 4.35 (s, 2 H) 5.59 (s, 2 H) 7.24 (s, 2 H) 7.34 (br. s., 1 H) 7.39 (s, 2 H) 7.69 (s, 2 H) 7.83 (s, 2 H) 7.93 (br. s., 1 H) 8.00 (s, 1 H); MS (ESI pos.) m/z: 458 [M+H]+
1H NMR (600 MHz, DMSO-d6) δ ppm 3.96 (s, 3 H) 4.35 (s, 2 H) 5.59 (s, 2 H) 7.24 (s, 2 H) 7.34 (br. S., 1 H) 7.39 (s, 2 H) 7.69 (s, 2 H) 7.83 (s, 2 H) 7.93 (br. S., 1 H) 8.00 (s, 1 H); MS (ESI pos.) M / z: 458 [M + H] +
実施例1と同様の手法を用いて、表5-1から表5-13に記載した実施例53から実施例128の化合物を得た。
In the same manner as in Example 1, the compounds of Example 53 to Example 128 described in Tables 5-1 to 5-13 were obtained.
実施例53 3-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例54 2-(2-ブロモ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例55 N-(2-ヒドロキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例56 2-(4-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例57 2-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例58 2-(3-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例59 2-(4-{5-[1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例60 2-(3-{5-[1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例61 2-[4-(5-{5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例62 2-[3-(5-{5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例63 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェノキシ)アセトアミド
実施例64 2-(3-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例65 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2-カルボキサミド
実施例66 2-(2-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例67 2-(2-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例68 2-{3-[5-(5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]-5-フルオロフェニル}アセトアミド
実施例69 2-(2-クロロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例70 2-メチル-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例71 2-(2-メチル-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例72 2-{4-[5-(5-{[(6-メトキシピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例73 2-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例74 3-クロロ-4-[5-(5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例75 3-クロロ-4-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例76 2-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例77 2-(2-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例78 2-(2-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例79 2-(3-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例80 4-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンゾイル}ピペラジン-2-オン
実施例81 4-{3-[5-(5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンゾイル}ピペラジン-2-オン
実施例82 4-(3-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンゾイル)ピペラジン-2-オン
実施例83 2-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例84 3-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパンアミド
実施例85 2-メチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパンアミド
実施例86 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例87 2-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例88 2-(4-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例89 2-{4-[5-(1-メチル-5-{[(5-メチルピリジン-2-イル)オキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例90 3-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例91 3-メトキシ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例92 2-メトキシ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例93 4-メトキシ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例94 2-{4-[5-(5-{[(5-シクロプロピルピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例95 2-メトキシ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例96 N-(2-アミノ-2-オキソエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例97 N-(2-アミノ-2-オキソエチル)-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例98 3-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例99 2-(3-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例100 2-{3-クロロ-4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例101 2-(3-クロロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例102 3-クロロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例103 2-(6-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-3-イル)アセトアミド
実施例104 2-(2-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例105 2-(5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2-イル)アセトアミド
実施例106 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノール
実施例107 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2-イル)メタノール
実施例108 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパン-2-オール
実施例109 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパン-2-オール
実施例110 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノール
実施例111 1-メチル-1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例112 1-{4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}ウレア
実施例113 1-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}ウレア
実施例114 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例115 1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例116 1-{4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}-3-メチルウレア
実施例117 1-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}-3-メチルウレア
実施例118 1-メチル-3-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例119 1-メチル-3-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例120 メチル {4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}カルバマート
実施例121 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2,3-ジヒドロ-1H-イソインドル-1-オン
実施例122 6-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2,3-ジヒドロ-1H-イソインドル-1-オン
実施例123 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-1,3-ジヒドロ-2H-インドル-2-オン
実施例124 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-1,3-ジヒドロ-2H-ベンゾイミダゾル-2-オン
実施例125 1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)イミダゾリジン-2-オン
実施例126 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)イミダゾリジン-2-オン
実施例127 1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ピロリジン-2-オン
実施例128 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ピロリジン-2-オン Example 53 3-Fluoro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl} benzamide Example 54 2- (2-Bromo-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 55 N- (2-hydroxyethyl) -3- {5- [1-methyl -5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 56 2 -(4-Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) acetamide Example 57 2-Fluoro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Tyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 58 2- (3-Fluoro-5- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 59 2- (4- {5- [1-Methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3- Yl} phenyl) acetamide Example 60 2- (3- {5- [1-Methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 61 2- [4- (5- {5-[(3,4-difluorophenoxy) methyl] -1-methyl-1H- Pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 62 2- [3- (5- {5-[(3,4-difluorophenoxy) methyl] -1- Mechi -1H-pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 63 2- (3- {5- [1-methyl-5-({[5- (tri Fluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenoxy) acetamide Example 64 2- (3-Fluoro-4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3- Yl} phenyl) acetamide Example 65 5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl]- 1,2,4-oxadiazol-3-yl} pyridine-2-carboxamide Example 66 2- (2-Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine] -2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 67 2- (2-fur Rho-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) acetamide Example 68 2- {3- [5- (5-{[(5-chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4- Yl) -1,2,4-oxadiazol-3-yl] -5-fluorophenyl} acetamide Example 69 2- (2-Chloro-5- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 70 2-methyl-5- {5 -[1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} Benzamide Example 71 2- (2-Methyl-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxa Azol-3-yl} phenyl) acetamide Example 72 2- {4- [5- (5-{[(6-methoxypyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazol-4- Yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 73 2-Chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2 -Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 74 3-Chloro-4- [5- (5-{[(5- Chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 75 3-chloro-4- {5- [5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 76 2-Methyl-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4- Oxadiazol-3-yl} benzamide Example 77 2- (2-Chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl)- 1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 78 2- (2-methyl-4- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 79 2- (3-Methyl -4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol -3-yl} phenyl) acetamide Example 80 4- {3- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl ) -1,2,4-oxadiazol-3-yl] benzoyl} piperazin-2-one Example 81 4- {3- [5- (5-{[(5-chloropyridin-2-yl) oxy] methyl } -1- Methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzoyl} piperazin-2-one Example 82 4- (3- {5- [5-({[5- ( Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzoyl) piperazin-2-one Example 83 2 -Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl} benzamide Example 84 3- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole -4-yl] -1,2,4-oxadiazol-3-yl} phenyl) propanamide Example 85 2-methyl-2- (4- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) propanamide Example 86 1- (3- {5 - [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl ) Ethanone Example 87 2-Fluoro-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 88 2- (4- {5- [5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1- Methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 89 2- {4- [5- (1-methyl-5-{[(5-methyl Pyridin-2-yl) oxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 90 3-Fluoro-5- {5- [1- Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 91 3-Methoxy-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} benzamide Example 92 2-Methoxy-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 93 4-Methoxy-3- {5- [1-methyl-5-({[5- (trifluoro Methyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 94 2- {4- [5- (5- { [(5-Cyclopropylpyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 95 2- Methoxy-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadia Ru-3-yl} benzamide Example 96 N- (2-amino-2-oxoethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 97 N- (2-amino-2-oxoethyl) -4- {5- [1- Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 98 3-chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} benzamide Example 99 2- (3-Chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 100 2- {3-Chloro-4- [5- (5-{[(5-fluoro Pyridine-2-y L) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 101 2- (3-Chloro-5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl ) Acetamide Example 102 3-Chloro-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 103 2- (6- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} pyridin-3-yl) acetamide Example 104 2- (2-Fluoro-5- {5- [1-methyl) -5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) a Cetamide Example 105 2- (5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl} pyridin-2-yl) acetamide Example 106 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) ethanol Example 107 (4- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} pyridin-2-yl) methanol Example 108 2 -(3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) propan-2-ol Example 109 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) propan-2-ol Example 110 (4- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanol Example 111 1-methyl-1- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol -3-yl} phenyl) urea Example 112 1- {4- [5- (5-{[(5-fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl ) -1,2,4-oxadiazol-3-yl] phenyl} urea Example 113 1- {3- [5- (5-{[(5-fluoropyridin-2-yl) oxy] methyl} -1- Methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} urea Example 114 1- (3- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] Xyl} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 115 1- (4- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 116 1- {4- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} -3-Methylurea Example 117 1- {3- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1, 2,4-oxadiazol-3-yl] phenyl} -3-methylurea Example 118 1-methyl-3- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine- 2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 119 1-methyl-3- (4- {5- [1 -Methyl-5-({[5- (trifluoro Methyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 120 methyl {4- [5- (5- {[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} carbamate Example 121 5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3- Yl} -2,3-dihydro-1H-isoindol-1-one Example 122 6- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -2,3-dihydro-1H-isoindol-1-one Example 123 5- {5- [1-Methyl- 5-({[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -1,3-dihydro -2H-I Dol-2-one Example 124 5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl]- 1,2,4-oxadiazol-3-yl} -1,3-dihydro-2H-benzimidazol-2-one Example 125 1- (4- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) imidazolidin-2-one Example 126 1 -(3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) imidazolidin-2-one Example 127 1- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) pyrrolidin-2-one Example 128 1- (3- {5- [1-Methyl-5- ( {[5- (trifluoromethyl) pi 2-yl] oxy} methyl)-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) pyrrolidin-2-one
実施例54 2-(2-ブロモ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例55 N-(2-ヒドロキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例56 2-(4-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例57 2-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例58 2-(3-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例59 2-(4-{5-[1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例60 2-(3-{5-[1-メチル-5-({[4-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例61 2-[4-(5-{5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例62 2-[3-(5-{5-[(3,4-ジフルオロフェノキシ)メチル]-1-メチル-1H-ピラゾル-4-イル}-1,2,4-オキサジアゾル-3-イル)フェニル]アセトアミド
実施例63 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェノキシ)アセトアミド
実施例64 2-(3-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例65 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2-カルボキサミド
実施例66 2-(2-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例67 2-(2-フルオロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例68 2-{3-[5-(5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]-5-フルオロフェニル}アセトアミド
実施例69 2-(2-クロロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例70 2-メチル-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例71 2-(2-メチル-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例72 2-{4-[5-(5-{[(6-メトキシピリジン-3-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例73 2-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例74 3-クロロ-4-[5-(5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンズアミド
実施例75 3-クロロ-4-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例76 2-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例77 2-(2-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例78 2-(2-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例79 2-(3-メチル-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例80 4-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンゾイル}ピペラジン-2-オン
実施例81 4-{3-[5-(5-{[(5-クロロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]ベンゾイル}ピペラジン-2-オン
実施例82 4-(3-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンゾイル)ピペラジン-2-オン
実施例83 2-フルオロ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例84 3-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパンアミド
実施例85 2-メチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパンアミド
実施例86 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例87 2-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例88 2-(4-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例89 2-{4-[5-(1-メチル-5-{[(5-メチルピリジン-2-イル)オキシ]メチル}-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例90 3-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例91 3-メトキシ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例92 2-メトキシ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例93 4-メトキシ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例94 2-{4-[5-(5-{[(5-シクロプロピルピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例95 2-メトキシ-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例96 N-(2-アミノ-2-オキソエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例97 N-(2-アミノ-2-オキソエチル)-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例98 3-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例99 2-(3-クロロ-4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例100 2-{3-クロロ-4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}アセトアミド
実施例101 2-(3-クロロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例102 3-クロロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例103 2-(6-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-3-イル)アセトアミド
実施例104 2-(2-フルオロ-5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例105 2-(5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2-イル)アセトアミド
実施例106 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノール
実施例107 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2-イル)メタノール
実施例108 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパン-2-オール
実施例109 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)プロパン-2-オール
実施例110 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノール
実施例111 1-メチル-1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例112 1-{4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}ウレア
実施例113 1-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}ウレア
実施例114 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例115 1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例116 1-{4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}-3-メチルウレア
実施例117 1-{3-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}-3-メチルウレア
実施例118 1-メチル-3-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例119 1-メチル-3-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ウレア
実施例120 メチル {4-[5-(5-{[(5-フルオロピリジン-2-イル)オキシ]メチル}-1-メチル-1H-ピラゾル-4-イル)-1,2,4-オキサジアゾル-3-イル]フェニル}カルバマート
実施例121 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2,3-ジヒドロ-1H-イソインドル-1-オン
実施例122 6-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2,3-ジヒドロ-1H-イソインドル-1-オン
実施例123 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-1,3-ジヒドロ-2H-インドル-2-オン
実施例124 5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-1,3-ジヒドロ-2H-ベンゾイミダゾル-2-オン
実施例125 1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)イミダゾリジン-2-オン
実施例126 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)イミダゾリジン-2-オン
実施例127 1-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ピロリジン-2-オン
実施例128 1-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)ピロリジン-2-オン Example 53 3-Fluoro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl} benzamide Example 54 2- (2-Bromo-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 55 N- (2-hydroxyethyl) -3- {5- [1-methyl -5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 56 2 -(4-Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) acetamide Example 57 2-Fluoro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Tyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 58 2- (3-Fluoro-5- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 59 2- (4- {5- [1-Methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3- Yl} phenyl) acetamide Example 60 2- (3- {5- [1-Methyl-5-({[4- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 61 2- [4- (5- {5-[(3,4-difluorophenoxy) methyl] -1-methyl-1H- Pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 62 2- [3- (5- {5-[(3,4-difluorophenoxy) methyl] -1- Mechi -1H-pyrazol-4-yl} -1,2,4-oxadiazol-3-yl) phenyl] acetamide Example 63 2- (3- {5- [1-methyl-5-({[5- (tri Fluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenoxy) acetamide Example 64 2- (3-Fluoro-4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3- Yl} phenyl) acetamide Example 65 5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl]- 1,2,4-oxadiazol-3-yl} pyridine-2-carboxamide Example 66 2- (2-Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine] -2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 67 2- (2-fur Rho-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) acetamide Example 68 2- {3- [5- (5-{[(5-chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4- Yl) -1,2,4-oxadiazol-3-yl] -5-fluorophenyl} acetamide Example 69 2- (2-Chloro-5- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 70 2-methyl-5- {5 -[1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} Benzamide Example 71 2- (2-Methyl-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxa Azol-3-yl} phenyl) acetamide Example 72 2- {4- [5- (5-{[(6-methoxypyridin-3-yl) oxy] methyl} -1-methyl-1H-pyrazol-4- Yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 73 2-Chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2 -Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 74 3-Chloro-4- [5- (5-{[(5- Chloropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzamide Example 75 3-chloro-4- {5- [5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 76 2-Methyl-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4- Oxadiazol-3-yl} benzamide Example 77 2- (2-Chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl)- 1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 78 2- (2-methyl-4- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 79 2- (3-Methyl -4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol -3-yl} phenyl) acetamide Example 80 4- {3- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl ) -1,2,4-oxadiazol-3-yl] benzoyl} piperazin-2-one Example 81 4- {3- [5- (5-{[(5-chloropyridin-2-yl) oxy] methyl } -1- Methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] benzoyl} piperazin-2-one Example 82 4- (3- {5- [5-({[5- ( Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzoyl) piperazin-2-one Example 83 2 -Fluoro-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl} benzamide Example 84 3- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole -4-yl] -1,2,4-oxadiazol-3-yl} phenyl) propanamide Example 85 2-methyl-2- (4- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) propanamide Example 86 1- (3- {5 - [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl ) Ethanone Example 87 2-Fluoro-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 88 2- (4- {5- [5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1- Methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 89 2- {4- [5- (1-methyl-5-{[(5-methyl Pyridin-2-yl) oxy] methyl} -1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 90 3-Fluoro-5- {5- [1- Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 91 3-Methoxy-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} benzamide Example 92 2-Methoxy-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 93 4-Methoxy-3- {5- [1-methyl-5-({[5- (trifluoro Methyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 94 2- {4- [5- (5- { [(5-Cyclopropylpyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 95 2- Methoxy-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadia Ru-3-yl} benzamide Example 96 N- (2-amino-2-oxoethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 97 N- (2-amino-2-oxoethyl) -4- {5- [1- Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 98 3-chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} benzamide Example 99 2- (3-Chloro-4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 100 2- {3-Chloro-4- [5- (5-{[(5-fluoro Pyridine-2-y L) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} acetamide Example 101 2- (3-Chloro-5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl ) Acetamide Example 102 3-Chloro-5- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 103 2- (6- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} pyridin-3-yl) acetamide Example 104 2- (2-Fluoro-5- {5- [1-methyl) -5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) a Cetamide Example 105 2- (5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl} pyridin-2-yl) acetamide Example 106 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) ethanol Example 107 (4- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} pyridin-2-yl) methanol Example 108 2 -(3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) propan-2-ol Example 109 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) propan-2-ol Example 110 (4- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanol Example 111 1-methyl-1- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol -3-yl} phenyl) urea Example 112 1- {4- [5- (5-{[(5-fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl ) -1,2,4-oxadiazol-3-yl] phenyl} urea Example 113 1- {3- [5- (5-{[(5-fluoropyridin-2-yl) oxy] methyl} -1- Methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} urea Example 114 1- (3- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] Xyl} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 115 1- (4- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 116 1- {4- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} -3-Methylurea Example 117 1- {3- [5- (5-{[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1, 2,4-oxadiazol-3-yl] phenyl} -3-methylurea Example 118 1-methyl-3- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine- 2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 119 1-methyl-3- (4- {5- [1 -Methyl-5-({[5- (trifluoro Methyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) urea Example 120 methyl {4- [5- (5- {[(5-Fluoropyridin-2-yl) oxy] methyl} -1-methyl-1H-pyrazol-4-yl) -1,2,4-oxadiazol-3-yl] phenyl} carbamate Example 121 5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3- Yl} -2,3-dihydro-1H-isoindol-1-one Example 122 6- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -2,3-dihydro-1H-isoindol-1-one Example 123 5- {5- [1-Methyl- 5-({[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -1,3-dihydro -2H-I Dol-2-one Example 124 5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl]- 1,2,4-oxadiazol-3-yl} -1,3-dihydro-2H-benzimidazol-2-one Example 125 1- (4- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) imidazolidin-2-one Example 126 1 -(3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) imidazolidin-2-one Example 127 1- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) pyrrolidin-2-one Example 128 1- (3- {5- [1-Methyl-5- ( {[5- (trifluoromethyl) pi 2-yl] oxy} methyl)-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) pyrrolidin-2-one
実施例50と同様の手法を用いて、表6-1から表6-8に記載した実施例129から実施例175の化合物を得た。
Using the same method as in Example 50, the compounds of Examples 129 to 175 described in Table 6-1 to Table 6-8 were obtained.
実施例129 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-(2,2,2-トリフルオロエチル)アセトアミド
実施例130 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-[2-(プロパン-2-イルオキシ)エチル]アセトアミド
実施例131 N-(2-ヒドロキシエチル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例132 N-[2-(2-ヒドロキシエトキシ)エチル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例133 N-メチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例134 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-[2-(モルホリン-4-イル)エチル]アセトアミド
実施例135 N2-[(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセチル]グリシンアミド
実施例136 (3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(ピロリジン-1-イル)メタノン
実施例137 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-1-(モルホリン-4-イル)エタノン
実施例138 N,N-ジメチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例139 1-(4-メチルピペラジン-1-イル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例140 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-(オキセタン-3-イル)アセトアミド
実施例141 N-[2-(ジメチルアミノ)エチル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例142 1-メチル-4-[(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセチル]ピペラジン-2-オン
実施例143 N-tert-ブチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例144 N-(2-メトキシエチル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例145 1-[(3S)-3-ヒドロキシピロリジン-1-イル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例146 1-[(3R)-3-ヒドロキシピロリジン-1-イル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例147 4-[(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセチル]ピペラジン-2-オン
実施例148 N-[(2S)-2-ヒドロキシプロピル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例149 N-[(2R)-2-ヒドロキシプロピル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例150 N-(2-ヒドロキシ-2-メチルプロピル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例151 アゼチジン-1-イル(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例152 (3-ヒドロキシアゼチジン-1-イル)(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例153 N-[2-(ジメチルアミノ)-2-オキソエチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例154 N-[2-(ジメチルアミノ)-2-オキソエチル]-N-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例155 N-[2-(メチルアミノ)-2-オキソエチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例156 1-メチル-4-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンゾイル)ピペラジン-2-オン
実施例157 (4-メチルピペラジン-1-イル)(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例158 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-N-(オキセタン-3-イル)ベンズアミド
実施例159 (3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(モルホリン-4-イル)メタノン
実施例160 [(3S)-3-ヒドロキシピロリジン-1-イル](3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例161 [(3R)-3-ヒドロキシピロリジン-1-イル](3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例162 4-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンゾイル)ピペラジン-2-オン
実施例163 N-(2-メトキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例164 N-[2-(ジメチルアミノ)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例165 N-(2-ヒドロキシ-2-メチルプロピル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例166 N-[(2R)-2-ヒドロキシプロピル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例167 N-[(2S)-2-ヒドロキシプロピル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例168 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-N-[2-(モルホリン-4-イル)エチル]ベンズアミド
実施例169 N-(2-アミノ-2-オキソエチル)-N-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例170 N-(1,3-ジヒドロキシ-2-メチルプロパン-2-イル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例171 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-1-(ピロリジン-1-イル)エタノン
実施例172 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-1-(ピロリジン-1-イル)エタノン
実施例173 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(ピロリジン-1-イル)メタノン
実施例174 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(モルホリン-4-イル)メタノン
実施例175 2-(3-クロロ-4-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド Example 129 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) -N- (2,2,2-trifluoroethyl) acetamide Example 130 2- (3- {5- [1-methyl-5-({[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -N- [2- (propan-2- Iloxy) ethyl] acetamide Example 131 N- (2-hydroxyethyl) -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 132 N- [2- (2-hydroxyethoxy) ethyl] -2- (4- { 5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl } Phenyl) Cetamide Example 133 N-methyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 134 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -N- [2- (morpholin-4-yl) ethyl] acetamide Example 135 N 2 -[(4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} phenyl) acetyl] glycinamide Example 136 (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) (pyrrolidin-1-yl) methanone Example 137 2- (4- {5- [1-methyl- 5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -1- ( Morpholin-4-yl) ethanone Example 138 N, N-dimethyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 139 1- (4-Methylpiperazin-1-yl) -2- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl ) Ethanone Example 140 2- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl]- 1,2,4-oxadiazol-3-yl} phenyl) -N- (oxetan-3-yl) acetamide Example 141 N- [2- (dimethylamino) ethyl] -2- (4- {5- [1 -Methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 142 1-Methyl-4- [(4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) acetyl] piperazin-2-one Example 143 N-tert-butyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine] -2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 144 N- (2-methoxyethyl) -2- (4 -{5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3 -Yl} phenyl) acetamide Example 145 1-[(3S) -3-Hydroxypyrrolidin-1-yl] -2- (4- {5- [1-methyl-5-({[5- (trifluoro Methyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) ethanone Example 146 1-[(3R) -3-hydroxy Pyrrolidin-1-yl] -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl} phenyl) ethanone Example 147 4-[(4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetyl] piperazin-2-one Example 148 N-[(2S) -2-hydroxy Propyl] -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) acetamide Example 149 N-[(2R) -2-hydroxypropyl] -2- (4- {5- [1-methyl-5-({[5- ( (Trifluoromethyl) Lysin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 150 N- (2-hydroxy-2-methylpropyl) -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} phenyl) acetamide Example 151 Azetidin-1-yl (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 152 (3-hydroxyazetidin-1-yl) (3- {5- [1- Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 153 N- [2- (dimethylamino) -2-oxoethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pi Gin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 154 N- [2- (dimethylamino) -2-oxoethyl] -N-methyl-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2 , 4-Oxadiazol-3-yl} benzamide Example 155 N- [2- (Methylamino) -2-oxoethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) Pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 156 1-methyl-4- (3- {5- [1 -Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzoyl) piperazine -2-one Example 157 (4-methylpiperazin-1-yl) (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 158 3- {5- [1-methyl-5-({[5- (tri Fluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -N- (oxetan-3-yl) benzamide Example 159 3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol- 3-yl} phenyl) (morpholin-4-yl) methanone Example 160 [(3S) -3-hydroxypyrrolidin-1-yl] (3- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 161 [(3R) -3-hydroxy Pyrrolidin-1-yl] (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 162 4- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] ] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzoyl) piperazin-2-one Example 163 N- (2-methoxyethyl) -3- {5 -[1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} Benzamide Example 164 N- [2- (Dimethylamino) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H -Pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 165 N- (2-hydroxy-2-methylpropyl) -3- {5- [1-methyl-5- ( {[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Examples 66 N-[(2R) -2-hydroxypropyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole -4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 167 N-[(2S) -2-hydroxypropyl] -3- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 168 3- {5- [1 -Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -N- [2- (Morpholin-4-yl) ethyl] benzamide Example 169 N- (2-amino-2-oxoethyl) -N-methyl-3- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 170 N- (1,3-Dihydroxy-2 -Mechi Rupropan-2-yl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl} benzamide Example 171 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -1- (pyrrolidin-1-yl) ethanone Example 172 2- (4- {5- [1-methyl -5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -1- (Pyrrolidin-1-yl) ethanone Example 173 (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4 -Yl] -1,2,4-oxadiazol-3-yl} phenyl) (pyrrolidin-1-yl) methanone Example 174 (4- {5- [1-methyl-5-({[5- (trifluoro Methyl) pyridine-2-y ] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) (morpholin-4-yl) methanone Example 175 2- (3-Chloro-4- { 5- [5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} Phenyl) acetamide
実施例130 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-[2-(プロパン-2-イルオキシ)エチル]アセトアミド
実施例131 N-(2-ヒドロキシエチル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例132 N-[2-(2-ヒドロキシエトキシ)エチル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例133 N-メチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例134 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-[2-(モルホリン-4-イル)エチル]アセトアミド
実施例135 N2-[(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセチル]グリシンアミド
実施例136 (3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(ピロリジン-1-イル)メタノン
実施例137 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-1-(モルホリン-4-イル)エタノン
実施例138 N,N-ジメチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例139 1-(4-メチルピペラジン-1-イル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例140 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-N-(オキセタン-3-イル)アセトアミド
実施例141 N-[2-(ジメチルアミノ)エチル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例142 1-メチル-4-[(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセチル]ピペラジン-2-オン
実施例143 N-tert-ブチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例144 N-(2-メトキシエチル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例145 1-[(3S)-3-ヒドロキシピロリジン-1-イル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例146 1-[(3R)-3-ヒドロキシピロリジン-1-イル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)エタノン
実施例147 4-[(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセチル]ピペラジン-2-オン
実施例148 N-[(2S)-2-ヒドロキシプロピル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例149 N-[(2R)-2-ヒドロキシプロピル]-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例150 N-(2-ヒドロキシ-2-メチルプロピル)-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例151 アゼチジン-1-イル(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例152 (3-ヒドロキシアゼチジン-1-イル)(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例153 N-[2-(ジメチルアミノ)-2-オキソエチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例154 N-[2-(ジメチルアミノ)-2-オキソエチル]-N-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例155 N-[2-(メチルアミノ)-2-オキソエチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例156 1-メチル-4-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンゾイル)ピペラジン-2-オン
実施例157 (4-メチルピペラジン-1-イル)(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例158 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-N-(オキセタン-3-イル)ベンズアミド
実施例159 (3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(モルホリン-4-イル)メタノン
実施例160 [(3S)-3-ヒドロキシピロリジン-1-イル](3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例161 [(3R)-3-ヒドロキシピロリジン-1-イル](3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)メタノン
実施例162 4-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンゾイル)ピペラジン-2-オン
実施例163 N-(2-メトキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例164 N-[2-(ジメチルアミノ)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例165 N-(2-ヒドロキシ-2-メチルプロピル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例166 N-[(2R)-2-ヒドロキシプロピル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例167 N-[(2S)-2-ヒドロキシプロピル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例168 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-N-[2-(モルホリン-4-イル)エチル]ベンズアミド
実施例169 N-(2-アミノ-2-オキソエチル)-N-メチル-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例170 N-(1,3-ジヒドロキシ-2-メチルプロパン-2-イル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例171 2-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-1-(ピロリジン-1-イル)エタノン
実施例172 2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)-1-(ピロリジン-1-イル)エタノン
実施例173 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(ピロリジン-1-イル)メタノン
実施例174 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)(モルホリン-4-イル)メタノン
実施例175 2-(3-クロロ-4-{5-[5-({[5-(ジフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1-メチル-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド Example 129 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) -N- (2,2,2-trifluoroethyl) acetamide Example 130 2- (3- {5- [1-methyl-5-({[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -N- [2- (propan-2- Iloxy) ethyl] acetamide Example 131 N- (2-hydroxyethyl) -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 132 N- [2- (2-hydroxyethoxy) ethyl] -2- (4- { 5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl } Phenyl) Cetamide Example 133 N-methyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 134 2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -N- [2- (morpholin-4-yl) ethyl] acetamide Example 135 N 2 -[(4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} phenyl) acetyl] glycinamide Example 136 (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) (pyrrolidin-1-yl) methanone Example 137 2- (4- {5- [1-methyl- 5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -1- ( Morpholin-4-yl) ethanone Example 138 N, N-dimethyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl ) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 139 1- (4-Methylpiperazin-1-yl) -2- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl ) Ethanone Example 140 2- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl]- 1,2,4-oxadiazol-3-yl} phenyl) -N- (oxetan-3-yl) acetamide Example 141 N- [2- (dimethylamino) ethyl] -2- (4- {5- [1 -Methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 142 1-Methyl-4- [(4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} phenyl) acetyl] piperazin-2-one Example 143 N-tert-butyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine] -2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 144 N- (2-methoxyethyl) -2- (4 -{5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3 -Yl} phenyl) acetamide Example 145 1-[(3S) -3-Hydroxypyrrolidin-1-yl] -2- (4- {5- [1-methyl-5-({[5- (trifluoro Methyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) ethanone Example 146 1-[(3R) -3-hydroxy Pyrrolidin-1-yl] -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl} phenyl) ethanone Example 147 4-[(4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetyl] piperazin-2-one Example 148 N-[(2S) -2-hydroxy Propyl] -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) acetamide Example 149 N-[(2R) -2-hydroxypropyl] -2- (4- {5- [1-methyl-5-({[5- ( (Trifluoromethyl) Lysin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) acetamide Example 150 N- (2-hydroxy-2-methylpropyl) -2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} phenyl) acetamide Example 151 Azetidin-1-yl (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 152 (3-hydroxyazetidin-1-yl) (3- {5- [1- Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 153 N- [2- (dimethylamino) -2-oxoethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pi Gin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 154 N- [2- (dimethylamino) -2-oxoethyl] -N-methyl-3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2 , 4-Oxadiazol-3-yl} benzamide Example 155 N- [2- (Methylamino) -2-oxoethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) Pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 156 1-methyl-4- (3- {5- [1 -Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzoyl) piperazine -2-one Example 157 (4-methylpiperazin-1-yl) (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 158 3- {5- [1-methyl-5-({[5- (tri Fluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -N- (oxetan-3-yl) benzamide Example 159 3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol- 3-yl} phenyl) (morpholin-4-yl) methanone Example 160 [(3S) -3-hydroxypyrrolidin-1-yl] (3- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 161 [(3R) -3-hydroxy Pyrrolidin-1-yl] (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl} phenyl) methanone Example 162 4- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] ] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzoyl) piperazin-2-one Example 163 N- (2-methoxyethyl) -3- {5 -[1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} Benzamide Example 164 N- [2- (Dimethylamino) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H -Pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 165 N- (2-hydroxy-2-methylpropyl) -3- {5- [1-methyl-5- ( {[5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Examples 66 N-[(2R) -2-hydroxypropyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole -4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 167 N-[(2S) -2-hydroxypropyl] -3- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 168 3- {5- [1 -Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -N- [2- (Morpholin-4-yl) ethyl] benzamide Example 169 N- (2-amino-2-oxoethyl) -N-methyl-3- {5- [1-methyl-5-({[5- ( Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 170 N- (1,3-Dihydroxy-2 -Mechi Rupropan-2-yl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1 , 2,4-oxadiazol-3-yl} benzamide Example 171 2- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -1- (pyrrolidin-1-yl) ethanone Example 172 2- (4- {5- [1-methyl -5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) -1- (Pyrrolidin-1-yl) ethanone Example 173 (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4 -Yl] -1,2,4-oxadiazol-3-yl} phenyl) (pyrrolidin-1-yl) methanone Example 174 (4- {5- [1-methyl-5-({[5- (trifluoro Methyl) pyridine-2-y ] Oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} phenyl) (morpholin-4-yl) methanone Example 175 2- (3-Chloro-4- { 5- [5-({[5- (Difluoromethyl) pyridin-2-yl] oxy} methyl) -1-methyl-1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} Phenyl) acetamide
実施例176 N-(1,3-ジオキソラン-2-イルメチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
1)N-(2,2-ジメトキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
製造例4で得られた1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-カルボン酸(969 mg)のN,N-ジメチルホルムアミド(5.0 mL)溶液に、室温にて1,1’-カルボニルジイミダゾール(626 mg)を加え1時間撹拌した。反応液に製造例5で得られたN-(2,2-ジメトキシエチル)-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド(846 mg)を加え、120 ℃にて10時間撹拌した。反応液を室温まで放冷し、ISOLUTE HM-Nを加え、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=90:10)にて精製した。得られた固体をジエチルエーテルにて洗浄して、表題化合物(1.00 g)を無色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 533 [M+H]+
2)N-(1,3-ジオキソラン-2-イルメチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
N-(2,2-ジメトキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド(30 mg)のトルエン(3.0 mL)溶液に、p-トルエンスルホン酸 1水和物(9.7 mg)及びエタン-1,2-ジオール(16 μL)を加え、60 ℃にて2時間攪拌した。反応液を減圧下濃縮した後、残渣を逆相カラムクロマトグラフィー(CAPCELL PAK MG II、0.1%トリフルオロ酢酸含有水:0.1%トリフルオロ酢酸含有アセトニトリル=90:10~10:90)にて精製して、表題化合物(18 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 3.40 (dd, J=5.6, 4.75 Hz, 2 H) 3.75 - 3.81 (m, 2 H) 3.88 - 3.92 (m, 2 H) 4.01 (s, 3 H) 4.96 (t, J=4.5 Hz, 1 H) 5.93 (s, 2 H) 7.07 (d, J=8.7 Hz, 1 H) 7.59 (t, J=7.6 Hz, 1 H) 7.98 - 8.05 (m, 2 H) 8.09 (dd, J=8.7, 2.48 Hz, 1 H) 8.24 (s, 1 H) 8.46 (d, J=3.3 Hz, 1 H) 8.65 (d, J=2.5 Hz, 1 H) 8.84 (t, J=5.8 Hz, 1 H); MS (ESI pos.) m/z: 531 [M+H]+ Example 176 N- (1,3-dioxolan-2-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl)- 1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
1) N- (2,2-dimethoxyethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole- 4-yl] -1,2,4-oxadiazol-3-yl} benzamide 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl obtained in Preparation Example 4 ) -1H-pyrazole-4-carboxylic acid (969 mg) in N, N-dimethylformamide (5.0 mL) was added 1,1′-carbonyldiimidazole (626 mg) at room temperature and stirred for 1 hour. did. N- (2,2-dimethoxyethyl) -3- (N′-hydroxycarbamimidoyl) benzamide (846 mg) obtained in Production Example 5 was added to the reaction solution, and the mixture was stirred at 120 ° C. for 10 hours. The reaction mixture was allowed to cool to room temperature, ISOLUTE HM-N was added, and the mixture was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 90: 10). The obtained solid was washed with diethyl ether to give the title compound (1.00 g) as a colorless solid.
MS (ESI / APCI Dual pos.) M / z: 533 [M + H] +
2) N- (1,3-Dioxolan-2-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H -Pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
N- (2,2-dimethoxyethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} benzamide (30 mg) in toluene (3.0 mL) was added p-toluenesulfonic acid monohydrate (9.7 mg) and ethane-1 , 2-diol (16 μL) was added and stirred at 60 ° C. for 2 hours. After the reaction solution was concentrated under reduced pressure, the residue was subjected to reverse phase column chromatography (CAPCELL PAK MG II, water containing 0.1% trifluoroacetic acid: acetonitrile containing 0.1% trifluoroacetic acid = 90: 10 to 10:90). To give the title compound (18 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 3.40 (dd, J = 5.6, 4.75 Hz, 2 H) 3.75-3.81 (m, 2 H) 3.88-3.92 (m, 2 H) 4.01 (s, 3 H ) 4.96 (t, J = 4.5 Hz, 1 H) 5.93 (s, 2 H) 7.07 (d, J = 8.7 Hz, 1 H) 7.59 (t, J = 7.6 Hz, 1 H) 7.98-8.05 (m, 2 H) 8.09 (dd, J = 8.7, 2.48 Hz, 1 H) 8.24 (s, 1 H) 8.46 (d, J = 3.3 Hz, 1 H) 8.65 (d, J = 2.5 Hz, 1 H) 8.84 ( t, J = 5.8 Hz, 1 H); MS (ESI pos.) m / z: 531 [M + H] +
製造例4で得られた1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-カルボン酸(969 mg)のN,N-ジメチルホルムアミド(5.0 mL)溶液に、室温にて1,1’-カルボニルジイミダゾール(626 mg)を加え1時間撹拌した。反応液に製造例5で得られたN-(2,2-ジメトキシエチル)-3-(N'-ヒドロキシカルバムイミドイル)ベンズアミド(846 mg)を加え、120 ℃にて10時間撹拌した。反応液を室温まで放冷し、ISOLUTE HM-Nを加え、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=90:10)にて精製した。得られた固体をジエチルエーテルにて洗浄して、表題化合物(1.00 g)を無色固体として得た。
MS (ESI/APCI Dual pos.) m/z: 533 [M+H]+
2)N-(1,3-ジオキソラン-2-イルメチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
N-(2,2-ジメトキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド(30 mg)のトルエン(3.0 mL)溶液に、p-トルエンスルホン酸 1水和物(9.7 mg)及びエタン-1,2-ジオール(16 μL)を加え、60 ℃にて2時間攪拌した。反応液を減圧下濃縮した後、残渣を逆相カラムクロマトグラフィー(CAPCELL PAK MG II、0.1%トリフルオロ酢酸含有水:0.1%トリフルオロ酢酸含有アセトニトリル=90:10~10:90)にて精製して、表題化合物(18 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 3.40 (dd, J=5.6, 4.75 Hz, 2 H) 3.75 - 3.81 (m, 2 H) 3.88 - 3.92 (m, 2 H) 4.01 (s, 3 H) 4.96 (t, J=4.5 Hz, 1 H) 5.93 (s, 2 H) 7.07 (d, J=8.7 Hz, 1 H) 7.59 (t, J=7.6 Hz, 1 H) 7.98 - 8.05 (m, 2 H) 8.09 (dd, J=8.7, 2.48 Hz, 1 H) 8.24 (s, 1 H) 8.46 (d, J=3.3 Hz, 1 H) 8.65 (d, J=2.5 Hz, 1 H) 8.84 (t, J=5.8 Hz, 1 H); MS (ESI pos.) m/z: 531 [M+H]+ Example 176 N- (1,3-dioxolan-2-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl)- 1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
MS (ESI / APCI Dual pos.) M / z: 533 [M + H] +
2) N- (1,3-Dioxolan-2-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H -Pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
N- (2,2-dimethoxyethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4- Yl] -1,2,4-oxadiazol-3-yl} benzamide (30 mg) in toluene (3.0 mL) was added p-toluenesulfonic acid monohydrate (9.7 mg) and ethane-1 , 2-diol (16 μL) was added and stirred at 60 ° C. for 2 hours. After the reaction solution was concentrated under reduced pressure, the residue was subjected to reverse phase column chromatography (CAPCELL PAK MG II, water containing 0.1% trifluoroacetic acid: acetonitrile containing 0.1% trifluoroacetic acid = 90: 10 to 10:90). To give the title compound (18 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 3.40 (dd, J = 5.6, 4.75 Hz, 2 H) 3.75-3.81 (m, 2 H) 3.88-3.92 (m, 2 H) 4.01 (s, 3 H ) 4.96 (t, J = 4.5 Hz, 1 H) 5.93 (s, 2 H) 7.07 (d, J = 8.7 Hz, 1 H) 7.59 (t, J = 7.6 Hz, 1 H) 7.98-8.05 (m, 2 H) 8.09 (dd, J = 8.7, 2.48 Hz, 1 H) 8.24 (s, 1 H) 8.46 (d, J = 3.3 Hz, 1 H) 8.65 (d, J = 2.5 Hz, 1 H) 8.84 ( t, J = 5.8 Hz, 1 H); MS (ESI pos.) m / z: 531 [M + H] +
実施例176と同様の手法を用いて、実施例177及び実施例178の化合物を得た。
Example 177 and Example 178 were obtained using the same method as in Example 176.
実施例177 N-(1,3-ジオキサン-2-イルメチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
MS (ESI pos.) m/z: 545 [M+H]+
RT=1.07 (Condition A) Example 177 N- (1,3-dioxan-2-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl)- 1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
MS (ESI pos.) M / z: 545 [M + H] +
RT = 1.07 (Condition A)
RT=1.07 (Condition A) Example 177 N- (1,3-dioxan-2-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl)- 1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
RT = 1.07 (Condition A)
実施例178 N-(5,7-ジオキサスピロ[2.5]オクト-6-イルメチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
MS (ESI pos.) m/z: 571 [M+H]+
RT=1.10 (Condition A) Example 178 N- (5,7-dioxaspiro [2.5] oct-6-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
MS (ESI pos.) M / z: 571 [M + H] +
RT = 1.10 (Condition A)
RT=1.10 (Condition A) Example 178 N- (5,7-dioxaspiro [2.5] oct-6-ylmethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
RT = 1.10 (Condition A)
実施例179 N-{2-[(3S)-3-フルオロピロリジン-1-イル]エチル}-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例176-1)で得られたN-(2,2-ジメトキシエチル)-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド(52 mg)のテトラヒドロフラン(1.0 mL)溶液に、p-トルエンスルホン酸 1水和物(8.4 mg)を加え、室温にて19時間攪拌した。p-トルエンスルホン酸 1水和物(8.4 mg)を追加し、50 ℃にて5時間攪拌した。反応液を室温まで放冷後、(3S)-3-フルオロピロリジン(25 mg)、トリエチルアミン(41 μL)及び水素化ホウ素トリアセトキシナトリウム(62 mg)を反応液に加え、室温にて10分間攪拌した。減圧下濃縮した後、残渣を逆相カラムクロマトグラフィー(CAPCELL PAK MG II、0.1%トリフルオロ酢酸含有水:0.1%トリフルオロ酢酸含有アセトニトリル=90:10~10:90)にて精製して、表題化合物(17 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 1.77 - 1.93 (m, 1 H) 2.03 - 2.19 (m, 1 H) 2.32 - 2.41 (m, 1 H) 2.57 - 2.72 (m, 3 H) 2.79 - 2.91 (m, 2 H) 3.38 - 3.45 (m, 2 H) 4.05 (s, 3 H) 5.05 - 5.34 (m, 1 H) 5.97 (s, 2 H) 7.11 (d, J=8.7 Hz, 1 H) 7.63 (t, J=7.8 Hz, 1 H) 8.01 - 8.07 (m, 2 H) 8.12 (dd, J=8.7, 2.48 Hz, 1 H) 8.27 (s, 1 H) 8.48 (s, 1 H) 8.64 - 8.73 (m, 2 H);MS (ESI pos.) m/z: 560 [M+H]+ Example 179 N- {2-[(3S) -3-fluoropyrrolidin-1-yl] ethyl} -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2 -Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
N- (2,2-dimethoxyethyl) -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy obtained in Example 176-1) } Methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide (52 mg) in tetrahydrofuran (1.0 mL) and p-toluenesulfonic acid monohydrate (8.4 mg) was added, and the mixture was stirred at room temperature for 19 hours. p-Toluenesulfonic acid monohydrate (8.4 mg) was added, and the mixture was stirred at 50 ° C. for 5 hr. The reaction mixture was allowed to cool to room temperature, (3S) -3-fluoropyrrolidine (25 mg), triethylamine (41 μL) and sodium triacetoxyborohydride (62 mg) were added to the reaction mixture, and the mixture was stirred at room temperature for 10 min. did. After concentration under reduced pressure, the residue was purified by reverse-phase column chromatography (CAPCELL PAK MG II, water containing 0.1% trifluoroacetic acid: acetonitrile containing 0.1% trifluoroacetic acid = 90: 10 to 10:90). The title compound (17 mg) was obtained as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 1.77-1.93 (m, 1 H) 2.03-2.19 (m, 1 H) 2.32-2.41 (m, 1 H) 2.57-2.72 (m, 3 H) 2.79- 2.91 (m, 2 H) 3.38-3.45 (m, 2 H) 4.05 (s, 3 H) 5.05-5.34 (m, 1 H) 5.97 (s, 2 H) 7.11 (d, J = 8.7 Hz, 1 H ) 7.63 (t, J = 7.8 Hz, 1 H) 8.01-8.07 (m, 2 H) 8.12 (dd, J = 8.7, 2.48 Hz, 1 H) 8.27 (s, 1 H) 8.48 (s, 1 H) 8.64-8.73 (m, 2 H); MS (ESI pos.) M / z: 560 [M + H] +
1H NMR (600 MHz, DMSO-d6) δ ppm 1.77 - 1.93 (m, 1 H) 2.03 - 2.19 (m, 1 H) 2.32 - 2.41 (m, 1 H) 2.57 - 2.72 (m, 3 H) 2.79 - 2.91 (m, 2 H) 3.38 - 3.45 (m, 2 H) 4.05 (s, 3 H) 5.05 - 5.34 (m, 1 H) 5.97 (s, 2 H) 7.11 (d, J=8.7 Hz, 1 H) 7.63 (t, J=7.8 Hz, 1 H) 8.01 - 8.07 (m, 2 H) 8.12 (dd, J=8.7, 2.48 Hz, 1 H) 8.27 (s, 1 H) 8.48 (s, 1 H) 8.64 - 8.73 (m, 2 H);MS (ESI pos.) m/z: 560 [M+H]+ Example 179 N- {2-[(3S) -3-fluoropyrrolidin-1-yl] ethyl} -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2 -Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide
1H NMR (600 MHz, DMSO-d6) δ ppm 1.77-1.93 (m, 1 H) 2.03-2.19 (m, 1 H) 2.32-2.41 (m, 1 H) 2.57-2.72 (m, 3 H) 2.79- 2.91 (m, 2 H) 3.38-3.45 (m, 2 H) 4.05 (s, 3 H) 5.05-5.34 (m, 1 H) 5.97 (s, 2 H) 7.11 (d, J = 8.7 Hz, 1 H ) 7.63 (t, J = 7.8 Hz, 1 H) 8.01-8.07 (m, 2 H) 8.12 (dd, J = 8.7, 2.48 Hz, 1 H) 8.27 (s, 1 H) 8.48 (s, 1 H) 8.64-8.73 (m, 2 H); MS (ESI pos.) M / z: 560 [M + H] +
実施例179と同様の手法を用いて、表7-1から表7-2に記載した実施例180から実施例187の化合物を得た。
In the same manner as in Example 179, the compounds of Example 180 to Example 187 described in Table 7-1 to Table 7-2 were obtained.
実施例180 N-[2-(アゼチジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例181 N-[2-(3,3-ジフルオロアゼチジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例182 N-[2-(3-フルオロアゼチジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例183 N-[2-(3,3-ジフルオロピロリジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例184 N-{2-[(3R)-3-フルオロピロリジン-1-イル]エチル}-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例185 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-N-[2-(2-オキサ-6-アザスピロ[3.3]ヘプト-6-イル)エチル]ベンズアミド
実施例186 N-[2-(4-フルオロピペリジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例187 N-[2-(4,4-ジフルオロピペリジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド Example 180 N- [2- (azetidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 181 N- [2- (3,3-difluoroazetidin-1-yl) ethyl] -3- { 5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl } Benzamide Example 182 N- [2- (3-Fluoroazetidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 183 N- [2- (3,3-difluoropyrrolidin-1-yl) ethyl ] -3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} benz Example 184 N- {2-[(3R) -3-fluoropyrrolidin-1-yl] ethyl} -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine- 2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 185 3- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -N- [2- (2-oxa-6 -Azaspiro [3.3] hept-6-yl) ethyl] benzamide Example 186 N- [2- (4-fluoropiperidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 187 N- [2- (4 , 4-Difluoropiperidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol- 4-yl] -1,2,4-o Sajiazoru-3-yl} benzamide
実施例181 N-[2-(3,3-ジフルオロアゼチジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例182 N-[2-(3-フルオロアゼチジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例183 N-[2-(3,3-ジフルオロピロリジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例184 N-{2-[(3R)-3-フルオロピロリジン-1-イル]エチル}-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例185 3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-N-[2-(2-オキサ-6-アザスピロ[3.3]ヘプト-6-イル)エチル]ベンズアミド
実施例186 N-[2-(4-フルオロピペリジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド
実施例187 N-[2-(4,4-ジフルオロピペリジン-1-イル)エチル]-3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ベンズアミド Example 180 N- [2- (azetidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 181 N- [2- (3,3-difluoroazetidin-1-yl) ethyl] -3- { 5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl } Benzamide Example 182 N- [2- (3-Fluoroazetidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine-2- Yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 183 N- [2- (3,3-difluoropyrrolidin-1-yl) ethyl ] -3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} benz Example 184 N- {2-[(3R) -3-fluoropyrrolidin-1-yl] ethyl} -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridine- 2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 185 3- {5- [1-methyl-5-({[5 -(Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} -N- [2- (2-oxa-6 -Azaspiro [3.3] hept-6-yl) ethyl] benzamide Example 186 N- [2- (4-fluoropiperidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[ 5- (Trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol-3-yl} benzamide Example 187 N- [2- (4 , 4-Difluoropiperidin-1-yl) ethyl] -3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol- 4-yl] -1,2,4-o Sajiazoru-3-yl} benzamide
実施例188 N-アセチル-2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド
実施例1で得られた2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド(100 mg)、無水酢酸(67 μL)及びピリジン(2.0 mL)の混合物を、85 ℃にて終夜攪拌した。反応液を室温まで放冷後、水を加え、酢酸エチルで抽出した。有機層を水で洗浄し、無水硫酸ナトリウムにて乾燥した後、減圧下濃縮した。残渣を逆相カラムクロマトグラフィー(CAPCELL PAK MG II、0.1%トリフルオロ酢酸含有水:0.1%トリフルオロ酢酸含有アセトニトリル=90:10~10:90)にて精製して、表題化合物(32 mg)を黄色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 2.08 (s, 3 H) 3.77 (s, 2 H) 3.95 (s, 3 H) 5.84 (s, 2 H) 7.01 (d, J=8.7 Hz, 1 H) 7.31 (d, J=8.3 Hz, 2 H) 7.76 (d, J=7.8 Hz, 2 H) 8.03 (dd, J=8.7, 2.5 Hz, 1 H) 8.15 (s, 1 H) 8.59 (s, 1 H) 10.76 (s, 1 H); MS (ESI/APCI Dual pos.) m/z: 501 [M+H]+ Example 188 N-acetyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl} phenyl) acetamide
2- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl obtained in Example 1 ] -1,2,4-oxadiazol-3-yl} phenyl) acetamide (100 mg), acetic anhydride (67 μL) and pyridine (2.0 mL) were stirred at 85 ° C. overnight. The reaction mixture was allowed to cool to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (CAPCELL PAK MG II, water containing 0.1% trifluoroacetic acid: acetonitrile containing 0.1% trifluoroacetic acid = 90: 10 to 10:90) to give the title compound ( 32 mg) was obtained as a yellow solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 2.08 (s, 3 H) 3.77 (s, 2 H) 3.95 (s, 3 H) 5.84 (s, 2 H) 7.01 (d, J = 8.7 Hz, 1 H) 7.31 (d, J = 8.3 Hz, 2 H) 7.76 (d, J = 7.8 Hz, 2 H) 8.03 (dd, J = 8.7, 2.5 Hz, 1 H) 8.15 (s, 1 H) 8.59 (s , 1 H) 10.76 (s, 1 H); MS (ESI / APCI Dual pos.) M / z: 501 [M + H] +
1H NMR (600 MHz, DMSO-d6) δ ppm 2.08 (s, 3 H) 3.77 (s, 2 H) 3.95 (s, 3 H) 5.84 (s, 2 H) 7.01 (d, J=8.7 Hz, 1 H) 7.31 (d, J=8.3 Hz, 2 H) 7.76 (d, J=7.8 Hz, 2 H) 8.03 (dd, J=8.7, 2.5 Hz, 1 H) 8.15 (s, 1 H) 8.59 (s, 1 H) 10.76 (s, 1 H); MS (ESI/APCI Dual pos.) m/z: 501 [M+H]+ Example 188 N-acetyl-2- (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl ] -1,2,4-oxadiazol-3-yl} phenyl) acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 2.08 (s, 3 H) 3.77 (s, 2 H) 3.95 (s, 3 H) 5.84 (s, 2 H) 7.01 (d, J = 8.7 Hz, 1 H) 7.31 (d, J = 8.3 Hz, 2 H) 7.76 (d, J = 7.8 Hz, 2 H) 8.03 (dd, J = 8.7, 2.5 Hz, 1 H) 8.15 (s, 1 H) 8.59 (s , 1 H) 10.76 (s, 1 H); MS (ESI / APCI Dual pos.) M / z: 501 [M + H] +
実施例189 (4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトニトリル
実施例1で得られた2-(4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)アセトアミド(100 mg)のピリジン(2.0 mL)溶液に、氷冷下、オキシ塩化リン(40 μL)を加え、室温にて3時間攪拌した。反応液を氷-水に注ぎ、析出した固体をろ取した。得られた固体を水、イソプロピルエーテル及びヘキサンで洗浄し、表題化合物(98 mg)を黄色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 4.01 (s, 3 H) 4.06 - 4.19 (m, 2 H) 5.91 (s, 2 H) 7.07 (d, J=8.7 Hz, 1 H) 7.47 (d, J=8.3 Hz, 2 H) 7.82 - 7.99 (m, 2 H) 8.09 (dd, J=8.7, 2.5 Hz, 1 H) 8.22 (s, 1 H) 8.66 (s, 1 H) ; MS (ESI/APCI Dual pos.) m/z: 441 [M+H]+ Example 189 (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} phenyl) acetonitrile
2- (4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl obtained in Example 1 ] To a solution of 1,2,4-oxadiazol-3-yl} phenyl) acetamide (100 mg) in pyridine (2.0 mL) under ice-cooling, phosphorus oxychloride (40 μL) was added at room temperature. Stir for hours. The reaction solution was poured into ice-water, and the precipitated solid was collected by filtration. The obtained solid was washed with water, isopropyl ether and hexane to give the title compound (98 mg) as a yellow solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 4.01 (s, 3 H) 4.06-4.19 (m, 2 H) 5.91 (s, 2 H) 7.07 (d, J = 8.7 Hz, 1 H) 7.47 (d , J = 8.3 Hz, 2 H) 7.82-7.99 (m, 2 H) 8.09 (dd, J = 8.7, 2.5 Hz, 1 H) 8.22 (s, 1 H) 8.66 (s, 1 H); MS (ESI / APCI Dual pos.) M / z: 441 [M + H] +
1H NMR (600 MHz, DMSO-d6) δ ppm 4.01 (s, 3 H) 4.06 - 4.19 (m, 2 H) 5.91 (s, 2 H) 7.07 (d, J=8.7 Hz, 1 H) 7.47 (d, J=8.3 Hz, 2 H) 7.82 - 7.99 (m, 2 H) 8.09 (dd, J=8.7, 2.5 Hz, 1 H) 8.22 (s, 1 H) 8.66 (s, 1 H) ; MS (ESI/APCI Dual pos.) m/z: 441 [M+H]+ Example 189 (4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2, 4-oxadiazol-3-yl} phenyl) acetonitrile
1H NMR (600 MHz, DMSO-d6) δ ppm 4.01 (s, 3 H) 4.06-4.19 (m, 2 H) 5.91 (s, 2 H) 7.07 (d, J = 8.7 Hz, 1 H) 7.47 (d , J = 8.3 Hz, 2 H) 7.82-7.99 (m, 2 H) 8.09 (dd, J = 8.7, 2.5 Hz, 1 H) 8.22 (s, 1 H) 8.66 (s, 1 H); MS (ESI / APCI Dual pos.) M / z: 441 [M + H] +
実施例190 2-[4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2-オキソピリジン-1(2H)-イル]アセトアミド
1)4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2(1H)-オン
製造例4で得られた1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸(100 mg)のN,N-ジメチルホルムアミド(2.0 mL)溶液に、室温にて1,1’-カルボニルジイミダゾール(65 mg)を加え1時間撹拌した。反応液に製造例5で得られたN'-ヒドロキシ-2-オキソ-1,2-ジヒドロピリジン-4-カルボキシミドアミド(62 mg)を加え、室温にて30分間、110 ℃にて14時間撹拌した。反応液を室温まで放冷し、水を加えた後、析出した結晶をろ取した。これを酢酸エチルにて再結晶して表題化合物(74 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 4.04 (s, 3 H) 5.92 (s, 2 H) 6.61 (d, J=6.6 Hz, 1 H) 6.87 (d, J=1.2 Hz, 1 H) 7.11 (d, J=8.7 Hz, 1 H) 7.54 (d, J=7.0 Hz, 1 H) 8.13 (dd, J=8.9, 2.7 Hz, 1 H) 8.26 (s, 1 H) 8.67 (s, 1 H)
MS (ESI/APCI Dual pos.) m/z: 419 [M+H]+
2)2-[4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2-オキソピリジン-1(2H)-イル]アセトアミド
4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2(1H)-オン(47 mg)、2-ブロモアセトアミド(20 mg)及び炭酸カリウム(26mg)のN,N-ジメチルホルムアミド(1.0 mL)溶液を室温にて18時間、60 ℃にて4時間攪拌した。反応液を酢酸エチル(70 mL)で希釈し、水(20 mL)-飽和食塩水(20 mL)、飽和食塩水(30 mL)で順次洗浄した。有機層にISOLUTE HM-Nを加え、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=60:40~0:100~クロロホルム:メタノール=95:5~90:10)にて精製した。得られた固体を酢酸エチル-ヘキサンにて洗浄して、表題化合物(42 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 4.56 (s, 2 H) 5.92 (s, 2 H) 6.68 (dd, J=7.0, 1.7 Hz, 1 H) 6.91 (d, J=1.7 Hz, 1 H) 7.11 (d, J=8.7 Hz, 1 H) 7.22 (brs, 1 H) 7.65 (brs, 1 H) 7.76 (d, J=7.0 Hz, 1 H) 8.12 (dd, J=8.7, 2.5 Hz, 1 H) 8.26 (s, 1 H) 8.66 (s, 1 H)
MS (ESI/APCI Dual pos.) m/z: 476 [M+H]+ Example 190 2- [4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} -2-oxopyridin-1 (2H) -yl] acetamide
1) 4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} pyridin-2 (1H) -one 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H- obtained in Preparation Example 4 To a solution of pyrazole-4-carboxylic acid (100 mg) in N, N-dimethylformamide (2.0 mL) was added 1,1′-carbonyldiimidazole (65 mg) at room temperature and stirred for 1 hour. N'-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide (62 mg) obtained in Production Example 5 was added to the reaction solution, and the mixture was stirred at room temperature for 30 minutes and at 110 ° C. for 14 hours. did. The reaction solution was allowed to cool to room temperature, water was added, and the precipitated crystals were collected by filtration. This afford the title compound recrystallized from ethyl acetate (74 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δppm 4.04 (s, 3 H) 5.92 (s, 2 H) 6.61 (d, J = 6.6 Hz, 1 H) 6.87 (d, J = 1.2 Hz, 1 H) 7.11 (d, J = 8.7 Hz, 1 H) 7.54 (d, J = 7.0 Hz, 1 H) 8.13 (dd, J = 8.9, 2.7 Hz, 1 H) 8.26 (s, 1 H) 8.67 (s, 1 H )
MS m / z (ESI / APCI Dual pos.): 419 [M + H] +
2) 2- [4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2 , 4-Oxadiazol-3-yl} -2-oxopyridin-1 (2H) -yl] acetamide
4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol- A solution of 3-yl} pyridin-2 (1H) -one (47 mg), 2-bromoacetamide (20 mg) and potassium carbonate (26 mg) in N, N-dimethylformamide (1.0 mL) at room temperature for 18 The mixture was stirred at 60 ° C. for 4 hours. The reaction mixture was diluted with ethyl acetate (70 mL), and washed successively with water (20 mL) -saturated brine (20 mL) and saturated brine (30 mL). Added ISOLUTE HM-N in the organic layer was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 60: 40 to 0: 100 to chloroform: methanol = 95: 5 to 90:10). The obtained solid was washed with ethyl acetate-hexane to give the title compound (42 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 4.56 (s, 2 H) 5.92 (s, 2 H) 6.68 (dd, J = 7.0, 1.7 Hz, 1 H) 6.91 (d , J = 1.7 Hz, 1 H) 7.11 (d, J = 8.7 Hz, 1 H) 7.22 (brs, 1 H) 7.65 (brs, 1 H) 7.76 (d, J = 7.0 Hz, 1 H) 8.12 (dd , J = 8.7, 2.5 Hz, 1 H) 8.26 (s, 1 H) 8.66 (s, 1 H)
MS m / z (ESI / APCI Dual pos.): 476 [M + H] +
製造例4で得られた1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸(100 mg)のN,N-ジメチルホルムアミド(2.0 mL)溶液に、室温にて1,1’-カルボニルジイミダゾール(65 mg)を加え1時間撹拌した。反応液に製造例5で得られたN'-ヒドロキシ-2-オキソ-1,2-ジヒドロピリジン-4-カルボキシミドアミド(62 mg)を加え、室温にて30分間、110 ℃にて14時間撹拌した。反応液を室温まで放冷し、水を加えた後、析出した結晶をろ取した。これを酢酸エチルにて再結晶して表題化合物(74 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δppm 4.04 (s, 3 H) 5.92 (s, 2 H) 6.61 (d, J=6.6 Hz, 1 H) 6.87 (d, J=1.2 Hz, 1 H) 7.11 (d, J=8.7 Hz, 1 H) 7.54 (d, J=7.0 Hz, 1 H) 8.13 (dd, J=8.9, 2.7 Hz, 1 H) 8.26 (s, 1 H) 8.67 (s, 1 H)
MS (ESI/APCI Dual pos.) m/z: 419 [M+H]+
2)2-[4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2-オキソピリジン-1(2H)-イル]アセトアミド
4-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}ピリジン-2(1H)-オン(47 mg)、2-ブロモアセトアミド(20 mg)及び炭酸カリウム(26mg)のN,N-ジメチルホルムアミド(1.0 mL)溶液を室温にて18時間、60 ℃にて4時間攪拌した。反応液を酢酸エチル(70 mL)で希釈し、水(20 mL)-飽和食塩水(20 mL)、飽和食塩水(30 mL)で順次洗浄した。有機層にISOLUTE HM-Nを加え、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=60:40~0:100~クロロホルム:メタノール=95:5~90:10)にて精製した。得られた固体を酢酸エチル-ヘキサンにて洗浄して、表題化合物(42 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 4.56 (s, 2 H) 5.92 (s, 2 H) 6.68 (dd, J=7.0, 1.7 Hz, 1 H) 6.91 (d, J=1.7 Hz, 1 H) 7.11 (d, J=8.7 Hz, 1 H) 7.22 (brs, 1 H) 7.65 (brs, 1 H) 7.76 (d, J=7.0 Hz, 1 H) 8.12 (dd, J=8.7, 2.5 Hz, 1 H) 8.26 (s, 1 H) 8.66 (s, 1 H)
MS (ESI/APCI Dual pos.) m/z: 476 [M+H]+ Example 190 2- [4- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} -2-oxopyridin-1 (2H) -yl] acetamide
1H NMR (600 MHz, DMSO-d6) δppm 4.04 (s, 3 H) 5.92 (s, 2 H) 6.61 (d, J = 6.6 Hz, 1 H) 6.87 (d, J = 1.2 Hz, 1 H) 7.11 (d, J = 8.7 Hz, 1 H) 7.54 (d, J = 7.0 Hz, 1 H) 8.13 (dd, J = 8.9, 2.7 Hz, 1 H) 8.26 (s, 1 H) 8.67 (s, 1 H )
MS m / z (ESI / APCI Dual pos.): 419 [M + H] +
2) 2- [4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2 , 4-Oxadiazol-3-yl} -2-oxopyridin-1 (2H) -yl] acetamide
4- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4-oxadiazol- A solution of 3-yl} pyridin-2 (1H) -one (47 mg), 2-bromoacetamide (20 mg) and potassium carbonate (26 mg) in N, N-dimethylformamide (1.0 mL) at room temperature for 18 The mixture was stirred at 60 ° C. for 4 hours. The reaction mixture was diluted with ethyl acetate (70 mL), and washed successively with water (20 mL) -saturated brine (20 mL) and saturated brine (30 mL). Added ISOLUTE HM-N in the organic layer was concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 60: 40 to 0: 100 to chloroform: methanol = 95: 5 to 90:10). The obtained solid was washed with ethyl acetate-hexane to give the title compound (42 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 4.56 (s, 2 H) 5.92 (s, 2 H) 6.68 (dd, J = 7.0, 1.7 Hz, 1 H) 6.91 (d , J = 1.7 Hz, 1 H) 7.11 (d, J = 8.7 Hz, 1 H) 7.22 (brs, 1 H) 7.65 (brs, 1 H) 7.76 (d, J = 7.0 Hz, 1 H) 8.12 (dd , J = 8.7, 2.5 Hz, 1 H) 8.26 (s, 1 H) 8.66 (s, 1 H)
MS m / z (ESI / APCI Dual pos.): 476 [M + H] +
実施例191
2-[5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2-オキソピリジン-1(2H)-イル]アセトアミド
実施例190と同様の手法を用いて、表題化合物を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 4.02 (s, 3 H) 4.65 (s, 2 H) 5.92 (s, 2 H) 6.52 (d, J=9.5 Hz, 1 H) 7.11 (d, J=8.7 Hz, 1 H) 7.25 (brs, 1 H) 7.70 (brs, 1 H) 7.85 (dd, J=9.5, 2.9 Hz, 1 H) 8.13 (dd, J=8.7, 2.5 Hz, 1 H) 8.20 (s, 1 H) 8.39 (d, J=2.5 Hz, 1 H) 8.65 (s, 1 H)
MS (ESI/APCI Dual pos.) m/z: 476 [M+H]+ Example 191
2- [5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl} -2-oxopyridin-1 (2H) -yl] acetamide
Using a method similar to that in Example 190, the title compound was obtained as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 4.02 (s, 3 H) 4.65 (s, 2 H) 5.92 (s, 2 H) 6.52 (d, J = 9.5 Hz, 1 H) 7.11 (d, J = 8.7 Hz, 1 H) 7.25 (brs, 1 H) 7.70 (brs, 1 H) 7.85 (dd, J = 9.5, 2.9 Hz, 1 H) 8.13 (dd, J = 8.7, 2.5 Hz, 1 H) 8.20 (s, 1 H) 8.39 (d, J = 2.5 Hz, 1 H) 8.65 (s, 1 H)
MS m / z (ESI / APCI Dual pos.): 476 [M + H] +
2-[5-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}-2-オキソピリジン-1(2H)-イル]アセトアミド
1H NMR (600 MHz, DMSO-d6) δ ppm 4.02 (s, 3 H) 4.65 (s, 2 H) 5.92 (s, 2 H) 6.52 (d, J=9.5 Hz, 1 H) 7.11 (d, J=8.7 Hz, 1 H) 7.25 (brs, 1 H) 7.70 (brs, 1 H) 7.85 (dd, J=9.5, 2.9 Hz, 1 H) 8.13 (dd, J=8.7, 2.5 Hz, 1 H) 8.20 (s, 1 H) 8.39 (d, J=2.5 Hz, 1 H) 8.65 (s, 1 H)
MS (ESI/APCI Dual pos.) m/z: 476 [M+H]+ Example 191
2- [5- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4 -Oxadiazol-3-yl} -2-oxopyridin-1 (2H) -yl] acetamide
1H NMR (600 MHz, DMSO-d6) δ ppm 4.02 (s, 3 H) 4.65 (s, 2 H) 5.92 (s, 2 H) 6.52 (d, J = 9.5 Hz, 1 H) 7.11 (d, J = 8.7 Hz, 1 H) 7.25 (brs, 1 H) 7.70 (brs, 1 H) 7.85 (dd, J = 9.5, 2.9 Hz, 1 H) 8.13 (dd, J = 8.7, 2.5 Hz, 1 H) 8.20 (s, 1 H) 8.39 (d, J = 2.5 Hz, 1 H) 8.65 (s, 1 H)
MS m / z (ESI / APCI Dual pos.): 476 [M + H] +
実施例192 N-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)スルフリック ジアミド
1)3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}アニリン
製造例4で得られた1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸(800 mg)のN,N-ジメチルホルムアミド(3.0 mL)溶液に室温にて1,1’-カルボニルジイミダゾール(517 mg)を加え30分間撹拌した。反応液に製造例5で得られた3-アミノ-N'-ヒドロキシベンゼンカルボキシミドアミド(480 mg)を加え、室温にて1時間、110 ℃にて16時間撹拌した。反応液を減圧下濃縮し、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=88:12~50:50)にて精製した。得られた固体をテトラヒドロフラン-イソプロピルエーテルより再結晶し、表題化合物(464 mg)を無色固体として得た。
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.78 (br. s., 2 H) 4.05 (s, 3 H) 5.95 (s, 2 H) 6.81 (dd, J=8.1, 1.4 Hz, 1 H) 6.88 (d, J=8.7 Hz, 1 H) 7.22 - 7.26 (m, 1 H) 7.41 (s, 1 H) 7.46 (d, J=7.4 Hz, 1 H) 7.82 (dd, J=8.7, 2.48 Hz, 1 H) 8.14 (s, 1 H) 8.48 (s, 1 H)
2)N-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)スルフリック ジアミド
t-ブタノール(181 μL)のクロロホルム(3.2 mL)溶液に、氷冷下、スルフリソシアナチドイル クロリド(166 μL)を加え、同温にて10分間攪拌した。トリエチルアミン(319 μL)及び3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}アニリン(159 mg)を、氷冷下、反応液に加え、室温にて21時間攪拌した。反応液に飽和炭酸水素ナトリウム水溶液(1.6 mL)及び水(1.6 mL)を加え、2層を分離した。有機層をフェーズセパレーター(バイオタージ社製)に通し、水分を除去後、減圧下濃縮した。残渣にクロロホルムを加え、氷冷下、トリフルオロ酢酸(3.2 mL)を加え、室温にて1.5時間攪拌した。反応液を減圧下濃縮し、残渣にクロロホルム(6.4 mL)、飽和炭酸水素ナトリウム水溶液(3.2 mL)、水(6.4 mL)及びメタノール(3.2 mL)を加えた。2層を分離後、水層をクロロホルム(3.2 mL)-メタノール(1.6 mL)の混合溶媒で抽出した。一緒にした有機層をフェーズセパレーターに通し、水分を除去後、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=100:0~90:10)にて精製し、表題化合物(99 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 5.93 (s, 2 H) 7.10 - 7.13 (m, 1 H) 7.15 (br. s, 2 H) 7.37 - 7.44 (m, 2 H) 7.48 - 7.51 (m, 1 H) 7.83 - 7.85 (m, 1 H) 8.11 - 8.14 (m, 1 H) 8.23 (s, 1 H) 8.67 (br. s, 1 H) 9.75 (br. s, 1 H); MS (ESI/APCI Dual neg.) m/z: 494 [M-H]- Example 192 N- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) sulfuric diamide
1) 3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2,4- Oxadiazol-3-yl} aniline 1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazole-4-carboxylic acid obtained in Production Example 4 To a solution of 800 mg) in N, N-dimethylformamide (3.0 mL) was added 1,1′-carbonyldiimidazole (517 mg) at room temperature and stirred for 30 minutes. To the reaction solution, 3-amino-N′-hydroxybenzenecarboxymidoamide (480 mg) obtained in Production Example 5 was added, and the mixture was stirred at room temperature for 1 hour and at 110 ° C. for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography (silica gel cartridge, hexane: ethyl acetate = 88: 12 to 50:50). The obtained solid was recrystallized from tetrahydrofuran-isopropyl ether to give the title compound (464 mg) as a colorless solid.
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.78 (br. S., 2 H) 4.05 (s, 3 H) 5.95 (s, 2 H) 6.81 (dd, J = 8.1, 1.4 Hz, 1 H) 6.88 (d, J = 8.7 Hz, 1 H) 7.22-7.26 (m, 1 H) 7.41 (s, 1 H) 7.46 (d, J = 7.4 Hz, 1 H) 7.82 (dd, J = 8.7, 2.48 Hz , 1 H) 8.14 (s, 1 H) 8.48 (s, 1 H)
2) N- (3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2 , 4-Oxadiazol-3-yl} phenyl) sulfuric diamide t-butanol (181 μL) in chloroform (3.2 mL) was added with sulfrocyanocyanidyl chloride (166 μL) under ice cooling, and the same temperature. at the mixture was stirred for 10 minutes. Triethylamine (319 μL) and 3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} aniline (159 mg) was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 21 hours. A saturated aqueous sodium hydrogen carbonate solution (1.6 mL) and water (1.6 mL) were added to the reaction solution, and the two layers were separated. The organic layer was passed through a phase separator (manufactured by Biotage Corp.), water was removed, and the mixture was concentrated under reduced pressure. Chloroform was added to the residue, trifluoroacetic acid (3.2 mL) was added under ice cooling, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure, and chloroform (6.4 mL), saturated aqueous sodium hydrogen carbonate solution (3.2 mL), water (6.4 mL) and methanol (3.2 mL) were added to the residue. After separating the two layers, the aqueous layer was extracted with a mixed solvent of chloroform (3.2 mL) -methanol (1.6 mL). The combined organic layers were passed through a phase separator to remove moisture, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 100: 0 to 90:10) to give the title compound (99 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 5.93 (s, 2 H) 7.10-7.13 (m, 1 H) 7.15 (br. S, 2 H) 7.37-7.44 (m, 2 H) 7.48-7.51 (m, 1 H) 7.83-7.85 (m, 1 H) 8.11-8.14 (m, 1 H) 8.23 (s, 1 H) 8.67 (br. S, 1 H) 9.75 (br. s, 1 H); MS (ESI / APCI Dual neg.) m / z: 494 [MH]-
製造例4で得られた1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾール-4-カルボン酸(800 mg)のN,N-ジメチルホルムアミド(3.0 mL)溶液に室温にて1,1’-カルボニルジイミダゾール(517 mg)を加え30分間撹拌した。反応液に製造例5で得られた3-アミノ-N'-ヒドロキシベンゼンカルボキシミドアミド(480 mg)を加え、室温にて1時間、110 ℃にて16時間撹拌した。反応液を減圧下濃縮し、残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、ヘキサン:酢酸エチル=88:12~50:50)にて精製した。得られた固体をテトラヒドロフラン-イソプロピルエーテルより再結晶し、表題化合物(464 mg)を無色固体として得た。
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.78 (br. s., 2 H) 4.05 (s, 3 H) 5.95 (s, 2 H) 6.81 (dd, J=8.1, 1.4 Hz, 1 H) 6.88 (d, J=8.7 Hz, 1 H) 7.22 - 7.26 (m, 1 H) 7.41 (s, 1 H) 7.46 (d, J=7.4 Hz, 1 H) 7.82 (dd, J=8.7, 2.48 Hz, 1 H) 8.14 (s, 1 H) 8.48 (s, 1 H)
2)N-(3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}フェニル)スルフリック ジアミド
t-ブタノール(181 μL)のクロロホルム(3.2 mL)溶液に、氷冷下、スルフリソシアナチドイル クロリド(166 μL)を加え、同温にて10分間攪拌した。トリエチルアミン(319 μL)及び3-{5-[1-メチル-5-({[5-(トリフルオロメチル)ピリジン-2-イル]オキシ}メチル)-1H-ピラゾル-4-イル]-1,2,4-オキサジアゾル-3-イル}アニリン(159 mg)を、氷冷下、反応液に加え、室温にて21時間攪拌した。反応液に飽和炭酸水素ナトリウム水溶液(1.6 mL)及び水(1.6 mL)を加え、2層を分離した。有機層をフェーズセパレーター(バイオタージ社製)に通し、水分を除去後、減圧下濃縮した。残渣にクロロホルムを加え、氷冷下、トリフルオロ酢酸(3.2 mL)を加え、室温にて1.5時間攪拌した。反応液を減圧下濃縮し、残渣にクロロホルム(6.4 mL)、飽和炭酸水素ナトリウム水溶液(3.2 mL)、水(6.4 mL)及びメタノール(3.2 mL)を加えた。2層を分離後、水層をクロロホルム(3.2 mL)-メタノール(1.6 mL)の混合溶媒で抽出した。一緒にした有機層をフェーズセパレーターに通し、水分を除去後、減圧下濃縮した。残渣をカラムクロマトグラフィー(シリカゲルカートリッジ、クロロホルム:メタノール=100:0~90:10)にて精製し、表題化合物(99 mg)を無色固体として得た。
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 5.93 (s, 2 H) 7.10 - 7.13 (m, 1 H) 7.15 (br. s, 2 H) 7.37 - 7.44 (m, 2 H) 7.48 - 7.51 (m, 1 H) 7.83 - 7.85 (m, 1 H) 8.11 - 8.14 (m, 1 H) 8.23 (s, 1 H) 8.67 (br. s, 1 H) 9.75 (br. s, 1 H); MS (ESI/APCI Dual neg.) m/z: 494 [M-H]- Example 192 N- (3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} phenyl) sulfuric diamide
1H NMR (600 MHz, CHLOROFORM-d) δ ppm 3.78 (br. S., 2 H) 4.05 (s, 3 H) 5.95 (s, 2 H) 6.81 (dd, J = 8.1, 1.4 Hz, 1 H) 6.88 (d, J = 8.7 Hz, 1 H) 7.22-7.26 (m, 1 H) 7.41 (s, 1 H) 7.46 (d, J = 7.4 Hz, 1 H) 7.82 (dd, J = 8.7, 2.48 Hz , 1 H) 8.14 (s, 1 H) 8.48 (s, 1 H)
2) N- (3- {5- [1-Methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1,2 , 4-Oxadiazol-3-yl} phenyl) sulfuric diamide t-butanol (181 μL) in chloroform (3.2 mL) was added with sulfrocyanocyanidyl chloride (166 μL) under ice cooling, and the same temperature. at the mixture was stirred for 10 minutes. Triethylamine (319 μL) and 3- {5- [1-methyl-5-({[5- (trifluoromethyl) pyridin-2-yl] oxy} methyl) -1H-pyrazol-4-yl] -1, 2,4-oxadiazol-3-yl} aniline (159 mg) was added to the reaction mixture under ice cooling, and the mixture was stirred at room temperature for 21 hours. A saturated aqueous sodium hydrogen carbonate solution (1.6 mL) and water (1.6 mL) were added to the reaction solution, and the two layers were separated. The organic layer was passed through a phase separator (manufactured by Biotage Corp.), water was removed, and the mixture was concentrated under reduced pressure. Chloroform was added to the residue, trifluoroacetic acid (3.2 mL) was added under ice cooling, and the mixture was stirred at room temperature for 1.5 hours. The reaction mixture was concentrated under reduced pressure, and chloroform (6.4 mL), saturated aqueous sodium hydrogen carbonate solution (3.2 mL), water (6.4 mL) and methanol (3.2 mL) were added to the residue. After separating the two layers, the aqueous layer was extracted with a mixed solvent of chloroform (3.2 mL) -methanol (1.6 mL). The combined organic layers were passed through a phase separator to remove moisture, and then concentrated under reduced pressure. The residue was purified by column chromatography (silica gel cartridge, chloroform: methanol = 100: 0 to 90:10) to give the title compound (99 mg) as a colorless solid.
1H NMR (600 MHz, DMSO-d6) δ ppm 4.04 (s, 3 H) 5.93 (s, 2 H) 7.10-7.13 (m, 1 H) 7.15 (br. S, 2 H) 7.37-7.44 (m, 2 H) 7.48-7.51 (m, 1 H) 7.83-7.85 (m, 1 H) 8.11-8.14 (m, 1 H) 8.23 (s, 1 H) 8.67 (br. S, 1 H) 9.75 (br. s, 1 H); MS (ESI / APCI Dual neg.) m / z: 494 [MH]-
試験例1
(ヒト型代謝型グルタミン酸受容体(mGlu2)安定発現CHO細胞の粗膜画分調製)
ヒト型mGlu2受容体安定発現CHO細胞を、10%透析牛胎児血清含有ダルベッコ改変イーグル培地[1% proline、50units/mL penicillin、50μg/mL streptomycin、400μg/mL Hygromycin B、2mM L-glutamine(用時添加)]を用いて、37℃、5%CO2下で培養した。コンフルエント状態の細胞をPBS(-)で2回洗浄した後、セルスクレ-パ-で剥離し、4℃、1000rpm、5分間遠心分離を行って細胞を回収した。得られた沈さを、20mM HEPES緩衝液(pH7.4)に懸濁し、当該懸濁液をテフロン(登録商標)ホモジナイザ-でホモジナイズした後、4℃、48,000×g、20分間遠心分離することにより、再び沈さを得た。さらに得られた沈さを2回遠心洗浄した後に、上記緩衝液でホモジナイズすることにより粗膜画分を得た。得られた粗膜画分は、-80℃で保存した。 Test example 1
(Preparation of crude membrane fraction of CHO cells stably expressing human metabotropic glutamate receptor (mGlu2))
CHO cells stably expressing human mGlu2 receptor were mixed with Dulbecco's modified Eagle medium containing 10% dialyzed fetal bovine serum [1% proline, 50 units / mL penicillin, 50 μg / mL streptomycin, 400 μg / mL Hygromycin B, 2 mM L-glutamine (for use) Added)] and cultured at 37 ° C. under 5% CO 2 . Confluent cells were washed twice with PBS (−), detached with a cell scraper, and centrifuged at 4 ° C. and 1000 rpm for 5 minutes to collect the cells. The obtained precipitate was suspended in 20 mM HEPES buffer (pH 7.4), the suspension was homogenized with a Teflon (registered trademark) homogenizer, and then centrifuged at 4 ° C., 48,000 × g for 20 minutes. By getting sunk again. Further, the resulting precipitate was washed twice by centrifugation and then homogenized with the above buffer solution to obtain a crude membrane fraction. The obtained crude membrane fraction was stored at −80 ° C.
(ヒト型代謝型グルタミン酸受容体(mGlu2)安定発現CHO細胞の粗膜画分調製)
ヒト型mGlu2受容体安定発現CHO細胞を、10%透析牛胎児血清含有ダルベッコ改変イーグル培地[1% proline、50units/mL penicillin、50μg/mL streptomycin、400μg/mL Hygromycin B、2mM L-glutamine(用時添加)]を用いて、37℃、5%CO2下で培養した。コンフルエント状態の細胞をPBS(-)で2回洗浄した後、セルスクレ-パ-で剥離し、4℃、1000rpm、5分間遠心分離を行って細胞を回収した。得られた沈さを、20mM HEPES緩衝液(pH7.4)に懸濁し、当該懸濁液をテフロン(登録商標)ホモジナイザ-でホモジナイズした後、4℃、48,000×g、20分間遠心分離することにより、再び沈さを得た。さらに得られた沈さを2回遠心洗浄した後に、上記緩衝液でホモジナイズすることにより粗膜画分を得た。得られた粗膜画分は、-80℃で保存した。 Test example 1
(Preparation of crude membrane fraction of CHO cells stably expressing human metabotropic glutamate receptor (mGlu2))
CHO cells stably expressing human mGlu2 receptor were mixed with Dulbecco's modified Eagle medium containing 10% dialyzed fetal bovine serum [1% proline, 50 units / mL penicillin, 50 μg / mL streptomycin, 400 μg / mL Hygromycin B, 2 mM L-glutamine (for use) Added)] and cultured at 37 ° C. under 5% CO 2 . Confluent cells were washed twice with PBS (−), detached with a cell scraper, and centrifuged at 4 ° C. and 1000 rpm for 5 minutes to collect the cells. The obtained precipitate was suspended in 20 mM HEPES buffer (pH 7.4), the suspension was homogenized with a Teflon (registered trademark) homogenizer, and then centrifuged at 4 ° C., 48,000 × g for 20 minutes. By getting sunk again. Further, the resulting precipitate was washed twice by centrifugation and then homogenized with the above buffer solution to obtain a crude membrane fraction. The obtained crude membrane fraction was stored at −80 ° C.
([35S]GTPγS結合試験)
上記で調製した凍結膜画分を用時融解して、結合試験用緩衝液(終濃度;20mM HEPES、100mM NaCl、10mM MgCl2、8.4μM GDP、10μg/mL saponin、0.1% BSA)にて希釈した。膜タンパク質10μg/assayの膜画分に実施例化合物を添加して、30℃で20分間インキュベ-ションを行った。その後、グルタミン酸(終濃度20μM)と[35S]GTPγS(終濃度0.15nM)を添加して、30℃で1時間インキュベ-ションを行った。インキュベ-ションの後、上記反応液を20mM HEPES緩衝液(pH7.4)に予め浸したWhatman GF/Cフィルタ-上に吸引濾過し、上記フィルタ-を氷冷20mM HEPES緩衝液(pH7.4)300μLで3回洗浄した。得られたフィルタ-にシンチレーションカクテルを添加して、液体シンチレーションカウンターで膜結合放射活性を測定した。
グルタミン酸非存在下で上記反応を行った場合における[35S]GTPγS結合量を非特異的結合とし、グルタミン酸存在下で得られた[35S]GTPγS結合量との差を特異的結合とした。各実施例化合物の様々な濃度における特異的結合阻害率より、非線形解析を用いて阻害曲線を得た。特異的[35S]GTPγS結合量が50%抑制される各実施例化合物の濃度(IC50値)を阻害曲線より算出した。
本発明化合物中、IC50値が0.1μM以下の化合物をA、0.1μM~1μMの化合物をB、1μM~10μMの化合物をC、10μM以上の化合物をDと表記し、表8に示す。更に本発明化合物の幾つかについて、IC50値を表9に例示する。 ([ 35 S] GTPγS binding test)
The frozen membrane fraction prepared above was thawed before use, and a binding test buffer (final concentration; 20 mM HEPES, 100 mM NaCl, 10 mM MgCl 2 , 8.4 μM GDP, 10 μg / mL saponin, 0.1% BSA) Diluted with Example compounds were added to a membrane fraction of membrane protein 10 μg / assay and incubated at 30 ° C. for 20 minutes. Thereafter, glutamic acid (final concentration 20 μM) and [ 35 S] GTPγS (final concentration 0.15 nM) were added, followed by incubation at 30 ° C. for 1 hour. After the incubation, the reaction solution was suction filtered onto a Whatman GF / C filter pre-soaked in 20 mM HEPES buffer (pH 7.4), and the filter was ice-cooled 20 mM HEPES buffer (pH 7.4). Washed 3 times with 300 μL. A scintillation cocktail was added to the obtained filter, and membrane-bound radioactivity was measured with a liquid scintillation counter.
The amount of [ 35 S] GTPγS binding when the above reaction was performed in the absence of glutamic acid was defined as non-specific binding, and the difference from the amount of [ 35 S] GTPγS binding obtained in the presence of glutamic acid was defined as specific binding. Inhibition curves were obtained from the specific binding inhibition rates at various concentrations of each Example compound using nonlinear analysis. The concentration (IC 50 value) of each Example compound at which the specific [ 35 S] GTPγS binding amount was suppressed by 50% was calculated from the inhibition curve.
Among the compounds of the present invention, a compound having an IC 50 value of 0.1 μM or less is represented by A, a compound having 0.1 μM to 1 μM is represented by B, a compound having 1 μM to 10 μM is represented by C, and a compound having 10 μM or more is represented by D. . Further, for some of the compounds of the present invention, IC 50 values are exemplified in Table 9.
上記で調製した凍結膜画分を用時融解して、結合試験用緩衝液(終濃度;20mM HEPES、100mM NaCl、10mM MgCl2、8.4μM GDP、10μg/mL saponin、0.1% BSA)にて希釈した。膜タンパク質10μg/assayの膜画分に実施例化合物を添加して、30℃で20分間インキュベ-ションを行った。その後、グルタミン酸(終濃度20μM)と[35S]GTPγS(終濃度0.15nM)を添加して、30℃で1時間インキュベ-ションを行った。インキュベ-ションの後、上記反応液を20mM HEPES緩衝液(pH7.4)に予め浸したWhatman GF/Cフィルタ-上に吸引濾過し、上記フィルタ-を氷冷20mM HEPES緩衝液(pH7.4)300μLで3回洗浄した。得られたフィルタ-にシンチレーションカクテルを添加して、液体シンチレーションカウンターで膜結合放射活性を測定した。
グルタミン酸非存在下で上記反応を行った場合における[35S]GTPγS結合量を非特異的結合とし、グルタミン酸存在下で得られた[35S]GTPγS結合量との差を特異的結合とした。各実施例化合物の様々な濃度における特異的結合阻害率より、非線形解析を用いて阻害曲線を得た。特異的[35S]GTPγS結合量が50%抑制される各実施例化合物の濃度(IC50値)を阻害曲線より算出した。
本発明化合物中、IC50値が0.1μM以下の化合物をA、0.1μM~1μMの化合物をB、1μM~10μMの化合物をC、10μM以上の化合物をDと表記し、表8に示す。更に本発明化合物の幾つかについて、IC50値を表9に例示する。 ([ 35 S] GTPγS binding test)
The frozen membrane fraction prepared above was thawed before use, and a binding test buffer (final concentration; 20 mM HEPES, 100 mM NaCl, 10 mM MgCl 2 , 8.4 μM GDP, 10 μg / mL saponin, 0.1% BSA) Diluted with Example compounds were added to a membrane fraction of membrane protein 10 μg / assay and incubated at 30 ° C. for 20 minutes. Thereafter, glutamic acid (final concentration 20 μM) and [ 35 S] GTPγS (final concentration 0.15 nM) were added, followed by incubation at 30 ° C. for 1 hour. After the incubation, the reaction solution was suction filtered onto a Whatman GF / C filter pre-soaked in 20 mM HEPES buffer (pH 7.4), and the filter was ice-cooled 20 mM HEPES buffer (pH 7.4). Washed 3 times with 300 μL. A scintillation cocktail was added to the obtained filter, and membrane-bound radioactivity was measured with a liquid scintillation counter.
The amount of [ 35 S] GTPγS binding when the above reaction was performed in the absence of glutamic acid was defined as non-specific binding, and the difference from the amount of [ 35 S] GTPγS binding obtained in the presence of glutamic acid was defined as specific binding. Inhibition curves were obtained from the specific binding inhibition rates at various concentrations of each Example compound using nonlinear analysis. The concentration (IC 50 value) of each Example compound at which the specific [ 35 S] GTPγS binding amount was suppressed by 50% was calculated from the inhibition curve.
Among the compounds of the present invention, a compound having an IC 50 value of 0.1 μM or less is represented by A, a compound having 0.1 μM to 1 μM is represented by B, a compound having 1 μM to 10 μM is represented by C, and a compound having 10 μM or more is represented by D. . Further, for some of the compounds of the present invention, IC 50 values are exemplified in Table 9.
本発明化合物は、グループII mGlu受容体に対して拮抗作用を有し、グループII mGlu受容体に関連する疾患の予防薬及び治療薬、具体的には、気分障害(うつ病性障害、双極性障害等)、不安障害(全般性不安障害、パニック障害、強迫性障害、社会不安障害、外傷後ストレス障害、特定の恐怖症、急性ストレス障害等)、統合失調症、アルツハイマー病、認知機能障害、認知症、薬物依存、痙攣、振戦、疼痛、及び睡眠障害等の予防薬又は治療薬として利用できる。
The compound of the present invention has an antagonistic action on Group II mGlu receptor, and is a preventive and therapeutic agent for diseases related to Group II mGlu receptor, specifically mood disorders (depressive disorder, bipolar) Disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobia, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, It can be used as a preventive or therapeutic agent for dementia, drug dependence, convulsions, tremors, pain, sleep disorders and the like.
Claims (11)
- 式[I]
R1は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R2は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
環Aは、フェニル基、ヘテロアリール基、インドリン-2-オン-5-イル基、イソインドリン-1-オン-5-イル基、イソインドリン-1-オン-6-イル基、ベンゾ[d]イミダゾール-2-オン-5-イル基又はピリドニル基を示し、
環Aがインドリン-2-オン-5-イル基、イソインドリン-1-オン-5-イル基、イソインドリン-1-オン-6-イル基又はベンゾ[d]イミダゾール-2-オン-5-イル基のとき、
R3及びR4は、同一又は異なって、水素原子、ハロゲン原子又はC1-6アルキル基を示し、
環Aがフェニル基、ヘテロアリール基又はピリドニル基のとき、
R3は、水素原子、ハロゲン原子、C1-6アルコキシ基又はC1-6アルキル基(ここで該C1-6アルコキシ基又はC1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R4は、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc、シアノ基又は水酸基で置換されている。)、-CONRaRb、-O-CONRaRb、-NRa1Rb1、-CORc、シアノ基、-NRdCORe又は-NRdSO2Reを示し、
Ra及びRbは、同一又は異なって、水素原子、C1-6アルキル基
{ここで該C1-6アルキル基は、
水酸基、
ハロゲン原子、
C1-6アルコキシ基
(ここで該C1-6アルコキシ基は、1から2個の水酸基で置換されてもよい。)、
-CONRfRg、
アミノ基、
モノ-C1-6アルキルアミノ基、
ジ-C1-6アルキルアミノ基、
モルホリノ基、
ピペリジノ基、
ピロリジノ基、
アゼチジノ基、
1,3-ジオキソラン-2-イル基、
1,3-ジオキサン-2-イル基、
2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル基及び
5,7-ジオキサスピロ[2.5]オクタン-6-イル基
(ここで該モルホリノ基、ピペリジノ基、ピロリジノ基、アゼチジノ基、1,3-ジオキソラン-2-イル基、1,3-ジオキサン-2-イル基、2-オキサ-6-アザスピロ[3.3]ヘプタン-6-イル基及び5,7-ジオキサスピロ[2.5]オクタン-6-イル基
は1から2個のハロゲン原子で置換されてもよい。)
からなる群より選択される1から3個の置換基で置換されてもよい。}、
C1-6アルカノイル基、オキセタニル基、テトラヒドロフラニル基又はテトラヒドロピラニル基を示すか、
又は、Ra及びRbは、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の4から6員環(ここで該飽和又は不飽和の4から6員環は、C1-6アルキル基、オキソ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)を形成してもよく、
Ra1及びRb1は、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の4から6員環(ここで該飽和又は不飽和の4から6員環は、C1-6アルキル基、オキソ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)を形成し、
Rcは、C1-6アルキル基、水酸基又はC1-6アルコキシ基を示し、
Rdは、水素原子又はC1-6アルキル基を示し、
Reは、C1-6アルコキシ基、アミノ基、モノ-C1-6アルキルアミノ基又はジ-C1-6アルキルアミノ基を示し、
Rf及びRgは、同一又は異なって、水素原子又はC1-6アルキル基を示し、
Y1は、-(CH2)n-O-又は-(CH2)m-を示し、
nは、1から6の整数を示し、
mは、0から6の整数を示し、
Y2は、アリール基又はヘテロアリール基{ここで該アリール基又はヘテロアリール基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}を示し、
Y3は、5員ヘテロアリーレンを示す]
で表される化合物又はその医薬上許容される塩。 Formula [I]
R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A includes a phenyl group, a heteroaryl group, an indoline-2-one-5-yl group, an isoindoline-1-one-5-yl group, an isoindoline-1-one-6-yl group, a benzo [d] Represents an imidazol-2-one-5-yl group or a pyridonyl group;
Ring A is an indoline-2-one-5-yl group, an isoindoline-1-one-5-yl group, an isoindoline-1-one-6-yl group or a benzo [d] imidazol-2-one-5 when yl group,
R 3 and R 4 are the same or different and each represents a hydrogen atom, a halogen atom or a C 1-6 alkyl group,
When ring A is a phenyl group, heteroaryl group or pyridonyl group,
R 3 represents a hydrogen atom, a halogen atom, a C 1-6 alkoxy group or a C 1-6 alkyl group (wherein the C 1-6 alkoxy group or C 1-6 alkyl group is substituted with 1 to 3 halogen atoms) May be)
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is —CONR a R b , —COR c , a cyano group or a hydroxyl group) -CONR a R b , —O—CONR a R b , —NR a1 R b1 , —COR c , a cyano group, —NR d COR e or —NR d SO 2 R e ,
R a and R b are the same or different and each represents a hydrogen atom, a C 1-6 alkyl group (wherein the C 1-6 alkyl group is
A hydroxyl group,
A halogen atom,
A C 1-6 alkoxy group (wherein the C 1-6 alkoxy group may be substituted with 1 to 2 hydroxyl groups),
-CONR f R g ,
An amino group,
Mono-C 1-6 alkylamino group,
Di-C 1-6 alkylamino group,
Morpholino group,
Piperidino group,
Pyrrolidino group,
Azetidino group,
1,3-dioxolan-2-yl group,
1,3-dioxane-2-yl group,
2-oxa-6-azaspiro [3.3] heptan-6-yl group and 5,7-dioxaspiro [2.5] octan-6-yl group (wherein the morpholino group, piperidino group, pyrrolidino group, azetidino group 1,3-dioxolan-2-yl group, 1,3-dioxane-2-yl group, 2-oxa-6-azaspiro [3.3] heptan-6-yl group and 5,7-dioxaspiro [2. 5] The octan-6-yl group may be substituted with 1 to 2 halogen atoms.
May be substituted with 1 to 3 substituents selected from the group consisting of },
A C 1-6 alkanoyl group, an oxetanyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group,
Alternatively, R a and R b are formed together with a nitrogen atom to be bonded, and are a saturated or unsaturated 4- to 6-membered ring (here, which may further contain one or more nitrogen atom, oxygen atom or sulfur atom (wherein The saturated or unsaturated 4- to 6-membered ring may be substituted with 1 to 2 substituents selected from the group consisting of a C 1-6 alkyl group, an oxo group and a hydroxyl group. Well,
R a1 and R b1 are formed together with a nitrogen atom to which they are bonded, and are a saturated or unsaturated 4- to 6-membered ring that may contain one or more nitrogen atoms, oxygen atoms, or sulfur atoms, Or an unsaturated 4- to 6-membered ring may be substituted with 1 to 2 substituents selected from the group consisting of a C 1-6 alkyl group, an oxo group and a hydroxyl group.
R c represents a C 1-6 alkyl group, a hydroxyl group or a C 1-6 alkoxy group,
R d represents a hydrogen atom or a C 1-6 alkyl group,
R e represents a C 1-6 alkoxy group, an amino group, a mono-C 1-6 alkylamino group or a di-C 1-6 alkylamino group,
R f and R g are the same or different and each represents a hydrogen atom or a C 1-6 alkyl group,
Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —,
n represents an integer of 1 to 6,
m represents an integer of 0 to 6,
Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6 alkyl group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom It may be substituted with 3 substituents. },
Y 3 represents a 5-membered heteroarylene]
Or a pharmaceutically acceptable salt thereof. - 式[I]中、
R1は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R2は、水素原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
環Aは、フェニル基又はヘテロアリール基を示し、
R3は、水素原子、ハロゲン原子又はC1-6アルキル基(ここで該C1-6アルキル基は1から3個のハロゲン原子で置換されてもよい。)を示し、
R4は、C1-6アルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基又はC1-6アルコキシ基は、-CONRaRb、-CORc又はシアノ基で置換されている。)、-CONRaRb、-O-CONRaRb、-CORc又はシアノ基を示し、
Ra及びRbは、同一又は異なって、水素原子、C1-6アルキル基、(ここで該C1-6アルキル基はアミノ基、モノ-C1-6アルキルアミノ基、ジ-C1-6アルキルアミノ基及び水酸基からなる群より選択される1から2個の置換基で置換されてもよい。)、オキセタニル基、テトラヒドロフラニル基又はテトラヒドロピラニル基を示すか、
又は、Ra及びRbは、結合する窒素原子と共に一緒になって形成され、さらに窒素原子、酸素原子又は硫黄原子を1つ以上含んでもよい飽和又は不飽和の5又は6員環を形成してもよく、
Rcは、水酸基又はC1-6アルコキシ基を示し、
Y1は、-(CH2)n-O-又は-(CH2)m-を示し、
nは、1から6の整数を示し、
mは、0から6の整数を示し、
Y2は、アリール基又はヘテロアリール基{ここで該アリール基又はヘテロアリール基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}を示し、
Y3は、5員ヘテロアリーレンを示す、
請求項1に記載の化合物又はその医薬上許容される塩。 In the formula [I],
R 1 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 2 represents a hydrogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
Ring A represents a phenyl group or a heteroaryl group,
R 3 represents a hydrogen atom, a halogen atom or a C 1-6 alkyl group (wherein the C 1-6 alkyl group may be substituted with 1 to 3 halogen atoms);
R 4 represents a C 1-6 alkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl group or C 1-6 alkoxy group is substituted with —CONR a R b , —COR c or a cyano group). -CONR a R b , -O-CONR a R b , -COR c, or a cyano group,
R a and R b are the same or different and are each a hydrogen atom, a C 1-6 alkyl group, wherein the C 1-6 alkyl group is an amino group, a mono-C 1-6 alkylamino group, di-C 1 -6 may be substituted with 1 to 2 substituents selected from the group consisting of an alkylamino group and a hydroxyl group.), Represents an oxetanyl group, a tetrahydrofuranyl group or a tetrahydropyranyl group,
Alternatively, R a and R b are formed together with the nitrogen atom to be bonded to form a saturated or unsaturated 5- or 6-membered ring which may further contain one or more nitrogen atom, oxygen atom or sulfur atom. You can,
R c represents a hydroxyl group or a C 1-6 alkoxy group,
Y 1 represents — (CH 2 ) n —O— or — (CH 2 ) m —,
n represents an integer of 1 to 6,
m represents an integer of 0 to 6,
Y 2 represents an aryl group or heteroaryl group (wherein the aryl group or heteroaryl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1- A 6 alkyl group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 selected from the group consisting of a cyano group and a halogen atom It may be substituted with 3 substituents. },
Y 3 represents a 5-membered heteroarylene,
The compound according to claim 1 or a pharmaceutically acceptable salt thereof. - 環Aが、フェニル基又は6員ヘテロアリール基である、請求項1又は2に記載の化合物又はその医薬上許容される塩。 The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein ring A is a phenyl group or a 6-membered heteroaryl group.
- 環Aが、フェニル基又はピリジル基である、請求項3に記載の化合物又はその医薬上許容される塩。 The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein ring A is a phenyl group or a pyridyl group.
- Y1が、-CH2-O-である、請求項1~4のいずれか1項に記載の化合物又はその医薬上許容される塩。 The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein Y 1 is -CH 2 -O-.
- Y2が、フェニル基又はピリジル基{ここで該フェニル基又はピリジル基は、C1-6アルキル基、C3-6シクロアルキル基、C1-6アルコキシ基(ここで該C1-6アルキル基、C3-6シクロアルキル基又はC1-6アルコキシ基は、1から3個のハロゲン原子で置換されてもよい。)、シアノ基及びハロゲン原子からなる群より選択される1から3個の置換基で置換されてもよい。}である、請求項1~5のいずれか1項に記載の化合物又はその医薬上許容される塩。 Y 2 is a phenyl group or a pyridyl group (wherein the phenyl group or pyridyl group is a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-6 alkoxy group (wherein the C 1-6 alkyl is Group, a C 3-6 cycloalkyl group or a C 1-6 alkoxy group may be substituted with 1 to 3 halogen atoms.), 1 to 3 selected from the group consisting of a cyano group and a halogen atom It may be substituted with a substituent. } Or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.
- R3が、水素原子又はハロゲン原子である、請求項1~7のいずれか1項に記載の化合物又はその医薬上許容される塩。 R 3 is a hydrogen atom or a halogen atom, a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7.
- 請求項1~8のいずれか1項に記載の化合物又はその医薬上許容される塩を有効成分として含有する医薬。 A medicament comprising the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient.
- グループII代謝型グルタミン酸受容体拮抗物質である、請求項9に記載の医薬。 The medicament according to claim 9, which is a group II metabotropic glutamate receptor antagonist.
- 請求項1~10のいずれか1項に記載の化合物又はその医薬上許容される塩を有効成分とする、気分障害、不安障害、統合失調症、アルツハイマー病、認知機能障害、認知症、薬物依存、痙攣、振戦、疼痛、又は睡眠障害の予防又は治療剤。 A mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence comprising the compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof as an active ingredient , Preventive or therapeutic agent for convulsions, tremors, pain, or sleep disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-010912 | 2011-01-21 | ||
JP2011010912A JP2014062047A (en) | 2011-01-21 | 2011-01-21 | Pyrazole derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012099200A1 true WO2012099200A1 (en) | 2012-07-26 |
Family
ID=46515822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/051070 WO2012099200A1 (en) | 2011-01-21 | 2012-01-19 | Pyrazole derivative |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2014062047A (en) |
TW (1) | TW201245187A (en) |
WO (1) | WO2012099200A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013111796A1 (en) * | 2012-01-25 | 2013-08-01 | 大正製薬株式会社 | N-substituted pyrazole derivative |
EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
WO2016141258A1 (en) * | 2015-03-04 | 2016-09-09 | Medivation Technologies, Inc. | Sterol regulatory element-binding proteins (srebps) inhibitors |
US10183015B2 (en) | 2015-03-04 | 2019-01-22 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040110A1 (en) * | 2003-10-08 | 2005-05-06 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
WO2007039439A1 (en) * | 2005-09-27 | 2007-04-12 | F.Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
WO2007110337A1 (en) * | 2006-03-29 | 2007-10-04 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
WO2008119689A1 (en) * | 2007-04-02 | 2008-10-09 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
WO2009078432A1 (en) * | 2007-12-18 | 2009-06-25 | Taisho Pharmaceutical Co., Ltd. | 1-alkyl-4-amino-1h-pyrazole-3-carboxamide compound |
WO2010142628A1 (en) * | 2009-06-08 | 2010-12-16 | Merck Serono S.A. | Pyrazole oxadiazole derivatives as s1p1 agonists |
WO2012020820A1 (en) * | 2010-08-11 | 2012-02-16 | 大正製薬株式会社 | Heteroaryl-pyrazole derivative |
-
2011
- 2011-01-21 JP JP2011010912A patent/JP2014062047A/en active Pending
-
2012
- 2012-01-19 WO PCT/JP2012/051070 patent/WO2012099200A1/en active Application Filing
- 2012-01-20 TW TW101102684A patent/TW201245187A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005040110A1 (en) * | 2003-10-08 | 2005-05-06 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
WO2007039439A1 (en) * | 2005-09-27 | 2007-04-12 | F.Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
WO2007110337A1 (en) * | 2006-03-29 | 2007-10-04 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
WO2008119689A1 (en) * | 2007-04-02 | 2008-10-09 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
WO2009078432A1 (en) * | 2007-12-18 | 2009-06-25 | Taisho Pharmaceutical Co., Ltd. | 1-alkyl-4-amino-1h-pyrazole-3-carboxamide compound |
WO2010142628A1 (en) * | 2009-06-08 | 2010-12-16 | Merck Serono S.A. | Pyrazole oxadiazole derivatives as s1p1 agonists |
WO2012020820A1 (en) * | 2010-08-11 | 2012-02-16 | 大正製薬株式会社 | Heteroaryl-pyrazole derivative |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013111796A1 (en) * | 2012-01-25 | 2013-08-01 | 大正製薬株式会社 | N-substituted pyrazole derivative |
EP3000814A1 (en) | 2014-09-26 | 2016-03-30 | Domain Therapeutics | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors |
WO2016141258A1 (en) * | 2015-03-04 | 2016-09-09 | Medivation Technologies, Inc. | Sterol regulatory element-binding proteins (srebps) inhibitors |
US10183015B2 (en) | 2015-03-04 | 2019-01-22 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
US10189826B2 (en) | 2015-03-04 | 2019-01-29 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
Also Published As
Publication number | Publication date |
---|---|
JP2014062047A (en) | 2014-04-10 |
TW201245187A (en) | 2012-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230113085A1 (en) | Novel small molecule inhibitors of tead transcription factors | |
US7074809B2 (en) | Compounds | |
CA2957046C (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
JP2020045347A (en) | Flt3 receptor antagonists | |
US11434245B2 (en) | WNT pathway modulators | |
WO2011043371A1 (en) | Oxazole compound | |
US20090163508A1 (en) | Amide compound | |
ES2638398T3 (en) | Pyrazol oxadiazole derivatives as S1P1 agonists | |
US20130137865A1 (en) | Heteroaryl-pyrazole derivative | |
US20150011751A1 (en) | Novel triazine derivative | |
EP1701959A1 (en) | Triazole derivatives as vasopressin antagonists | |
US8202856B2 (en) | Triazole oxadiazoles derivatives | |
IL182945A (en) | 3-phenyl-pyrazole derivatives, pharmaceutical compositions comprising them and their use in the preparation of medicaments useful for the treatment of disorders related to the 5-ht2a serotonin receptor | |
JP6183451B2 (en) | 2-acylaminothiazole derivatives or salts thereof | |
US20050261327A1 (en) | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | |
KR20160037986A (en) | 1,3-disubstituted cyclopentane derivatives | |
RU2690154C2 (en) | Morpholine-pyridine derivatives | |
WO2012099200A1 (en) | Pyrazole derivative | |
WO2012015024A1 (en) | Ethinyl-pyrazole derivative | |
US10494363B2 (en) | Non-steroidal glucocorticoid receptor modulators for local drug delivery | |
TW201341381A (en) | N-substituted pyrazole derivatives | |
US7816380B2 (en) | 1-hydroxycycloalkanecarboxamide derivatives | |
RU2772507C2 (en) | Therapeutic remedy or preventive remedy against alopecia areata | |
WO2013062074A1 (en) | Imidazolone derivative | |
KR20100135737A (en) | Substituted piperidines as renin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12736906 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12736906 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |